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ABSTRACT 
Tuberculosis (TB) has remained one of the leading causes of the death worldwide and recently 
surpassed HIV/AIDS as lethal disease caused by a single infectious agent. Further, development 
of resistance against frontline anti-tubercular drugs has worsened the existing alarming 
condition. Therefore, there is an urgent need to develop novel, more effective, inexpensive and 
accessible antitubercular agents possessing broad spectrum of potency short duration of drug 
regimen, less side effects, which can counter the drug resistant TB and reduce the burden on the 
society. Global scientific communities and pharmaceutical industries are aggressively involved 
in research to develop a novel broad spectrum anti-tubercular agent to address this rising threat 
to human kind. In continuation of our work, focused in developing new anti-TB agents, we have 
attempted to develop some potential quinazoline based DNA gyrase and topoisomerase IV 
inhibitors as potential anti-tubercular agents. In addition, we have developed novel green and 
efficient catalyst-free, mild one-pot tandem synthetic strategy to synthesize benzoxazine 
derivatives, that can be further exploited as building blocks for the synthesis of multifaceted 
molecular structures, especially for anti-tuberculosis agents.  
Chapter 1 gives a brief overview on  drug discovery and medicinal chemistry, history of 
antibiotic expansion, development of resistance in bacteria, history of anti-TB drugs discovery, 
line of treatment for TB, anti-tubercular drugs and their specific targets, classification of TB 
drugs, DNA gyrase and topoisomerase IV as a key target for anti-tubercular agents, marketed 
drugs and recently reported DNA gyrase inhibitors, importance of benzoxazine and quinazoline 
scaffold as well as significance of fluorine containing heterocycles in medicinal chemistry. 
Chapter 2 describes, the development of a novel methodology which is green, efficient 
catalyst-free and is a mild one-pot, multicomponent synthetic strategy to construct substituted 
3,4-dihydro-2H-benzo[b][1,4]oxazine. The reaction proceeds via in-situ formation of Schiff-
base followed by base mediated alkylation with phenacyl bromide/substituted phenacyl 
bromide, finally leading to intramolecular cyclization to give a mixture of diastereomers with 
excellent diastereoselectivity (up to dr = 99:1), which were isolated as single diastereomer in 
moderate to excellent yields (41-92%). Besides, this new versatile methodology provides a wide 
scope for the synthesis of different functionally substituted benzoxazine scaffolds and can be 
further exploited as building blocks for the synthesis of multifaceted molecular structures, 
especially for pharmaceutical applications. 
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In Chapter 3, 15 novel fluorinated quinazoline derivatives have been synthesized and 
characterized with Infrared (IR) and Nuclear Magnetic Resonance (NMR) spectroscopic 
methods. This chapter also describes the influence of various substituents on the core scaffold 
(Fluorinated quinazoline) on its molecular conformations, intermolecular interactions and on the 
photoluminescent properties. Hirshfeld surfaces was used to investigate the structure-directing 
effects of functional groups in controlling their solid-state behaviour.  
In Chapter 4, a total 21 novel quinazoline derivatives (10a-q and 17a-c) were synthesized in 
good to moderate yields. The synthesized compounds were well-characterized by spectroscopic 
studies (IR and NMR) and evaluated for their preliminary in vitro screening against 
Mycobacterium tuberculosis H37Rv strain, which was conducted at TB Discovery Research, 
Infectious Disease Research Institute (IDRI), USA. The only notable % zone of inhibition was 
observed against Mycobacterium tuberculosis strain H37Rv for compounds 10m which showed 
33% inhibition after 24 h incubation which can be considered for further study which includes 
MIC, MBC etc.  
In Chapter 5, total 23 novel N/O-methylated quinazoline derivatives (10a-o, 16a-d and 16aa-
ad) were synthesized in good to moderate yields. All synthesized compounds were well-
characterized by spectroscopic studies (IR and NMR) and evaluated for preliminary in-vitro 
screening for anti-mycobacterium activity at 20 µM concentration against Mycobacterium 
tuberculosis H37Rv strain at TB Discovery Research, Infectious Disease Research Institute 
(IDRI), USA.  The % zone of inhibition for compounds 16a, against Mycobacterium 
tuberculosis strain H37Rv was found to be 34% after 24 h incubation. 
Chapter 6 describes, the development of novel quinazoline based DNA gyrase inhibitors as 
potential antibacterial agents. Bacterial type II topoisomerase (DNA gyrase and topoisomerase 
IV) control the topological state of DNA during replication and are validated targets for 
antibacterial agents. Type II topoisomerase is essential in all bacteria. It is also present in 
eukaryotic cells but unlike the prokaryotic enzymes eukaryotic topoisomerase II is 
homodimeric, this difference in structure makes highly attractive targets in antibacterial drug 
discovery. Fluoroquinolones are an example of very active gyrase-based drugs, but the rise in 
bacterial resistance to these agents alarm the risk. We have replaced the central core quinolone 
with quinazoline ring and synthesized 22 derivatives and evaluated against DNA gyrase and 
topoisomerase IV enzyme of Escherichia coli. The most potent compound (10l) displayed 
balanced IC50 value of 0.49 and 13.22 μM for DNA Gyrase and topoisomerase IV of 
Escherichia coli respectively. This result is intresting for the further studies as it showed 
 
iv 
 
promising well-balanced duel inhibiton in the low micromolar range against DNA gyrase and 
topoisomerase IV in E. coli.
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CHAPTER 1 
1. General Introduction 
1.1. Drug discovery and medicinal chemistry 
The field of Medicinal chemistry along with pharmacology has played a crucial role in the 
discovery of new medicines, which has inturn improved the quality of life for the human kind. 
Since last century medicinal chemists have been using perception in designing the molecules to 
exhibit biological activity.1 It is originally stated by eminent Chemist, Professor Alfred Burger, 
Medicinal Chemistry still “…remains a challenging science which provides profound 
satisfaction to its practitioners…”.2 The IUPAC defines Medicinal Chemistry as “…a 
chemistry-based discipline, also involving aspects of biological, medical and pharmaceutical 
sciences. It is concerned with the invention, discovery, design, identification and preparation of 
biologically active compounds, the study of their metabolism, the interpretation of their mode of 
action at the molecular level and the construction of structure-activity relationships”.3 
Several pharmaceutical companies are investing millions of dollars in medicinal chemistry 
programs. However, the correct approach is key differentiator for fast and efficient drug 
discovery which involves interrogation of hypothesis in a cycle involving design, synthesis, test 
and analysis (Figure 1). There are several stages for approval of the drug for the market (Figure 
1) of which most stages are performed in industry. Public sector including academia is involved 
mainly in biochemical pathways, early stage compound identification/generation and target 
identification.4  
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Figure 1: Stages in drug development and several approaches in medicinal chemistry. 
The synthesis of antibiotics dates back to a century. The complete lineage for the development 
of antibiotics has been summarized in Figure 2.  
 
Figure 2: History of antibiotic development. 
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Over the years antibiotic drug resistance has become a major challenge currently faced by 
research and development (R&D) centers, pharmaceutical industries and medicinal chemists 
(Figure 3). Microorganisms are diverse organisms consisting of bacteria, fungi, archaea, 
protozoa, etc., responsible for several infectious diseases in humans and animals.  
 
Figure 3: Development of resistance in bacteria. 
According to the World Health Organization (WHO), several million deaths occure every year 
from bacterial  infections alone, such as Scarlet fever (Streptococcus pyogenes), Food poisoning 
(Escherichia coli), Pneumonia (Streptococcus pneumoniae), Syphilis (Treponema pallidum), 
Tuberculosis (Mycobacterium tuberculosis) etc.5 Emergence of HIV has further complicated the 
treatment and management of patience due to microbial co-infectious, especially 
Mycobacterium tuberculosis (M. tuberculosis) alone leading to 1.5 million deaths annually.6 It 
is well documented that TB is more prevalent in people with HIV due to their compromised 
immunity responsible for several millon deaths annually.7-9 According to WHO in 2017 alone, 
10.0 million fell sick and 1.3 million died due to this life-threatening ailment.10 The WHO 
estimates (2016), about 124,000 people in South Africa (about 330 daily), which is about 80 %, 
were found to be infected with HIV. South Africa has the highest TB incidence rate in the world 
at 340 persons per 100 000 population, with a budget expenditure of 271 million US $.11 It has 
become country’s leading death cause even greater than HIV. 
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TB results from bacterial infection which is a formidable, contagious and airborne disease. The 
causative organism for this fatal disease was unknown until 24th March 1882 when Dr Robert 
Koch revealed the discovery of bacillus M. tuberculosis, as the main causative bacteria of TB. 
This day is now commemorated as World TB Day every year.12 During late 18th centuary, TB 
TB was raging in America and Europe with one death for seven people. Koch discovery of M. 
tuberculosis as the causative microorganism opened the broad idea of finding the cure for TB 
including its diagnosis. M. tuberculosis genome comprises of approximately 3950 genes of 
which ∼10% (nearly 461 genes) are required for growth and survival of the bacillus in vitro 
under standard aerobic growth conditions.13 
1.2. Treating TB  
Several remarkable drug discoveries have been made worldwide after the discovery of M. 
tuberculosis (Figure 4).14 Pyrazinamide was the first synthesized anti TB drug but was only in 
full use after 1972 along with isoniazid, rifampicin and ethambutol. 
 
 
Figure 4: Time line depicting the discovery of various Anti-TB drugs. 
In this field, there has been outstanding growth achieved for the treatment of TB after the 
introduction of Streptomycin in 1947. However, its potential as drug was completely utilized 
along with isoniazid in 1952. Following the drug discovery program, ethambutol (1961) and 
rifampin (1962) were introduced as the first line treatment TB drugs.11, 15 In addition, second 
line drugs like para-aminosalicylic acid (PAS), ethionamide, cycloserine, amikacin and 
capreomycin have been accepted by FDA, but are known to elicit severe adverse reactions 
frequently.16 Fluoroquinolones, delamanid, bedaquiline, ethionamide, rifabutin, macrolides 
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related drugs and some rifampin related congeners are the recent additions to anti-TB drug 
regimen. Figure 5 shows the development of TB drugs.  
 
Figure 5: Schematic representation of anti-TB Drug development against M. tuberculosis. 
The treatment for TB by standard combination of four anti-microbial drugs (isoniazid, 
rifampicin ethambutol and pyrazinamide)is performed under directly observed treatment short 
course (DOTS) for a span of six months (Figure 6).17, 18 Due to constant increment in the field 
of drug discovery and the line of treatment for TB, the decrement of mortality rate has been 
witnessed in recent years with 53 million lives saved until 2017.19 However, there is an urgency 
for the development of new TB drugs due to the rapid emergence of multidrug-resistant (MDR) 
and extensively drug-resistant (XDR) TB strains, which are posing a serious threat to 
mankind.20 Drug resistance in M. tuberculosis was predicted based upon two mechanisms viz., 
acquired drug resistance and primary drug resistance.18, 20 Currently, delamanid finds application 
against MDR-TB and bedaquiline in treating both XDR-TB and MDR-TB.21, 22  
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Figure 6: TB drug regimen for treatment. 
1.3. Classification of TB drugs and targets 
Anti-TB drugs are broadly classified as bactericidal and bacteriostatic with various targets onto 
bacteria which includes inhibitors of cell wall, protein synthesis, nucleic acid and membrane 
energy metabolism as shown in Figure 7. Each category comprises of drugs from first line and 
second line of treatment as shown in Figure 8.23-25 Apart from the above, p-aminosalicylic 
acid26 which is a prodrug targeting dihydrofolate reductase (DHFR) in M. tuberculosis and 
Clofazimine (initially referred to as B.663.254) effective against MDR-TB are also known for 
treatment of TB.27 
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Figure 7: Antibiotics and their specific targets. 
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Figure 8: Classification of anti-TB drugs.23-25 
1.4. Mechanism of bacterial drug resistance 
In order to combat the bacterial resistance of TB, it is crucial to understand the drug resistance 
mechanism which they develop to overcome the damage which is caused by antibiotic 
treatments.  This adaptive mechanism plays a key role for microbial survival and evaluation. 
Drug resistance can be due to enzymatic inactivation of the antibiotic molecule, decreased cell 
wall permeability to antibiotics, modification of a target site to prevent antibiotic interaction, 
promotion of an efflux mechanism to remove the antibiotic from the cell (Figure 9). The hunt 
for newer anti-TB drugs has been epicenter since last few decades due to constant increment of 
MDR/XDR-TB cases.  
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Figure 9: Different mechanism for drug resistance.  
1.5. DNA topoisomerases as key target 
DNA topoisomerases are set of enzymes which are responsible for changing the topology of 
DNA.28, 29 These enzymes are found in both eukaryotic and prokaryotic cells and hence are 
essential for survival. They are divided mainly into 2 types, I and II 29, 30 (Figure 10). In general, 
all topoisomerases are known to relax super coiled DNA but only type II (also known as DNA 
gyrase) introduces negative supercoils which in turn requires ATP hydrolysis.31 DNA gyrase 
comprises of two subunits A and B which forms heterodimer structure (A2B2 complex). DNA 
Gyrase A also known as Gyr A is involved in nicking and ligation of DNA (N-terminal with 59-
64 KDa) and DNA protein interaction (C-terminal 33 kDa). DNA Gyrase B also known as Gyr 
B is the powerhouse in DNA replication as it has a key role in controlling ATPase activity (N-
terminal with 43 KDa) and interacts with both Gyr A and DNA (C-terminal 47 kDa).32 The 
mechanism of supercoiling of DNA Gyrase has been demonstrated by a generic model known 
as “two-gate mechanism” which makes it an attractive antibacterial target.30 Currently, there are 
two main groups of antibiotics targeting DNA Gyrase. Firstly, coumarine (natural antibiotic) 
which are known to inhibit DNA Gyrases by competing with ATP for binding to Gyr B33 and 
quinolones (synthetic antibiotics) which react with N-terminal of Gyr A to inhibit DNA 
segregation and induce irreversible DNA damage.34 Although DNA Gyrase is the main target 
for quinolones in Gram-negative bacteria but in case of Gram-positive organisms’ 
topoisomerase IV is also the preferred target. Quinolones are known to interact with DNA 
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mainly by enzymatic interaction and disrupting the DNA cleavage-religation process32 which 
has been revealed by X-ray structures of fragments of gyrase (and topo IV) complexed with 
DNA and quinolone drugs.35 However, a small category of TB drugs (fluoroquinolones, like 
moxifloxacin and gatifloxacin) targets DNA Gyrase for the treatment of MDR-TB.36  
 
Figure 10: Topoisomerase and their subunit with Inhibitors. 
1.6. DNA Gyrase and topoisomerase IV inhibitors 
DNA gyrase and topoisomerase IV are the established and validated targets of aminocoumarin 
and quinolones/fluoroquinolones (Figure 11).32, 37 Although these two types of inhibitors target 
different parts of the enzymes. Well known and broadly used synthetic antibiotics 
(quinolones/fluoroquinolones) target GyrA and ParC subunits, while natural product 
aminocoumarins (novobiocin and clorobiocin) target GyrB and ParE subunits. Over the past few 
years, revalent research has been underway by many research groups to discover novel DNA 
gyrase inhibitors (Figure 11)38-41 with improved enzyme affinities, more effective antibacterial 
activities, and favourable pharmacokinetic. 
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Figure 11: Marketed drugs and recently reported DNA gyrase inhibitors.32, 37-41 
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1.7. Benzoxazine: An important scaffold for medicinal chemistry 
Benzoxazines are important class of heterocyclic scaffolds known for their widespread 
pharmacological and biological significance (Figure 12),42-47 and have therefore attracted 
considerable interest in design and development of new greener synthetic strategies for the 
construction of these heterocycles. It is well documented that benzoxazine moiety has been used 
as a building block in developing new pharmaceutical lead compounds, which have displayed 
wide range for pharmaceutical applications such as neuroprotective agents,48, 49 antidiabetic,50 
antiarrhythmics against ischemia-reperfusion injury,51 calcium antagonist,52 potassium channel 
modulators,53 and antihyperlipidemic agents54 etc. Owing to broader range of pharmacological 
properties, enormous number of synthetic approaches have been developed to synthesize novel 
1,4-benzoxazine derivatives (Figure 13). 
 
Figure 12: Commercial drugs bearing benzoxazines moiety.42-47  
Traditionally, the reported methods used multistep synthetic approaches for the synthesis of 1,4-
benzoxazine moiety (Figure 13) such as; a) cyclocondensation of amino phenols with α-
halogeno acyl bromides along with reduction of carbonyl with BH3, b) alkylation of o-
nitrophenol with haloester followed by reductive cyclization,55 c) intramolecular copper-
catalysed O-arylation of β-aminoalcohols56 and d) epoxide ring opening with O-
halosulfonamides followed by cyclization was used to render these 1,4 benzoxazine moieties.57 
e) Recently, in 2017 Cuie Wang and co-workers reported a new method for the synthesis of 1,4 
benzoxazine by the cyclization of Schiff-base with α-haloketones using DMAP as catalyst in 
DMF at 120°C58 and f) in the following year Abhijit Mall et al. (2018) reported an efficient 
strategy for the synthesis of 3,4-dihydro 1,4 benzoxazine derivatives via Lewis acid catalysed 
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SN2 type ring opening of activated aziridine with 2-halophenol followed by Cu(I)-catalysed 
cyclization.46  
 
Figure 13: Some reported approach for the synthesis of 1,4 benzoxazine derivatives.46, 55-58 
1.8. Benzoxazine and TB 
Benzoxazine based core moieties are also known to exhibit activity against M. tuberculosis. 
Undoubtedly levofloxacin and ofloxacin are the well-known and noteworthy marketed drugs 
containing benzoxazine heterocycle as its core moiety (Figure 14) have been extensively used 
as anti-tuberculosis agent.59, 60  Some benzoxazine analogues have been reported in literature to 
be highly effective against in-vitro anti-tubercular with minimum inhibitory concentration as 
shown in Figure 14.61 
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Figure 14: Benzoxazine based marketed drugs and recent reported derivatives with potent anti-
tubercular activity.21, 59-61 
1.9. Quinazoline: An important scaffold for medicinal chemistry 
Quinazoline is one of the most predominant skeletons in organic chemistry which finds 
application in medicinal chemistry.62-65 The first synthesis of quinazoline dates to late 1890s 
with extensive studies on the quinazoline (1, 3-diazanaphthalene) structure in 1903 by Gabriel 
and was isolated from Chinese plant aseru. Quinazoline derivatives are present in high 
concentration in Rutaceae plant family.66 However, the name was proposed by Widdege in 
1887.67, 68 However, since then several protocols/methods have been proposed to synthesize 
quinazoline derivatives. Quinazoline derivatives synthesis are based on the substitution on 
ring.69 Several commercial drugs bearing quinazoline core unit are known in market (Figure 
15). Quinazoline derivatives are well documented as known sedatives, but are also known to 
exhibit anti-inflammatory,70 antimicrobial,71, 72  anticancer,73-75 anticonvulsant,76 and antifungal 
activities.77 
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Figure 15: Commercial drugs bearing quinazoline moiety. 
1.10. Quinazoline and TB 
Quinazoline based molecules are also known to exhibit activity against M. tuberculosis.78 Some 
quinazoline analogues have been reported in literature to be highly effective against in-vitro 
anti-tubercular with minimum inhibitory concentration (MIC) as shown in Figure 16.79 In 
another report, several quinazoline derivatives have been shown to display significant anti-
tubercular activity against M. tuberculosis H37Rv with substantial low cytotoxicity.80. 
Tryptanthrin analogues have been known to show potency against multi-resistant TB strains. 
These derivatives are reported to be close in efficacy compared to known anti-tubercular 
compounds streptomycin and ethambutol.81 Several other reports have also reported the 
synthesis of quinazoline based derivatives having high anti-tubercular activity.82, 83 
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Figure 16: Quinazoline based derivatives with potent anti-tubercular activity.79, 83 
1.11. Significance of fluorine in medicinal chemistry 
Fluorine being small (van der Waals radius 1.47 Å) and most electronegative element in the 
Periodic Table (3.98 Pauling scale), has been influencing organic chemistry since decades.84, 85 
However, since last few decades it has become kingpin in medicinal chemistry as it alters the 
biological properties of the drugs. Till date, 20-25% drugs approved by food and drug 
administration (FDA) contain fluorine (F) or CF3. In 2018 alone, 17 drugs bearing F or CF3 has 
been approved by FDA.86 Fluorine is known to influence molecular conformation, owing to the 
large dipole moment of the C-F bond. Fluorine is quite comparable with hydrogen counterparts 
and is known to cause significantly less steric perturbations and increases the lipophilicity. In 
addition, fluorine containing molecules are also known to increase the membrane permeability 
of the compounds as it reduces the basicity of the molecule.87, 88 
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Figure 17: Fluorine containing DNA Gyrase and topoisomerase IV inhibitors (marketed drugs). 
In view of the above literature, we realize that DNA Gyrase for M. tuberculosis inhibition (for 
anti-tubercular) has not been explored much. Owing to the high rate of antibiotic resistance 
against M. tuberculosis there is an urgency to look for new targets. DNA Gyrase provides us 
with an opportunity to synthesize quinazoline based derivatives which are expected to possess 
anti-tubercular activity. 
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2. Objectives of the Present Research Work 
The aims and objectives of the present research work are- 
1. To carryout widespread literature survey for designing of quinazoline and benzoxazine based 
new chemical entities as potential antitubercular agents and type II topoisomerase (DNA 
gyrase and topoisomerase IV) inhibitors. 
2. To develop a convenient and efficient method for the synthesis of novel quinazoline and 
benzoxazine based scaffold. 
3. To generate a library of novel quinazoline and benzoxazine based analogues using the 
developed synthetic methodology. 
4. To purify the synthesized compounds by chromatographic techniques using combi flash 
column chromatography. 
5. To establish the structure of synthesized compounds by spectral characterization (IR, 1H 
NMR, 13C NMR 2D-NMR) and also with single crystal X- ray crystallography. 
6. To carry out the preliminary biological evaluation of the synthesized compounds for their 
antitubercular activity and type II topoisomerase (DNA gyrase and topoisomerase IV) 
inhibition. 
  
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 19                                         UKZN-2020 
 
3. References 
1. Kneller, R., The importance of new companies for drug discovery: origins of a decade 
of new drugs. Nat. Rev. Drug Discov. 2010, 9 (11), 867-882. 
2. Wermuth, C. G., The practice of medicinal chemistry. Academic Press: 2011. 
3. Wermuth, C.; Ganellin, C.; Lindberg, P.; Mitscher, L., Glossary of terms used in 
medicinal chemistry (IUPAC Recommendations 1998). Pure. Appl. Chem 1998, 70 (5), 
1129-1143. 
4. Satyanarayanajois, S. D.; Hill, R. A., Medicinal chemistry for 2020. Future Med. Chem. 
2011, 3 (14), 1765-1786. 
5. Farha, M. A.; Brown, E. D., Drug repurposing for antimicrobial discovery. Nat. 
Microbiol. 2019, 4 (4), 565-577. 
6. Espert, L.; Beaumelle, B.; Vergne, I., Autophagy in Mycobacterium tuberculosis and 
HIV infections. Front. Cell Infect. Microbiol. 2015, 5 (49), 1-8. 
7. Antonucci, G.; Girardi, E.; Raviglione, M. C.; Ippolito, G.; Almi, P.; Angarano, G.; 
Armignacco, O.; Babudieri, S.; Bevilacqua, N.; Bini, A.; Bottura, P.; Boumis, E.; 
Costigliola, P.; Chirianni, A.; Di Perri, G.; Errante, I.; Libanore, M.; Manzillo, E.; 
Minoli, L.; Narciso, P.; Pagano, G.; Pellizzer, G.; Rapiti, E.; Rusconi, S.; Santoro, D.; 
Savalli, E.; Tavio, M.; Traverso, A.; Viale, P., Risk Factors for Tuberculosis in HIV-
lnfected Persons: A Prospective Cohort Study. JAMA 1995, 274 (2), 143-148. 
8. Sun, J.; Boing, A. C.; Silveira, M. P. T.; Bertoldi, A. D.; Ziganshina, L. E.; 
Khaziakhmetova, V. N.; Khamidulina, R. M.; Chokshi, M. R.; McGee, S.; Suleman, F., 
Efforts to secure universal access to HIV/AIDS treatment: a comparison of BRICS 
countries. J. Evid. Based Med. 2014, 7 (1), 2-21. 
9. Bell, L. C. K.; Noursadeghi, M., Pathogenesis of HIV-1 and Mycobacterium 
tuberculosis co-infection. Nat. Rev. Microbiol. 2017, 16 (2), 80-90. 
10. Anderson, L.; Baddeley, A.; Dias, H. M.; Floyd, K.; Baena, I. G.; Gebreselassie, N.; 
Gilpin, C.; Glaziou, P.; Law, I.; Nishikiori, N.; Rangaka, M.; Siroka, A.; Sismanidis, C.; 
Syed, L.; Timimi, H.; Xia, Y.; Zignol, M. Global tuberculosis report 2018. World 
Health Organization.; CC BY-NC-SA 3.0 IGO; Geneva, 2018. 
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 20                                         UKZN-2020 
 
11. Knight, L. K.; Lehloenya, R. J.; Sinanovic, E.; Pooran, A., Cost of managing severe 
cutaneous adverse drug reactions to first-line tuberculosis therapy in South Africa. 
Trop. Med. Int. Health 2019, 24 (8), 994-1002. 
12. Sakula, A., Robert koch: centenary of the discovery of the tubercle bacillus, 1882. Can. 
Vet. J. 1983, 24 (4), 127-131. 
13. DeJesus, M. A.; Gerrick, E. R.; Xu, W.; Park, S. W.; Long, J. E.; Boutte, C. C.; Rubin, 
E. J.; Schnappinger, D.; Ehrt, S.; Fortune, S. M.; Sassetti, C. M.; Ioerger, T. R., 
Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via 
Saturating Transposon Mutagenesis. mBio 2017, 8 (1), e02133-16. 
14. Rendon, A.; Tiberi, S.; Scardigli, A.; D’Ambrosio, L.; Centis, R.; Caminero, J. A.; 
Migliori, G. B., Classification of drugs to treat multidrug-resistant tuberculosis (MDR-
TB): evidence and perspectives. J. Thorac. Dis 2016, 8 (10), 2666-2671. 
15. Coninx, R.; Mathieu, C.; Debacker, M.; Mirzoev, F.; Ismaelov, A.; de Haller, R.; 
Meddings, D. R., First-line tuberculosis therapy and drug-resistant Mycobacterium 
tuberculosis in prisons. Lancet. 1999, 353 (9157), 969-973. 
16. Shi, R.; Itagaki, N.; Sugawara, I., Overview of anti-tuberculosis (TB) drugs and their 
resistance mechanisms. Mini Rev. Med. Chem. 2007, 7 (11), 1177-1185. 
17. Campaniço, A.; Moreira, R.; Lopes, F., Drug discovery in tuberculosis. New drug 
targets and antimycobacterial agents. Eur. J. Med. Chem. 2018, 150, 525-545. 
18. Joshi, J., Tuberculosis chemotherapy in the 21st century: Back to the basics. Lung India 
2011, 28 (3), 193-200. 
19. Consalvi, S.; Scarpecci, C.; Biava, M.; Poce, G., Mycobacterial tryptophan 
biosynthesis: A promising target for tuberculosis drug development? Bioorg. Med. 
Chem. Lett. 2019, 126731. 
20. Chan, E. D.; Iseman, M. D., Multidrug-resistant and extensively drug-resistant 
tuberculosis: a review. Curr. Opin. Infect. Dis. 2008, 21 (6), 587-595. 
21. Rode, H. B.; Lade, D. M.; Grée, R.; Mainkar, P. S.; Chandrasekhar, S., Strategies 
towards the synthesis of anti-tuberculosis drugs. Org. Biomol. Chem. 2019, 17, 5428-
5459. 
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 21                                         UKZN-2020 
 
22. Vasava, M. S.; Bhoi, M. N.; Rathwa, S. K.; Borad, M. A.; Nair, S. G.; Patel, H. D., 
Drug development against tuberculosis: Past, present and future. Ind.J. Tuberculosis 
2017, 64 (4), 252-275. 
23. Tiberi, S.; Scardigli, A.; Centis, R.; D’Ambrosio, L.; Munoz-Torrico, M.; Salazar-
Lezama, M. A.; Spanevello, A.; Visca, D.; Zumla, A.; Migliori, G. B., Classifying new 
anti-tuberculosis drugs: rationale and future perspectives. Int. J. Infect. Dis. 2017, 56, 
181-184. 
24. Organization, W. H., Companion handbook to the WHO guidelines for the 
programmatic management of drug-resistant tuberculosis. World Health Organization: 
2014. 
25. Caminero, J. A.; Sotgiu, G.; Zumla, A.; Migliori, G. B., Best drug treatment for 
multidrug-resistant and extensively drug-resistant tuberculosis. Lancet. Infect. Dis 2010, 
10 (9), 621-629. 
26. Zheng, J.; Rubin, E. J.; Bifani, P.; Mathys, V.; Lim, V.; Au, M.; Jang, J.; Nam, J.; Dick, 
T.; Walker, J. R., para-Aminosalicylic acid is a prodrug targeting dihydrofolate 
reductase in Mycobacterium tuberculosis. J. Biol. Chem. 2013, 288 (32), 23447-23456. 
27. Lechartier, B.; Cole, S. T., Mode of action of clofazimine and combination therapy with 
benzothiazinones against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 
2015, 59 (8), 4457. 
28. Wang, J. C., A Journey in the World of DNA Rings and Beyond. Annu. Rev. Biochem. 
2009, 78 (1), 31-54. 
29. Liu, L. F.; Liu, C.-C.; Alberts, B. M., Type II DNA topoisomerases: Enzymes that can 
unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 
1980, 19 (3), 697-707. 
30. Schoeffler, A. J.; Berger, J. M., DNA topoisomerases: harnessing and constraining 
energy to govern chromosome topology. Q. Rev. Biophys 2008, 41 (1), 41-101. 
31. Bates, A. D.; Maxwell, A., Energy Coupling in Type II Topoisomerases: Why Do They 
Hydrolyze ATP? Biochem. 2007, 46 (27), 7929-7941. 
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 22                                         UKZN-2020 
 
32. Collin, F.; Karkare, S.; Maxwell, A., Exploiting bacterial DNA gyrase as a drug target: 
current state and perspectives. Appl. Microbiol. Biotechnol. 2011, 92 (3), 479-497. 
33. Heide, L., New aminocoumarin antibiotics as gyrase inhibitors. Int. J. Med. Microbiol. 
2014, 304 (1), 31-36. 
34. King, D. E.; Malone, R.; Lilley, S. H., New classification and update on the quinolone 
antibiotics. Am. Fam. Physician 2000, 61 (9), 2741-2748. 
35. Bax, B. D.; Chan, P. F.; Eggleston, D. S.; Fosberry, A.; Gentry, D. R.; Gorrec, F.; 
Giordano, I.; Hann, M. M.; Hennessy, A.; Hibbs, M.; Huang, J.; Jones, E.; Jones, J.; 
Brown, K. K.; Lewis, C. J.; May, E. W.; Saunders, M. R.; Singh, O.; Spitzfaden, C. E.; 
Shen, C.; Shillings, A.; Theobald, A. J.; Wohlkonig, A.; Pearson, N. D.; Gwynn, M. N., 
Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010, 
466 (7309), 935-940. 
36. Reiche, M. A.; Warner, D. F.; Mizrahi, V., Targeting DNA Replication and Repair for 
the Development of Novel Therapeutics against Tuberculosis. Front. Mol. Biosci. 2017, 
4 (75), 1-18. 
37. Ellsworth, E. L.; Tran, T. P.; Hollis Showalter, H.; Sanchez, J. P.; Watson, B. M.; Stier, 
M. A.; Domagala, J. M.; Gracheck, S. J.; Joannides, E. T.; Shapiro, M. A., 3-
aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent 
antibacterial activity against wild-type and multidrug resistant organisms. J. Med. 
Chem. 2006, 49 (22), 6435-6438. 
38. Starr, J. T.; Sciotti, R. J.; Hanna, D. L.; Huband, M. D.; Mullins, L. M.; Cai, H.; Gage, 
J. W.; Lockard, M.; Rauckhorst, M. R.; Owen, R. M., 5-(2-Pyrimidinyl)-imidazo [1, 2-
a] pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and 
topoisomerase IV. Bioorg. Med. Chem. Lett. 2009, 19 (18), 5302-5306. 
39. Charifson, P. S.; Grillot, A.-L.; Grossman, T. H.; Parsons, J. D.; Badia, M.; Bellon, S.; 
Deininger, D. D.; Drumm, J. E.; Gross, C. H.; LeTiran, A., Novel dual-targeting 
benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent 
antibacterial activity: Intelligent design and evolution through the judicious use of 
structure-guided design and stucture− activity relationships. J. Med. Chem. 2008, 51 
(17), 5243-5263. 
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 23                                         UKZN-2020 
 
40. Tanitame, A.; Oyamada, Y.; Ofuji, K.; Terauchi, H.; Kawasaki, M.; Wachi, M.; 
Yamagishi, J.-i., Synthesis and antibacterial activity of a novel series of DNA gyrase 
inhibitors: 5-[(E)-2-arylvinyl] pyrazoles. Bioorg. Med. Chem. Lett. 2005, 15 (19), 4299-
4303. 
41. East, S. P.; White, C. B.; Barker, O.; Barker, S.; Bennett, J.; Brown, D.; Boyd, E. A.; 
Brennan, C.; Chowdhury, C.; Collins, I., DNA gyrase (GyrB)/topoisomerase IV (ParE) 
inhibitors: synthesis and antibacterial activity. Bioorg. Med. Chem. Lett. 2009, 19 (3), 
894-899. 
42. Macías, F. A.; Marín, D.; Oliveros-Bastidas, A.; Molinillo, J. M., Rediscovering the 
bioactivity and ecological role of 1, 4-benzoxazinones. Nat. Prod. Rep. 2009, 26 (4), 
478-489. 
43. Achari, B.; Mandal, S. B.; Dutta, P. K.; Chowdhury, C., Perspectives on 1, 4-
benzodioxins, 1, 4-benzoxazines and their 2, 3-dihydro derivatives. Synlett 2004, 2004 
(14), 2449-2467. 
44. Torisu, K.; Kobayashi, K.; Iwahashi, M.; Nakai, Y.; Onoda, T.; Nagase, T.; Sugimoto, 
I.; Okada, Y.; Matsumoto, R.; Nanbu, F., Discovery of a new class of potent, selective, 
and orally active prostaglandin D2 receptor antagonists. Bioorg. Med. Chem. 2004, 12 
(20), 5361-5378. 
45. Morrissey, I.; Hoshino, K.; Sato, K.; Yoshida, A.; Hayakawa, I.; Bures, M. G.; Shen, L. 
L., Mechanism of differential activities of ofloxacin enantiomers. Antimicrob. Agents 
Chemother. 1996, 40 (8), 1775-1784. 
46. Mal, A.; Wani, I. A.; Goswami, G.; Ghorai, M. K., Synthesis of nonracemic 1, 4-
benzoxazines via ring opening/cyclization of activated aziridines with 2-halophenols: 
formal synthesis of levofloxacin. J. Org. Chem. 2018, 83 (15), 7907-7918. 
47. Bouyssou, T.; Casarosa, P.; Naline, E.; Pestel, S.; Konetzki, I.; Devillier, P.; Schnapp, 
A., Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor 
agonist exerting a 24-hour-long duration of action in preclinical models. J. Pharmacol. 
Exp. Ther. 2010, 334 (1), 53-62. 
48. Wang, L.; Ankati, H.; Akubathini, S. K.; Balderamos, M.; Storey, C. A.; Patel, A. V.; 
Price, V.; Kretzschmar, D.; Biehl, E. R.; D'Mello, S. R., Identification of novel 1, 4‐
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 24                                         UKZN-2020 
 
benzoxazine compounds that are protective in tissue culture and in vivo models of 
neurodegeneration. J. Neurosci. Res. 2010, 88 (9), 1970-1984. 
49. Blattes, E.; Lockhart, B.; Lestage, P.; Schwendimann, L.; Gressens, P.; Fleury, M.-B.; 
Largeron, M., Novel 2-alkylamino-1, 4-benzoxazine derivatives as potent 
neuroprotective agents: structure− activity relationship studies. J. Med. Chem. 2005, 48 
(4), 1282-1286. 
50. Rybczynski, P. J.; Zeck, R. E.; Dudash, J.; Combs, D. W.; Burris, T. P.; Yang, M.; 
Osborne, M. C.; Chen, X.; Demarest, K. T., Benzoxazinones as PPARγ agonists. 2. 
SAR of the amide substituent and in vivo results in a type 2 diabetes model. J. Med. 
Chem. 2004, 47 (1), 196-209. 
51. Koini, E. N.; Papazafiri, P.; Vassilopoulos, A.; Koufaki, M.; Horváth, Z.; Koncz, I.; 
Virág, L.; Papp, G. J.; Varro, A.; Calogeropoulou, T., 5, 7, 8-Trimethyl-benzopyran and 
5, 7, 8-Trimethyl-1, 4-benzoxazine Aminoamide Derivatives as Novel Antiarrhythmics 
against Ischemia− Reperfusion Injury. J. Med. Chem. 2009, 52 (8), 2328-2340. 
52. Bourlot, A.-S.; Sánchez, I.; Dureng, G.; Guillaumet, G.; Massingham, R.; Monteil, A.; 
Winslow, E.; Pujol, M. D.; Mérour, J.-Y., New substituted 1, 4-benzoxazine derivatives 
with potential intracellular calcium activity. J. Med. Chem. 1998, 41 (17), 3142-3158. 
53. Caliendo, G.; Grieco, P.; Perissutti, E.; Santagada, V.; Santini, A.; Albrizio, S.; 
Fattorusso, C.; Pinto, A.; Sorrentino, R., Synthesis, biological activity and 
conformational study of 1, 4-benzoxazine derivatives as potassium channel modulators. 
Eur. J. Med. Chem 1998, 33 (12), 957-967. 
54. Matralis, A. N.; Katselou, M. G.; Nikitakis, A.; Kourounakis, A. P., Novel benzoxazine 
and benzothiazine derivatives as multifunctional antihyperlipidemic agents. J. Med. 
Chem. 2011, 54 (15), 5583-5591. 
55. Matsumoto, Y.; Tsuzuki, R.; Matsuhisa, A.; Takayama, K.; Yoden, T.; Uchida, W.; 
Asano, M.; Fujita, S.; Yanagisawa, I.; Fujikura, T., Novel potassium channel activators: 
Synthesis and structure-activity relationship studies of 3, 4-dihydro-2H-1, 4-
benzoxazine derivatives. Chem. Pharm. Bull. 1996, 44 (1), 103-114. 
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 25                                         UKZN-2020 
 
56. Liu, Z.; Chen, Y., Efficient synthesis of 2, 3-dihydro-1, 4-benzoxazines via 
intramolecular copper-catalyzed O-arylation. Tetrahedron Lett. 2009, 50 (27), 3790-
3793. 
57. Albanese, D.; Landini, D.; Lupi, V.; Penso, M., Straightforward Synthesis of 2-
Substituted 3, 4-Dihydro-2 H-1, 4-benzoxazines under Solid− Liquid Phase Transfer 
Catalysis Conditions. Ind. Eng. Chem. Res. 2003, 42 (4), 680-686. 
58. Wang, C.; He, X.; Liu, X.; Shang, Y., DMAP-catalyzed cyclization of Schiff bases with 
α-halo ketones: Synthesis of 1, 4-benzoxazines. Synth. Commun. 2017, 47 (9), 878-885. 
59. Yew, W. W.; Chan, C. K.; Leung, C. C.; Chau, C. H.; Tam, C. M.; Wong, P. C.; Lee, J., 
Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant 
tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003, 
124 (4), 1476-1481. 
60. Marra, F.; Marra, C. A.; Moadebi, S.; Shi, P.; Elwood, R. K.; Stark, G.; FitzGerald, J. 
M., Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 
2005, 128 (3), 1406-1413. 
61. Li, X.; Liu, N.; Zhang, H.; Knudson, S. E.; Slayden, R. A.; Tonge, P. J., Synthesis and 
SAR studies of 1, 4-benzoxazine MenB inhibitors: Novel antibacterial agents against 
Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 2010, 20 (21), 6306-6309. 
62. Patil, P. K.; Jagdale, A., Quinazoline a scaffold with antimicrobial and anticonvulsant 
activity: Overview. World J. Pharm. Res. 2018, 8 (2), 440-449. 
63. Jafari, E.; Khajouei, M. R.; Hassanzadeh, F.; Hakimelahi, G. H.; Khodarahmi, G. A., 
Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial 
and cytotoxic activities. Res. Pharm. Sci 2016, 11 (1), 1-14. 
64. Gupta, T.; Rohilla, A.; Pathak, A.; Akhtar, M. J.; Haider, M. R.; Yar, M. S., Current 
perspectives on quinazolines with potent biological activities: A review. Synth. 
Commun. 2018, 48 (10), 1099-1127. 
65. Hameed, A.; Al-Rashida, M.; Uroos, M.; Ali, S. A.; Arshia; Ishtiaq, M.; Khan, K. M., 
Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent 
review (2011–2016). Expert Opin. Ther. Pat. 2018, 28 (4), 281-297. 
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 26                                         UKZN-2020 
 
66. Aniszewski, T., Chapter 2 - Alkaloid chemistry. In Alkaloids (Second Edition), 
Aniszewski, T., Ed. Elsevier: Boston, 2015; pp 99-193. 
67. Grieß, P., Ueber die Einwirkung des Cyans auf Anthranilsäure. Ber. Dtsch. Chem. Ges. 
1869, 2 (1), 415-418. 
68. Bischler, A.; Lang, M., Zur Kenntniss der Phenmiazinderivate. Ber. Dtsch. Chem. Ges. 
1895, 28 (1), 279-293. 
69. Connolly, D. J.; Cusack, D.; O'Sullivan, T. P.; Guiry, P. J., Synthesis of quinazolinones 
and quinazolines. Tetrahedron 2005, 61 (43), 10153-10202. 
70. Brullo, C.; Rocca, M.; Fossa, P.; Cichero, E.; Barocelli, E.; Ballabeni, V.; Flammini, L.; 
Giorgio, C.; Saccani, F.; Domenichini, G.; Bruno, O., Synthesis of new 5,6-
dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic 
activities evaluation. Bioorg. Med. Chem. Lett. 2012, 22 (2), 1125-1129. 
71. Ghannoum, M.; Abu Elteen, K.; el-Rayyes, N. R., Antimicrobial activity of some 2-
aminopyrimidines. Microbios 1989, 60 (242), 23-33. 
72. Habib, O. M. O.; Hassan, H. M.; El-Mekabaty, A., Novel quinazolinone derivatives: 
synthesis and antimicrobial activity. Med. Chem. Res. 2013, 22 (2), 507-519. 
73. Cao, S.-L.; Feng, Y.-P.; Jiang, Y.-Y.; Liu, S.-Y.; Ding, G.-Y.; Li, R.-T., Synthesis and 
in vitro antitumor activity of 4(3H)-quinazolinone derivatives with dithiocarbamate side 
chains. Bioorg. Med. Chem. Lett. 2005, 15 (7), 1915-1917. 
74. Al-Obaid, A. M.; Abdel-Hamide, S. G.; El-Kashef, H. A.; Abdel-Aziz, A. A. M.; El-
Azab, A. S.; Al-Khamees, H. A.; El-Subbagh, H. I., Substituted quinazolines, part 3. 
Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-
4(3H)-quinazolinone analogs. Eur. J. Med. Chem. 2009, 44 (6), 2379-2391. 
75. Marzaro, G.; Guiotto, A.; Chilin, A., Quinazoline derivatives as potential anticancer 
agents: a patent review (2007 – 2010). Expert Opin. Ther. Pat. 2012, 22 (3), 223-252. 
76. Aly, M. M.; Mohamed, Y. A.; El-Bayouki, K. A. M.; Basyouni, W. M.; Abbas, S. Y., 
Synthesis of some new 4(3H)-quinazolinone-2-carboxaldehyde thiosemicarbazones and 
their metal complexes and a study on their anticonvulsant, analgesic, cytotoxic and 
antimicrobial activities – Part-1. Eur. J. Med. Chem. 2010, 45 (8), 3365-3373. 
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 27                                         UKZN-2020 
 
77. Mohamed, M. S.; Kamel, M. M.; Kassem, E. M. M.; Abotaleb, N.; Abd El-moez, S. I.; 
Ahmed, M. F., Novel 6,8-dibromo-4(3H)quinazolinone derivatives of anti-bacterial and 
anti-fungal activities. Eur. J. Med. Chem. 2010, 45 (8), 3311-3319. 
78. Kuneš, J.; Bažant, J.; Pour, M.; Waisser, K.; Šlosárek, M.; Janota, J., Quinazoline 
derivatives with antitubercular activity. Farmaco 2000, 55 (11), 725-729. 
79. Harbut, M. B.; Yang, B.; Liu, R.; Yano, T.; Vilchèze, C.; Cheng, B.; Lockner, J.; Guo, 
H.; Yu, C.; Franzblau, S. G., Small molecules targeting mycobacterium tuberculosis 
type II NADH dehydrogenase exhibit antimycobacterial activity. Angew. Chem. 2018, 
130 (13), 3536-3540. 
80. Maurya, H. K.; Verma, R.; Alam, S.; Pandey, S.; Pathak, V.; Sharma, S.; Srivastava, K. 
K.; Negi, A. S.; Gupta, A., Studies on substituted benzo[h]quinazolines, 
benzo[g]indazoles, pyrazoles, 2,6-diarylpyridines as anti-tubercular agents. Bioorg. 
Med. Chem. Lett. 2013, 23 (21), 5844-5849. 
81. Anette, W.; Jan, B., Recent Developments in the Field of Quinazoline Chemistry. Curr. 
Org. Chem. 2003, 7 (7), 659-677. 
82. Selvam, T. P.; Sivakumar, A.; Prabhu, P. P., Design and synthesis of quinazoline 
carboxylates against Gram-positive, Gram-negative, fungal pathogenic strains, and 
Mycobacterium tuberculosis. J. Pharm. Bioallied Sci. 2014, 6 (4), 278-284. 
83. Pandit, U.; Dodiya, A., Synthesis and antitubercular activity of novel pyrazole–
quinazolinone hybrid analogs. Med. Chem. Res. 2013, 22 (7), 3364-3371. 
84. Shah, P.; Westwell, A. D., The role of fluorine in medicinal chemistry. J. Enzyme Inhib. 
Med. Chem. 2007, 22 (5), 527-540. 
85. Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V. A.; Izawa, 
K.; Liu, H., Next Generation of Fluorine-Containing Pharmaceuticals, Compounds 
Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New 
Structural Trends and Therapeutic Areas. Chem. Rev. 2016, 116 (2), 422-518. 
86. Mei, H.; Han, J.; Fustero, S.; Medio-Simon, M.; Sedgwick, D. M.; Santi, C.; Ruzziconi, 
R.; Soloshonok, V. A., Fluorine-Containing Drugs Approved by the FDA in 2018. 
Chem.: Eur. J. 2019, 25 (51), 11797-11819. 
                                                                                                                                                     Chapter 1 
Narva Deshwar Kushwaha 28                                         UKZN-2020 
 
87. Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelly, D. J.; Meanwell, N. A., Applications 
of Fluorine in Medicinal Chemistry. J. Med. Chem. 2015, 58 (21), 8315-8359. 
88. Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, 
S.; Soloshonok, V. A.; Liu, H., Fluorine in Pharmaceutical Industry: Fluorine-
Containing Drugs Introduced to the Market in the Last Decade (2001–2011). Chem. 
Rev. 2014, 114 (4), 2432-2506. 
 
                                                                                                                                                     Chapter 2 
Narva Deshwar Kushwaha 29                                         UKZN-2020 
 
CHAPTER 2 
One-pot, multicomponent, diastereoselective, green synthesis of 3,4-dihydro-2H-
benzo[b][1,4]oxazine analogues 
Narva Deshwar Kushwaha, Babita Kushwaha, Rajshekhar Karpoormath,* Mavela 
Cleopus Mahlalela, Suraj Raosaheb Shinde 
Department of Pharmaceutical Chemistry, Discipline of Pharmaceutical Sciences, College of 
Health Sciences, University of KwaZulu-Natal (Westville), Durban-4000, South Africa 
 Graphical Abstract 
 
 
 
  
 
✓ Catalyst-free 
✓ Hazardous solvent free 
✓ Green approach 
✓ One-pot operation 
✓ Mild condition 
✓ Diastereoselective 
✓ Wide substrate scope 
 
 
                                                                                                                                                     Chapter 2 
Narva Deshwar Kushwaha 30                                         UKZN-2020 
 
Abstract  
A novel green and efficient catalyst-free, the mild one-pot, multicomponent synthetic strategy 
has been developed to construct substituted 3,4-dihydro-2H-benzo[b][1,4]oxazine. This reaction 
proceeds via in-situ formation of Schiff-base followed by base mediated alkylation with 
phenacyl bromide/substituted phenacyl bromide, finally leading to intramolecular cyclization to 
give a mixture of diastereomers with excellent diastereoselectivity (up to dr = 99:1), which were 
isolated as single diastereomer in moderate to excellent yields (41-92%). Besides, this new 
versatile methodology provides a wide scope for the synthesis of different functionally 
substituted benzoxazine scaffolds and can be further exploited as building blocks for the 
synthesis of multifaceted molecular structures, especially for pharmaceutical applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords 
1, 4-benzoxazine, Diastereoselective, Green, one-pot, multicomponent synthesis. 
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1. Introduction  
Benzoxazines are important heterocyclic scaffolds known for their extensive pharmacological 
and biological significance.1-4 It is well documented that benzoxazine moiety has been used as a 
building block in developing new pharmaceutical lead compounds, which have displayed wide 
range for pharmaceutical applications such as neuroprotective agents,5, 6 antidiabetic,7 
antiarrhythmics against ischemia-reperfusion injury,8 calcium antagonist,9 potassium channel 
modulators,10 and antihyperlipidemic agents11etc. The medicinal significance of benzoxazine 
skeleton is further validated by its presence in several marketed pharmaceutical drugs1-4, 12-14 as 
displayed in Figure 1. Undoubtedly one of the most well-known and noteworthy marketed drug 
containing benzoxazine heterocycle as its core moiety is levofloxacin (Figure 1). It is an FDA 
approved potent antibiotic for the treatment and management of various human diseases such as 
pneumonia, acute bacterial sinusitis, urinary tract infections and acute pyelonephritis.15, 16 In 
addition, 1,4-benzoxazine scaffold has also found its application in agricultural industry in 
developing potential herbicides17 (Figure 1).  
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Figure 1: Some important marketed pharmaceuticals and agrochemicals containing 1, 4-
benzoxazine as core moiety. 
Further, 1, 4-benzoxazine is also widely used as a building block for the synthesis of more 
complex molecular structures, active pharmaceutical ingredients, herbicides and pesticides.17, 18 
Thus, have attracted considerable intrest of chemists in designing and developing new greener 
synthetic strategies to construct different functionally substituted 1,4-benzoxazine scaffolds. 
The previous reported methods used multistep synthetic approaches for the synthesis of 1,4-
benzoxazine moiety (Scheme 1) such as a) cyclocondensation of amino phenols with α-
halogeno acyl bromides futher reduction of carbonyl with BH3, b) alkylation of o-nitrophenol 
with haloester followed by reductive cyclization,19 c) intramolecular copper-catalysed O-
arylation of β-aminoalcohols20 and d) epoxide ring opening with O-halosulfonamides and then 
cyclization was carried out to render 1,4 benzoxazine moieties.21 and e) Recently, in 2018 
Abhijit Mall et al. reported an efficient strategy for the synthesis of 3,4-dihydro 1,4 benzoxazine 
derivatives via Lewis acid catalysed SN2 type ring opening of activated aziridine with 2-
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halophenol followed by Cu(I)-catalysed cyclization.22 However, all of the above mentioned 
multistep methods/procedures had drawbacks such as high temperature, long reaction time, low 
yield, lack of diastereomer selectivity, use of expensive catalyst and hazardous solvents, non-
eco-friendly and most importantly the method were not versatile enough to synthesize 
differentially substituted 1,4 benzoxazine. Hence, an alternate, efficient route of synthesis was 
needed. Scheme 1 presents the previously reported methods (a-e) and our present work (f).  
Keeping in mind the shortcomings of the previously reported methods, we envisaged to develop 
a simple, yet efficient, low cost, multicomponent, one pot, catalyst-free, green alternative 
method to synthesize 1,4-benzoxazine skeleton with diverse functionality and 
diastereoselectivity. The reaction proceeds via in situ formation of Schiff base, followed by mild 
base mediated O-alkylation and finally intramolecular cyclization to yield a mixture of 
diastereomers with excellent diastereoselectivity, which were isolated as single diastereomer in 
moderate to excellent yields (41-92%).  
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Scheme 1: a-e) Previous work for the synthesis of 3,4-dihydro-2H-benzo[b][1,4]oxazine, f) 
present work: One-pot, multicomponent, catalyst-free, diastereospecific, green approach 
(K2CO3/EtOH/ rt/7 h) for the synthesis of 3,4-dihydro-2H-benzo[b][1,4]oxazine. 
2. Results & Discussion  
Our one pot study commenced by reacting 2-amino-4-chlorophenol, aldehydes and alpha 
bromoketones in the presence of mild base Na2CO3, in DMF at 120°C for 5 h. The progress of 
the reaction was monitored by TLC and it was observed that the reaction was not clean, had 
several spots including that of starting material. Thus, indicating that the reaction did not go to 
completion. In order to obtain the desired product with improved yields and diastereoselectivity, 
further optimization of the reaction was initiated by changing various reaction parameters 
including base, temperature and solvents as shown in Table 1. Thus, we decided to first start by 
screening several bases (organic and inorganic) and it was observed that the use of K2CO3 led to 
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the completion of the reaction with slight improved yield of 47%, (Table 1, entry2). However, 
the reaction was not clean, and the TLC displayed several spots. Further solvent screening was 
performed, and it was observed that ethanol resulted in improved yield (56%) at 90°C (Table 1, 
entry 3), but the reaction was still not clean. From these results we believed that higher 
temperature could be responsible for the formation of undesired side products. In order to 
improve the yield as well as to have a clean reaction, the reaction was carried out at lower 
temperature (60°C) in ethanol, K2CO3 for 5 h, which resulted in significantly improved yield of 
68% (Table 1, entry 4). Encouraged by these results we then decided to perform this reaction at 
room temperature (rt) and it was noted that after for 5 hours an intense single spot of the desired 
product was observed, but still the reaction was incomplete. Thus, the reaction was further 
continued for 7 h, resulting in a clean, single spot of the corresponding cyclic product 4 with 
excellent cis-diastereoselectivity, which was isolated with a significant improved yield of 91% 
(Table 1, entry 5). Its configuration was determined by 1H-1H NOESY analysis.23 Hence, the 
best optimized reaction conditions for the synthesis of differently functionalized 1,4-
benzoxazines was K2CO3 in ethanol at room temperature (rt) for 7 h (Table 1, entry 5).  
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Table 1. Optimization of the Reaction Conditionsa. 
 
Entry Base Solvent Time (h) Temp (°C) Yield of 4 (%)b,c 
1. Na2CO3 DMF 5 120 43 
2. K2CO3 DMF 5 120 47 
3. K2CO3 EtOH 5 90 56 
4. K2CO3 EtOH 5 60 68 
5. K2CO3 EtOH 7 rt 91 
6. Na2CO3 EtOH 7 rt 51 
7. Cs2CO3 EtOH 7 rt 86 
8. NaOH EtOH 7 rt 45 
9. TEA EtOH 7 rt 48 
10. DIPEA EtOH 7 rt 52 
11. NaHCO3 EtOH 7 rt Trace 
12. K2CO3 MeOH 7 rt 84 
13. K2CO3 ACN 7 rt 64 
14. K2CO3 Acetone 7 rt 49 
15. K2CO3 Dioxane 7 rt 60 
16. K2CO3 THF 7 rt 57 
17. K2CO3 DMF 7 rt 52 
18. K2CO3 DCM 7 rt Trace 
19. K2CO3 H2O 7 rt Trace 
20. K2CO3 Toluene 7 rt Trace 
aReaction conditions: 1 (1 equiv), 2 (1 equiv), 3a (1 equiv), base (1.5 equiv), solvent (2 mL). 
bDiastereomeric ratio of 4 from the 1H NMR of crude reaction mixture was >5:1 in all reactions. 
cIsolated yield of major diastereomer. 
To expand the scope of this protocol, aliphatic and various substituted aryl/heteroaryl aldehydes 
(2) possessing both electron donating (-CH3, -OCH3) and withdrawing groups (-NO2, -Cl, -Br, -
F) were reacted with chloro, methyl, and nitro substituted 2-aminophenols (1) and phenacyl 
bromide (3a) under optimized reaction condition. The chloro and methyl substituted 2-
aminophenol gave excellent results yielding desired product as a mixture of diastereomers 
resepectively. These mixtures were further purified and isolated as diastereomerically pure 
compounds 4-19 and 21-22 (Table 2) in moderate to excellent yields (62-91%). However, no 
desired product was obtained with nitro-substituted 2-aminophenol, only O-alkylated 
intermediate was formed, which could be attributed to the strong ring deactivating aspects of 
meta nitro group with respect to amine (NH2). Furthermore, All the substituted aryl/hetroaryl 
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aldehydes gave admirable yields (62-91%), while alicylic aldehyde (compound 20) presented 
relatively lower yield 41%. Further in the case of linear aliphatic aldehyde, the diastereomeric 
mixtures (combined yield 86%; dr = 3:2) could not be separated due to indistinguishable Rf 
difference (compound 23). All the synthesized derivatives were well-characterized by IR and 
NMR. In addition, it was observed that halo and nitro substituted aryl aldehydes were well 
tolerated and their corresponding desired products (5, 6, 9a, 10, 12, 13a, 16, 17 and 22) were 
obtained in good to excellent yields (62-88%). In all the above reactions the major 
diastereomeric product was isolated in high yields, which provided the scope for further 
functionalization and their applications as building blocks in pharmaceuticals.  
Remarkably, in most of the cases (4-6, 8, 10, 12, 14-19 and 22) the major diastereomers 
precipitated from the reaction mixtures, which was filtered, washed with water and n-pentane to 
remove impurities, followed by drying under vacuum. However, in the case of 9, both the 
diastereomeric mixtures (major and minor) precipitated, which were then separated as 9a and 9b 
by using combi-flash column chromatography. However, in the case of 7, 11a, 11b, 13a, 13b, 
20 21 and 23 no precipitation of the product was observed, hence the crude reaction mixture 
was concentrated and diluted with water and then extracted with ethyl acetate. These 
diastereomers were then purified and separated using combi-flash column chromatography. 
Structures of compound 9b, 15 and 17 were further confirmed by single crystal X-ray analysis 
(See appendix 1), and the relative configuration of other products were deduced by analogy. 
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Table 2. Substrate scope of aldehydes with substituted 2-aminophenola.  
 
 
aReaction conditions: Substituted 2-aminophenol [(1);1 equiv], substituted aldehydes [(2);1 
equiv], phenacyl bromides [(3a);1 equiv], K2CO3 (1.5 equiv), EtOH (2 mL). bIsolated yields of 
major diastereomer. cIsolated yield of minor diastereomer. dDiastereomeric ratios determined by 
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1H NMR of the crude reaction mixture. eIsolated combined yield of diastereomeric mixture (cis 
and trans). 
Next to widen the scope and versatility of this new methodology, substituted phenacyl bromide 
(3) was treated with 2-amino-4-chlorophenol (1) and various substituted aryl/hetero aryl 
aldehydes (2) under optimized condition to obtain corresponding substituted 1, 4-benzoxazine 
analogues in good to excellent yields as summarised in Table 3. The electron donating groups 
at ortho/meta/para position of benzaldehyde resulted in desired products (24, 27, 31 and 33), 
respectively with excellent yields (79-90%) and diastereoselectivity, while the electron-
withdrawing groups comparatively gave slightly lower yields (69-76%) and less 
diastereoselectivity (25, 26, 30a and 32). In addition, we had performed a reaction with ethyl α-
bromo acetate, but the reaction did not go to completion and resulted only in the formation of an 
intermediate compound, which did not undergo intramolecular cyclization to yield the desired 
product. 
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Table 3. Substrate scope of aldehyde with substituted phenacyl bromidea.  
 
 
aReaction conditions: 2-amino-4-chlorophenol [(1);1 equiv], substituted aldehydes [(2);1 equiv], 
substituted phenacyl bromides [(3a);1 equiv], K2CO3 (1.5 equiv), EtOH (2 mL).bIsolated yields 
of major diastereomer. cIsolated yield of minor diastereomer. dDiastereomeric ratios have been 
determined by 1H NMR analysis of the crude reaction mixture. 
A plausible mechanism as outlined in Scheme 2 was proposed on the basis of our experimental 
observations and from the previously reported literature.24-25 The reaction proceeds via the 
nucleophilic attack by the amine of I (amino phenol) on the carbonyl carbon of the aldehyde (II) 
leading to the formation the intermediate III, which further undergoes proton shift, followed by 
dehydration to give a Schiff base (V). Further, the in-situ reaction proceeds via base mediated 
SN2 type substitution reaction, wherein the hydroxyl group on the Schiff base (V) acts as a 
nucleophile and attacks the α-carbon of the phenacyl bromide (VI) generating a corresponding 
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O-alkylated intermediate (VII). The acidic proton of VII is abstracted by the base K2CO3 
resulting in the generation of a carbanion VIII or IX (Keto-enol tautomer), which further 
undergoes base mediated intramolecular cyclization to yield respective 1,4-benzoxazines (X). 
To validate the plausible mechanism, both the key intermediates V and VII were isolated and 
confirmed by 1H and 13C NMR (See Appendix 1). Thus, confirming the plausible mechanism as 
presented in scheme 2. 
 
Scheme 2: Plausible reaction pathway via insitu formation of the intermediates V and VII (as 
highlighted), which were isolated and charecterized. 
3. Conclusion 
In conclusion, we have developed a simple, yet efficient one-pot, multicomponent, green, 
catalyst-free, and diastereoselective synthesis of 1,4-benzoxazines in modrate to excellent 
yields. This one-pot, in-situ reaction proceeds by the formation of a Schiff base followed by 
base mediated O-alkylation with the phenacyl bromide and finally catalyst free intramolecular 
cyclization. Further, this versatile novel methodology provides a wide scope for the synthesis of 
differentially substituted/functionalised 1,4-benzoxazine analogues, which can be exploited by 
the researchers in academia, pharmaceutical and agrochemical industries in developing new 
building blocks or for the synthesis of new active pharmaceutical ingredients (API’s), drugs and 
pesticides. 
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4. Experimental  
4.1. General consideration 
All the fine chemicals, reagents and solvents were purchased from Sigma Aldrich and Merck 
and were used without further purification unless otherwise stated. The progress of the reactions 
and the purity of the compounds were monitored by thin-layer chromatography (TLC) on pre-
coated silica gel plates procured from E. Merck and Co. (Darmstadt, Germany) visualized by 
UV lamp (254 or 365 nm). Purification was performed by using combi-flash (CombiFlash® 
NextGen 300+) column chromatography. The melting points of the synthesized compounds 
have been determined and uncorrected using a digital Stuart SMP10 melting point Apparatus. 
The Fourier transform infrared (FTIR) spectra were recorded in the spectral range of 400-4000 
cm-1 on a Bruker Alpha FT-IR spectrometer using the ATR technique. The NMR spectra (1H & 
13C) were recorded using CDCl3 and DMSO-d6 on Bruker AVANCE III 400 and 600 MHz 
spectrometer. Chemical shifts were determined relative to internal standard TMS at δ 0.0 parts 
per million (ppm) and the coupling constants were reported in Hertz. The multiplicities of the 
NMR resonances were abbreviated as s (singlet), d (doublet), dd (doublet of doublet), t (triplet), 
q (quartet), m (multiplet) and brs (broad singlet). Elemental analysis was performed on Vario 
EL cube instrument. High resolution mass spectrometry (HRMS) in positive-ion mode. X-ray 
crystallography analysis was performed on Bruker SMART APEX II, X-ray diffractometer.  
4.2. Chemistry 
4.2.1. Synthesis and Spectral characterization of intermediate compounds (V and VII); 
4.2.1.1. Synthesis of (E)-4-chloro-2-((4-chlorobenzylidene)amino)phenol (V); 
 
A mixture of 2-amino-4-chlorophenol (0.2 g, 1 equiv) and 4-chlorobenzaldehyde (1 equiv) in 
ethanol (2 mL) was stirred for 1 h at room temperature, precipitate was formed filtered and 
washed with pentane to afford pure title Schiff base intermediate. 1H NMR (400 MHz, CDCl3, 
25°C) δ 8.60 (s, 1H), 7.84 (d, J = 8.30 Hz, 2H), 7.46 (d, J = 8.40 Hz, 2H), 7.27 – 7.25 (m, 1H), 
7.15 (dd, J = 8.66 Hz, J = 2.35 Hz, 1H), 7.05 (s, 1H), 6.94 (d, J = 8.74 Hz, 1H). 13C{1H} NMR 
(100 MHz, CDCl3, 25°C) δ 156.9, 151.0, 138.3, 136.0, 134.0, 130.2, 129.4, 128.9, 125.2, 
116.34, 116.31. 
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4.2.1.2. Synthesis of (E)-2-(4-chloro-2-((4-chlorobenzylidene)amino)phenoxy)-1-phenylethan-1-
one (VII); 
 
To the solution of (E)-4-chloro-2-((4-chlorobenzylidene)amino)phenol (0.2 g, 1 equiv), in 
ethanol (2 mL), potassium carbonate (1.5 equiv) and phenacyl bromide (1 equiv) were added. 
The resultant mixture was stirred for 30 min at ambient temperature then diluted with water and 
extracted with ethyl acetate. The organic phase was dried over anhydrous Na2SO4 and 
evaporated under vaccum to get crude intermediate which was purified by column 
chromatography to afford solid title intermediate. 1H NMR (400 MHz, CDCl3, 25°C) δ  8.59 (s, 
1H), 7.97 (d, J = 7.53 Hz, 2H), 7.83 (d, J = 8.37 Hz, 2H), 7.59 (t, J = 7.37 Hz, 1H), 7.49 – 7.44 
(m, 3H), 7.25 – 7.24 (m, 1H), 7.14 (dd, J = 8.65 Hz, J = 2.05 Hz, 1H), 7.04 (s, 1H), 6.92 (d, J = 
8.65 Hz, 1H), 4.44 (s, 2H). 13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 191.4, 156.9, 151.0, 
138.3, 136.0, 134.1, 134.09, 134.03, 131.0, 130.2, 129.6, 129.4, 129.07, 129.01, 128.9, 126.7, 
125.2, 116.3, 31.0. 
4.2.2. General procedure A for the synthesis of compounds (4-6, 8, 10, 12, 14-19, 22, 24-29 
and 31-36); 
A mixture of substituted 2-aminophenol (0.2 g, 1 equiv) and corresponding aldehydes (1 equiv) 
in ethanol (2 mL) was stirred for 1 h at room temperature, then potassium carbonate (1.5 equiv) 
and phenacyl bromide/substituted phenacyl bromide (1 equiv) were added and further continued 
with the stirring for 6 h at ambient temperature. The solid precipitate was formed in reaction 
mixture which was directly filtered and washed with water followed by n-pentane to afford pure 
solid of title products as major diastereomer. 
4.2.3. General procedure B for the synthesis of compounds (7, 9a-b, 11a-b, 13a-b, 20, 21, 23 
and 30a-b); 
A mixture of substituted 2-aminophenol (0.2 g, 1 equiv) and corresponding aldehydes (1 equiv) 
in ethanol (2 mL) was stirred for 1 h at room temperature, then potassium carbonate (1.5 equiv) 
and phenacyl bromide/substituted phenacyl bromide (1 equiv) were added and continued the 
stirring for 6 h at ambient temperature. The solvent was removed under reduced pressure, 
diluted with water and extracted with ethyl acetate (3 x 10 mL). The combined organic phase 
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was dried over anhydrous Na2SO4 and evaporated under reduced pressure to afford a mixture 
of two diastereomers (major and minor). The mixtures were separated by combi flash column 
chromatography using EtOAc/Hexane as an eluent to afford title products. 
4.2.2.1. (6-Chloro-3-(2,3-dimethoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (4); 
 
Off white solid, (521 mg, 91% yield). mp: 188-190°C; FTIR (ATR, Vmax, cm-1): 3417 (N-H str.), 
2971 (Ar-H str.), 1683 (C=O str.), 1508 (Ar C=C str.), 1269 (C-N str.), 1062 (C-O-C str.), 685 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ 8.07 (d, J = 8.12 Hz, 2H), 7.58 (t, J = 7.22 Hz, 
1H), 7.50 – 7.44 (m, 2H), 6.97 (t, J = 7.42 Hz, 1H), 6.86 (d, J = 7.84 Hz, 2H), 6.75 (d, J = 8.04 
Hz, 1H), 6.63 – 6.61 (m, 2H), 5.66 (d, J = 2.91 Hz, 1H), 5.24 (t, J = 3.39 Hz, 1H), 4.24 (s, 1H), 
3.88 (s, 3H), 3.87 (s, 3H).13C{1H} NMR (100 MHz, CDCl3,25°C) δ 195.1, 152.4, 145.8, 141.2, 
134.6, 133.8, 133.5, 133.3, 128.9, 128.5, 126.5, 119.2, 118.5, 117.5, 114.2, 112.3, 78.1, 60.5, 
55.8, 49.4.Anal.Calcd for C23H20ClNO4: C, 67.40; H, 4.92; N, 3.42; O, 15.61. Found: C, 67.16; 
H, 4.90; N, 3.60; O, 18.67. 
4.2.2.2. (3-(2-Bromophenyl)-6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (5); 
 
Yellow solid, (504 mg, 84% yield). mp: 130-134°C; FTIR (ATR, Vmax, cm-1): 3409 (N-H str.), 
2938 (Ar-H str.), 1672 (C=O str.), 1496 (Ar C=C str.), 1292 (C-N str.), 1183 (C-O-C str.), 752 
(C-Cl str.), 690 (C-Br str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.99 (d, J = 7.79 Hz, 2H), 7.57 
- 7.53 (m, 2H), 7.43 – 7.36 (m, 3H), 7.28 (d, J = 7.52 Hz, 1H), 7.17 – 7.12 (m, 1H), 6.66 (d, J = 
2.32 Hz, 1H), 6.62 (d, J = 8.56 Hz, 1H), 6.53 (dd, J = 8.45 Hz, J = 2.39 Hz, 1H), 5.53 (dd, J = 
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4.60 Hz, J = 2.35 Hz, 1H), 5.50 (d, J = 2.40 Hz, 1H), 4.45 (d, J = 4.56 Hz, 1H). 13C{1H} NMR 
(100 MHz, CDCl3, 25°C) δ 195.62, 140.0, 139.6, 134.8, 133.7, 133.6, 133.1, 129.6, 129.2, 
129.1, 128.5, 128.0, 127.4, 122.3, 118.3, 114.5, 77.4, 53.2. Anal.Calcd for C21H15BrClNO2: C, 
58.83; H, 3.53; N, 3.27; O, 7.46. Found: C, 57.75; H, 3.51; N, 3.30; O, 9.70. 
 
4.2.2.3. (6-Chloro-3-(3,4-difluorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (6); 
 
Off white solid, (425 mg, 79% yield). mp: 140-144°C; FTIR (ATR, Vmax, cm-1): 3349 (N-H str.), 
2977 (Ar-H str.), 1681 (C=O str.), 1490 (Ar C=C str.), 1291 (C-N str.), 1116 (C-F str.), 1059 
(C-O-C str.), 692 (C-Cl str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 7.95 (d, J = 7.85 Hz, 2H), 
7.64 (t, J = 6.95 Hz, 1H), 7.53 – 7.45 (m, 3H), 7.40 – 7.33 (m, 1H), 7.22 – 7.20 (m, 1H), 6.87 
(d, J = 3.92 Hz, 1H), 6.71 – 6.69 (m, 2H), 6.50 (dd, J = 8.54 Hz, J = 2.43 Hz, 1H), 5.97 (d, J = 
3.57 Hz, 1H), 4.83 (t, J = 3.54 Hz, 1H). 13C{1H} NMR (100 MHz, DMSO-d6, 25°C) δ 194.8, 
150.4 – 147.9 (dd, JC-F= 246.20 Hz, JC-F = 12.64 Hz, 1C), 149.9 – 147.3 (dd, JC-F = 246.20 Hz, 
JC-F = 12.64 Hz, 1C), 140.6, 137.9 – 137.8 (d, JC-F= 8.38 Hz, 1C), 137.9, 134.52 – 134.50 (d, JC-
F = 2.98 Hz, 1C), 133.6, 128.7, 128.6, 125.1, 124.05 – 124.01 (d, JC-F = 3.42 Hz, 1C), 117.4 – 
117.2 (d, JC-F = 17.68 Hz, 1C), 117.1, 116.3, 116.1, 113.2, 77.3, 52.4. Anal.Calcd for 
C21H14ClF2NO2: C, 65.38; H, 3.66; N, 3.63; O, 8.29. Found: C, 66.52; H, 4.54; N, 3.73; O, 
10.91. 
4.2.3.1. (6-Chloro-3-(3-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (7); 
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Yellow solid, (438 mg, 73% yield). Rf  0.6 (6% ethyl acetate in hexane); mp 83-87°C; FTIR 
(ATR, Vmax, cm-1): 3349 (N-H str.), 3061 (Ar-H, str.), 1674 (C=O str.), 1492 (Ar C=C str.), 1254 
(C-N str.), 1160 (C-F str.); 1062 (C-O-C str.), 691 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 
25°C) δ 7.82 (s, 2H), 7.52 – 7.37 (m, 5H), 7.09 (s, 2H), 6.77 – 6.63 (m, 3H), 5.33 (s, 1H), 4.83 
(s, 1H), 4.45 (s, 1H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.7, 149.5, 141.1, 135.1, 
133.8, 133.7, 130.2, 128.8, 128.6, 127.1, 126.0, 121.7, 120.8, 120.1, 119.1, 118.6, 118.0, 114.7, 
78.3, 54.9. Anal.Calcd for C22H15ClF3NO3: C, 60.91; H, 3.49; N, 3.23; O, 11.06. Found: C, 
61.96; H, 3.54; N, 3.16; O, 14.11. 
4.2.2.4. (6-Chloro-3-(3,4-dimethoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (8); 
 
Off white solid, (424 mg, 74% yield). mp: 145-150°C; FTIR (ATR, Vmax, cm-1): 3350 (N-H str.), 
2973 (Ar-H str.), 1690 (C=O str.), 1491 (Ar C=C str.), 1246 (C-N str.), 1026 (C-O-C str.), 698 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ 7.81 (d, J = 7.87 Hz, 2H), 7.51 (t, J = 7.23 Hz, 
1H), 7.36 (t, J = 7.73 Hz,  2H), 6.87 (d, J = 8.21 Hz, 1H), 6.82 – 6.80 (m, 2H), 6.73 (d, J = 8.21 
Hz, 1H), 6.68 (d, J = 2.05 Hz, 1H), 6.63 (dd, J = 8.40 Hz, J = 2.13 Hz, 1H), 5.26 (d, J = 6.50 
Hz, 1H), 4.72 (d, J = 6.21 Hz, 1H), 4.20 (s, 1H), 3.80 (s, 3H), 3.78 ( s, 3H) .13C{1H} NMR (100 
MHz, CDCl3, 25°C) δ 194.9, 149.3, 149.2, 141.4, 135.6, 134.2, 133.7, 130.3, 128.9, 128.6, 
127.0, 120.1, 118.4, 117.9, 114.6, 111.4, 110.7, 78.9, 56.0, 55.4. Anal.Calcd for C23H20ClNO4: 
C, 67.40; H, 4.92; N, 3.42; O, 15.61. Found: C, 67.54; H, 5.12; N, 3.40; O, 19.47. 
4.2.3.2. (6-Chloro-3-(4-chlorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (9a); 
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Off white solid, (468 mg, 87% yield). Rf 0.45 (6% ethyl acetate in hexane); mp: 159-162°C; 
FTIR (ATR, Vmax, cm-1): 3407 (N-H str.), 2974 (Ar-H str.), 1687 (C=O str.), 1522 (Ar C=C str.), 
1205 (C-N str.), 691 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ 7.85 (d, J = 7.64 Hz, 2H), 
7.54 (t, J = 7.13 Hz, 1H), 7.39 (d, J = 7.63 Hz,  2H), 7.28 – 7.23 (m, 4H), 6.76 (d, J = 8.52 Hz, 
1H), 6.66 (d, J = 2.16 Hz, 1H), 6.61 (dd, J = 7.48 Hz, J = 2.35 Hz,  1H), 5.26 (d, J = 5.56 Hz, 
1H), 4.86 (d, J = 4.20 Hz, 1H), 4.22 (s, 1H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.6, 
141.2, 137.3, 135.2, 134.4, 133.9, 133.8, 129.1, 129.03, 129.0, 128.7, 127.2, 118.6, 118.0, 
114.7, 78.7, 54.5. Anal.Calcd for C21H15Cl2NO2: C, 65.64; H, 3.93; N, 3.65; O, 8.33. Found: C, 
64.20; H, 3.88; N, 3.66; O, 10.58. 
4.2.3.3. (6-Chloro-3-(4-chlorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (9b); 
 
Off white solid, (27 mg, 5% yield). Rf 0.4 (8% ethyl acetate in hexane); mp: 190-193°C; FTIR 
(ATR, Vmax, cm-1): 3341 (N-H str.), 2977 (Ar-H str.), 1688 (C=O str.), 1492 (Ar C=C str.), 1256 
(C-N str.), 1088 (C-O-C str.), 684 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.69 (d, J= 
7.46 Hz, 2H), 7.54 (t, J = 7.42 Hz, 1H), 7.38 (t, J = 7.74 Hz, 2H), 7.12 (d, J = 8.40 Hz, 2H), 
6.99 (d, J = 7.40 Hz, 2H), 6.93 (d, J = 8.12 Hz, 1H), 6.72 - 6.69 (m, 2H), 5.62 (d, J = 2.92 Hz, 
1H), 4.96 (t, J = 2.84 Hz, 1H), 4.38 (d, J = 1.93 Hz, 1H).13C{1H} NMR (100 MHz, CDCl3, 
40°C) δ 194.7, 141.5, 137.0, 135.9, 134.3, 133.8, 133.5, 128.9, 128.8, 128.7, 128.6, 127.6, 
118.8, 118.2, 114.6, 78.9, 55.7. Anal.Calcd for C21H15Cl2NO2: C, 65.64; H, 3.93; N, 3.65; O, 
8.33. Found: C, 65.49; H, 3.97; N, 3.71; O, 12.99.   
4.2.2.5. (3-(4-Bromophenyl)-6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (10); 
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Off white solid, (528 mg, 88% yield). mp: 118-122°C; FTIR (ATR, Vmax, cm-1): 3328 (N-H str.), 
2977 (Ar-H str.), 1672 (C=O str.), 1488 (Ar C=C str.), 1228 (C-N str.), 1063 (C-O-C str.), 689 
(C-Cl str.), 510 (C-Br str.); 1H NMR (400 MHz, CDCl3, 25°C) δ 7.85 (d, J = 8.38 Hz, 2H), 7.55 
(t, J = 7.46 Hz, 1H), 7.41 – 7.38 (m, 4H), 7.20 (d, J = 8.31 Hz, 2H), 6.76 (d, J = 8.68 Hz, 1H), 
6.67 – 6.66 (m, 1H), 6.61 (dd, J = 8.52 Hz, J = 1.97 Hz, 1H), 5.26 (d, J = 5.41 Hz, 1H), 4.83 (t, 
J = 3.06 Hz, 1H), 4.25 (s, 1H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.7, 141.2, 137.9, 
135.2, 134.0, 133.8, 132.1, 129.4, 129.1, 128.8, 127.2, 122.6, 118.7, 118.1, 114.8, 78.7, 54.6. 
Anal.Calcd for C21H15BrClNO2: C, 58.83; H, 3.53; N, 3.27; O, 7.46. Found: C, 58.75; H, 3.48; 
N, 3.35; O, 10.87. 
4.2.3.4. (6-Chloro-3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (11a); 
 
Yellow solid, (429 mg, 81% yield). Rf 0.4 (15% ethyl acetate in hexane); mp: 90-92°C; FTIR 
(ATR, Vmax, cm-1): 3340 (N-H str.), 2923 (Ar-H str.), 1669 (C=O str.), 1500 (Ar C=C str.), 1225 
(C-N str.), 1054(C-O-C str.), 692 (C-Cl str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 7.93 (d, J 
= 7.50 Hz,  2H), 7.62 (t, J = 7.34 Hz, 1H), 7.49 (t, J = 7.77 Hz, 2H), 7.29 (d, J = 8.58 Hz, 2H), 
6.85 (d, J = 8.60 Hz, 2H), 6.75 (d, J = 1.44 Hz, 1H), 6.72 (d, J = 8.52 Hz, 1H), 6.69 (d, J = 2.36 
Hz, 1H), 6.50 (dd, J = 8.46 Hz, J = 2.38 Hz, 1H), 5.83 (d, J = 4.28 Hz, 1H), 4.67 (t, J = 2.71 Hz, 
1H), 3.68 (s, 3H).13C{1H} NMR (100 MHz, DMSO-d6, 25°C) δ 195.0, 158.7, 140.9, 135.1, 
134.7, 133.6, 131.4, 128.7, 128.5, 128.4, 124.9, 116.9, 115.8, 113.8, 113.1, 77.6, 55.0, 53.1. 
Anal.Calcd for C22H18ClNO3: C, 69.57; H, 4.78; N, 3.69; O, 12.64. Found: C, 69.63; H, 4.94; N, 
3.72; O, 14.36. 
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4.2.3.5. (6-Chloro-3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (11b); 
  
Yellow solid, (22 mg, 4% yield). Rf 0.32 (18% ethyl acetate in hexane); mp:184-188°C; FTIR 
(ATR, Vmax, cm-1): 3349 (N-H str.), 2982 (Ar-H str.), 1686 (C=O str.), 1503 (Ar C=C str.), 1248 
(C-N str.), 1040 (C-O-C str.), 686 (C-Cl str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 7.67 (d, J 
= 7.35 Hz,  2H), 7.56 (t, J = 7.41 Hz,  1H), 7.40 (t, J = 7.71 Hz,  2H), 6.89 – 6.83 (m, 4H), 6.72 
(d, J = 2.50 Hz, 1H), 6.68 (d, J = 8.54 Hz, 2H),  6.55 (dd, J = 8.71 Hz, J = 2.85 Hz,  1H), 5.99 
(d, J = 3.22 Hz, 1H), 4.83 (t, J = 2.93 Hz, 1H), 3.62 (s, 3H).13C{1H} NMR (100 MHz, DMSO-
d6, 25°C) δ 195.3, 159.1, 141.5, 136.2, 136.1, 133.6, 130.9, 128.9, 128.8, 128.6, 125.6, 117.5, 
116.3, 113.8, 113.5, 77.6, 55.4, 54.4. Anal.Calcd for C22H18ClNO3: C, 69.57; H, 4.78; N, 3.69; 
O, 12.64. Found: C, 69.35; H, 4.94; N, 3.77; O, 14.07. 
4.2.2.6. (6-Chloro-3-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (12); 
 
Light yellow solid, (408 mg, 74% yield). mp 187-190°C; FTIR (ATR, Vmax, cm-1): 3334 (N-H 
str.), 2977 (Ar-H str.), 1685 (C=O str.), 1490 (Ar C=C str.), 1343 (Ar-NO2 Str.), 1222 (C-N str.), 
1057 (C-O-C str.), 685 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 40°C) δ 8.13 – 7.89 (m, 4H), 
7.53 – 7.41 (m, 5H), 6.70 – 6.61 (m, 3H), 5.32 (s, 1H), 5.10 (s, 1H), 4.36 (s, 1H).13C{1H} NMR 
(100 MHz, CDCl3, 40°C) δ 194.4, 148.0, 146.8, 140.9, 135.0, 134.1, 133.3, 129.1, 128.8, 128.5, 
127.6, 124.1, 119.2, 118.3, 115.1, 78.7, 54.4. Anal.Calcd for C21H15ClN2O4: C, 63.89; H, 3.83; 
N, 7.10; O, 16.21. Found: C, 63.18; H, 3.72; N, 7.11; O, 18.63. 
4.2.3.6. (6-Chloro-3-(3-fluorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (13a); 
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Off white solid, (318 mg, 62% yield). Rf 0.42 (6% ethyl acetate in hexane); mp: 177-180°C; 
FTIR (ATR, Vmax, cm-1): 3370 (N-H str.), 2976 (Ar-H str.), 1688 (C=O str.), 1490 (Ar C=C str.), 
1247 (C-N str.), 1191 (C-F str.), 1078 (C-O-C str.), 689 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 
25°C) δ 7.69 (dd, J = 7.24 Hz, J = 1.66 Hz, 2H), 7.52 (t, J = 7.59 Hz, 1H), 7.37 (t, J = 7.59 Hz, 
2H), 7.15 – 7.09 (m, 1H), 6.93 (d, J = 9.19 Hz, 1H), 6.88 – 6.84 (m, 2H), 6.80 – 6.76 (m, 1H), 
6.72 – 6.70 (m, 2H), 5.62 (d, J = 3.08 Hz, 1H), 4.98 (t, J = 3.98 Hz, 1H), 4.40 (d, J = 2.08 Hz, 
1H). 13C{1H} NMR (100 MHz, CDCl3, 40°C) δ 194.8, 164.1 – 161.7 (d, JC-F = 247.08 Hz, 1C), 
141.5, 141.0, 136.0, 133.7, 133.5, 130.2 – 130.1 (d, JC-F = 8.35 Hz, 1C), 128.7 – 128.6 (d, JC-F = 
6.61 Hz, 1C), 127.6, 123.2, 118.9, 118.3, 115.4, 115.2, 114.8 – 114.5 (d, JC-F = 22.33 Hz, 1C), 
114.7, 78.8, 55.8. HRMS (ESI-TOF) calcd for C21H16ClFNO2 [M + H]+ 368.0854, found 
368.1180. 
4.2.3.7. (6-Chloro-3-(3-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (13b); 
 
Yellow semi solid, (72 mg, 14% yield). Rf 0.35 (10% ethyl acetate in hexane); FTIR (ATR, 
Vmax, cm-1): 3337 (N-H str.), 3070 (Ar-H str.), 1685 (C=O str.), 1593 (Ar C=C str.), 1221 (C-N 
str.), 687 (C-Cl str.);  1H NMR (400 MHz, CDCl3, 25°C) δ 8.06 (d, J = 8.08 Hz, 2H), 7.74 (t, J = 
7.76 Hz, 1H), 7.59 (t, J = 8.41 Hz, 2H), 7.43 – 7.40 (m, 1H), 7.31 – 7.28 (m, 2H), 7.14 – 7.09 
(m, 1H), 6.96 (d, J = 8.53 Hz, 1H), 6.89 (d, J = 2.34 Hz, 1H), 6.81 (dd, J = 8.41, J = 2.22 Hz, 
1H), 5.54 (d, J = 5.05 Hz, 1H), 5.05 (d, J = 5.57 Hz, 1H), 4.67 (s, 1H). 13C{1H} NMR (100 
MHz, CDCl3, 25°C) δ 194.7, 164.1 – 161.7 (d, JC-F = 244.81 Hz, 1C), 141.5 - 141.4 (d, J = 7.26 
Hz, 1C), 141.0, 135.0, 133.8, 133.7, 130.4, 128.8 – 128.6, 128.3 127.0, 123.1, 118.3, 117.9, 
115.4 – 115.2 (d, JC-F = 21.09 Hz, 1C), 114.6, 78.4, 54.9. Anal.Calcd for C21H15ClFNO2: C, 
68.58; H, 4.11; Cl, 9.64; F, 5.17; N, 3.81; O, 8.70. Found: C, 66.97; H, 3.98; N, 3.80; O, 10.73. 
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4.2.2.7.  (6-Chloro-3-(3-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (14); 
 
Off white solid, (398 mg, 75% yield). mp: 177-180°C; FTIR (ATR, Vmax, cm-1): 3364 (N-H str.), 
2976 (Ar-H str.), 1687 (C=O str.), 1493 (Ar C=C str.), 1254 (C-N str.), 1054 (C-O-C str.), 690 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ 7.64 (d, J = 7.40 Hz, 2H), 7.48 (t, J = 7.40 Hz, 
1H), 7.32 (t, J = 7.76 Hz, 2H), 7.07 (t, J = 7.92 Hz, 1H), 6.91 (d, J = 9.24 Hz, 1H), 6.71 – 6.67 
(m, 4H), 6.58 (s, 1H), 5.66 (d, J = 3.16 Hz, 1H), 4.92 (t, J = 2.74 Hz, 1H), 4.34 (d, J = 1.4 Hz, 
1H), 3.59 (s, 3H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.84, 159.6, 141.5, 139.3, 136.0, 
133.9, 133.2, 129.6, 128.8, 126.9, 119.6, 118.6, 117.8, 114.4, 113.9, 112.9, 78.3, 56.0, 55.10. 
Anal.Calcd for C22H18ClNO3; C, 69.57; H, 4.78; N, 3.69; O, 12.64. Found: C, 68.66; H, 4.71; N, 
3.73; O, 15.16. 
4.2.2.8. (6-Chloro-3-(p-tolyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)(phenyl)methanone 
(15); 
 
Off white solid, (438 mg, 86% yield). mp: 177-180°C; FTIR (ATR, Vmax, cm-1): 3395 (N-H str.), 
2974 (Ar-H str.), 1689 (C=O str.), 1495 (Ar C=C str.), 1257 (C-N str.), 1057 (C-O-C str.), 684 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ 7.83 (d, J = 8.58 Hz, 2H), 7.50 (t, J = 7.40 Hz, 
1H), 7.36 (t, J = 7.75 Hz, 2H), 7.19 (d, J = 7.99 Hz, 2H), 7.06 (d, J = 7.96 Hz, 2H), 6.77 (d, J = 
8.48 Hz, 1H), 6.64 (d, J = 2.28 Hz, 1H), 6.60 (dd, J = 8.40 Hz, J = 2.36 Hz, 1H), 5.27 (d, J = 
5.88 Hz, 1H), 4.79 (d, J = 5.64 Hz, 1H), 4.19 (s, 1H), 2.26 (s, 3H).13C{1H} NMR (100 MHz, 
CDCl3, 25°C) δ 194.85, 141.2, 138.3, 135.3, 135.2, 134.0, 133.5, 129.5, 128.5, 127.3, 126.8, 
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118.2, 117.8, 114.4, 78.9, 54.9, 21.0. Anal.Calcd for C22H18ClNO2: C, 72.63; H, 4.99; N, 3.85; 
O, 8.79. Found: C, 72.22; H, 5.18; N, 3.92; O, 11.31. 
4.2.2.9. (6-Chloro-3-(3-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (16); 
 
Off white solid, (430 mg, 78% yield). mp:180-184°C; FTIR (ATR, Vmax, cm-1): 3324 (N-H str.), 
2976 (Ar-H str.), 1682 (C=O str.), 1490 (Ar C=C str.), 1356 (Ar-NO2 str.),  1249 (C-N str.), 
1058 (C-O-C str.), 681 (C-Cl str.); 1H NMR (600 MHz, CDCl3, 50°C) δ 8.02 (d, J = 8.10 Hz, 
1H), 7.90 (s, 1H), 7.74 (d, J = 7.68 Hz, 2H), 7.53 (t, J = 7.41 Hz, 1H), 7.49 (d, J = 7.74 Hz, 1H), 
7.40 – 7.34 (m, 3H), 6.95 (d, J = 8.16 Hz, 1H), 6.75 – 6.73 (m, 2H), 5.60 (d, J = 2.82 Hz, 1H), 
5.11 (t, J = 3.06 Hz, 1H), 4.46 (s, 1H).13C{1H} NMR (150 MHz, CDCl3, 50°C) δ 194.4, 148.4, 
141.4, 141.0, 135.8, 133.8, 133.6, 133.3, 129.7, 128.87, 128.84, 128.1, 123.2, 122.8, 119.2, 
118.5, 114.9, 78.9, 55.8. Anal.Calcd for C21H15ClN2O4: C, 63.89; H, 3.83; N, 7.10; O, 16.21. 
Found: C, 63.31; H, 3.79; N, 7.32; O, 17.98. 
4.2.2.10. (6-Chloro-3-(2-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (17); 
 
Green solid, (425 mg, 77% yield). mp: 189-191°C; FTIR (ATR, Vmax, cm-1): 3406 (N-H str.), 
2976 (Ar-H str.), 1673 (C=O str.), 1494 (Ar C=C str.), 1338 (Ar-NO2 str.),  1245 (C-N str.), 
1058 (C-O-C str.), 694 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  8.03 – 7.98 (m, 3H), 
7.59 (d, J = 4.11 Hz, 2H), 7.55 (d, J = 8.07 Hz,  1H), 7.48 – 7.46 (m, 1H), 7.44 – 7.40 (m, 2H), 
6.67 (d, J = 2.0 Hz, 1H), 6.59 (d, J = 8.51 Hz, 1H), 6.51 (dd, J = 8.60 Hz, J = 2.26 Hz,  1H), 
5.85 (d, J = 5.56 Hz, 1H), 5.58 (s, 1H), 4.58 (d, J = 5.44 Hz, 1H).13C{1H} NMR (100 MHz, 
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CDCl3, 25°C) δ 194.7, 147.7, 139.5, 137.1, 134.4, 133.8, 133.7, 133.6, 129.9, 129.2, 128.6, 
128.5, 127.7, 124.9, 118.4, 118.3, 114.6, 77.5, 49.8. Anal.Calcd for C21H15ClN2O4: C, 63.89; H, 
3.83; N, 7.10; O, 16.21. Found: C, 63.47; H, 3.79; N, 7.08; O, 16.76. 
4.2.2.11. (6-Chloro-3-(furan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (18); 
 
Brown solid, (398 mg, 84% yield). mp: 170-174°C; FTIR (ATR, Vmax, cm-1): 3364 (N-H str.), 
2976 (Ar-H str.), 1689 (C=O str.), 1497 (Ar C=C str.), 1262 (C-N str.), 1060 (C-O-C str.), 691 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.80 (d, J = 8.01 Hz, 2H), 7.55 (t, J = 7.31 Hz, 
1H), 7.42 (t, J = 7.64 Hz,  2H), 7.18 (s, 1H), 6.89 (d, J = 8.24 Hz, 1H),  6.71 – 6.69 (m,  2H), 
6.18 – 6.16 (m, 1H), 6.10 (d, J = 3.20 Hz,  1H), 5.63 (d, J = 2.48 Hz, 1H), 5.06 (s, 1H), 4.35 (s, 
1H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.7, 150.7, 142.1, 141.6, 135.5, 133.5, 133.0, 
128.7, 128.6, 127.1, 119.4, 118.1, 115.5, 110.6, 108.2, 77.8, 50.1.Anal.Calcd for C19H14ClNO3: 
C, 67.16; H, 4.15; N, 4.12; O, 14.13. Found: C, 70.97; H, 4.43; N, 4.42; O, 16.53. 
4.2.2.12. (6-Chloro-3-(thiophen-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (19); 
 
Off white solid, (358 mg, 72% yield). mp: 195-198°C; FTIR (ATR, Vmax, cm-1): 3366 (N-H str.), 
2976 (Ar-H str.), 1688 (C=O str.), 1496 (Ar C=C str.), 1226 (C-N str.), 1057 (C-O-C str.), 694 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.79 (d, J = 7.74 Hz, 2H), 7.55 (t, J = 7.34 Hz, 
1H), 7.41 (t, J = 7.64 Hz, 2H), 7.11 (d, J = 4.88 Hz, 1H), 6.94 (d, J = 8.52 Hz, 1H), 6.82 – 6.79 
(m, 2H), 6.73 – 6.71 (m, 1H), 6.67 (d, J = 1.80 Hz, 1H), 5.63 (d, J = 2.28 Hz, 1H), 5.29 (s, 1H), 
4.40 (s, 1H). 13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 141.5, 133.5, 133.0, 128.8, 128.6, 
127.5, 126.6, 126.1, 125.8, 119.3, 118.2, 115.3, 78.99, 51.80. The signals for the three aromatic 
quaternary carbons were not observed in the 13C NMR spectrum. Anal.Calcd for C19H14ClNO2S: 
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C, 64.13; H, 3.97; N, 3.94; O, 8.99; S, 9.01. Found: C, 63.34; H, 3.92; N, 4.02; O, 11.58; S, 
8.73. 
4.2.3.11. (6-Chloro-3-cyclohexyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)(phenyl)methanone 
(20); 
 
Off white solid, (205 mg, 41% yield). Rf 0.5 (5% ethyl acetate in hexane); mp: 110-115°C; 
FTIR (ATR, Vmax, cm-1): 3380 (N-H str.), 2923 (Ar-H str.), 1688 (C=O str.), 1497 (Ar C=C str.), 
1219 (C-N str.), 689 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  8.04 - 8.02 (m, 2H), 7.46 
– 7.42 (m, 4H), 7.09 (dd, J = 8.65 Hz, J = 2.22 Hz, 1H), 6.85 (d, J = 8.65 Hz, 1H), 5.41 (d, J = 
8.59 Hz, 1H),  3.75 – 3.71 (m, 1H), 1.90 – 1.83 (m, 2H), 1.74 - 1.67 (m, 1H), 1.53 - 1.49 (m, 
1H),  1.45 (d, J = 5.69 Hz, 1H), 1.27 -1.23 (m, 4H), 1.19 – 1.13 (m, 1H).13C{1H} NMR (100 
MHz, CDCl3, 25°C) δ 162.0, 143.4, 136.9, 134.9, 131.3, 128.6, 128.3, 127.8, 127.2, 126.9, 
116.9, 73.1, 70.7, 39.9, 29.7, 26.55, 26.51, 26.2, 25.5. HRMS (ESI-TOF) calcd for C21H23ClNO2 
[M + H]+ 356.1417, found 356.1786. 
4.2.3.12. (3-(2,3-Dimethoxyphenyl)-6-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (21); 
 
Yellow solid, (488 mg, 77% yield). Rf 0.32 (21% ethyl acetate in hexane); mp: 144-147°C; 
FTIR (ATR, Vmax, cm-1): 3356 (N-H str.), 3070 (Ar-H str.), 1689 (C=O str.), 1596 (Ar C=C str.), 
1206 (C-N str.), 1077 (C-O-C str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  8.08 (d, J = 7.91 Hz, 
2H), 7.56 (t, J = 7.11 Hz, 1H), 7.44 (t, J = 7.67 Hz, 2H), 6.98 – 6.91 (m, 2H), 6.84 (d, J = 7.67 
Hz, 1H), 6.74 (d, J = 7.79 Hz, 1H), 6.49 – 6.47 (m, 2H), 5.61 (d, J = 2.91 Hz, 1H), 5.24 (d, J = 
2.88 Hz, 1H), 4.12 (brs, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 2.23 (s, 3H). 13C{1H} NMR (100 MHz, 
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CDCl3, 25°C) δ 195.5, 152.4, 146.0, 140.6, 135.0, 134.3, 133.3, 132.1, 131.3, 128.9, 128.4, 
124.2, 119.6, 119.5, 116.4, 115.5, 112.1, 78.4, 60.5, 55.8, 49.7, 20.8. Anal.Calcd for C24H23NO4: 
C, 74.02; H, 5.95; N, 3.60; O, 16.43. Found: C, 74.11; H, 6.01; N, 3.66; O, 16.73. 
4.2.2.13. (3-(4-Chlorophenyl)-6-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)(phenyl)methanone (22); 
 
Off white solid, (490 mg, 83% yield). mp: 155-160°C; FTIR (ATR, Vmax, cm-1): 3399 (N-H str.), 
1687 (C=O str.), 1596 (Ar C=C str.), 1207 (C-N str.), 690 (C-Cl str.); 1H NMR (400 MHz, 
CDCl3, 25°C) δ  7.84 (d, J = 7.68 Hz, 2H), 7.49 (t, J = 7.24 Hz, 1H), 7.35 (t, J = 7.54 Hz, 2H), 
7.25 – 7.18 (m, 4H), 6.72 (d, J = 7.92 Hz, 1H), 7.47- 7.45 (m, 2H), 5.21 (d, J = 5.74 Hz, 1H), 
6.49 – 6.47 (m, 2H), 5.61 (d, J = 2.91 Hz, 1H), 5.24 (d, J = 2.88 Hz, 1H), 4.12 (brs, 1H), 4.80 
(d, J = 5.36 Hz, 1H), 4.06 (s, 1H), 2.20 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 
195.0, 140.5, 137.7, 135.3, 134.0, 133.6, 132.4, 131.8, 129.0, 128.9, 128.8, 128.5, 119.5, 116.7, 
115.6, 79.0, 54.93, 20.8. Anal.Calcd for C22H18ClNO2: C, 72.63; H, 4.99; N, 3.85; O, 8.79. 
Found: C, 71.74; H, 5.14; N, 3.96; O, 9.72. 
4.2.3.11. (6-chloro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)(phenyl)methanone (23, 
major diastereomer);  
 
Yellow liquid, (3:2 diastereomeric mixture, combined yield 344 mg, 86%). Rf 0.4 (3.9% ethyl 
acetate in hexane); 1H NMR (400 MHz, CDCl3, 25°C) δ 7.95 (d, J = 7.87 Hz, 2H), 7.49 – 7.47 
(m, 3H), 7.42 (d, J = 2.37 Hz, 1H), 7.12 – 7.09 (m, 1H), 6.91 (d, J = 8.46 Hz, 1H), 5.25 (d, J = 
6.56 Hz, 1H), 4.08 – 4.02 (m, 1H), 2.28 (s, 1H), 1.10 (d, J = 6.40 Hz, 3H). 13C{1H} NMR (100 
MHz, CDCl3, 25°C) δ 160.3, 136.0, 134.6, 134.1, 131.6, 129.0, 128.6, 127.4, 127.3, 127.1, 
116.7, 76.1, 66.5, 19.0 
4.2.2.14. (4-Bromophenyl)(6-chloro-3-(2,3-dimethoxyphenyl)-3,4-dihydro-2H-
benzo[b][1,4]oxazin-2-yl)methanone (24); 
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Reddish solid, (592 mg, 87% yield). mp: 160-162°C; FTIR (ATR, Vmax, cm-1): 3402 (N-H str.), 
2973 (Ar-H str.), 1691 (C=O str.), 1473 (Ar C=C str.), 1269 (C-N str.), 1060 (C-O-C str.); 1H 
NMR (400 MHz, CDCl3, 25°C) δ  7.92 (d, J = 8.45 Hz, 2H), 7.59 (d, J = 8.42 Hz, 2H),7.00 - 
6.96 (m, 1H), 6.87 - 6.84 (m, 2H), 6.73 (d, J = 8.80 Hz, 1H),  6.64 – 6.60 (m, 2H), 5.56 (d, J = 
2.67 Hz, 1H), 5.21 (t, J = 3.16 Hz, 1H), 4.24 (d, J = 3.07 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 
3H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.3, 152.4, 145.7, 140.9, 133.5, 133.4, 133.3, 
131.8, 130.4, 128.8, 126.7, 124.3, 119.2, 118.5, 117.6, 114.3, 112.4, 78.2, 60.6, 55.8, 49.4. 
Anal.Calcd for C23H19BrClNO4: C, 56.52; H, 3.92; N, 2.87; O, 13.09. Found: C, 56.30; H, 3.92; 
N, 3.08; O, 15.43. 
 
4.2.2.15. (4-Bromophenyl)(3-(4-bromophenyl)-6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-
2-yl)methanone (25); 
 
Yellow solid, (532 mg, 75% yield). mp: 143-146°C; FTIR (ATR, Vmax, cm-1): 3366 (N-H str.), 
2976 (Ar-H str.), 1674 (C=O str.), 1486 (Ar C=C str.), 1215 (C-N str.), 1061 (C-O-C str.), 768 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.74 (d, J = 8.18 Hz, 2H), 7.55 (d, J = 8.56 
Hz, 2H), 7.42 (d, J = 8.39 Hz, 2H), 7.20 (d, J = 8.38 Hz, 2H), 6.73 (d, J = 8.55 Hz, 1H),  6.67 
(d, J = 2.23 Hz, 1H), 6.61 (dd, J = 8.65 Hz, J = 2.37 Hz, 1H), 5.18 (d, J = 5.45 Hz, 1H), 4.86 
(dd, J = 5.32 Hz, J = 2.58 Hz, 1H), 4.24 (d, J = 1.88 Hz, 1H).13C{1H} NMR (100 MHz, CDCl3, 
25°C) δ 193.4, 140.8, 137.8, 133.8, 133.7, 132.15, 132.12, 130.5, 129.3, 129.2, 127.4, 122.6, 
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118.7, 118.1, 114.7, 78.9, 54.4. Anal.Calcd for C21H14Br2ClNO2: C, 49.69; H, 2.78; N, 2.76; O, 
6.30. Found: C, 49.17; H, 2.77; N, 2.81; O, 9.29. 
4.2.2.16. (4-Bromophenyl)(6-chloro-3-(4-chlorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-
2-yl)methanone (26); 
 
Yellow solid, (458 mg, 71% yield). mp: 138-140°C; FTIR (ATR, Vmax, cm-1): 3352 (N-H str.), 
2976 (Ar-H str.), 1663 (C=O str.), 1489 (Ar C=C str.), 1225 (C-N str.), 1063 (C-O-C str.), 676 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.74 (d, J = 8.67 Hz, 2H), 7.55 (d, J = 8.45 
Hz, 2H), 7.27 – 7.26 (m, 4H), 6.74 (d, J = 8.52 Hz, 1H), 6.67 (d, J = 2.31 Hz, 1H),  6.62 (dd, J = 
8.88 Hz, J = 2.36 Hz, 1H), 5.19  (d, J = 5.56 Hz,  1H), 4.87 (dd, J = 5.47 Hz, J = 2.66 Hz, 1H), 
4.23 (d, J = 2.66 Hz, 1H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 193.8, 140.8, 137.2, 134.5, 
133.8, 132.1, 130.5, 129.3, 129.2, 128.9, 127.4, 118.7, 118.1, 114.7, 78.9, 54.4. Anal.Calcd for 
C21H14BrCl2NO2: C, 54.46; H, 3.05; N, 3.02; O, 6.91. Found: C, 52.80; H, 2.99; N, 2.99; O, 
10.78. 
4.2.2.17. (4-Bromophenyl)(6-chloro-3-(3-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-
2-yl)methanone (27); 
 
Off white solid, (507 mg, 79% yield). mp: 170-174°C; FTIR (ATR, Vmax, cm-1): 3371 (N-H str.), 
2970 (Ar-H str.), 1686 (C=O str.), 1494 (Ar C=C str.), 1255 (C-N str.), 1054 (C-O-C str.), 695 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.46 – 7.41 (m, 4H), 7.09 (t, J = 7.61 Hz, 1H), 
6.88 (d, J = 8.88 Hz, 1H), 6.72 – 6.71 (m, 2H), 6.70 – 6.69 (m, 2H),  6.60 (t, J = 1.91 Hz, 1H),  
5.55 (d, J = 3.26 Hz, 1H), 4.91 (t, J = 2.81 Hz, 1H), 4.35 (d, J = 1.62 Hz, 1H), 3.62 (s, 
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3H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.6, 141.4, 139.4, 134.8, 133.9, 131.7, 130.0, 
129.9, 128.5, 127.2, 119.7, 118.8, 117.9, 114.6, 113.8, 113.3, 79.0, 56.1, 55.3. Anal.Calcd for 
C22H17BrClNO3: C, 57.60; H, 3.74; N, 3.05; O, 10.46. Found: C, 56.72; H, 3.70; N, 3.13; O, 
12.76.  
4.2.2.18.  (4-Bromophenyl)(6-chloro-3-(furan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)methanone (28); 
 
Off white solid, (422 mg, 72% yield). mp: 150-152°C; FTIR (ATR, Vmax, cm-1): 3365 (N-H str.), 
2976 (Ar-H str.), 1691(C=O str.), 1490 (Ar C=C str.), 1241 (C-N str.), 1059 (C-O-C str.), 736 
(C-Cl str.); 1H NMR (600 MHz, CDCl3, 40°C) δ  7.66 (d, J = 8.36 Hz, 2H), 7.54 (d, J = 8.33 
Hz, 2H), 7.17 (s, 1H), 6.85 (d, J = 8.37 Hz, 1H), 6.71 – 6.69 (m, 2H), 6.17 (s, 1H), 6.10 (d, J = 
2.82 Hz, 1H), 5.49 (d, J = 2.28 Hz, 1H), 5.05 (d, J = 2.99 Hz, 1H), 4.33 (s, 1H). 13C{1H} NMR 
(150 MHz, CDCl3, 40°C) δ 194.3, 150.8, 142.2, 141.5, 134.4, 133.0, 131.9, 130.3, 128.7, 127.3, 
119.5, 118.0, 115.6, 110.7, 108.3, 78.4, 50.2. Anal.Calcd for C19H13BrClNO3: C, 54.51; H, 3.13; 
N, 3.35; O, 11.46. Found: C, 52.68; H, 3.09; N, 3.30; O, 14.04. 
4.2.2.19. (4-Bromophenyl)(6-chloro-3-(thiophen-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)methanone (29); 
 
Off white solid, (395 mg, 65% yield). mp: 150-152°C; FTIR (ATR, Vmax, cm-1): 3348 (N-H str.), 
2976 (Ar-H str.), 1679 (C=O str.), 1492 (Ar C=C str.), 1233 (C-N str.), 1060 (C-O-C str.), 711 
(C-Cl str.); 1H NMR (600 MHz, CDCl3, 40°C) δ  7.75 (d, J = 8.0 Hz, 2H), 7.55 (d, J = 8.02, Hz, 
2H), 7.21 (d, J = 4.20 Hz, 1H), 6.97 (s, 1H), 6.88 (s, 1H), 6.77 (d, J = 8.04 Hz, 1H), 6.65 – 6.63 
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(m, 2H), 5.31 (d, J = 4.98 Hz, 1H), 5.17 (d, J = 4.03 Hz, 1H), 4.32 (s, 1H). 13C{1H} NMR (150 
MHz, CDCl3, 40°C) δ 193.8, 141.6, 141.2, 134.1, 133.1, 132.1, 130.4, 129.2, 127.3, 127.2, 
126.2, 126.0, 119.2, 118.0, 115.2, 78.9, 51.2. Anal.Calcd for C19H13BrClNO2S: C, 52.49; H, 
3.01; N, 3.22; O, 7.36; S, 7.37. Found: C, 52.24; H, 2.96; N, 3.56; O, 9.91; S, 6.89. 
4.2.3.11. (4-Bromophenyl)(6-chloro-3-(3-fluorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)methanone (30a); 
 
Light yellow solid, (530 mg, 76% yield). Rf 0.7 (3% ethyl acetate in hexane); mp: 135-138°C; 
FTIR (ATR, Vmax, cm-1): 3398 (N-H str.), 2976 (Ar-H str.), 1678 (C=O str.), 1491 (Ar C=C str.), 
1218 (C-N str.), 1112 (C-F str.), 1064 (C-O-C str.), 687 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 
25°C) δ  7.75 (d, J = 8.14 Hz, 2H), 7.54 (d, J = 8.39 Hz, 2H), 7.28 – 7.26 (m, 1H), 7.10 – 7.04 
(m, 2H), 6.98 – 6.94 (m, 1H),  6.74 (d, J = 8.24 Hz, 1H), 6.68 (d, J = 1.83 Hz, 1H), 6.62 (dd, J = 
8.24 Hz, J = 1.83 Hz, 1H), 5.23 (d, J = 5.16 Hz, 1H), 4.90 (d, J = 3.22 Hz, 1H), 4.27 (s, 1H). 
13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.0, 164.3 – 161.8 (d, JC-F = 248.02 Hz, 1C), 141.5 
– 141.4 (d, JC-F = 6.50 Hz, 1C), 140.7, 133.8, 133.6, 132.0, 130.6, 130.5, 129.3, 127.4, 123.2 – 
123.1 (d, JC-F = 2.86 Hz, 1C), 118.7, 118.1, 115.7 – 115.5 (d, JC-F = 20.96 Hz, 1C), 114.7, 114.6 
– 114.4 (d, JC-F= 22.05 Hz, 1C), 78.8, 54.5. Anal.Calcd for C21H14BrClFNO2: C, 56.47; H, 3.16; 
N, 3.14; O, 7.16. Found: C, 56.63; H, 3.18; N, 3.01; O, 8.32. 
4.2.3.12. (4-Bromophenyl)(6-chloro-3-(3-fluorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)methanone (30b); 
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Light yellow solid, (49 mg, 7% yield). Rf 0.6 (5% ethyl acetate in hexane); mp: 135-138°C; 
FTIR (ATR, Vmax, cm-1): 3366 (N-H str.), 2964 (Ar-H str.), 1686 (C=O str.), 1490 (Ar C=C str.), 
1256 (C-N str.), 1063 (C-O-C str.), 788 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.53 – 
7.47 (m, 4H), 7.16 – 7.11 (m, 1H), 6.91 – 6.86 (m, 3H), 6.81 (d, J = 9.68 Hz, 1H), 6.72 – 6.70 
(m, 2H),  5.51 (d, J = 3.32 Hz, 1H), 4.97 (s, 1H), 4.41 (s, 1H). 13C{1H} NMR (100 MHz, 
CDCl3, 25°C) δ 194.4, 164.1, 141.2, 140.8, 134.5, 133.6, 131.9, 130.4, 130.2, 128.8, 127.7, 
123.2, 118.9, 118.2, 115.6 – 115.4 (d, JC-F = 22.10 Hz, 1C), 114.6, 114.5, 79.2, 55.7. HRMS 
(ESI-TOF) calcd for C21H15BrClFNO2 [M + H]+ 445.9959, found 446.0160. 
4.2.2.20. (4-Bromophenyl)(6-chloro-3-(p-tolyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-
yl)methanone (31); 
 
Reddish solid, (520 mg, 84% yield). mp: 175-177°C; FTIR (ATR, Vmax, cm-1): 3374 (N-H str.), 
2976 (Ar-H str.), 1679 (C=O str.), 1489 (Ar C=C str.), 1285 (C-N str.), 1061 (C-O-C str.), 677 
(C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.70 (d, J = 8.50 Hz, 2H), 7.51 (d, J = 8.48 
Hz, 2H), 7.18 (d, J = 7.98 Hz, 2H), 7.08 (d, J = 7.93 Hz, 2H), 6.76 (d, J = 8.50 Hz, 1H),  6.65 
(d, J = 2.26 Hz, 1H), 6.61 (dd, J = 8.56 Hz, J = 2.27 Hz, 1H), 5.20 (d, J = 5.91 Hz, 1H), 4.77 (d, 
J = 5.77 Hz, J = 1.76 Hz, 1H), 4.22 (s, 1H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 194.1, 
141.0, 138.6, 135.2, 134.14, 134.1, 131.9, 130.5, 129.6, 129.0, 127.4, 127.1, 118.3, 117.9, 
114.5, 79.1, 55.1, 21.2. Anal.Calcd for C22H17BrClNO2: C, 59.68; H, 3.87; N, 3.16; O, 7.23. 
Found: C, 59.55; H, 3.94; N, 3.43; O, 9.52. 
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4.2.2.21. (4-Bromophenyl)(6-chloro-3-(3,4-difluorophenyl)-3,4-dihydro-2H-
benzo[b][1,4]oxazin-2-yl)methanone (32); 
 
Brown solid, (448 mg, 69% yield). mp: 139-143°C; FTIR (ATR, Vmax, cm-1): 3344 (N-H str.), 
2921 (Ar-H str.), 1689 (C=O str.), 1493 (Ar C=C str.), 1224 (C-N str.), 1114 (C-F str.), 1060 
(C-O-C str.), 768 (C-Cl str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.75 (d, J = 7.19 Hz, 2H), 
7.55 (d, J = 7.63 Hz, 2H), 7.19 - 7.05 (m, 3H), 6.73 – 6.60 (m, 3H),  5.11 (d, J = 4.31 Hz, 1H), 
4.86 (d, J = 3.18 Hz, 1H), 4.30 (brs, 1H).13C{1H} NMR (100 MHz, CDCl3, 25°C) δ 193.7, 151.8 
– 149.2 (dd, JC-F = 250.08 Hz, JC-F = 13.37 Hz, 1C), 151.5 – 148.9 (dd, JC-F = 250.08 Hz, JC-F = 
12.90 Hz, 1C), 140.7, 135.98 – 135.93 (d, JC-F = 4.46 Hz, 1C), 133.6, 133.5, 132.1, 130.5, 
129.4, 127.5, 123.7 – 123.6 (dd, JC-F = 3.61 Hz, JC-F = 3.61 Hz, 1C), 118.8, 118.1, 117.8 -117.6 
(d, JC-F = 17.91 Hz, 1C), 116.7 – 116.5 (d, JC-F = 18.47 Hz, 1C), 114.8, 78.7, 53.9. HRMS (ESI-
TOF) calcd for C21H14BrClF2NO2 [M + H]+ 463.9865, found 464.0126. 
4.2.2.22. (4-Bromophenyl)(6-chloro-3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-
2-yl)methanone (33); 
 
Red solid, (578 mg, 90% yield). mp: 142-145°C; FTIR (ATR, Vmax, cm-1): 3368 (N-H str.), 2929 
(Ar-H str.), 1681 (C=O str.), 1491 (Ar C=C str.), 1224 (C-N str.), 1061 (C-O-C str.), 794 (C-Cl 
str.); 1H NMR (400 MHz, CDCl3, 25°C) δ  7.69 (d, J = 8.62 Hz, 2H), 7.51 (d, J = 8.62 Hz, 2H), 
7.21 (d, J = 8.68 Hz, 2H), 6.80 - 6.77 (m, 3H), 6.66 – 6.61 (m, 2H),  5.17 (d, J = 6.25 Hz, 1H), 
4.74 (d, J = 6.13 Hz, 1H), 4.19 (brs, 1H), 3.74 (s, 3H).13C{1H} NMR (100 MHz, CDCl3, 25°C) 
δ 194.1, 159.9, 141.1, 134.2, 132.0, 130.5, 129.9, 129.0, 128.8, 127.1, 118.4, 117.9, 114.6, 
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114.4, 79.2, 55.4, 54.9. Anal.Calcd for C22H17BrClNO3: C, 57.60; H, 3.74; N, 3.05; O, 10.46. 
Found: C, 56.13; H, 3.65; N, 3.57; O, 14.18. 
4.2.2.23. (6-Chloro-3-(4-chlorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)(4-
chlorophenyl)methanone (34); 
 
Light yellow solid, (538 mg, 92% yield). mp: 148-150°C; FTIR (ATR, Vmax, cm-1): 3356 (N-H 
str.), 2908 (Ar-H str.), 1664 (C=O str.), 1585 (Ar C=C str.), 1223 (C-N str.), 795 (C-Cl str.); 1H 
NMR (400 MHz, CDCl3, 25°C) δ  7.74 (d, J = 8.45 Hz, 2H), 7.29 (d, J = 8.45 Hz, 2H), 7.20 – 
7.18 (m, 4H), 6.66 (d, J = 8.52 Hz, 1H), 6.59 (d, J = 1.87 Hz, 1H), 6.53 (dd, J  = 8.50 Hz, J = 
1.82 Hz, 1H), 5.11 (d, J = 5.44 Hz, 1H), 4.78 (d, J = 5.18 Hz, 1H), 4.18 (s, 1H). 13C{1H} NMR 
(100 MHz, CDCl3, 25°C) δ 193.5, 140.7, 140.4, 137.1, 134.4, 133.6, 133.3, 130.3, 129.08, 
129.0, 128.8, 127.3, 118.5, 118.0, 114.6, 78.8, 54.3. Anal.Calcd for C21H14Cl3NO2: C, 60.24; H, 
3.37; N, 3.35; O, 7.64. Found: C, 59.62; H, 3.35; N, 3.37; O, 8.26. 
4.2.2.24. (6-Chloro-3-(4-chlorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)(4-
methoxyphenyl)methanone (35); 
Off white solid, (498 mg, 86% yield). mp: 145-148°C; FTIR (ATR, Vmax, cm-1): 3339 (N-H str.), 
2931 (Ar-H str.), 1665 (C=O str.), 1591 (Ar C=C str.), 1230 (C-N str.), 745 (C-Cl str.); 1H NMR 
(400 MHz, CDCl3, 25°C) δ  7.86 (d, J = 8.70 Hz, 2H), 7.28 – 7.23 (m, 4H), 6.86 (d, J = 8.70 Hz, 
2H), 6.78 (d, J = 8.50 Hz, 1H), 6.67 (s, 1H), 6.62 (d, J  = 8.51 Hz, 1H), 5.21 (d, J = 5.72 Hz, 
1H), 4.83 (d, J = 7.04 Hz, 1H), 4.27 (s, 1H), 3.85 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3, 
25°C) δ 192.7, 164.2, 141.3, 137.4, 134.3, 133.9, 131.5, 129.07, 129.05, 128.1, 127.1, 118.5, 
118.0, 114.7, 114.0, 78.6, 55.6, 54.6. Anal.Calcd for C22H17Cl2NO3: C, 63.78; H, 4.14; N, 3.38; 
O, 11.59. Found: C, 63.38; H, 4.03; N, 3.46; O, 12.09. 
4.2.2.25. (6-Chloro-3-(4-chlorophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)(p-
tolyl)methanone (36); 
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Off white solid, (416 mg, 75% yield). mp: 149-152°C; FTIR (ATR, Vmax, cm-1): 3334 (N-H str.), 
2921 (Ar-H str.), 1672 (C=O str.), 1602 (Ar C=C str.), 1235 (C-N str.), 800 (C-Cl str.); 1H NMR 
(400 MHz, CDCl3, 25°C) δ  7.84 (d, J = 7.68 Hz, 2H), 7.49 (t, J = 7.24 Hz, 1H), 7.35 (t, J = 
7.54 Hz, 2H), 7.25 – 7.18 (m, 4H), 6.72 (d, J = 7.92 Hz, 1H), 7.47- 7.45 (m, 2H), 5.21 (d, J = 
5.74 Hz, 1H), 6.49 – 6.47 (m, 2H), 5.61 (d, J = 2.91 Hz, 1H), 5.24 (d, J = 2.88 Hz, 1H), 4.12 
(brs, 1H), 4.80 (d, J = 5.36 Hz, 1H), 4.06 (s, 1H), 2.20 (s, 3H). 13C{1H} NMR (100 MHz, 
CDCl3, 25°C) δ 194.0, 144.9, 141.1, 137.2, 134.2, 133.7, 132.6, 129.3, 129.0, 128.99, 128.91, 
127.0, 118.4, 117.9, 114.6, 78.5, 54.5, 21.7. Anal.Calcd for C22H17Cl2NO2: C, 66.35; H, 4.30; N, 
3.52; O, 8.03. Found: C, 66.68; H, 4.47; N, 3.42; O, 8.63. 
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CHAPTER 3 
Synthesis, Crystal structure, spectroscopic and photophysical studies of novel 
fluorinated quinazoline derivatives 
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Abstract 
Fifteen fluorinated quinazoline derivatives have been synthesized and well-characterized with 
Infrared (IR) and Nuclear Magnetic Resonance (NMR) spectroscopic methods (1H, 13C, COSY, 
HMBC, HSQC and NOESY). In addition, crystal structure of 4 derivatives (13b, 13e, 13f and 
13g) were solved by single X-ray diffractometer. In this chapter, we have described the 
influence of various substituents on the core scaffold (Fluorinated quinazoline) on its molecular 
conformations, intermolecular interactions and on the photoluminescent properties. Hirshfeld 
surfaces was used to investigate the structure-directing effects of functional groups in 
controlling their solid-state behaviour. The photo-physical properties of all compounds have 
been studied including UV and fluorescence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords  
Quinazoline, Crystal structure, fluorescence. 
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1. Introduction 
In the past two decades there has been considerable efforts to develop new fluorophores with  
intramolecular charge transfer (ICT) emissions, as they have significant applications in non-
linear optics (NLO),1 organic-light emitting diodes (OLEDs), luminescence sensors,2 emissive 
material for sensor,3 dye-sensitized solar cells (DSSCs)4 and field effect transistors.5 
Quinazolines are important class of heterocyclic compounds and continue to attract significant 
attention in research because of their interesting photophysical (electronic absorption and 
emission) properties and wide pharmacological applications. Quinazoline is a π-deficient, 
nitrogen containing fused benzo-pyrimidine aromatic ring system. This π-deficient aromatic 
ring is responsible for the intramolecular charge transfer (ICT) property.6-8 In general, 
quinazoline scaffold along with ICT has a significant impact on the luminescence properties and 
is also required for nonlinear optical (NLO) processes. The nitrogen atom of quinazoline ring 
plays a critical role in the formation of supramolecular assemblies9 and sensors,10 by allowing 
protonation, hydrogen bond formation and chelation.  
Further, quinazoline ring is present as a core moiety in a wide variety of bioactive natural 
products and some important marketed pharmaceutical drugs such as gefitinib,11 lapatinib12 and 
erlotinib13 (Figure 1). From literature it is quite evident that analogues of quinazoline  also 
display a broad array of activities such as anti-cancer,14 antiviral,15 anti-tubercular,16 
antimalarial,17 anticonvulsant,18 anti-inflammatory19 and anti-hypertensive.20 Owing to the 
comprehensive application of this pharmacophore, it has attracted the attention of organic 
chemists to develop novel synthetic approaches to synthesize novel functionalized quinazolines 
and their derivatives.21, 22 
 
Figure 1: Structures of some biologically active quinazoline cores. 
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Additionally, presence of fluorine in organic molecules has considerable importance in both 
material science as well as pharmaceuticals. Introducing fluorine into the molecules provides a 
unique way of achieving distinctive modification with minimal changes in structural 
configuration. Fluorinated organic compounds have potential application in organic light-
emitting diodes (OLEDs),23, 24 organic photovoltaic devices (OPV)25 and organic field effect 
transistors (OTFT).26 In addition it is well documented that replacing a hydrogen atom of the 
natural substrate with fluorine may enhance biological activity27 along with several biological 
properties such as solubility, lipophilicity, metabolic stability and binding selectivity.28 With 
this in mind, we envisaged to synthesize novel fluorinated quinazoline derivatives and study the 
influence of the various substituents on the molecular conformation and intermolecular 
interactions on the photoluminescent properties. 
2. Result and Discussion 
2.1. Synthesis and spectral characterization 
 
Scheme 1: Reagents and conditions: i) 28% aqueous ammonia solution, EDC.HCl, HOBt, 
DMF, 3–5 h; ii) pTSA, MeOH, 70°C, 16 h; iii) KMnO4, DMSO, 100°C, 16 h; iv) CH3I, K2CO3, 
DMF, 0°C - rt, 16 h; v) K2CO3, DMF, 0°C - rt, 24 h; vi) Fe, NH4Cl, Dioxane: EtOH: H2O 
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(7:5:3), 100°C, 5 h; vii) TEA, DCM, 0°C - rt, 4 h. or Pyridine, DCM, 0°C - rt, 16 h. or 
EDC.HCl, HOBT, DIPEA, DMF, rt, 16 h. 
A brief description of synthetic route for all compounds is presented in Scheme 1. 2-amino-5-
nitrobenzamide (2) was synthesized adopting the procedure described by M. Tobe et al.29 where 
acid was converted to amide by treatment with aqueous ammonia in the presence of coupling 
reagent (EDC.HCl and HOBt) in DMF which was then cyclized with aldehyde (3) in presence 
of dehydrating agent pTSA in methanol followed by oxidation of 2-(3,4-difluorophenyl)-6-
nitro-2,3-dihydroquinazolin-4(1H)-one (4) with KMnO4 in DMSO. The obtained 6-
nitroquinazolin-4-ol (5) was alkylated with iodoethane in presence of K2CO3 in DMF at ambient 
temperature for 24 h and then reduced with Fe/NH4Cl, yielding 2-(3,4-difluorophenyl)-4-
ethoxyquinazolin-6-amine (8) which was condensed with various acid chloride in presence of 
TEA in DCM and numerous sulfonyl chloride along with pyridine in DCM at 0°C - rt for 16 h 
yielding a series of corresponding final compounds (10a-h). 
In the other series, compound (4) was alkylated with iodomethane in presence of K2CO3 in 
DMF at ambient temperature for 16 h followed by reduction with Fe/NH4Cl in dioxane, ethanol 
and water (3:2:1) to yield 6-amino-2-(3,4-difluorophenyl)-1,3-dimethyl-2,3-dihydroquinazolin-
4(1H)-one (12) which was treated with various acid, acid chlorides, and sulfonyl chlorides to 
yield another series of corresponding final compounds (13a-g). 
The structures of all the new compounds were confirmed by spectroscopic data obtained from 
UV, IR, NMR (1H, 13C, 19F and 2D). All derivatives and intermediates were evaluated using IR 
spectroscopy30-33. The stretching frequencies of C-F in all cases were observed in the region 
between 1050–1150 cm-1.31 The stretching frequencies around 1250 – 1350 cm-1 in case of 2, 4, 
5, and 7 indicated the presence of nitro (NO2) group30. The frequencies with medium to strong 
intensities in the range of 1450–1650 cm-1 is assigned for C=N stretching32, 33. The stretching 
frequencies in the region 1600–1750 cm-1 and 3200–3400 cm-1 in some of derivatives (10a-f and 
13a-e) indicates the presence of amide C=O and N-H group, respectively.31 In the IR spectra of 
10g, 10h, 13f and 13g show broad band in the regions of 3200–3400 cm-1 are assigned for N-H 
stretching and high intense bands in the ranges 1250–1350 and 1100-1200 cm-1 for asymmetric 
and symmetric stretching modes of O=S=O group33.  
In case of 1H NMR spectrum of compound 2, two singlets at 8.18 and 7.36 clearly indicating 
different chemical environments of amide protons along with broad singlet at 7.87 of amine 
protons. Construction of 4 via cyclization was confirmed by appearance of singlet chiral proton 
at 6.09 ppm along with singlets at 8.79 and 8.57 ppm for adjacent NH and disappearance of 
amide and amine protons (Figure 2A and 2B). Formation of 5 by oxidation was confirmed by 
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disappearance of singlet at 6.09 along with adjacent NH protons at 8.79 and 8.57 ppm, in 
addition, the presence of informative broad singlet at around 12.93 ppm confirms the presence 
of OH proton (Figure 2B and 2C). The synthesis of alkylated compound 7 was confirmed by 
disappearance of -OH proton with appearance of quartet and triplet of -CH2, -CH3 at 4.80 ppm (J 
= 7.08 Hz) and 1.62 ppm (J = 7.19 Hz), respectively (Figure 2C and 2D). The conversion of 
nitro to amine (8) was confirmed by appearance of broad singlet of -NH2 at around 5.88 ppm 
(Figure 2D and 2E). 
 
Figure 2: Consecutive validation of intermediate compounds by 1H NMR overlapping. 
Further, the formation of 11 by N-methylation was confirmed by appearance of two singlets at 
2.97 and 2.89 of -CH3 protons as well as disappearance of two -NH protons. (Figure 3A and 
3B). The reduction of compound 11 was confirmed by the appearance of broad singlet of -NH2 
protons at around 4.75 ppm. (Figure 3B and 3C). 
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Figure 3: Successive confirmation of intermediate compounds by 1H NMR overlapping. 
The 1H NMR spectrum of the final compounds (10a-10h) displayed some characteristic signals 
at around δ 11.16-10.12 ppm for N-H proton, and δ 4.79-4.65, 1.51-1.37 ppm for ethyl (-
CH2CH3) protons although the 1H spectrum of the other series final compounds (13a-13g) 
showed distinct signals at around δ 10.69-9.68 ppm for N-H, 2.91-2.84 and 2.81-2.73 ppm for 
methyl (-CH3) protons. 
These findings were further verified from their respective 13C NMR spectra of the title 
compounds. Formation of 4 was supported by appearance of new carbon signal at around δ 
65.12 and conversion to 5 was supported by disappearance of signal at 65.12 ppm along with 
appearance of quaternary carbon in de-shielded region at around 153.33 ppm. The alkylated 
product 7 was supported by presence of carbon signals at around δ 64.2 and 14.41 ppm which 
are assign for ethoxy (-CH2-CH3) and the N- methylated product 11 was supported by presence 
of carbon signals at 35.40 and 31.71 ppm which confirm the presence of methyl groups. 
The 13C NMR spectrum of the final compounds (10a-10h and 13a-13g) displayed some 
characteristic double doublet signals at around δ 154−147 and 151−146 ppm which showed JC-F 
254-242 Hz, 15-10 Hz and 248-241 Hz, 13-10 Hz respectively, verified the presence of two 
                                                                                                                                                     Chapter 3 
Narva Deshwar Kushwaha 75                                         UKZN-2020 
 
fluorine atoms in aromatic ring which was also confirmed by 19F NMR spectrum while the 
various aromatic carbons resonated around δ 169.6−100.8 ppm. 
2.2. 2D NMR (NOESY, COSY, HSQC, and HMBC) investigation of 13b, 13e, 13f and 13g 
                        13b (COSY & HMBC)                             13b (NOESY) 
  
13e (COSY & HMBC) (13e ) NOESY 
  
13f (COSY & HMBC) 13f (NOESY) 
 
 
13g (COSY & HMBC) 13g (NOESY) 
 
 
Figure 4: 2D (NOESY, COSY, HSQC, and HMBC) correlations of compounds 13b, 13e, 13f 
and 13g.  
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The solution phase conformational investigation of compounds 13b, 13e, 13f and 13g was 
carried out using 2D NMR (HMBC, HSQC, COSY and NOESY) analysis which are depicted in 
figure 4. Each molecule composed of 3,4 difluoro phenyl (DFP), 1,3-dimethyl-2,3-
dihydroquinazolinone (DMHQ) and amide (13b and 13e) or sulphonamide (13f and 13g) 
moieties. The HMBC study of all molecules revealed that chiral carbon (2C) has correlation 
with 4C, 10C, 14C and 18C through the bond and the NOESY study revealed that chiral proton 
(2H) showing connectivity with 11H, 12H, 14H and 18H through the space. It indicates that 
chiral proton is in the centre of 11H, 12H, 14H and 18H. Furthermore, the 2D NMR study also 
revealed the absence of characteristic NOESY correlation between the proton of DMHQ and 
alkyl or aryl group of amide chain in compounds 13b, 13e and 13g suggesting the non-existence 
of proximity. This indicate that the substituted amide groups of these compounds may away 
from DMHQ ring in solution phase. For 13f the 2D NOESY failed to provide desired 
information about through space proton-proton connectivity between the aromatic proton of 
DMHQ ring and sulphonamide ring which is suggesting that the molecule is not in U shape in 
solution phase as confirmed by crystal structure. 
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2.3. Crystal structure descriptions of 13b, 13e, 13f, and 13g 
 
Figure 5: ORTEP diagrams of compounds 13b, 13e, 13f, and 13g drawn at 50% thermal 
ellipsoid probability. All hydrogen atoms, solvent molecules in 13b and 13e including one of 
the two quinazoline molecules of compound 13e have been omitted for clarity. 
The fluorinated quinazoline molecules of compounds 13b, 13e, 13f, and 13g observed in their 
respective asymmetric units, are depicted in Figure 5. Each molecule composes of a 3,4-
difluorophenyl (DFP), 1,3-dimethyl-2,3-dihydroquinazolinonyl (DMHQ), amide (13b and 13e), 
sulfonamide (13f and 13g) moieties. The DMHQ moiety in all the compounds was found to be 
non-planar with root mean squared deviation of 10 fitted atoms of the fused rings ranging from 
0.110 Å to 0.123 Å. Furthermore, the DFP groups were almost orthogonal with respect to the 
core DMHQ unit with dihedral angle between the two moieties ranging from 84.823° to 
96.556°. Interestingly, it appears that the presence of the electron donating substituent on the 
sulphonamide unit in 13f narrows C5—N3—S1—C17 torsion angle from -74.661 (13g) to 
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56.3215(7) which results in 13f having a bended, U-shaped molecular structure. All bond angles 
and distances are comparable to those of closely related structures.34, 35  
 
Figure 6: Selected hydrogen bonding patterns (shown as dashed orange bonds) found in crystal 
packing of compounds 13b, 13e, 13f, and 13g.  
Selected intermolecular hydrogen bonding parameters observed in 13b, 13e, 13f, and 13g are 
listed in Table 1 whilst the hydrogen bonding patterns are depicted in Figure 6. Classical 
intermolecular N—H…O hydrogen bonds between the amide (13b and 13e) and sulphonamide 
(13f) link two neighbouring molecules to form 14-membered ring with a graphset notation 
𝑅2
2(14). Another N—H…O hydrogen bonding pattern observed in 13e and 13g sew together 
neighbouring molecules to form chains that propagate along the crystallographic c axis. Since 
13b and 13e contained polar, protic solvent molecules, O—H…O hydrogen bonds were also 
observed in their respective crystal packing. The methanol molecule in 13e forms a dimer via 
O—H…O hydrogen bonds with the carbonyl oxygen of the amide functional group. On the 
other hand, the water molecule in 13b links the DMHQ’s and amide’s carbonyl oxygen atoms 
of neighbouring molecules via O—H…O hydrogen bonds to form a 2-D supramolecular 
structure shown in Figure 6. Non-classical C—H…F hydrogen bonding patterns also exist in 
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13e and 13g between the aromatic hydrogens and DFP moieties’ fluorine atoms of neighbouring 
molecules. Linking molecules in this manner results in the formation of 2-D supramolecular 
architectures which extend along the crystallographic ac planes. Lastly, the C—H…O hydrogen 
bonds between the aromatic hydrogens (H19 and H15B) and O2 and O3 atoms of neighbouring 
sulphonamide moieties also form 2-D supramolecular structures which grow along the 
crystallographic ab planes. 
Table 1: Selected hydrogen-bonding parameters (Å, º) for 13b, 13e, 13f, and 13g. 
D—H···A D—H H···A D···A D—H···A 
Compound 13b     
O3—H3A···O2i 0.87 1.91 2.756 (2) 164 
O3—H3B···O1 0.87 1.96 2.811 (2) 166 
N3—H3···O1ii 0.88 2.02 2.897 (2) 177 
Compound 13e     
N3A—H3A···O1Ai 0.88 1.98 2.854 (3) 173 
N3B—H3B···O1Bii 0.88 2.01 2.855 (3) 160 
C12C—H12C···F1Aiii 0.95 2.31 3.248 (8) 171 
O4—H4···O2A 0.84 1.92 2.753 (3) 169 
Compound 13f     
C19—H19···O2i 0.95 2.35 3.2967 (2) 174 
C15B—H15B···O3ii 0.95 2.36 3.228 (5) 151 
N3—H3···O1iii 0.88 (1) 1.96 (1) 2.817 (1) 166 
Compound 13g     
N3—H3···O1i 0.88 1.95 2.739 (8) 149 
C21—H21···F2Bii 0.95 2.23 3.05 (2) 144 
C16B—H16B···F1Biii 0.95 1.18 2.02 (2) 143 
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Symmetry codes: 13b (i) x, −y−1/2, z−1/2; (ii) −x+1, −y, −z; 13e (i) −x+1, −y+1, −z+2; (ii) x, 
−y+3/2, z−1/2; (iii) −x, −y+1, −z+2; 13f (i) x−1, y, z; (ii) −x+3/2, y+1/2, −z+1/2; (iii) −x+1, 
−y+1, −z. 13g (i) x, −y+1, z+1/2; (ii) x−1/2, y−1/2, z; (iii) x, −y+1, z−1/2. 
2.4. Hirshfeld Surface Analysis 
The molecular interactions of compounds 13b, 13e, 13f, and 13g were studied by Hirshfeld 
surface analysis, which detailed the proximity of intermolecular interactions in their respective 
crystal packing. The Hirshfeld dnorm surface maps and the corresponding fingerprint plots for the 
H···H, H···O/O···H, C···H/H···C, and F···H/ H···F interactions are depicted in Figure 7 and 8, 
respectively. The red areas on the Hirshfeld surfaces around the DMHQ moiety highlight the 
reciprocal O···H/H···O contacts which are represented by a pair of broad spikes in the lower 
left (donor) area of the fingerprint plot and they are attributed to the N—H…O and C—H···O 
hydrogen bonds. Generally, the sulfonamides have larger O…H/H…O contribution to the dnorm 
surface than the amide derivatives due to a higher number of oxygen atoms. The H···H contacts 
were found to be the major contributor to the Hirshfeld surfaces with the amide derivatives 
having higher percentage values than the sulfonamides. Interestingly, it appears that the 
presence of the sterically demanding iso-propyl group in 13b results in the highest H…H and 
H…F/F…H contributions in this series. As for the sulfonamides, the decrease in the H···H and 
H…F/F…H contributions from 34.1% (13f) to 27.3% (13g) and from 16% (13f) to 14.5% (13g) 
could be attributed to the widening of the C5—N3—S1—C17 torsion angle from 56.3(1) (13f) 
to -74.6(6) (13g).  
 
Figure 7: dnorm mapped on Hirshfeld surfaces. 
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Figure 8: 2D fingerprint plots depicting relative contributions of various intermolecular 
contacts. 
2.5. Photophysical studies 
The UV-vis and fluorescence data were acquired in acetonitrile at 25°C and are summarized in 
Table 2. All compounds appear to have a λmax ranging from 264 to 354 nm along with one or 
two maxima at shorter wavelengths. Alkylation of compound 5 results in a hypsochromic shift 
from 354 nm to 327 nm (7) and reduction of the NO2 group to NH2 causes a slight absorption 
bathochromic shift to 330 nm and an emission at 442 nm (8). Converstion of the amino group to 
various amide derivatives (10a-f) and (13a-e) results in an absorption hypsochromic shift from 
330 nm (8) to 264-327 nm (10a-f) and 302-321 nm (13a-e). Intriguingly, increasing the carbon 
chain (10e) on the amide group and introducing a cyclic, bulky unit (10f) has little or no effect 
on the absorption λmax relative to 10c. However, it appears that having an acyclic, bulky group 
results in a significant bathochromic shift from 307 nm (10c) to 321 nm (10b). A similar trend 
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was observed for 13b and 13c. Having the cyclopropylamino amide unit in 10d results in the 
disappearance of the absorption band around 300 nm whilst a significant bathochromic shift was 
observed for 13d (321 nm) relative to other amides derivatives of series-2. The presence of an 
electron donating group (-OMe) on the amide units in 10g causes an absorption bathochromic 
shift from 301 nm (10h) to 310 nm, whereas a large hypsochromic shift was observed from 354 
nm (13g) to 309 nm (13f). The presence of nitro groups in 5 and 7, oxalyl amide units in 10a 
and 13a including conjugated amide in 13e, appear to quench the fluorescence ability of 
quinazoline. It was also noted that the presence of sulphonamide units in 10g-h luminescence at 
a shorter wavelength range (380-385 nm) compared to that containing the amide units in 10a-f 
(399-447 nm). In case of 13a-g, there is an overlay in the emission wavelength maxima for the 
amides (437-456 nm) and sulphonamides (402-443 nm). Compounds 10c-h (70-183 nm) have 
lower Stokes shift values relative that of compound 8 (112 nm) and 13b-g (98-154 nm) with the 
exception of compound 10d (183 nm). 
Table 2: Summarized details from UV and fluorescence spectra of compounds 5, 7, 8, 10a-h 
and 13a-g. 
Compound UV/vis λmax, nm Emission λmax, nm Stokes shift, nm 
5 214, 354 -  
7 258, 327 -  
8 259, 330 442 112 
10a 260, 327 -  
10b 225, 321 -  
10c 251, 307 399 92 
10d 264 447 183 
10e 252, 308 400 92 
10f 252, 309 401 92 
10g 252, 310 380 70 
10h 249, 301 384 83 
13a 252, 319 - - 
13b 220, 310 454 144 
13c 220, 302 456 154 
13d 225, 321 437 116 
13e 218, 307 - - 
13f 252, 309 443 134 
13g 215, 354 402 98 
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2.6. Theoretical calculation  
Gaussian09 program package was employed for theoretical calculations. Geometry optimization 
of the structures was performed by using density functional theory (DFT) employing the 
B3LYP (Becke three parameters Lee–Yang–Parr exchange correlation functional), which 
combines the hybrid exchange functional of Becke with the gradient-correlation functional of 
Lee, Yang and Parr using 6-311G++(d,p) basis set was performed in gas phase. No solvent 
corrections were made with these calculations as gas phase calculations frequently correspond 
quite well with crystal structures. Starting geometries for were taken from X-ray refined data. 
All the distorted geometry was removed while generating the input file. The optimized 
geometry results in the free molecule state were compared to those in the crystalline state. No 
negative vibrational modes were obtained. The DFT calculated structure and geometric 
parameters (bond lengths and bond angles) agreed with each other. All optimized structures had 
a C1 point group.  
The bond length between C9-O3 and N8-H54 in case of 13f, was found to be 1.225 Å and 1.014 
Å which is slightly higher than carbonyl (C=O) (usually 1.22 Å) and NH of sulphonamide, 
indicating presence of inter molecular H-bonding. Similar pattern of H-bonding was also 
determined in case of 13b, 13e and 13g as shown by the increase of bond length compared to 
usual.  
Frontier Orbital Energy and TD DFT calculations 
Molecular Total Energy and Frontier Orbital energy levels were calculated using DFT (Table 
3). Energy gap (ΔE) has been calculated for all 4 crystals as shown in the Table 3. 
Table 3: Total energy and frontier orbital energy [B3LYP/6-311++G (d, p)].  
-- 13b 13e 13f 13g 
Etotal (Hartree) -1366.01639120 -1594.66296551 -1952.49439920 -1937.20477708 
EHOMO -0.21182 -0.20315 -0.21891 -0.22316 
ELUMO -0.06395 -0.06965 -0.06343 -0.06602 
ΔEa (eV) 4.33 3.63 4.23 4.27 
aΔE = ELUMO - EHOMO.   
The energy gap between HOMO and LUMO was calculated by the B3LYP method using the 6-
311G++(d,p) basis set. The compounds showed an energy gap (ΔE) for HOMO → LUMO in a 
range from 3.63-4.33 eV (Table 3). HOMO and LUMO are important factors that affect 
bioactivity, chemical reactivity and electron affinity and ionization potential. Thus, study of the 
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frontier orbital energy can provide useful information about the biological and chemical reaction 
mechanism. TD-DFT calculations have also been performed to bring insight into the absorption 
spectra of the derivatives to calculate the excited states. 
Table 4: Calculation of absorption spectra using TD-DFT calculations. 
Compound Transitions from 
Calculated 
f 
λmax (nm) λmax (eV) 
13b 
HOMO-LUMO 367.93 3.37 0.0453 
HOMO-LUMO+1 324.41 3.82 0.0402 
HOMO-LUMO+2 300.08 4.13 0.0507 
13e 
HOMO-LUMO 380.20 3.26 0.6693 
HOMO-LUMO+1 361.48 3.43 0.0495 
HOMO-LUMO+2 327.36 3.79 0.0033 
13f 
HOMO-LUMO 349.13 3.55 0.0409 
HOMO-LUMO+1 313.46 3.96 0.0040 
HOMO-LUMO+2 305.50 4.06 0.0991 
13g 
HOMO-LUMO 344.95 3.59 0.0442 
HOMO-LUMO+1 311.03 3.99 0.1482 
HOMO-LUMO+2 303.23 4.09 0.0041 
Electronic transition properties including λmax were calculated for all 4 crystals using TD-DFT 
calculations using Gaussian09 and the values of λmax (both in nm and eV) and oscillator strength 
have been calculated as shown in Table 4. From the calculated absorption spectrum, in case of 
13b, three intense bands were observed corresponding to transitions from HOMO to LUMO 
(367.93 nm), HOMO to LUMO+1 (324.41 nm) and HOMO to LUMO+2 (300.08 nm). In case 
of 13g the most prominent transition was observed from HOMO to LUMO+1 (311.03 nm) 
based on the oscillator strength whereas in case of 13e HOMO to LUMO was the most intense 
one at 380.20 nm. In case of 13f, shows one intense band envelope based on the oscillator 
strength, at λmax = 305.50 nm compared to other two signals at 349.13 and 313.46 nm. This 
intense band refers to the transition from HOMO to LUMO+2. 
3. Conclusion 
In this chapter, fifteen compounds based on fluorinated quinazoline derivatives have been 
synthesized and well-characterized with Infrared (IR) and Nuclear Magnetic Resonance (NMR) 
spectroscopic methods (1H, 13C, COSY, HMBC, HSQC and NOESY). Additionally, crystal 
structure of 4 derivatives (13b, 13e, 13f and 13g) were solved by single X-ray diffractometer 
and compare the confirmation of molecules in solution- phase using 2D NOESY experiments. 
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The influence of various substituents on the core scaffold (Fluorinated quinazoline) on its 
molecular conformations, intermolecular interactions and on the photoluminescent properties 
has been described. Hirshfeld surfaces was used to investigate the structure-directing effects of 
functional groups in controlling their solid-state behaviour. Among the series, compounds (8, 
10c-h, 13b-d and 13f-g) displayed good photoluminescent properties. 
4. Experimental 
4.1. General consideration 
All the fine chemicals, reagents and solvents were purchased from Sigma Aldrich and Merck 
and were used without further purification unless otherwise stated. The progress of the reactions 
and the purity of the compounds were monitored by thin-layer chromatography (TLC) on pre-
coated silica gel plates procured from E. Merck and Co. (Darmstadt, Germany) visualized by 
UV lamp (254 or 365 nm). Purification was performed by using combi-flash (CombiFlash® 
NextGen 300+) column chromatography. The melting points of the synthesized compounds 
have been determined and uncorrected using a digital Stuart SMP10 melting point Apparatus. 
The Fourier transform infrared (FTIR) spectra were recorded in the spectral range of 400-4000 
cm-1 on a Bruker Alpha FT-IR spectrometer using the ATR technique. The NMR spectra (1H, 
13C, 19F, & 2D) were recorded using CDCl3 and DMSO-d6 on Bruker AVANCE III 400 and 600 
MHz spectrometer. Chemical shifts were determined relative to internal standard TMS at δ 0.0 
parts per million (ppm) and the coupling constants were reported in Hertz. The multiplicities of 
the NMR resonances were abbreviated as s (singlet), d (doublet), dd (doublet of doublet), (t 
(triplet), q (quartet), m (multiplet) and brs (broad singlet). X-ray crystallography analysis was 
performed on Bruker SMART APEX II, X-ray diffractometer. 
4.2. Chemistry 
4.2.1. Synthesis and spectral characterization of intermediate compounds (2, 4, 5, 7, 8, 11 and 
12); 
4.2.1.1. Synthesis of 2-amino-5-nitrobenzamide (2);  
 
To the solution of 2-amino-5-nitrobenzoic acid (30 g, 164.83 mmol) and HOBt (26.70 g, 197.80 
mmol) in DMF (150 mL) was added EDC.HCl (37.78 g, 197.80 mmol). The mixture was stirred 
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at ambient temperature for 2 h then cooled to 0°C. Then a 28% ammonia solution was added 
and stirred for another 2 h at room temperature: the reaction mixture was monitored by TLC. 
After consumption of starting material, the mixture poured into ice cold water, the precipitate 
was filtered and dried under vacuum, washed with pentane followed by diethyl ether to afford 
yellow solid product (24.9 g, 83%); mp: 128-134°C; FTIR (ATR, Vmax, cm-1): 3412.37 (N-H str. 
of NH2), 3300.44 (N-H str.), 3198 (Ar-H str.), 1667.46 (C=O str.), 1613.56 (Ar C=C str.), 
1314.55 (Ar-NO2 str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ  8.54 (s, 1H), 8.18 (brs, 1H), 
8.00 (d, J = 8.99 Hz, 1H), 7.86 (brs, 2H), 7.36 (brs, 1H),  6.79 (d, J = 9.17 Hz, 1H). 13C NMR 
(150 MHz, DMSO-d6, 25°C) δ 169.6, 155.6, 134.8, 127.4, 126.3, 115.9, 112.0.  
4.2.1.2. Synthesis of 2-(3,4-difluorophenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)-one (4); 
 
To the solution of 2-amino-5-nitrobenzamide (10 g, 55.20 mmol) and 3,4-difluorobenzaldehyde 
(6.12 mL, 55.20 mmol) in methanol (20 mL) was added catalytic amount of p-toluenesulfonic 
acid (1.05 g, 5.52 mmol). The resultant mixture was reflux for 16 h, precipitate was formed, 
filtered and washed with methanol to afford yellow solid product (13.2 g, 78%). mp: 294-
296°C; UV/vis (CH3CN): λmax = 344 nm; FTIR (ATR, Vmax, cm-1): 3477.23 (N-H str.), 3357.74 
(N-H str.), 2973.94 (Ar-H str.), 1682.62 (C=O str.), 1487 (Ar C=C str.), 1324.68 (Ar-NO2 str.), 
1057 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ  8.79 (brs, 1H), 8.57 (brs, 1H), 8.42 (d, 
J = 3.33 Hz, 1H), 8.11 (dd, J = 8.97 Hz, J = 2.77 Hz, 1H), 7.56 – 7.46 (m, 2H), 7.33 – 7.30 (m, 
3H),  6.85 (d, J = 9.08 Hz, 1H), 6.05 (s, 1H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 161.2, 
151.8, 150.4 – 148.6 (dd, JC-F = 246.5 Hz, JC-F = 14.3 Hz, 1C), 150.1 – 148.4 (dd, JC-F = 245.6 
Hz, JC-F = 12.5 Hz, 1C), 138.7, 137.4, 129.0, 124.1, 123.4 – 123.4 (dd, JC-F = 6.6 Hz, JC-F = 3.31 
Hz, 1C), 117.7 – 117.6 (d, JC-F = 17.3 Hz, 1C), 115.9 – 115.8 (d, JC-F = 17.3 Hz, 1C), 114.4, 
112.6, 65.1. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -137.74 (d, JF-F = 22.21 Hz, 1F), -138.35 
(d, JF-F = 22.21 Hz, 1F).   
4.2.1.3. Synthesis of 2-(3,4-difluorophenyl)-6-nitroquinazolin-4-ol (5); 
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To the solution of 2-(3,4-difluorophenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)-one (8 g, 26.20 
mmol) in DMSO (50 mL) was added potassium permanganate (12.42 g, 78.62 mmol). The 
mixture was heated at 100°C for 16 h and monitored by TLC after consumption of starting 
material cooled to room temperature and filtered through celite. The filtrate was poured into 
water and stirred for 30 min precipitate was formed, filtered and washed with diethyl ether to 
afford title compound (5.6 g, 70%). mp 296-298°C; UV/vis (CH3CN): λmax = 354 nm; FTIR 
(ATR, Vmax, cm-1): 2973.93 (Ar-H str.), 2868.71 (Ar-H str.), 1674.85 (C=O str.), 1569.82 (Ar 
C=C str), 1339.13 (Ar-NO2 str.), 1056.77 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 
12.93 (brs, 1H), 8.70 (d, J = 2.81 Hz, 1H), 8.47 (dd, J = 9.10 Hz, J = 2.47 Hz, 1H), 8.21 – 8.17 
(m, 1H), 8.06 (t, J = 4.26 Hz, 1H), 7.80 (d, J = 9.11 Hz, 1H), 7.63 – 7.58 ( m, 1H). 13C NMR 
(150 MHz, DMSO-d6, 70°C) δ 161.3, 153.3, 152.7 – 151.0 (dd, JC-F = 252.7 Hz, JC-F = 12.5 Hz, 
1C), 152.3, 150.1 – 148.3 (dd, JC-F = 245.9, JC-F = 15.3 Hz, 1C), 144.7, 129.0, 128.4, 125.7 – 
125.6 (dd, JC-F = 7.41 Hz, JC-F = 2.9 Hz, 1C), 121.8, 120.8, 118.0 – 117.8 (d, JC-F = 17.6 Hz, 
1C), 117.4 – 117.3 (d, JC-F = 19.4 Hz, 1C). 19F NMR (376 MHz, DMSO-d6, 25°C) δ -132.80 (d, 
JF-F = 23.21 Hz, 1F), -137.27 (d, JF-F = 23.25 Hz, 1F).   
4.2.1.4. Synthesis of 2-(3,4-difluorophenyl)-4-ethoxy-6-nitroquinazoline (7); 
 
To the solution of 2-(3,4-difluorophenyl)-6-nitroquinazolin-4-ol (3.4 g, 11.21 mmol) in DMF 
(30 mL) was added potassium carbonate (2.32 g, 16.81 mmol), followed by iodoethane (1.35 
mL, 16.81 mmol). The resultant suspension was stirred at room temperature for 16 h then 
poured into ice cold water, precipitate was formed filtered under vacuum and washed with 
methanol to afford title compound (2.87 g, 77%). mp: 230-232°C; UV/vis (CH3CN): λmax = 327 
nm; FTIR (ATR, Vmax, cm-1): 3093.47 (Ar-H str.), 2992.85 (Ar-H str.), 1592.53 (C=N str.), 
1495.42 (Ar C=C str.), 1276.13 (Ar-NO2 str.), 1110.78 (C-F str.); 1H NMR (400 MHz, CDCl3, 
25°C) δ 9.05 (s, 1H), 8.56 (d, J = 9.45 Hz, 1H), 8.43 – 8.35 (m, 2H), 8.02 (d, J = 8.95 Hz, 1H), 
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7.31 – 7.25 (m, 1H), 4.80 (q, J = 7.08 Hz, 2H), 1.62 (t, J = 7.19 Hz, 3H). 13C NMR (100 MHz, 
CDCl3, 25°C) δ 167.9, 161.3, 154.6, 154.2 – 151.6 (dd, JC-F = 254.0 Hz,  JC-F = 12.2 Hz, 1C), 
151.9 – 149.3 (dd, JC-F = 248.9 Hz, JC-F = 12.9 Hz, 1C), 145.2, 134.5 – 134.4 (dd, JC-F = 5.79 
Hz, JC-F = 3.03 Hz, 1C), 129.6, 127.4, 125.6 – 125.5 (dd, JC-F = 7.3 Hz, JC-F = 4.1 Hz, 1C), 
121.0, 118.2 – 118.0 (d, JC-F = 19.1 Hz, 1C), 117.5 – 117.3 (d, JC-F = 18.1 Hz, 1C), 114.7, 64.2, 
14.4. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -133.14 (d, JF-F = 21.68 Hz, 1F), -137.21 (d, JF-F 
= 20.48 Hz, 1F). 
4.2.1.5. Synthesis of 2-(3,4-difluorophenyl)-4-ethoxyquinazolin-6-amine (8); 
 
2-(3,4-difluorophenyl)-4-ethoxy-6-nitroquinazoline (2.5 g, 7.54 mmol) was added into the 
mixture of dioxane (28 mL), ethanol (20 mL) and water (12 mL) followed by ammonium 
chloride (2.4 g, 45.27 mmol). To the resultant mixture iron powder (1.26 g, 22.63 mmol) was 
added with vigorous stirring and then heated at 100°C for 5 h. The reaction mixture was cool to 
room temperature and filtered through celite and washed with 10% MeOH/DCM. The filtrate 
was concentrated under reduce pressure and diluted with water then extracted with 10% 
IPA/CHCl3 (3 X 50 mL). Organic phase was dried over anhydrous Na2SO4, filtered and 
concentrated under reduce pressure to afford greenish solid product (2.2 g, 92%). mp: 148-
150°C; UV/vis (CH3CN): λmax = 330 nm; FTIR (ATR, Vmax, cm-1): 3443.08 (N-H str.), 2988.98 
(Ar-H str.), 1588.08 (C=N str.), 1519.27 (Ar C=C str.), 1426.90 (N-H bend), 1101.85 (C-F str.); 
1H NMR (400 MHz, DMSO-d6, 25°C) δ 8.32 – 8.24 (m, 2H), 7.67 (d, J = 9.22 Hz, 1H), 7.58 – 
7.51 (m, 1H), 7.28 (dd, J = 8.93 Hz, J = 2.42 Hz, 1H), 7.08 (d, J = 2.47 Hz, 1H), 5.88 (s, 2H), 
4.68 (q, J = 7.03 Hz, 2H), 1.48 (t, J = 7.45 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 
164.4, 151.9, 150.7, 149.2, 148.3, 143.6, 135.8, 128.4, 124.5, 123.9, 117.5 – 117.3 (d, JC-F = 
17.7 Hz, 1C), 116.1, 115.8 – 115.6 (d, JC-F = 18.8 Hz, 1C), 100.8, 62.2, 14.2.  19F NMR (376 
MHz, DMSO-d6, 25°C) δ -137.68 (d, JF-F = 22.50 Hz, 1F), -138.51 (d, JF-F = 22.11 Hz, 1F).  
4.2.1.6. Synthesis of 2-(3,4-difluorophenyl)-1,3-dimethyl-6-nitro-2,3-dihydroquinazolin-4(1H)-
one (11); 
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To the solution of 2-(3,4-difluorophenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)- one (4 g, 13.10 
mmol) in DMF was added potassium carbonate (9.04 g, 65.52 mmol) followed by iodomethane 
(4.09 mL, 65.52 mmol) at 0°C. The resultant mixture was stirred at room temperature for 24 h 
then poured into ice cold water precipitate was formed, filtered to get crude solid product. The 
crude was dissolved into DMSO (10 mL) and added water (50 mL) precipitate was formed 
filtered and dried under vacuum to afford yellow solid product (4.0g, 91%); mp 220-222°C; 1H 
NMR (400 MHz, DMSO-d6, 25°C) δ 8.52 (d, J = 1.69 Hz, 1H), 8.20 (dd, J = 8.90 Hz, J = 1.87 
Hz, 1H), 7.48 – 7.37 (m, 2H), 7.13 (s, 1H), 6.82 (d, J = 9.34 Hz, 1H), 6.04 (s, 1H), 2.97 (s, 3H), 
2.89 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 159.3, 151.2 – 148.6 (dd, JC-F = 246.5 Hz, 
JC-F = 10.6 Hz, 1C), 150.1, 137.6, 134.6, 129.3, 124.0, 122.8, 118.6 – 118.4 (d, JC-F = 17.4 Hz, 
1C), 115.7 – 115.6 (d, JC-F = 17.9 Hz, 1C), 113.4, 112.2, 77.0, 35.4. 31.71. 
4.2.1.7. Synthesis of 6-amino-2-(3,4-difluorophenyl)-1,3-dimethyl-1,2,3,4-tetrahydroquinazolin-
4-ol (12); 
 
 The title compound was synthesized from 2-(3,4-difluorophenyl)-1,3-dimethyl-6-nitro-1,2,3,4-
tetrahydroquinazolin-4-ol (4.52 g, 13.56 mmol) as described in the procedure for 8. Brown 
liquid, yield: (2.9 g, 70%). 1H NMR (400 MHz, DMSO-d6, 25°C) δ 7.40 – 7.33 (m, 1H), 7.20 – 
7.14 (m, 1H), 7.08 (d, J = 2.54 Hz, 1H), 6.98 – 6.95 (m, 1H), 6.67 (dd, J = 8.62 Hz, J = 2.67 Hz, 
1H), 6.42 (d, J = 8.59 Hz, 1H), 5.63 (s, 1H), 4.75 (s, 2H), 2.91 (s, 3H), 2.70 (s, 3H). 13C NMR 
(100 MHz, DMSO-d6, 25°C) δ 151.0 – 148.5 (dd, JC-F = 245.91 Hz, JC-F = 12.76 Hz, 1C), 150.8 
– 148.2 (dd, JC-F = 247.61 Hz, JC-F = 12.76 Hz, 1C), 142.0, 137.6, 135.5, 133.5, 120.6, 118.7, 
118.2 – 118.0 (d, JC-F = 17.89 Hz, 1C), 116.1 – 115.9 (d, JC-F = 7.24 Hz, 1C), 115.6 , 113.0, 
78.0, 37.0, 32.7.  
4.2.2. General procedure for synthesis and spectral characterization of derivatives (10a-c and 
13a-c), (10d and 13d) and (10g-h and 13f-g); 
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4.2.2.1. General procedure A for synthesis of derivatives (10a-c and 13a-c);  
To the suspension of 2-(3,4-difluorophenyl)-4-ethoxyquinazolin-6-amine (8)/ 6-amino-2-(3,4-
difluorophenyl)-1,3-dimethyl-2,3-dihydroquinazolin-4(1H)-one (12) (1.0 equiv) in DCM, were 
added triethyl amine (1.5 equiv), followed by appropriate acid chloride (1.5 equiv) at 0°C. The 
resultant mixture was stirred at room temperature for 2 h, quenched with sodium bicarbonate 
solution and extracted with DCM (3 x 30 mL). The combined organic layer was dried over 
anhydrous Na2SO4, filtered and evaporated under reduce pressure to get crude product which 
were purified by combi-flash column chromatography using MeOH/DCM as an eluent to afford 
the respective title products. 
4.2.2.2. Procedure B for synthesis of derivative (10d and 13d);  
To the solution of 2-(3,4-difluorophenyl)-4-ethoxyquinazolin-6-amine (8)/6-amino-2-(3,4-
difluorophenyl)-1,3-dimethyl-2,3-dihydroquinazolin-4(1H)-one (12) (1.0 equiv) in DCM (10 
mL) was added triethyl amine (1.5 equiv), followed by 2-bromoacetyl bromide (1.2 equiv) at 
0°C. The resultant mixture was stirred at room temperature for 2 h, precipitate was formed, 
filtered and washed with pentane to afford salt of 2-bromo-N-(2-(3,4-difluorophenyl)-4-
ethoxyquinazolin-6-yl) acetamide and 2-bromo-N-(2-(3,4-difluorophenyl)-1,3-dimethyl-4-oxo-
1,2,3,4-tetrahydroquinazolin-6-yl)acetamide, respectively which were  dissolved separately  in 
DMF then added potassium carbonate (1.5 equiv), followed by cyclopropanamine (1.5 equiv) at 
room temperature. The resultant mixture was stirred at room temperature for 16 h, then diluted 
with ethyl acetate and washed with cold brine solution (3 x 10 mL). The organic layer dried 
over anhydrous Na2SO4, filtered and evaporated under reduce pressure to yield crude product 
which were recrystallized with ethanol to afford the pure title products. 
4.2.2.3. General procedure C for synthesis of derivatives (10g-h and 13f-g);  
To the solution of 2-(3,4-difluorophenyl)-4-ethoxyquinazolin-6-amine (8)/6-amino-2-(3,4-
difluorophenyl)-1,3-dimethyl-2,3-dihydroquinazolin-4(1H)-one (12) (1.0 equiv) in DCM were 
added pyridine (8.0 equiv), followed by appropriate sulfonyl chloride (1.5 equiv) at 0°C. The 
resultant mixture was stirred at room temperature for 16 h, quenched with 2N-HCl solution and 
extracted with DCM (3 x 20 mL). The combined organic layer was dried over anhydrous 
Na2SO4 and evaporated under reduced pressure to yield the crude, which were triturated with 
diethyl ether, filtered to yield the title products. 
4.2.2.1.1. Ethyl 2-((2-(3,4-difluorophenyl)-4-ethoxyquinazolin-6-yl) amino)-2-oxoacetate (10a);  
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Yellow solid, yield: 67%, mp: 225-227°C; UV/vis (CH3CN): λmax = 327 nm; FTIR (ATR, Vmax, 
cm-1): 3338.84 (N-H str.), 1704.49 (C=O str.), 1564.65 (Ar C=N str.), 1430.34 (C=C str.), 
1095.83 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 11.00 (s, 1H), 8.63 (s, 1H), 8.39 – 
8.35 (m, 2H), 8.25 (d, J = 8.22 Hz, 1H), 7.96 (d, J = 9.21 Hz, 1H), 7.59 – 7.54 (m, 1H),  4.79 (q, 
J = 7.10 Hz, 2H), 4.38 (q, J = 7.27 Hz, 2H), 1.54 (t, J = 6.87 Hz, 3H), 1.37 (t, J = 6.82 Hz, 3H). 
13C NMR (100 MHz, DMSO-d6, 25°C) δ 165.9, 160.2, 156.0, 155.6, 152.3 – 149.9 (dd, JC-F = 
250.1 Hz, JC-F = 13.6 Hz, 1C), 150.7 – 148.2 (dd, JC-F = 243.7 Hz, JC-F = 12.7 Hz, 1C), 148.0, 
136.2, 135.1 – 135.0 (d, JC-F = 4.19 Hz, 1C), 128.1, 127.7, 124.8 – 124.7 (d, JC-F = 4.1 Hz, 1C), 
117.7 – 117.5 (d, JC-F = 17.0 Hz, 1C), 116.5 – 116.3 (d, JC-F = 19.0 Hz, 1C), 114.5, 112.4, 63.0, 
62.5, 14.1, 13.8. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -136.06 (d, JF-F = 22.27 Hz, 1F), -
138.19 (d, JF-F = 22.49 Hz, 1F).  
4.2.2.1.2. N-(2-(3,4-Difluorophenyl)-4-ethoxyquinazolin-6-yl)isobutyramide (10b); 
 
Off white solid, yield: 66%,  mp: 222-225°C; UV/vis (CH3CN): λmax = 321 nm; FTIR (ATR, 
Vmax, cm-1): 3268.11 (N-H str.), 2970.48 (Ar-H str.), 1655.45 (C=O str.), 1565.48 (C=N str.), 
1518.32 (Ar C=C str.), 1096.54 (C-F str.); 1HNMR (400 MHz, DMSO-d6, 25°C) δ 10.29 (s, 
1H), 8.60 (d, J = 2.30 Hz, 1H), 8.40 – 8.32 (m, 2H), 8.03 (dd, J = 9.02 Hz, J = 2.40 Hz, 1H), 
7.91 (d, J = 9.02 Hz, 1H), 7.63 – 7.56 (m, 1H), 4.75 (q, J = 7.56 Hz, 2H), 2.68 – 2.62 (m, 1H), 
1.51 (t, J = 6.97 Hz, 3H), 1.14 (d, J = 6.83 Hz, 6H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 
175.7, 165.8, 155.4, 150.8 – 148.2 (dd, JC-F = 243.67 Hz, JC-F = 16.72 Hz, 1C), 149.7, 147.2, 
138.2, 135.2, 128.1, 127.1, 124.67, 117.7 – 117.5 (d, JC-F = 17.89 Hz, 1C), 116.4 – 116.2 (d, JC-F 
= 18.97 Hz, 1C), 114.9, 110.3, 62.9, 35.0, 19.4, 14.2. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -
136.31 (d, JF-F = 23.15 Hz, 1F), -138.21 (d, JF-F = 22.33 Hz, 1F).   
4.2.2.1.3.  N-(2-(3,4-Difluorophenyl)-4-ethoxyquinazolin-6-yl)acetamide (10c);  
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Yellow solid, Yield: 43%, mp: 230-232°C; UV/vis (CH3CN): λmax = 307 nm; FTIR (ATR, Vmax, 
cm-1): 3263.95 (N-H str.), 2984.45 (Ar-H str.), 1680.83 (C=O str.), 1542.92 (C=N str.), 1517.22 
(Ar C=C str.), 1096.44 (C-F str.); 1HNMR (400 MHz, DMSO-d6, 25°C) δ 10.37 (s, 1H), 8.49 (d, 
J = 2.44 Hz, 1H), 8.36 – 8.28 (m, 2H), 8.00 (dd, J = 9.06 Hz, J = 2.66 Hz, 1H), 7.88 (d, J = 9.03 
Hz, 1H), 7.60 – 7.54 (m, 1H), 4.72 (q, J = 7.08 Hz, 2H), 2.11 (s, 3H), 1.49 (t, J = 7.24 Hz, 3H). 
13C NMR (100 MHz, DMSO-d6, 25°C) δ 168.7, 165.7, 155.3, 152.3 – 149.6 (dd, JC-F = 250.38 
Hz, JC-F = 14.26 Hz, 1C), 150.8 – 148.2 (dd, JC-F = 244.8 Hz, JC-F = 13.4 Hz, 1C), 147.2, 138.0, 
135.2, 128.2, 126.8, 124.6, 117.7 – 117.5 (d, JC-F = 17.46 Hz, 1C), 116.4 – 116.2 (d, JC-F = 18.45 
Hz, 1C), 114.8, 110.1, 62.9, 24.0, 14.1.  
4.2.2.2.1. 2-(Cyclopropylamino)-N-(2-(3,4-difluorophenyl)-4-ethoxyquinazolin-6 yl)acetamide 
(10d);  
 
Yellow solid, yield: 74%, mp: 170-173°C; UV/vis (CH3CN): λmax = 264 nm; FTIR (ATR, Vmax, 
cm-1): 3294.63 (N-H str.), 2968.45 (Ar-H str.), 1685.93 (C=O str.), 1578.51 (C=N str.), 1515.79 
(Ar C=C str.), 1094.47 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.24 (s, 1H), 8.58 
(d, J = 2.37 Hz, 1H), 8.39 – 8.30 (m, 2H), 8.07 (dd, J = 9.09 Hz, J = 2.40 Hz, 1H), 7.91 (d, J = 
8.92 Hz, 1H), 7.62 – 7.55 (m, 1H), 7.74 (q, J = 7.13 Hz, 2H), 3.40 (s, 2H), 2.22 – 2.17 (m, 1H), 
1.50 (t, J = 7.73 Hz, 3H), 0.40 – 0.35 (m, 2H), 0.32 – 0.29 (m, 2H).  13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 171.1, 165.7, 155.3, 152.3 – 149.7 (dd, JC-F = 247.09, JC-F = 11.49 Hz, 1C), 
150.8 – 148.2 (dd, JC-F = 245.70 Hz, JC-F = 13.00 Hz, 1C), 147.3, 137.6, 135.4 – 135.1 (dd, JC-F 
= 5.79 Hz, JC-F = 3.18 Hz, 1C), 128.2, 127.1, 124.6 – 124.6 (d, JC-F = 4.11 Hz, 1C), 117.6 – 
117.5 (d, JC-F = 17.54 Hz, 1C), 116.4 – 116.2 (d, JC-F = 18.48 Hz, 1C), 114.8, 110.4, 62.9, 52.7, 
30.0, 14.1, 6.1.  
4.2.2.1.4.  N-(2-(3,4-Difluorophenyl)-4-ethoxyquinazolin-6-yl)pentanamide (10e); 
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Light yellow solid, Yield: 75%, mp: 230-232°C; UV/vis (CH3CN): λmax = 308 nm; FTIR (ATR, 
Vmax, cm-1): 3284.73 (N-H str.), 2964.35 (Ar-H str.), 1656.81 (C=O str.), 1566.42 (C=N str.), 
1519.99 (Ar C=C str.), 1095.14 (C-F str.); 1HNMR (400 MHz, DMSO-d6, 25°C) δ 10.33 (s, 1H), 
8.56 (d, J = 2.26 Hz, 1H), 8.39 – 8.30 (m, 2H), 8.01 (dd, J = 9.09 Hz, J = 2.42 Hz, 1H), 7.90 (d, 
J = 9.06 Hz, 1H), 7.62 – 7.55 (m, 1H), 4.74 (q, J = 7.17 Hz, 2H), 2.37 (t, J = 7.43 Hz, 2H), 1.65 
– 1.57 (m, 2H), 1.50 (t, J = 6.90 Hz, 3H), 1.39 – 1.30 (m, 2H), 0.91 (t, J = 7.81 Hz, 3H). 13C 
NMR (100 MHz, DMSO-d6, 25°C) δ 171.7, 165.7, 155.2, 152.2 – 149.6 (dd, JC-F = 250.35 Hz, 
JC-F = 13.49 Hz, 1C), 150.7 – 148.2 (dd, JC-F = 245.2 Hz, JC-F = 13.4 Hz, 1C), 147.1, 138.0, 
135.26 – 135.20 (dd, JC-F = 5.9 Hz, JC-F = 5.9 Hz, 1C), 128.1, 126.8, 124.6, 117.6 – 117.4 (d, JC-
F = 21.9 Hz, 1C), 116.3 – 116.1 (d, JC-F = 18.4 Hz, 1C), 114.8, 110.1, 62.8, 36.1, 27.1, 21.8, 
14.1, 13.7. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -136.31 (d, JF-F = 22.75 Hz, 1F), -138.20 (d, 
JF-F = 22.14 Hz, 1F). 
4.2.2.1.5.  N-(2-(3,4-Difluorophenyl)-4-ethoxyquinazolin-6-yl)cyclobutanecarboxamide (10f):  
 
Yellow solid, Yield: 79%, mp: 214-216°C; UV/vis (CH3CN): λmax = 309 nm; FTIR (ATR, Vmax, 
cm-1): 3276 (N-H str.), 2966.05 (Ar-H str.), 1654.34 (C=O str.), 1564.29 (C=N str.), 1518.00 
(Ar C=C str.), 1097.10 (C-F str.); 1HNMR (400 MHz, DMSO-d6, 25°C) δ 10.12 (s, 1H), 8.48 (d, 
J = 2.25 Hz, 1H), 8.27 – 8.21 (m, 2H), 7.98 (dd, J = 9.12 Hz, J = 2.46 Hz, 1H), 7.81 (d, J = 8.97 
Hz, 1H), 7.54 – 7.47 (m, 1H), 4.65 (q, J = 6.82 Hz, 2H), 3.31 – 3.22 (m, 1H), 2.31 – 2.21 (m, 
2H), 2.18 – 2.10 (m, 2H), 2.10 – 1.91 (m, 1H), 1.89 – 178 (m, 1H), 1.48 (t, J = 7.58 Hz, 3H). 
13C NMR (100 MHz, DMSO-d6, 25°C) δ 173.3, 165.7, 155.2, 152.2 – 149.6 (dd, JC-F = 250.7 
Hz, JC-F = 14.1 Hz, 1C), 150.7 – 148.2 (d, JC-F = 243.7 Hz, JC-F = 12.0 Hz, 1C), 147.1, 138.1, 
135.2 – 135.1 (dd, JC-F = 6.3 Hz, JC-F = 3.1 Hz, 1C), 128.1, 126.9, 124.5, 117.6 – 117.4 (d, JC-F = 
17.6 Hz, 1C), 116.3 – 116.1 (d, JC-F = 18.7 Hz, 1C), 114.8, 110.2, 62.8, 24.5, 17.7, 14.1. 19F 
NMR (376 MHz, DMSO-d6, 25°C) δ -136.35 (d, JF-F = 22.38 Hz, 1F), -138.23 (d, JF-F = 22.52 
Hz, 1F).   
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4.2.2.3.1. N-(2-(3,4-Difluorophenyl)-4-ethoxyquinazolin-6-yl)-4-methoxybenzenesulfonamide 
(10g); 
 
Yellow solid, Yield: 68%, mp: 195-200°C; UV/vis (CH3CN): λmax = 310 nm; FTIR (ATR, Vmax, 
cm-1): 3232.25 (N-H str.), 2971.00 (Ar-H str.), 1561.08 (C=N str.), 1495.96 (Ar C=C str.), 
1261.54 (SO2 asym.), 1150.66 (SO2 sym.), 1091.42 (C-F str.);  1H NMR (400 MHz, DMSO-d6, 
25°C) δ 10.69 (brs, 1H), 8.32 – 8.24 (m, 2H), 7.84 (d, J = 9.08 Hz, 1H), 7.77 – 7.73 (m, 3H), 
7.69 (dd, J = 9.03 Hz, J = 2.51 Hz, 1H), 7.58 – 7.51 (m, 1H), 7.06 (d, J = 8.86 Hz, 2H), 4.68 ( q, 
J = 7.52 Hz, 2H), 3.73 (s, 3H), 1.47 (t, J = 7.19 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) 
δ 165.7, 162.6, 155.9, 152.4 – 149.8 (dd, JC-F = 248.4 Hz, JC-F = 13.8 Hz, 1C), 150.8 – 148.3 
(dd, JC-F = 245.2 Hz, JC-F = 13.8 Hz, 1C), 147.6, 136.8, 135.0, 130.7, 128.9, 127.3, 124.8, 117.8 
– 117.6 (d, JC-F = 18.1 Hz, 1C), 116.5 – 116.3 (d, JC-F = 18.1 Hz, 1C), 114.9, 114.5, 110.9, 63.1, 
55.6, 14.1.  
4.2.2.3.2. N-(2-(3,4-Difluorophenyl)-4-ethoxyquinazolin-6-yl)-4-fluorobenzenesulfonamide 
(10h); 
 
 Yellow solid, Yield: 76%, mp: 220-222°C; UV/vis (CH3CN): λmax = 301 nm;  FTIR (ATR, 
Vmax, cm-1): 3246.72 (N-H str.), 2995.45 (Ar-H str.), 1576.03 (C=N str.), 1506.43 (Ar C=C str.), 
1266.07 (SO2 asym.), 1151.71 (SO2 sym.), 1100.66 ( C-F str.);    1HNMR (400 MHz, DMSO-d6, 
250C) δ 10.84 (s, 1H), 8.36 – 8.28 (m, 2H), 7.89 – 7.84 (m, 3H), 7.78 (d, J = 2.42 Hz, 1H), 7.70 
(dd, J = 8.98 Hz, J = 2.50 Hz, 1H), 7.61 – 7.55 (m, 1H), 7.40 (t, J = 8.32 Hz, 2H), 4.71 (q, J = 
7.09 Hz, 2H), 1.48 (t, J = 6.91 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 165.7 – 163.2 
(d, JC-F = 250.8 Hz, 1C), 165.6, 155.9, 152.4 – 149.7 (dd, JC-F = 249.2 Hz, JC-F = 15.7 Hz, 1C), 
150.7 – 148.2 (dd, JC-F = 245 .1 Hz, JC-F = 14.6 Hz, 1C), 147.8, 136.3, 135.53 – 135.5 (d, JC-F = 
2.96 Hz, 1C), 134.93 – 134.0 (d, JC-F = 9.02 Hz, 1C), 129.8 – 129.7 (d, JC-F = 10.06 Hz, 1C), 
129.0, 127.5, 124.74 – 124.71 (d, JC-F = 4.0 Hz, 1C), 117.6 – 117.5 (d, JC-F = 18.00 Hz, 1C), 
116.7, 116.5, 116.5 – 116.3 (d, JC-F = 18.63 Hz, 1C), 114.8, 111.5, 63.0, 14.0. 19F NMR (376 
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MHz, DMSO-d6, 25°C) δ -105.43 (s, 1F), -135.95 (d, JF-F = 21.59 Hz, 1F), -138.13 (d, JF-F = 
22.08 Hz, 1F).   
4.2.2.1.6. Ethyl 2-((2-(3,4-difluorophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-6-
yl)amino)-2-oxoacetate (13a); 
 
Yellow solid, Yield: 72%, mp: 110-115°C; UV/vis (CH3CN): λmax = 319 nm; FTIR (ATR, Vmax, 
cm-1): 3337.34 (N-H str.), 2898.96 (Ar-H str.), 1692.16 (C=O str.), 1663.24 (Amide C=O str.), 
1099.09 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.69 (S, 1H), 8.21 (d, J = 2.48 Hz, 
1H), 7.73 (dd J = 8.60 Hz, J = 2.61 Hz, 1H), 7.44 – 7.37 (m, 1H), 7.28 – 7.23 (m, 1H), 7.02 – 
7.00 (m, 1H), 6.64 (d, J = 9.07 Hz, 1H), 5.82 (s, 1H), 4.29 (q, J = 7.08 Hz, 2H), 2.90 (s, 3H), 
2.81 (s, 3H), 1.30 (t, J = 7.21 Hz, 3H), 13C NMR (100 MHz, DMSO-d6, 25°C) δ  161.0, 160.6, 
155.0, 150.9 – 148.3 (dd, JC-F = 246.0 Hz, JC-F = 15.1 Hz, 1C), 150.5 – 147.9 (dd, JC-F = 247.9 
Hz, JC-F = 13.2 Hz, 1C), 143.0, 134.7 – 134.6 (d, JC-F = 5.22 Hz, 1C), 128.4, 126.6, 122.8, 119.9, 
118.2 – 118.0 (d, JC-F = 17.6 Hz, 1C), 115.6 – 115.4 (d, JC-F = 17.1Hz, 1C), 115.4, 112.5, 77.0, 
62.2, 34.9, 31.9, 13.8. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -137.34 (d, JF-F = 22.27 Hz, 1F), 
-138.10 (d, JF-F = 22.11 Hz, 1F).   
4.2.2.1.7. N-(2-(3,4-Difluorophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-6-
yl)isobutyramide (13b); 
 
Yellow solid, Yield: 69%, mp: 177-180°C; UV/vis (CH3CN): λmax = 310 nm; FTIR (ATR, Vmax, 
cm-1): 3271.56 (N-H str.), 2964.64 (Ar-H str.), 1663.45 (C=O str.), 1631.36 (C=O str.), 1513.08 
(Ar C=C str.), 1099.84 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 9.70 (s, 1H), 8.01 (d, 
J = 2.44 Hz, 1H), 7.64 (dd, J = 8.74 Hz, J = 2.62 Hz, 1H), 7.44 – 7.37 (m, 1H), 7.26 – 7.21 (m, 
1H), 7.01 – 6.98 (m, 1H), 6.58 (d, J = 8.91 Hz, 1H), 5.78 (s, 1H), 2.90 (s, 3H), 2.78 (s, 3H), 2.56 
– 2.51 (m, 1H), 1.08 (d, J = 6.72 Hz, 6H).13C NMR (100 MHz, DMSO-d6, 25°C) δ 161.3, 150.4 
– 148.2 (dd, JC-F = 245.7 Hz, JC-F = 12.9 Hz, 1C), 150.4 – 147.9 (dd, JC-F = 246.4 Hz, JC-F = 13.6 
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Hz, 1C), 141.9, 134.7, 130.7, 125.4, 122.89 – 122.82 (d, JC-F = 6.9 Hz, 1C), 118.7, 118.1 – 
118.0 (d, JC-F = 17.2 Hz, 1C), 115.8, 115.6 – 115.4 (d, JC-F = 17.0 Hz, 1C), 112.6, 77.1, 35.0, 
34.8, 32.0, 19.5. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -137.45 (d, JF-F = 22.54 Hz, 1F), -
138.26 (d, JF-F = 22.77 Hz, 1F).   
4.2.2.1.8. N-(2-(3,4-Difluorophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-6-
yl)cyclohexanecarboxamide (13c):  
 
Off white solid, Yield: 81%, mp: 240-244°C; UV/vis (CH3CN): λmax = 302 nm; FTIR (ATR, 
Vmax, cm-1): 3309.15 (N-H str.), 2924.78 (Ar-H str.), 1666 (C=O str.), 1639.73 (C=O str.), 
1499.5 (Ar C=C str.), 1109.27 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 9.68 (s, 1H), 
8.02 (d, J = 2.75 Hz, 1H), 7.61 (dd, J = 8.65 Hz, J = 2.64 Hz, 1H), 7.44 – 7.37 (m, 1H), 7.26 – 
7.21 (m, 1H), 7.01 – 6.98 (m, 1H), 6.57 (d, J = 8.94 Hz, 1H), 5.77 (s, 1H), 2.89 (s, 3H), 2.77 (s, 
3H), 2.30 – 2.22 (m, 1H), 1.78 – 1.72 (m, 4H), 1.65 – 1.62 (m, 1H), 1.44 – 1.36 (m, 2H), 1.30 – 
1.26 (m, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 173.8, 161.3, 150.8 – 148.2 (dd, JC-F = 
247.1 Hz, JC-F = 13.0 Hz, 1C), 150.4 – 147.8 (dd, JC-F = 246.7 Hz, JC-F = 12.0 Hz, 1C), 141.8, 
134.7, 130.8, 125.3, 122.8 – 122.7 (dd, JC-F = 6.9 Hz, JC-F = 3.4 Hz, 1C), 118.6, 118.1 – 117.9 
(d, JC-F = 17.3 Hz, 1C), 115.8, 115.6 – 115.4 (d, JC-F = 17.2 Hz, 1C), 112.6, 77.1, 56.0, 44.7, 
35.0, 31.9, 29.15, 22.2. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -137.46 (d, JF-F = 22.49 Hz, 
1F), -138.27 (d, JF-F = 22.21 Hz, 1F).   
4.2.2.2.2. 2-(Cyclopropylamino)-N-(2-(3,4-difluorophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl) acetamide (13d); 
 
Yellow solid, Yield: 71%, mp: 160-162°C; UV/vis (CH3CN): λmax = 321 nm; FTIR (ATR, Vmax, 
cm-1): 3287.39 (N-H str.), 2969.97 (Ar-H str.), 1655.16 (C=O str.), 1636.82 (C=O str.), 1515.19 
(Ar C=C str.), 1111.38 (C-F str.) 1H NMR (400 MHz, DMSO-d6, 25°C) δ 9.68 (s, 1H), 8.04 (d, 
J = 2.72 Hz, 1H), 7.63 (dd, J = 8.82 Hz, J = 2.59 Hz, 1H), 7.44 – 7.37 (m, 1H), 7.26 – 7.21 (m, 
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1H), 7.01 – 6.99 (m, 1H), 6.60 (d, J = 8.89 Hz, 1H), 5.78 (s, 1H), 3.29 (s, 2H), 2.90 (s, 3H), 2.78 
(s, 3H), 2.18 – 2.13 (m, 1H), 0.39 – 0.34 (m, 2H), 0.31 – 0.26 (m, 2H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 169.9, 161.3, 150.8 – 148.2 (dd, JC-F = 246.8 Hz, JC-F = 12.1 Hz, 1C), 150.4 
– 147.9 (dd, JC-F = 248.0 Hz, JC-F = 11.5 Hz, 1C), 142.1, 134.74 – 134.70 (d, JC-F = 3.2 Hz, 1C), 
130.0, 125.5, 122.85 – 122.82 (d, JC-F = 3.2 Hz, 1C), 118.7, 118.1 – 118.0 (d, JC-F = 18.2 Hz, 
1C), 115.8, 115.6 – 115.4 (d, JC-F = 17.5 Hz, 1C), 112.6, 77.1, 52.5, 35.0, 32.0, 30.1, 6.0. 19F 
NMR (376 MHz, DMSO-d6, 25°C) δ -137.43 (d, JF-F = 22.40 Hz, 1F), -138.23 (d, JF-F = 21.28 
Hz, 1F).   
4.2.3. Synthesis of (E)-N-(2-(3,4-difluorophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)-3-(4-methoxyphenyl)acrylamide (13e); 
 
To the solution of 6-amino-2-(3,4-difluorophenyl)-1,3-dimethyl-2,3-dihydroquinazolin-4(1H)-
one (0.2 g, 0.65 mmol) in DMF (10 mL) were added DIPEA (0.229 mL, 1.31 mmol), EDC.HCl 
(0.188 g, 0.98 mmol) and HOBT (0.133 g, 0.98 mmol), stirred for 10 min. then (E)-3-(4-
methoxyphenyl)acrylic acid (0.129 g, 0.72 mmol). The resultant mixture was stirred at room 
temperature for 16 h, poured into ice cold water precipitate formed was filtered to get crude 
solid, which was purified by column chromatography on silica gel (100−200 mesh) using 
MeOH/DCM as an eluent to afford the pure yellow solid, Yield: 85%, mp: 170-175°C; UV/vis 
(CH3CN): λmax = 307 nm; FTIR (ATR, Vmax, cm-1): 3232.25 (N-H str.), 3231.03 (N-H str.), 
1668.54 (C=O str.), 1636.89 (C=O str.), 1603.68 (Ar C=C str. alkene), 1510.78 (Ar C=C str.), 
1111.09 (C-F str.);   1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.04 (s, 1H), 8.11 (d, J = 2.84 Hz, 
1H), 7.75 (dd, J = 8.79 Hz, J = 2.42 Hz, 1H), 7.56 (d, J = 8.33 Hz, 2H), 7.50 (d, J = 15.7 Hz, 
1H), 7.45 – 7.38 (m, 1H), 7.28 – 7.23 (m, 1H), 7.03 – 6.99 (m, 3H), 6.67 (d, J = 15.26 Hz, 1H), 
6.62 (s, 1H), 5.80 (s, 1H), 3.80 (s, 3H), 2.91 (s, 3H), 2.80 (s, 3H). 13C NMR (100 MHz, DMSO-
d6, 25°C) δ 163.4, 161.3, 160.5, 150.8 – 148.3 (dd, JC-F = 244.1 Hz, JC-F = 9.5 Hz, 1C), 150.5 – 
147.9 (dd, JC-F = 247.5 Hz, JC-F = 12.9 Hz, 1C), 142.0, 139.4, 134.7, 130.7, 129.2, 127.3, 125.3, 
122.8, 119.7, 118.5, 118.2 – 118.0 (d, JC-F = 17.4 Hz, 1C), 115.8, 115.6 – 115.4 (d, JC-F = 17.3 
Hz, 1C), 114.4, 112.7, 77.1, 55.2, 35.0, 32.0. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -137.41 
(d, JF-F = 20.87 Hz, 1F), -138.20 (d, JF-F = 22.37 Hz, 1F).   
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4.2.2.3.3. N-(2-(3,4-Difluorophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)-4-
methoxybenzenesulfonamide (13f); 
 
Yellow solid, Yield: 81%, mp: 225-230°C; UV/vis (CH3CN): λmax = 309 nm; FTIR (ATR, Vmax, 
cm-1): 3144.97 (N-H str.), 2998.25 (Ar-H str.), 1637.23 (C=O str.), 1507.04 (Ar C=C str.), 
1251.94 (SO2 asym.), 1154.55 (SO2 sym.), 1021.06 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 9.72 (S, 1H), 7.57 (d, J = 9.48 Hz, 1H), 7.44 (d, J =2.47 Hz, 1H), 7.41 – 7.36 (m, 1H), 
7.16 – 7.07 (m, 2H), 7.02 (d, J = 8.66 Hz, 2H), 6.95 – 6.93 (m, 1H), 6.52 (d, J = 8.79 Hz, 1H), 
5.76 (s, 1H), 3.78 (s, 3H), 2.85 (s, 3H), 2.73 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 
162.3, 160.9, 150.9 – 148.3 (dd, JC-F = 246 .12 Hz, JC-F = 12.55 Hz, 1C), 150.5 – 147.9 (dd, JC-F 
= 246.2 Hz, JC-F = 12.06 Hz, 1C), 143.3, 134.5, 130.9, 128.9, 128.3, 128.2, 122.8, 121.5, 118.1 – 
117.9 (d, JC-F = 16.6 Hz, 1C), 115.9, 115.4 – 115.2 (d, JC-F = 18.4 Hz, 1C), 114.1, 113.0, 77.0, 
55.5, 34.93, 31.9. 19F NMR (376 MHz, DMSO-d6, 25°C) δ -137.27 (d, JF-F = 21.33 Hz, 1F), -
138.03 (d, JF-F = 22.03 Hz, 1F).   
4.2.2.3.4. N-(2-(3,4-Difluorophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)-4-
fluorobenzenesulfonamide (13g); 
 
Yellow solid, Yield: 58%, mp: 180-185°C ; UV/vis (CH3CN): λmax = 354 nm; FTIR (ATR, Vmax, 
cm-1): 2987.92 (Ar-H str.), 1636.31 (C=O str.), 1514.22 (Ar C=C str), 1317.80 (SO2 asym.), 
1148.41 (SO2 sym.), 1092.03 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 9.89 (s, 1H), 
7.71 – 7.67 (m, 2H), 7.44 – 7.34 (m, 4H), 7.15 – 7.08 (m, 2H), 6.96 – 6.93 (m, 1H), 6.54 (d, J = 
8.81 Hz, 1H), 5.77 (s, 1H), 2.84 (s, 3H), 2.74 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 
165.5 – 163.0 (d, JC-F = 251.7 Hz, 1C), 160.7, 150.95 – 148.3 (dd, JC-F = 246.7 Hz, JC-F = 11.7 
Hz, 1C), 150.5 – 147.9 (dd, JC-F = 247.2 Hz, JC-F = 12.6 Hz, 1C), 143.6, 135.5 – 135.4 (d, JC-F = 
2.4 Hz, 1C), 134.5, 129.8 – 129.7 (d, JC-F = 10.3 Hz, 1C), 128.8, 127.6, 122.9 – 122.8 (dd, JC-F = 
6.3 Hz, JC-F = 3.3 Hz, 1C), 121.9, 118.1 – 118.0 (d, JC-F = 18.2 Hz, 1C), 116.3 – 116.1 (d, JC-F = 
23.0 Hz, 1C), 115.8, 115.3 – 115.2 (d, JC-F = 16.9 Hz, 1C), 113.1, 76.9, 34.8, 31.8. 19F NMR 
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(376 MHz, DMSO-d6, 25°C) δ -106.25 (s, 1F), -137.25 (d, JF-F = 21.54 Hz, 1F), -138.08 (d, JF-F 
= 20.17 Hz, 1F).   
4.3. Structure Determination 
Colourless, X-ray quality crystals were obtained by slow evaporation using DMSO for 13b and 
13f whereas ethanol for 13e and 13g. Crystal evaluation and data collection were done on a 
Bruker Smart APEX2 diffractometer with a Mo Kα radiation source (λ = 0.71073 Å) equipped 
with an Oxford Cryostream low-temperature apparatus. Initial cell matrix determination was 
done using 36 frames (0.5° phi-scan) from three series of scans at an exposure time of ten 
seconds per frame. Each of the three series of scans was collected at different starting angles 
and the APEXII36  program suite used to index the reflections. The total number of images was 
based on results from the program COSMO37 whereby the expected redundancy was to be 4.0% 
and completeness of 100% out to 0.75 Å. Cell parameters were retrieved using APEXII and 
refined using SAINT38 on all observed reflections. Data reduction was performed using SAINT 
software, and the scaling and absorption corrections were applied using SADABS39 multi-scan 
technique. The structures were solved by the direct method using the SHELXS40 program and 
refined. The visual crystal structures were presented using, MERCURY41[6] and Olex242 system 
software. Non-hydrogen atoms were first refined isotropically and then by anisotropic 
refinement with full-matrix least squares based on F2 using SHELXL43. All hydrogens were 
positioned geometrically, allowed to ride on their parent atoms, and refined isotropically. In all 
crystal structures, the 3,4-difluorophenyl moieties exhibited disorder over two positions which 
was resolved using PART instructions. The major component was found to have a site 
occupancy of 70.3% and 76% (13e), 58.1% (13b), 52.8% (13f) and 55% (13g). Crystal data and 
structural refinement information are summarized in Table 5. 
Table 5: Crystallographic data and structural refinement details of 13b, 13e, 13f, and 13g. 
 
13b 13e 13f 13g 
Chemical 
formula 
4(C20H21F2N3O2)·3(H2
O) 
8(C26H23F2N3O3)·3(C2H6
O) 
C23H21F2N3O4
S 
C22H18F3N3O3
S 
Mr 1547.63 3845.98 473.49 461.45 
Crystal 
system, 
space group 
Monoclinic, P21/c Monoclinic, P21/c Monoclinic, 
P21/n 
Monoclinic, 
C2/c 
Temperatur
e (K) 
100 103 100 100 
a, b, c (Å) 9.4635 (2), 13.2122 29.2357 (7), 16.0622 (4), 7.8508 (1), 26.6621 (9), 
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(3), 14.9413 (3) 10.0866 (2) 15.7287 (2), 
18.4655 (3) 
15.6874 (5), 
10.1580 (4) 
β (°) 92.210 (1) 99.026 (1) 98.257 (1) 109.399 (2) 
V (Å3) 1866.78 (7) 4677.9 (2) 2256.54 (6) 4007.5 (2) 
Z 1 1 4 8 
µ (mm−1) 0.11 0.10 0.20 0.22 
Crystal size 
(mm) 
0.36 × 0.24 × 0.17 0.29 × 0.18 × 0.11 0.26 × 0.18 × 
0.13 
0.31 × 0.22 × 
0.14 
Tmin, Tmax 0.698, 0.746 0.677, 0.746 0.703, 0.746 0.620, 0.746 
No. of 
measured, 
independen
t and 
observed [I 
> 2σ(I)] 
reflections 
23526, 4632, 3901  37523, 8667, 7337  35588, 5717, 
4723  
31843, 4985, 
4703  
Rint 0.021 0.041 0.028 0.049 
(sin θ/λ)max 
(Å−1) 
0.669 0.606 0.673 0.669 
R[F2 > 
2σ(F2)], 
wR(F2), S 
0.047, 0.129, 1.05 0.065, 0.151, 1.18 0.036, 0.098, 
1.03 
0.137, 0.313, 
1.16 
No. of 
reflections 
4632 8667 5717 4985 
No. of 
parameters 
324 749 351 342 
No. of 
restraints 
140 111 14 59 
Δρmax, 
Δρmin (e 
Å−3) 
0.99, −0.60 0.88, −0.47 0.36, −0.44 1.27, −0.79 
4.4. Hirshfeld Surface Analysis 
Hirshfeld surface calculations were performed on compounds 13b, 13e, 13f and 13g using 
CrystalExplorer1744 whereby all Hirshfeld surfaces including 2D fingerprint 45-47plots were 
generated using a high standard surface resolution. All bond lengths to hydrogen were 
automatically modified to typical standard neutron values (C—H = 1.083 Å, and O—H = 0.983 
Å) when the crystallographic information file (CIF) of the respective compound was read into 
the CrystalExplorer17 program.48 The Hirshfeld surface maps are that of normalized contact 
                                                                                                                                                     Chapter 3 
Narva Deshwar Kushwaha 101                                        UKZN-2020 
 
distance, dnorm, which is defined in terms of the distance to the nearest atoms outside (de), the 
distance to the nearest atoms inside (di) and the van der Waals radii of the two atoms external 
and internal to the surface.49 The dnorm ranges used to map the Hirshfeld surfaces were -0.6316 
to 1.4140 (13b), -0.6457 to 1.5251 (13e), -0.6022 to 1.5912 (13f) and -1.2575 to 1.5440 (13g). 
4.5. Theoretical calculation  
A crystal unit was selected as the initial structure from the obtained crystals for theoretical 
calculations. DFT-B3LYP/6-311G++(d,p) methods in Gaussian09 were used to optimize the 
structures. No solvent corrections were made with these calculations. Vibration analysis showed 
that the optimized structure indeed represents a minimum on the potential energy surface (no 
negative eigenvalues). TD-DFT calculations were performed using the same basis set as above 
to analyse the UV spectrum. 
Supplementary information 
CCDC numbers 1956040, 1956041, 1956042 and1956043 contain the supplementary 
crystallographic data for this paper. These data can be obtained free of charge from the 
Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif. 
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CHAPTER 4 
Design, synthesis and spectral characterization of novel quinazoline derivatives as 
an anti-tubercular agent 
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Abstract 
A novel series of quinazoline derivatives (10a-q and 17a-c) were designed and synthesized in 
good to moderate yields. The synthesized compounds were well-characterized by spectroscopic 
studies (NMR and IR) and evaluated for preliminary screening for their in-vitro anti-
mycobacterium activity at 20 µM concentration against Mycobacterium tuberculosis H37Rv 
strain. In general, the compounds did not show significant anti-mycobacterium activity. The 
only notable % zone of inhibition was observed against Mycobacterium tuberculosis strain 
H37Rv for compounds 10m which showed 33% inhibition after 24 h incubation which can be 
considered for further study which includes MIC, MBC and enzyme inhibition study. These 
new compounds may serve as starting points for the designing of new series of inhibitors that 
prevent the growth of Mycobacterium tuberculosis. 
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1. Introduction 
Tuberculosis (TB)1 is one of the oldest diseases that has affected humans for several thousands 
of years. The main cause remained unknown until Dr. Robert Koch declared about his discovery 
of bacillus Mycobacterium tuberculosis on March 24, 1882 which is commemorated every year 
as World TB Day2. TB is the second leading cause of death and ranks after human 
immunodeficiency virus (HIV). Republic of South Africa (RSA) is one of the leading countries 
with the uppermost problem of TB and HIV. World Health Organization (WHO) estimates out 
of 500 000 incident cases about 330 000 (66%) people were infested with both HIV and TB 
infection3-6. There have been several approaches adopted to develop newer and more efficacious 
drugs for its treatment. In 1993, World Health Organization (WHO) declared TB as a global 
health emergency. In November 2017, the governments of Brazil, the Russian Federation, India, 
China and South Africa announced the establishment of a collaborative TB research network, 
the aim of which is to accelerate TB research and innovation through cooperation mechanisms7-
9.  
TB is considered as a contagious disease and attacks lungs of the infected human10, 11. 
Depending upon the stage of infection, M. tuberculosis resides in a variable microenvironment. 
It has a unique ability to survive against neutrophils, monocytes, macrophages and dendritic 
cells from the host cells by preventing the fusion between lysosomes and phagosomes. M. 
tuberculosis prolongs its survival by inhibiting the host cell apoptosis12. 
Heterocyclic chemistry in literature has been well documented for its immense application in 
medicinal chemistry towards hunt for new drugs. Owing to the drug resistance against available 
antibiotics in market, a need for the new drugs is high demand in the current scientific world13. 
Amongst, quinazoline is a class of heterocyclic compound which comprises of two conjoined 
aromatic rings with two nitrogen atoms as integral part of the ring and one carbon oxidized with 
keto-oxygen14. The first synthesis of quinazoline derivative dates to 1860s, involving reaction 
between anthranilic acid and various cyanogens15. Earlier these class of compounds found 
application only as sedatives. However, since the last century until recently, quinazoline and its 
related derivatives have gained immense acknowledgement in the field of medicinal chemistry 
owing to their wide and versatile spectrum of biological activity1, 16 (Figure 1)17.  
                                                                                                                                                     Chapter 4 
Narva Deshwar Kushwaha 110                                        UKZN-2020 
 
 
Figure 1: General structure of quinazoline ring with their biological goal. 
They are well known in literature as antiviral, antiallergic, antidiabetic, anticancer and 
antimicrobial agents12, 18-21. Recently, they have also been known to possess coronary 
vasodilatory and histamine receptor type 3 inverse agonism22, 23. Several drugs are based on 
quinazoline unit (Figure 2) like erlotinib (in the treatment of several types of tumors)24, 
prazosin (as an R-adrenergic blocker)25, gefitinib (epidermal growth factor receptor (EGFR) 
inhibitor)26, 27 and linagliptin (dipeptidyl peptidase-4 inhibitor), febrifugine (antimalarial) etc. 
have been approved by Food and Drug Administration (FDA). Wide applicability of 
quinazoline based derivatives as drugs prompted chemists towards development of strategies for 
easy synthesis. Motivated by this, in the present study, quinazoline based derivatives were 
synthesized, fully characterized and preliminary evaluation conducted for anti-tuberculosis 
activity. 
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Figure 2: Commercial drugs containing quinazoline ring. 
2. Results and Discussion 
2.1. Chemistry 
The synthesis of novel quinazoline derivatives (10a-q and 17a-c) and their respective 
intermediates were achieved through effective and easy synthetic routes as depicted in Scheme 
1 and 2. 2 was synthesized as per our previous report (Chapter 3), while 5 was obtained by 
nucleophilic substitution of 3,4-difluorobenzaldehyde with morpholine. Compounds 2 and 5 
were condensed in presence of pTSA in methanol to yield (2-(3-fluoro-4-morpholinophenyl)-6-
nitro-2,3-dihydroquinazolin-4(1H)-one) (6) which was subjected to oxidation with KMnO4 in 
DMSO to yield 2-(3-fluoro-4-morpholinophenyl)-6-nitroquinazolin-4-ol (7). The nitro reduction 
of 7 was performed in presence of Fe/NH4Cl to afford 6-amino-2-(3-fluoro-4-
morpholinophenyl)quinazolin-4-ol (8). Subsequently, a series of compounds (10a-q) were 
synthesized by reacting 8 with the acid/sulphonyl chloride in presence of TEA in DCM at 0°C 
to rt for 4 h and pyridine in DCM at 0°C to rt for 16 h correspondingly. The compound 10a was 
further hydrolyzed by 2N NaOH in ethanol at rt for 16 h to give 2-((2-(3-fluoro-4-
morpholinophenyl)-4-hydroxyquinazolin-6-yl)amino)-2-oxoacetic acid (11) as illustrated in 
Scheme 1. 
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In addition, compound (7) was chlorinated with POCl3 at 130°C for 16 h to yield 4-(4-(4-
chloro-6-nitroquinazolin-2-yl)-2-fluorophenyl) morpholine (12). Further, 12 was substituted 
with cyclopropyl amine in presence of K2CO3/DMF at rt for 16 h to afford N-cyclopropyl-2-(3-
fluoro-4-morpholinophenyl)-6-nitroquinazolin-4-amine (14) which in presence of Fe/NH4Cl 
undergoes nitro reduction to yield N4-cyclopropyl-2-(3-fluoro-4-morpholinophenyl) 
quinazoline-4,6-diamine (15). Further, another series of derivatives (17a-c) was synthesized by 
reaction of 15 with acid/sulphonyl chloride by using similar condition as mentioned in Scheme 
1.  
The structures of all intermediates (5-8, 12 and 14-15) and their corresponding final derivatives 
(10a-q and 17a-c) were established using IR and NMR (1H and 13C). All the newly synthesized 
intermediates and their corresponding final derivatives show the acceptable analysis of 
predicted structures which are summarized in experimental section. The conversion of 3 to 5 
was confirmed by the appearance of two triplet signal of 4H at around 3.86 ppm and 3.24 ppm 
in NMR spectra. The IR spectrum of intermediate compound 6 clearly showed characteristic 
absorption band around 3278.89 and 3198.58 cm-1 for amide and amine (N-H), 1662.36 cm-1 for 
carbonyl (C=O), 1334.63 cm-1 for nitro (NO2) and 1111.15 cm-1 for C-F, which confirm the 
formation of 6. These finding were further confirmed by 1H NMR which exhibited prominent 
signal of chiral proton at around 5.96 ppm along with broad singlets at around 8.65 and 8.47 
ppm, accounting for the adjacent N-H protons. Formation of 7 by oxidation of 6 was confirmed 
by disappearance of absorption band of amide and amine (N-H) in IR spectra and the signal of 
chiral proton along with N-H protons in NMR spectra. In addition, the presence of distinctive 
broad singlet at around 12.56 ppm confirms the presence of OH proton. The conversion of nitro 
to amine (8) was confirmed by disappearance of absorption band 1338.04 cm-1 of NO2 in IR 
spectra and presence of broad singlet of amine (-NH2) proton at around 5.63 ppm in NMR 
spectra. Furthermore, derivatization to the final compounds (10a-q) from scaffold 8 with 
acid/sulphonyl chloride were confirmed by disappearance of amine (NH2) proton and 
appearance of most distinctive amide proton at around 9.84 - 11.10 ppm in case of (10a-k and 
10m) and secondary amine (NH) proton at around 6.87 ppm for 10l. These finding were further 
supported by IR and 13C NMR analysis. The stretching frequencies in the region 1652.22-
1724.56 cm-1 and 3079.21-3393.66 cm-1 in IR spectra of compounds (10a-k and 10m) indicate 
the presence of amide (C=O and N-H) group. Although IR spectrum of some derivatives (10n-
q) showed the broad band in the region of 3067.19- 3085.09 cm-1, 1483.80-1442.19 cm-1 and 
1159.85-1165.30cm-1 are assigned for sulphonamide N-H, asymmetric and symmetric mode of 
O=S=O group, respectively. 
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In another series, the conversion of 7 to 12 was confirmed by the disappearance of OH proton in 
NMR spectra and supported by appearance of new absorption band around 735.50 cm-1 in IR for 
C-Cl. Subsequently, substitution of chloro with cyclopropyl amine to yield 14 was confirmed by 
the appearance of distinct N-H proton at around 9.28 ppm in NMR and disappearance of C-Cl 
absorption band in IR Spectra. The synthesis of intermediate (15) from the nitro reduction of 14 
was authenticated by the presence of characteristic NH2 proton at around 5.37 ppm in the NMR 
spectra as well as the disappearance of nitro (NO2) stretching frequency 1323.02 cm-1 in IR 
spectra. The conversion to the final derivatives (17a-c) from intermediate 15 was confirmed by 
the appearance of amide (N-H) proton at around 10.09–10.93 ppm along with disappearance of 
amine (NH2) protons. These results were further supported by IR spectral analysis. The 
absorption band in the region 3312.75 – 3333.80 cm-1 and 1666.39 – 1695.08 cm-1 in case of 
(17a-b) confirm the presence of amide group, while in the case of 17c the stretching frequency 
around 3414.18 cm-1, 1351.64 cm-1 and 1153.53 cm-1 assigned for sulphonamide N-H, 
asymmetric and symmetric mode of O=S=O group, respectively. 
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Scheme 1: Reagents and conditions: i) 28% aqueous ammonia solution, EDC.HCl, HOBt, 
DMF, 3–5 h; ii) K2CO3, DMF, 130°C, 16 h; iii) pTSA, MeOH, 70°C, 16 h; iv) KMnO4, DMSO, 
100°C, 16 h; v) Fe, NH4Cl, Dioxane: EtOH: H2O (7:5:3), 100°C, 5 h; vi) TEA, DCM, 0°C - rt, 4 
h. or Pyridine, DCM, 0°C - rt, 16 h. vii) NaOH, EtOH, rt, 16 h. 
 
Scheme 2: Reagents and conditions: i) POCl3, 130°C, 16 h; ii) K2CO3, DMF, rt, 16 h; iii) Fe, 
NH4Cl, Dioxane: EtOH: H2O (7:5:3), 100°C, 5 h; iv) TEA, DCM, 0°C - rt, 4 h. or Pyridine, 
DCM, 0°C - rt, 16 h. 
2.2. Biology 
The synthesized derivatives have been evaluated against M. tuberculosis (Strain H37Rv) and the 
results as % inhibition have been tabulated in Table 1.  
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Table 1: Compounds tested against M. tuberculosis strain H37Rv. 
Compound (20 µM) % Inhibition Compound (20 µM) % Inhibition 
10a 11 10m 33 
10b 4 10n -1 
10c 6 10o 7 
10d 2 10p -2 
10e -2 10q 5 
10f 0 11 0 
10g 3 12 0 
10h -1 10l 13 
10i -5 17a 3 
10j -2 17b 2 
10k 6 17c 25 
10l 13   
 
Compounds of these series were preliminary tested against M. tuberculosis strain H37Rv with 
20 µM concentration to find out percentage zone of inhibition, which are shown in Table 1. We 
used Rifampicin as a standard for this study. Compound 10m showed 33 (≥ 30) percentage zone 
of inhibition, which will be further consider for the study like MIC, MBC etc. 
3. Conclusion 
In this chapter, we report rational design-based synthesis, spectral studies and preliminary anti-
mycobacterial screening of novel quinazoline derivatives against Mycobacterium tuberculosis 
H37Rv strain. A total of 21 derivatives were synthesized, well-characterized by IR, NMR (1H, 
13C) and screened against Mycobacterium tuberculosis H37Rv strain. In broader way, the 
synthesized novel compounds did not show significant percentage zone of inhibition. The only 
notable percentage zone of inhibition was shown by compound 10m that was 33% after 24 h 
incubation. The further evaluation of this molecule for MIC and MBC can be of interest in 
future.  
4. Experimental 
4.1. General consideration 
All the fine chemicals, reagents and solvents were purchased from Sigma Aldrich and Merck 
and were used without further purification unless otherwise stated. The progress of the reactions 
and the purity of the compounds were monitored by thin-layer chromatography (TLC) on pre-
coated silica gel plates procured from E. Merck and Co. (Darmstadt, Germany) visualized by 
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UV lamp (254 or 365 nm). Purification was performed by using combi-flash (CombiFlash® 
NextGen 300+) column chromatography. The melting points of the synthesized compounds 
have been determined and uncorrected using a digital Stuart SMP10 melting point Apparatus. 
The Fourier transform infrared (FTIR) spectra were recorded in the spectral range of 400-4000 
cm-1 on a Bruker Alpha FT-IR spectrometer using the ATR technique. The NMR spectra (1H, 
and 13C,) were recorded using CDCl3 and DMSO-d6 on Bruker AVANCE III 400 and 600 MHz 
spectrometer. Chemical shifts were determined relative to internal standard TMS at δ 0.0 parts 
per million (ppm) and the coupling constants were reported in Hertz. The multiplicities of the 
NMR resonances were abbreviated as s (singlet), d (doublet), dd (doublet of doublet), (t 
(triplet), q (quartet), m (multiplet) and brs (broad singlet). 
4.2. Chemistry 
4.2.1. Synthesis and spectral characterization of compounds 5, 6, 7 and 8; 
4.2.1.1. Synthesis of 3-fluoro-4-morpholinobenzaldehyde (5); 
 
To the solution of 3,4-difluorobenzaldehyde (10 g, 70.37 mmol) in DMF (50 mL) were added 
K2CO3 (19.42 g, 140.74 mmol) followed by morpholine (7.38 mL, 84.44 mmol) at room 
temperature. The reaction mixture was stirred at 130°C for 16 h, monitored by TLC after 
consumption of starting material poured into  ice cold water precipitate was formed filtered and 
dried under vacuum, washed with pentane to afford yellow solid product (11.45 g, 78%); mp: 
63-66°C; FTIR (ATR, Vmax, cm-1): 2977.28 (Ar-H str.), 1677.18 (C=O str.), 1237.52 (C-N str.), 
1110.22 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ  9.82 (s, 1H), 7.58 (d, J = 8.46 Hz, 
1H), 7.52 (d, J = 13.50 Hz, 1H), 6.97 (t, J = 8.40 Hz, 1H), 3.86 (t, J = 5.12 Hz, 4H), 3.24 (t, J = 
5.06 Hz, 4H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 189.9, 155.7 – 154.0 (d, JC-F = 249 Hz, 
1C), 145.3 – 145.2 (d, JC-F = 8.47 Hz, 1C), 130.55 – 130.51 (d, JC-F = 6.60 Hz, 1C), 128.0 – 
127.9 (d, JC-F = 2.43 Hz, 1C), 117.79 – 117.77 (d, JC-F = 3.72 Hz, 1C), 116.3 – 116.1 (d, JC-F = 
22.32 Hz, 1C), 66.8, 50.1.  
4.2.1.2. Synthesis of 2-(3-fluoro-4-morpholinophenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)-one 
(6); 
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To the solution of 2-amino-5-nitrobenzamide (10 g, 55.2 mmol) and 3-fluoro-4-
morpholinobenzaldehyde (11.54 g, 55.2 mmol) in methanol (60 mL) was added catalytic 
amount of p-toluenesulfonic acid (2.1 g, 11.04 mmol). The resultant mixture was reflux for 4 h, 
precipitate was formed, filtered and washed with methanol to afford yellow solid product (17.3 
g, 84%); mp: 255-260°C; FTIR (ATR, Vmax, cm-1): 3278.89 (N-H str.), 3198.58 (N-H str.), 
2974.38 (Ar-H str.), 1662.36 (C=O str.), 1614.71 (Ar C=C str.), 1502.87 (N-H bend), 1334.63 
(Ar-NO2 str.), 1111.15 (C-F str.), 1056.88 (C-O-C str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ  
8.65 (s, 1H), 8.47 (s, 1H), 8.43 (d, J = 2.88 Hz, 1H), 8.09 (dd, J = 2.54 Hz, J = 9.22 Hz, 1H), 
7.23 – 7.19 (m, 2H), 7.06 (t, J = 8.48 Hz, 1H),  6.83 (d, J = 9.28 Hz, 1H), 5.95 (s, 1H), 7.32 (t, J 
= 5.01 Hz, 4H), 2.99 (t, J = 4.84, Hz, 4H).  13C NMR (150 MHz, DMSO-d6, 25°C) δ 161.2, 
155.2 – 153.6 (d, JC-F = 245 Hz, 1C), 151.9, 140.06 – 140.00 (d, JC-F = 8.01 Hz, 1C), 137.2, 
135.4 – 135.3 (d, JC-F = 6.80 Hz, 1C), 128.9, 124.1, 122.82 – 122.81 (d, JC-F = 3.35 Hz, 1C), 
118.94 – 118.92 (d, JC-F = 3.21 Hz, 1C), 114.3 – 114.2 (d, JC-F = 22.18 Hz, 1C), 114.3, 112.6, 
66.0, 65.2, 50.3.   
4.2.1.3. Synthesis of 2-(3-fluoro-4-morpholinophenyl)-6-nitroquinazolin-4-ol (7); 
 
 To the solution of 2-(3-fluoro-4-morpholinophenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)-one 
(25 g, 67.3 mmol) in DMSO (100 mL) was added potassium permanganate (31.82 g, 201.41 
mmol). The mixture was heated at 120°C for 24 h and monitored by TLC after consumption of 
starting material cooled to room temperature and filtered through celite. The filtrate was poured 
into ice cold water and stirred for 30 min precipitate was formed, filtered and washed with 
diethyl ether to afford title compound (21 g, 84%); mp: 295-297°C; FTIR (ATR, Vmax, cm-1): 
3175.84 (O-H str.), 2950.24 (Ar-H str.), 2856.00 (Ar-H str.), 1676.86 (C=O str.), 1516.20 (Ar 
C=C str.), 1338.87 (Ar-NO2 str.), 1243.19 (C-N str.), 1117.50 (C-F str.), 1074.99 (C-O-C str);  
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1H NMR (600 MHz, DMSO-d6, 70°C) δ 12.56 (brs, 1H), 8.77 (d, J = 2.05 Hz,1H), 8.46 (dd, J = 
8.88 Hz, J = 2.13 Hz, 1H), 8.04 – 7.99 (m, 2H), 7.79 (d, J = 8.92 Hz, 1H), 7.11 (t, J = 8.91 Hz, 
1H), 3.77 ( t, J = 4.32 Hz, 4H), 3.20 (t, J = 4.05 Hz, 4H). 13C NMR (150 MHz, DMSO-d6, 70°C) 
δ 161.0, 154.1 – 152.5 (d, JC-F = 244.28 Hz, 1C), 153.8, 152.5, 144.1, 142.5 – 142.4 (d, JC-F = 
7.81 Hz, 1C), 128.3, 127.9, 124.88 - 124.86 (d, JC-F = 2.27 Hz,1C), 124.16 – 124.11 (d, JC-F = 
7.74 Hz, 1C), 121.6, 120.3, 117.9 – 117.8 (d, JC-F = 3.63 Hz, 1C), 115.5 – 115.4 (d, JC-F = 24.94 
Hz 1C), 65.6, 49.5.   
4.2.1.4. Synthesis of 6-amino-2-(3-fluoro-4-morpholinophenyl)quinazolin-4-ol (8); 
 
2-(3-fluoro-4-morpholinophenyl)-6-nitroquinazolin-4-ol (6 g, 16.20 mmol) was added into the 
mixture of dioxane (42 mL), ethanol (30 mL) and water (18 mL) followed by ammonium 
chloride (8.66 g, 162.01 mmol). To the resultant mixture iron powder (4.52 g, 81 mmol) was 
added with vigorous stirring and then heated at 100°C for 4 h. The reaction mixture was cool to 
room temperature and filtered through celite and washed with 10% MeOH/DCM. The filtrate 
was concentrated under reduce pressure and diluted with water then extracted with 10% 
IPA/CHCl3 (3 X 50 mL). The combined organic layer was dried over anhydrous Na2SO4, 
filtered and evaporated under reduce pressure to afford yellow solid product (3.8 g, 68%); mp: 
280-283°C; FTIR (ATR, Vmax, cm-1): 3445.93 (N-H str. of NH2), 3305.38 (O-H str.), 3168.74 
(N-H str.), 2966.17 (Ar-H str.), 1660.92 (C=O str.), 1485.46 (Ar C=C str.), 1243.61 (C-N str.), 
1114.65 (C-F str.), 1042.63 (C-O-C str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ  11.99 (brs, 
1H)7.94 – 7.91 (m, 2H), 7.43 (dd, J = 8.92 Hz, J = 1.76 Hz, 1H), 7.21 (d, J = 1.76 Hz, 1H), 7.10 
– 7.09 (m, 2H), 5.63 (s, 2H), 3.75 (t, J = 4.27 Hz, 4H),  3.10 (t, J = 4.31 Hz, 4H).  13C NMR 
(150 MHz, DMSO-d6,  25°C) δ 162.1, 154.8 – 153.2 (d, JC-F = 242 Hz, 1C), 147.7, 145.9, 141.3 
– 141.2 (d, JC-F = 7.9 Hz, 1C), 139.5, 128.2, 126.7 – 126.6 (d, JC-F = 7.80 Hz, 1C), 123.6, 122.4, 
121.8, 118.3, 114.6 – 114.4 (d, JC-F = 24.50 Hz, 1C), 106.2, 66.0, 50.0.  
4.2.2. General procedure for synthesis and spectral characterization of derivatives (10a-l), 
10m and (10n-q); 
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4.2.2.1. General procedure A for synthesis of derivatives (10a-10l); To the suspension of 6-
amino-2-(3-fluoro-4-morpholinophenyl)quinazolin-4-ol (1.0 equiv) in DCM, were added 
triethyl amine (1.5 equiv), followed by appropriate acid chloride (9a-9l, 1.5 equiv) at 0°C. The 
resultant mixture was stirred at room temperature for 2 h, quenched with sodium bicarbonate 
solution and extracted with DCM (3 x 30 mL). The combined organic layer was dried over 
anhydrous Na2SO4, filtered and evaporated under reduce pressure to give solid residue which 
were triturated with diethyl ether and filtered to afford desired title compounds (10a-10l). 
4.2.2.2. Procedure B for synthesis of derivative (10m); To the solution of 6-amino-2-(3-fluoro-
4-morpholinophenyl)quinazolin-4-ol (0.1 g, 0.29 mmol) in DCM (10 mL) was added triethyl 
amine (0.06 mL, 0.44 mmol), followed by 2-bromoacetyl bromide (0.038 mL, 0.44 mmol) at 
0°C. The resultant mixture was stirred at room temperature for 4 h, precipitate was formed, 
filtered and washed with pentane to afford salt of 2-bromo-N-(2-(3-fluoro-4-
morpholinophenyl)-4-hydroxyquinazolin-6-yl)acetamide (0.15 g), which was  dissolved in 
DMF (7 mL) and were added potassium carbonate (0.12 gm, 0.88 mmol), followed by 
cyclopropanamine (0.04 mL, 0.58 mmol) at room temperature. The resultant mixture was stirred 
at room temperature for 16 h, then diluted with ethyl acetate and washed with cold brine 
solution (3 x 10 mL). The organic layer dried over anhydrous Na2SO4, filtered and evaporated 
under reduce pressure to yield crude product which was recrystallized with ethanol to afford the 
pure yellow solid product 
4.2.2.3. General procedure B for synthesis of derivatives (10n-10q); To the solution of 6-
amino-2-(3-fluoro-4-morpholinophenyl)quinazolin-4-ol (1.0 equiv) in DCM were added 
pyridine (8.0 equiv), followed by appropriate sulfonyl chloride (9m-9p, 1.5 equiv) at 0°C. The 
resultant mixture was stirred at room temperature for 16 h, quenched with 2N-HCl solution and 
extracted with DCM (3 x 20 mL). The combined organic layer was dried over anhydrous 
Na2SO4 and evaporated under reduced pressure to yield the crude, which was triturated with 
diethyl ether and filtered to afford the desired title compounds (10n-10q). 
4.2.2.1.1. ethyl 2-((2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)amino)-2-
oxoacetate (10a); 
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Off white solid, yield: 85%, mp: 295-297°C; FTIR (ATR, Vmax, cm-1): 3382.37 (N-H str.), 
3175.43 (O-H str), 2966.20 (Ar-H str.), 1663.13 (C=O str.), 1551.62 (Ar C=C str.), 1249.99 (C-
N str.), 1115.10 (C-F str), 1020.80 (C-O-C str); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 12.41 
(brs, 1H), 11.10 (s, 1H), 8.64 (s, 1H), 8.10 – 7.97 (m, 3H), 7.70 (d, J = 8.60 Hz, 1H), 7.13 (t, J = 
8.32 Hz, 1H), 4.33 (q, J = 5.89 Hz, 2H), 3.75 (t, J = 4.85 Hz, 4H), 3.13 (t, J = 4.68 Hz, 4H), 
1.33 (t, J = 6.57 Hz, 3H). 13C NMR (150 MHz, DMSO-d6,  25°C) δ 161.9, 160.4, 155.5, 155.1 – 
152.7 (d, JC-F = 243 Hz, 1C), 150.1, 145.6, 142.1, 136.6, 127.9, 127.3, 125.7 – 125.6 (d, JC-F = 
8.47 Hz, 1C), 124.3, 120.9, 118.4, 116.0, 115.3 – 115.0 (d, JC-F = 23.79 Hz, 1C), 66.0, 62.5, 
49.8, 13.8.  
3.2.2.1.2. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)isobutyramide (10b);  
 
Yellow solid, yield: 55%, mp: 290-292°C; FTIR (ATR, Vmax, cm-1): 3274.28 (O-H str.), 3175.33 
(N-H str.), 2963.45 (Ar-H str.), 1669.88 (C=O str.), 1545.57 (Ar C=C str.), 1250.41 (C-N str.), 
1116.76 (C-F str.), 1045.48 (C-O-C str); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.03 (s, 1H), 
8.35 (d, J = 2.61 Hz, 1H), 8.09 – 8.06 (m, 2H), 8.02 (d, J = 1.97 Hz, 1H), 7.85 (dd, J = 9.04 Hz, 
J = 2.40 Hz, 1H), 7.51 (d, J = 8.82 Hz, 1H), 7.06 (t, J = 9.11 Hz, 1H), 3.75 (t, J = 4.82 Hz, 4H), 
3.09 (t, J = 4.97 Hz, 4H), 2.66 – 2.60 (m, 1H), 1.12 (d, J = 6.87 Hz, 6H). 13C NMR (100 MHz, 
DMSO d6, 25°C) δ 175.0, 167.3, 155.4 – 153.0 (d, JC-F = 242 Hz, 1C), 154.6, 146.3, 140.8, 
140.7, 135.8, 126.8, 125.0, 124.1, 121.2, 118.0, 115.1 – 114.9 (d, JC-F = 22.72 Hz, 1C), 114.7, 
66.1, 50.1, 34.9, 19.5.   
4.2.2.1.3. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)-3-methylbutanamide 
(10c);  
  
Yellow solid, yield: 75%, mp: 292-295°C;  FTIR (ATR, Vmax, cm-1): 3270.09 (O-H str.), 
3167.60 (N-H str.), 2960.52 (Ar-H str.), 2866.94 (Ar-H str.), 1659.23 (C=O str.), 1529.07 (Ar 
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C=C str.), 1248.98 (C-N str.), 1117.72 (C-F str.), 1055.56 (C-O-C str);  1H NMR (600 MHz, 
DMSO-d6, 25°C) δ 10.10 (s, 1H), 8.42 (d, J = 2.28 Hz, 1H), 8.05 - 7.99 (m, 2H), 7.86 (dd, J = 
8.91 Hz, J = 2.31 Hz, 1H), 7.57 (d, J = 8.88 Hz, 1H), 7.08 (t, J = 9.05 Hz, 1H), 3.75 (t, J = 4.71 
Hz, 4H), 3.11 (t, J = 4.66 Hz, 4H), 2.23 (d, J = 7.14 Hz, 2H), 2.14 - 2.08 (m, 1H), 0.95 (d, J = 
6.64 Hz, 6H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 170.6, 164.8, 154.8 - 153.2 (d, JC-F  = 
246 Hz, 1C), 152.2, 145.5, 141.29 - 141.24 (d, JC-F = 9.07 Hz, 1C), 136.4, 128.7, 127.2, 125.5, 
124.1, 121.1, 118.16 – 118.13 (d, JC-F = 3.82 Hz, 1C), 115.0 - 114.9 (d, JC-F = 24.87 Hz, 1C), 
114.5, 66.0, 50.0, 45.6, 25.5, 22.2. 
4.2.2.1.4. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-
yl)cyclopropanecarboxamide (10d);  
 
Yellow solid, yield: 54%, mp: 278-280°C; FTIR (ATR, Vmax, cm-1): 3267.00 (O-H str.), 3170.92 
(N-H str.), 2970.39 (Ar-H str.), 2885.24 (Ar-H str.), 1654.85 (C=O str), 1533.04 (Ar C=C str.), 
1250.58 (C-N str.), 1115.19 (C-F str.), 1055.04 (C-O-C str);  1H NMR (600 MHz, DMSO-d6, 
25°C) δ 12.79 (brs, 1H), 10.49 (s, 1H), 8.46 (s, 1H), 8.00 - 7.92 (m, 3H), 7.64 (d, J = 9.18 Hz, 
1H), 7.11 (t, J = 8.82 Hz, 1H), 3.75 (t, J = 4.93 Hz, 4H), 3.13 (t, J = 4.82 Hz, 4H), 1.81 – 1.79 
(m, 1H) 0.85 – 0.82 (m, 4H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 171.8, 162.1, 154.7 – 
153.1 (d, JC-F = 242.87, 1C ), 149.4, 144.3, 141.87 – 141.82 (d, JC-F = 7.34 Hz, 1C),  137.4, 
127.8, 126.0, 126.0, 124.2 – 124.1 (d, JC-F = 2.98 Hz, 1C), 121.0, 118.36 – 118.34 (d, JC-F = 3.86 
Hz, 1C), 115.1 – 114.9 (d, JC-F = 23.71 Hz, 1C), 114.1, 65.9, 49.9, 14.6, 7.3.  
3.2.2.1.5 N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)butyramide (10e); 
 
Yellow solid, yield: 75%, mp: 282-284°C; FTIR (ATR, Vmax, cm-1): 3275.22 (O-H str.), 3168.10 
(N-H str.), 2960.50 (Ar-H str.), 2867.02 (Ar-H str.), 1654.63 (C=O str), 1530.81 (Ar C=C str.), 
1248.45 (C-N str.), 1117.10 (C-F str.), 1055.15 (C-O-C str.); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 10.11 (s, 1H), 8.39 (s, 1H), 8.05 – 7.99 (m, 2H), 7.85 (d, J = 8.26 Hz, 1H), 7.56 (d, J = 
8.66 Hz, 1H), 7.09 (t, J = 8.37 Hz, 1H), 3.75 (t, J = 3.82 Hz, 4H), 3.10 (t, J = 3.88 Hz, 4H), 2.32 
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(t, J = 7.44 Hz, 2H), 1.66 – 1.61 (m, 2H), 0.93 (t, J = 7.17 Hz, 3H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 171.2, 165.6, 155.3 – 152.9 (d, JC-F = 244 Hz, 1C), 145.7, 141.2, 141.1, 
136.3, 129.3, 127.2, 125.3, 124.1, 121.2, 118.1, 115.1 – 114.9 (d, JC-F = 23.44 Hz, 1C), 114.5, 
66.0, 50.1, 38.3, 18.3, 13.6. 
4.2.2.1.6. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)pentanamide (10f); 
 
Yellow solid, yield: 65%, mp: 286-288°C;  FTIR (ATR, Vmax, cm-1): 3281.07 (O-H str.), 
3169.33 (N-H str.), 2960.59 (Ar-H str.), 2866.04 (Ar-H str.), 1652.22 (C=O str), 1531.89 (Ar 
C=C str.), 1248.96 (C-N str.), 1118.24 (C-F str.), 1055.15 (C-O-C str); 1H NMR (600 MHz, 
DMSO-d6, 25°C) δ 12.33 (s, 1H), 10.23 (s, 1H), 8.50 (s, 1H), 7.99 – 7.91 (m, 3H), 7.65 (s, 1H), 
7.12 (s, 1H), 3.75 (t, J = 4.03 Hz, 4H), 3.13 (t, J = 4.30 Hz, 4H), 2.35 (t, J = 6.96 Hz, 2H), 1.67 
– 1.52 (m, 2H), 1.47 – 1.19 (m, 2H), 0.91 (t, J = 7.35 Hz, 3H). 13C NMR (150 MHz, DMSO d6, 
65°C) δ 171.2, 161.7, 154.5 – 152.9 (d, JC-F = 242.34 Hz, 1C), 149.1, 141.6 – 141.5 (d, JC-F = 
9.18 Hz, 1C), 137.3, 127.3, 126.0, 125.7, 123.9, 120.7, 118.0, 114.9 – 114.7 (d, JC-F = 23.78 Hz, 
1C), 114.2, 65.7, 49.7, 35.8, 26.8, 21.4, 13.2. 
4.2.2.1.7. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-
yl)cyclohexanecarboxamide (10g); 
 
Yellow solid, yield: 45%, mp: 293-296°C;  FTIR (ATR, Vmax, cm-1): 3269.25 (O-H str.), 
3166.55 (N-H str.), 2971.62 (Ar-H str.), 2865.58 (Ar-H str.), 1660.06 (C=O str), 1529.93 (Ar 
C=C str.), 1249.56 (C-N str.), 1119.77 (C-F str.), 1055.72 (C-O-C str); 1H NMR (600 MHz, 
DMSO-d6, 60°C) δ 12.20 (s, 1H), 10.01 (s, 1H), 8.57 (s, 1H), 8.08 – 7.93 (m, 3H), 7.73 (s, 1H), 
7.23 (s, 1H), 3.87 (t, J = 6.72 Hz, 4H), 2.60 (t, J = 6.83 Hz, 4H), 1.95 – 1.40 (m, 11H). 13C 
NMR (150 MHz, DMSO-d6, 60°C) δ 174.2, 161.7, 154.5 – 152.9 (d, JC-F = 243 Hz, 1C), 149.1, 
144.15, 141.6 – 141.5 (d, JC-F = 7.80 Hz, 1C), 137.4, 127.3, 126.0, 125.8 – 125.7 (d, JC-F = 8.22 
Hz, 1C), 123.9, 120.8, 118.1, 114.9 – 114.7 (d, JC-F = 23.83 Hz, 1C), 114.3, 65.7, 49.76, 44.6, 
28.8, 25.1, 24.9. 
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4.2.2.1.8. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)acetamide (10h);   
 
Yellow solid, yield: 90%, mp: 295-297°C;  FTIR (ATR, Vmax, cm-1): 3273.13 (O-H str.), 
3167.80 (N-H str.), 2972.46 (Ar-H str.), 2866.95 (Ar-H str.), 1656.52 (C=O str), 1530.92 (Ar 
C=C str.), 1246.14 (C-N str.), 1113.43 (C-F str.), 1055.54 (C-O-C str); 1H NMR (400 MHz, 
DMSO-d6, 25°C) δ 12.33 (brs, 1H), 10.28 (s, 1H), 8.45 (s, 1H), 8.01 – 7.79 (m, 2H), 7.89 – 7.86 
(m, 1H), 7.61 (d, J = 8.01 Hz, 1H), 7.10 (s, 1H), 3.75 (t, J = 3.97 Hz, 4H), 3.11 (t, J = 3.39 Hz, 
4H), 2.09 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 168.4, 155.3 – 152.8 (d, JC-F = 243 
Hz, 1C), 145.4, 141.4 – 141.3 (d, JC-F = 7.72 Hz, 1C), 136.6, 127.3, 125.4, 124.2, 121.1, 115.1 – 
114.9 (d, JC-F = 25 Hz, 1C), 114.3, 66.0, 50.0, 24.0. 
4.2.2.1.9 N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-
yl)cyclobutanecarboxamide (10i); 
 
Yellow solid, yield: 68%, mp: 290-294°C; FTIR (ATR, Vmax, cm-1): 3271.92 (O-H str.), 2989.00 
(Ar-H str.), 2858.87 (Ar-H str.), 1672.08 (C=O str), 1518.59 (Ar C=C str.), 1251.60 (C-N str.), 
1118.67 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 60°C) δ 9.84 (s, 1H), 8.41 (s, 1H), 8.02 – 
7.91 (m, 3H), 7.57 (d, J = 6.34 Hz, 1H), 7.08 (s, 1H), 3.76 (t, J = 4.74 Hz, 4H), 3.31 – 3.24 (m, 
1H), 3.14 (t, J = 4.27 Hz, 4H), 2.33 – 2.22 (m, 2H), 2.21 – 2.09 (m, 2H), 1.19 – 1.85 (m, 2H). 
13C NMR (150 MHz, DMSO-d6, 60°C) δ 172.7, 164.1, 154.6 – 153.0 (d, JC-F = 242 Hz, 1C), 
151.6, 145.1, 141.1 – 141.0 (d, JC-F = 9.37 Hz, 1C), 136.4, 128.2, 126.9, 125.5, 123.9, 120.9, 
117.9, 114.9 – 114.7 (d, JC-F = 23.76 Hz, 1C), 114.5, 78.8, 65.8, 49.8, 24.2, 17.49. 
4.2.2.1.10. 2-chloro-N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)acetamide 
(10j); 
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Yellow solid, yield: 68%, mp: 295-297°C; FTIR (ATR, Vmax, cm-1): 3247.85 (O-H str.), 3079.21 
(N-H str.), 2967.24 (Ar-H str.), 2859.64 (Ar-H str.), 1656.18 (C=O str), 1535.39 (Ar C=C str.), 
1246.48 (C-N str.), 1116.07 (C-F str.), 1046.04 (C-O-C str); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 12.38 (brs, 1H), 10.83 (s, 1H), 8.50 (s, 1H), 7.98 – 7.95 (m, 3H), 7.68 (s, 1H), 7.10 (s, 
1H), 4.33 (s, 2H), 3.74 (t, J = 5.10 Hz, 4H), 3.12 (t, J = 5.26 Hz, 4H). 13C NMR (150 MHz, 
DMSO-d6, 30°C) δ 164.8, 161.9, 154.6 – 153.0 (d, JC-F = 244 Hz, 1C), 149.8, 144.6, 142.0 – 
141.9 (d, JC-F = 7.78 Hz, 1C), 136.7, 127.7, 126.3, 125.5 – 125.5 (d, JC-F = 7.61 Hz, 1C), 124.3, 
120.9, 118.33 – 118.31 (d, JC-F = 4.09 Hz, 1C), 115.2 – 115.0 (d, JC-F = 24.26 Hz, 1C), 114.6, 
65.9, 49.8, 43.4. 
4.2.2.1.11. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)benzamide (10k);
 
Yellow solid, yield: 36%, mp: 296-298°C; FTIR (ATR, Vmax, cm-1): 3393.66 (N-H str.), 3277.16 
(O-H str.), 2966.37 (Ar-H str.), 2847.14 (Ar-H str.), 1724.56 (C=O str), 1671.73 (C=O str. 
Keto-enol), 1535.36 (Ar C=C str.), 1253.47 (C-N str.), 1089.48 (C-O-C str); 1H NMR (600 
MHz, DMSO-d6, 70°C) δ 12.13 (brs, 1H), 10.39 (s, 1H), 8.64 (s, 1H), 8.18 – 8.01 (m, 5H), 7.70 
– 7.54 (m, 4H), 7.13 (s, 1H), 3.77 (t, J = 5.15 Hz, 4H), 3.17 (t, J = 5.51 Hz, 4H). 13C NMR (150 
MHz, DMSO-d6, 70°C) δ 165.3, 152.8, 137.1, 134.4, 132.3, 131.2, 128.8, 128.4, 128.09, 128.02, 
127.3, 127.0, 123.9, 120.7, 118.1, 115.6, 114.9 – 114.8 (d, JC-F = 23.10 Hz, 1C), 65.7, 49.7. 
4.2.2.1.12. 2-(3-fluoro-4-morpholinophenyl)-6-((3-fluorobenzyl)amino)quinazolin-4-ol (10l); 
 
Yellow solid, yield: 41%, mp: 200-205°C; FTIR (ATR, Vmax, cm-1): 3456.45 (O-H str.), 3163.56 
(N-H str.), 2969.43 (Ar-H str.), 2865.71 (Ar-H str.), 1656.30 (C=O str keto-enol), 1591.82 (Ar 
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C=C str.), 1251.33 (C-N str.), 1117.52 (C-F str.), 1047.78 (C-O-C str); 1HNMR (600 MHz, 
DMSO-d6, 25°C) δ 12.07 (s, 1H), 7.94 – 7.91 (m, 2H), 7.48 (d, J = 8.62 Hz, 1H), 7.40 – 7.36 
(m, 1H), 7.24 – 7.17 (m, 3H), 7.11 – 7.04 (m, 3H), 6.87 (t, J = 6.15 Hz, 1H), 4.41 (d, J = 6.33 
Hz, 2H), 3.75 (t, J = 4.72 Hz, 4H), 3.11 (t, J = 4.52 Hz, 4H). 13C NMR (100 MHz, DMSO-d6, 
25°C) δ 163.5 – 161.1 (d, JC-F = 244.41 Hz, 1C), 162.0, 155.3 – 152.8 (d, JC-F = 244.20 Hz, 1C), 
147.7, 146.2, 142.89 – 142.82 (d, JC-F = 7.02 Hz, 1C), 141.4 – 141.3 (d, JC-F = 7.98 Hz, 1C), 
140.0, 130.38 – 130.30 (d, JC-F = 8.51 Hz, 1C), 128.3, 126.5 – 126.4 (d, JC-F = 8.12 Hz, 1C), 
123.6, 123.08 – 122.06 (d, JC-F = 2.50 Hz, 1C), 122.1, 121.8, 118.45 – 118.42 (d, JC-F = 3.35 Hz, 
1C), 114.7 – 114.4 (d, JC-F = 23.69 Hz, 1C), 113.7 – 113.6 (d, JC-F = 12.78 Hz, 1C), 113.5 – 
113.4 (d, JC-F = 11.77 Hz, 1C), 103.4, 66.0, 50.0, 45.8. 
4.2.2.2.1. Synthesis of 2-(cyclopropylamino)-N-(2-(3-fluoro-4-morpholinophenyl)-4-
hydroxyquinazolin-6-yl)acetamide (10m); 
    
Yellow solid, yield: 29%, mp: 252-255°C; FTIR (ATR, Vmax, cm-1): 3272.51 (O-H str.), 3173.07 
(N-H str.), 3078.83 (N-H str.), 2969.04 (Ar-H str.), 1662.95 (C=O str.), 1551.87 (Ar C=C str.), 
1249.10 (C-N str.), 1121.91 (C-F str.), 982.33(C-O-C str); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 12.34 (brs, 1H), 10.11 (s, 1H), 8.53 (d, J = 2.42 Hz, 1H), 8.02 – 7.94 (m, 3H), 7.67 (d, J 
= 8.39 Hz, 1H), 7.14 (t, J = 9.15 Hz, 1H), 3.76 (t, J = 4.23 Hz, 4H), 3.38 (s, 2H), 3.14 (t, J = 
4.47 Hz, 4H), 2.22 – 2.16 ( m, 1H), 0.40 – 0.34 (m, 2H), 0.32 – 029 (m, 2H). 13C NMR (100 
MHz, DMSO-d6, 25°C) δ 170.8, 162.0, 155.1 – 152.7 (d, JC-F = 243.99 Hz, 1C), 149.4, 144.6, 
142.1 – 141.9 (d, JC-F = 8.43 Hz, 1C), 137.0, 127.9, 126.3, 125.9 – 125.8 (d, JC-F = 8.17 Hz, 1C), 
124.2, 121.0, 118.45 – 118.41 (d, JC-F = 3.71 Hz, 1C), 115.2 – 114.9 (d, JC-F = 24.26 Hz, 1C), 
114.4, 66.0, 52.7, 49.96, 30.1, 6.0. 
4.2.2.3.1. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)benzenesulfonamide 
(10n); 
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Yellow solid, yield: 44%, mp: 297-299°C; FTIR (ATR, Vmax, cm-1): 3242.21 (O-H str.), 3067.19 
(N-H str.), 2853.86 (Ar-H str.), 1670.13 (C=O str. keto-enol), 1595.03 (Ar C=C str.), 1442.19 
(SO2 asym.), 1249.72 (C-N str.), 1161.71 (SO2 sym.), 1117.84 (C-F str.), 1088.03 (C-O-C str);   
1H NMR (400 MHz, DMSO-d6, 25°C) δ 11.97 (s, 1H), 7.95 – 7.90 (m, 2H), 7.75 (dd, J = 7.17 
Hz, J = 2.08 Hz, 2H), 7.65 (d, J = 2.49 Hz, 1H), 7.45 – 7.35 (m, 5H), 7.09 (t, J = 8.81 Hz, 1H), 
3.74 (t, J = 4.26 Hz, 4H), 3.11 (t, J = 4.26 Hz, 4H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 
162.3, 155.2 – 152.8 (d, JC-F = 245 Hz, 1C), 147.7, 143.8, 142.1, 141.5 – 141.4 (d, JC-F = 8.04 
Hz, 1C), 130.8, 128.6, 128.5, 127.6, 126.6, 126.3, 123.8, 121.2, 118.4, 114.8 – 114.6 (d, JC-F = 
23.56 Hz, 1C), 113.8, 66.0, 50.0. 
4.2.2.3.2. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)-4-
methylbenzenesulfonamide (10o); 
 
Yellow solid, yield: 31%, mp: 282-284°C, FTIR (ATR, Vmax, cm-1): 3245.94 (O-H str.), 3085.09 
(N-H str.), 2955.40 (Ar-H str.), 2857.50 (Ar-H str.), 1671.67 (C=O str. Of Keto-enol), 1551.91 
(Ar C=C str.), 1482.76 (SO2, asym), 1251.40 (C-N str.), 1159.85 (SO2, sym), 1119.25 (C-F str.), 
1088.37 (C-O-C str); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 11.96 (brs, 1H), 7.95 – 7.52 (m, 
7H), 7.32 – 7.11 (m, 3H), 3.74 (t, J = 4.35 Hz, 4H), 3.12 (t, J = 4.62 Hz, 4H), 2.30 (s, 3H). 13C 
NMR (100 MHz, DMSO-d6, 25°C) δ 162.1, 155.2 – 152.7 (d, JC-F = 243.63 Hz, 1C), 148.9, 
143.7, 142.2, 141.8 – 141.7 (d, JC-F = 8.04 Hz, 1C), 138.4, 129.4, 128.1, 127.6, 126.5, 126.2, 
126.1, 124.1, 121.2, 118.4, 115.0 – 114.8 (d, JC-F = 23.06 Hz, 1C), 114.4, 66.0, 49.9, 20.9.  
4.2.2.3.3. N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)-3-
(trifluoromethyl)benzenesulfonamide (10p); 
 
Yellow solid, yield: 32%, mp: 293-295°C;  FTIR (ATR, Vmax, cm-1): 3253.07 (O-H str.), 
3081.61 (N-H str.), 2966.92 (Ar-H str.), 2859.56 (Ar-H str.), 1672.36 (C=O str. keto-enol), 
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1593.75 (Ar C=C str.), 1483.63 (SO2 asym.), 1324.08 (C-CF3 str.), 1249.93 (C-N str.), 1161.62 
(SO2 sym.), 1123.14 (C-F str.), 1067.20 (C-O-C str); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 
12.26 (brs, 1H), 8.02 – 7.92 (m, 5H), 7.75 – 7.72 (m, 2H), 7.55 – 7.46 (m, 2H), 7.11 (t, J = 8.59 
Hz, 1H), 3.74 (t, J = 4.41 Hz, 4H), 3.12 (t, J = 3.62 Hz, 4H). 13C NMR (100 MHz, DMSO-d6, 
25°C) δ 161.7, 155.1 – 152.7 (d, JC-F = 246 Hz, 1C), 150.0, 142.0, 140.6, 135.9, 131.0, 130.6, 
129.7, 128.7, 127.7, 125.6, 124.3, 123.1, 121.2, 118.4, 115.9, 115.2 – 115.0 (d, JC-F = 23.31 Hz, 
1C), 66.0, 49.8. 
4.2.2.3.4. 4-fluoro-N-(2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-
yl)benzenesulfonamide (10q); 
 
Yellow solid, yield: 46%, mp: 293-296°C; FTIR (ATR, Vmax, cm-1): 3258.27 (O-H str.), 3067.49 
(N-H str.), 2955.72 (Ar-H str.), 2845.25 (Ar-H str.), 1672.39 (C=O str keto-enol), 1592.48 (Ar 
C=C str.), 1483.80 (SO2 asym.), 1236.36 (C-N str.), 1165.30 (SO2 sym.), 1121.56 (C-F str.), 
1089.25(C-O-C str); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.38 (brs, 1H), 10.70 (brs, 1H), 
7.95 – 7.92 (m, 2H), 7.82 – 7.80 (m, 3H), 7.63 – 7.53 (m, 2H), 7.39 (t, J = 8.12 Hz, 2H), 7.10 (t, 
J = 8.32 Hz, 1H), 3.74 (t, J = 4.84 Hz,4H), 3.12 (t, J = 4.36 Hz, 4H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 165.6 – 163.1 (d, JC-F = 245 Hz, 1C), 161.8, 155.1 -152.7 (d, JC-F = 243.59 
Hz, 1C), 150.1, 145.4, 142.1 – 142.0 (d, JC-F = 8.01 Hz, 1C), 135.6, 135.57 – 135.54 (d, JC-F = 
3.41 Hz, 1C), 129.8 – 129.7 (d, JC-F = 9.76 Hz, 1C), 128.7, 127.4, 125.7 – 125.6 (d, JC-F = 7.71 
Hz, 1C), 124.4, 121.3, 118.46 -118.42 (d, JC-F = 3.21 Hz, 1C), 116.7 – 116.5 (d, JC-F = 23.15 Hz, 
1C), 115.6, 115.3 – 115.0 (d, JC-F = 23.58 Hz, 1C), 66.0, 49.9. 
4.2.2.1.1.1. Synthesis of 2-((2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-yl)amino)-
2-oxoacetic acid (11);  
 
To the suspension of ethyl 2-((2-(3-fluoro-4-morpholinophenyl)-4-hydroxyquinazolin-6-
yl)amino)-2-oxoacetate (0.2 g, 0.45 mmol) in ethanol was added 2N-NaOH (0.036 g, 0.908 
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mmol). The resultant mixture was stirred at room temperature for 16 h, diluted with water and 
washed with ethyl acetate .The aqueous layer was acidified with 6N-HCl , precipitate was 
formed , filtered and washed with diethyl ether to afford off white solid product (0.103 g, 55%); 
mp: 285-288°C; FTIR (ATR, Vmax, cm-1): 3671.54 (O-H str.), 2973.14 (Ar-H str.), 2867.85 (Ar-
H str.), 1659.51 (C=O str.), 1249.36 (C-N str.), 1056.03 (C-O-C str.); 1H NMR (400 MHz, 
DMSO-d6, 25°C) δ 12.40 (brs, 1H), 11.00 (s, 1H), 8.68 (d, J = 2.08 Hz, 1H), 8.09 (dd, J = 8.91 
Hz, J = 1.91 Hz, 1H), 8.01 - 7.97 (m, 2H), 7.69 (d, J = 9.20 Hz, 1H), 7.13 (t, J = 8.57 Hz, 1H), 
3.75 (t, J = 4.36 Hz, 4H), 3.13 (t, J = 4.81 Hz, 4H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 
161.9, 157.7, 155.1 – 152.7 (d, JC-F = 244 Hz, 1C), 142.1 – 142.0 (d, JC-F = 8.55 Hz, 1C) 135.9, 
127. 9, 127.2, 125.8 – 125.7 (d, JC-F = 7.81 Hz, 1C), 124.4, 120.9, 118.4, 115.7, 115.3 – 115.0 
(d, JC-F = 23.60 Hz, 1C), 66.0, 49.9.  
4.2.2. Synthesis and spectral characterization of compounds 12, 14, 15 and (17a-c); 
4.2.2.1. Synthesis of 4-(4-(4-chloro-6-nitroquinazolin-2-yl)-2-fluorophenyl)morpholine (12); 
 
2-(3-fluoro-4-morpholinophenyl)-6-Nitroquinazolin-4-ol (4 g, 10.80 mmol) was mixed with 20 
mL phosphoryl chloride and was then reflux for 16 h. After completion of reaction solvent was 
evaporated under reduced pressure then ice-cold water was added to residue, the formed 
precipitate was neutralized with ammonium hydroxide and filtered off to get crude product 
which was purified by column chromatography on silica gel (100−200 mesh) using 
MeOH/DCM as an eluent to afford the pure orange solid product (2 g, 47%); mp: 250-253°C; 
FTIR (ATR, Vmax, cm-1): 2963.23 (Ar-H str.), 1544.56 (Ar C=C str.), 1340.50 (Ar-NO2 str.), 
1241.01 (C-N str.), 1118.94 (C-F str.), 1042.58 (C-O-C str.), 735.50 (C-Cl str.); 1H NMR (400 
MHz, CDCl3, 25°C) δ 9.05 (d, J = 2.50 Hz, 1H), 8.60 (dd, J = 9.17 Hz, J = 2.77 Hz, 1H), 8.26 
(dd, J = 7.71 Hz, J = 1.75 Hz, 1H), 8.18 (dd, J = 14,54 Hz, J = 1.90 Hz, 1H), 8.07 (d, J = 9.26 
Hz, 1H), 6.96 (t, J = 8.79 Hz, 1H), 3.89 (t, J = 4.50 Hz, 4H), 3.25 (t, J = 4.89 Hz,  4H). 13C 
NMR (150 MHz, DMSO-d6, 25°C) δ 164.2, 161.8 – 161.7 (d, JC-F = 2.89 Hz, 1C), 156.2 – 153.7 
(d, JC-F = 245 Hz, 1C), 154.2, 145.8, 143.6 – 143.5 (d, JC-F = 8.09 Hz, 1C), 130.6, 129.3 – 129.2 
(d, JC-F = 8.20 Hz, 1C), 128.3, 126.25 – 126.22 (d, JC-F = 2.76 Hz, 1C), 122.9 , 121.4, 117.96 – 
117.93 (d, JC-F = 3.14 Hz, 1C), 117.1 – 116.9 ( d, JC-F = 263.52 Hz, 1C), 66.9, 50.3. 
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4.2.2.2. Synthesis of N-cyclopropyl-2-(3-fluoro-4-morpholinophenyl)-6-nitroquinazolin-4-amine 
(14); 
 
To the solution of 4-(4-(4-chloro-6-nitroquinazolin-2-yl)-2-fluorophenyl)morpholine (0.96 g, 
2.46 mmol) in DMF (15 mL) was added K2CO3 (0.511 g, 3.70 mmol) followed by 
cyclopropanamine (0.25 mL, 3.70 mmol) at room temperature. The reaction mixture was stirred 
at room temperature for 16 h, monitored by TLC after consumption of starting material poured 
into  ice cold water, precipitate was formed filtered and dried under vacuum, washed with 
diethyl ether to afford orange solid product (0.610 g, 60%); mp: 240-245°C; FTIR (ATR, Vmax, 
cm-1): 3392.57 (N-H str.), 2951.82 (Ar-H str.), 2856.40 (Ar-H str.), 1580.30 (Ar C=C), 1323.02 
(Ar-NO2), 1242.86 (C-N str.), 1115.79 (C-F str.), 1043.88 (C-O-C str.). 1H NMR (400 MHz, 
DMSO-d6, 25°C) δ  9.28 (s, 1H), 8.90 (s, 1H), 8.42 – 8.40 (m, 1H), 8.27 (d, J = 8.91 Hz, 1H), 
8.17 – 8.13 (m, 1H), 7.80 (d, J = 8.92 Hz, 1H), 7.11 (t, J = 8.83 Hz, 1H), 3.76 (t, J = 4.75 Hz, 
4H),  3.13 (t, J = 4.70 Hz, 4H). 0.90 – 0.89 (m, 2H), 0.79 – 0.74 (m, 2H). 
4.2.2.3. Synthesis of N4-cyclopropyl-2-(3-fluoro-4-morpholinophenyl)quinazoline-4,6-diamine 
(15); 
 
N-cyclopropyl-2-(3-fluoro-4-morpholinophenyl)-6-nitroquinazolin-4-amine (0.5 g, 1.22 mmol) 
was added into the mixture of dioxane (14 mL), ethanol (10 mL) and water (6 mL) followed by 
ammonium chloride (0.65 g, 12.22 mmol). To the resultant mixture iron powder (0.34 g, 6.10 
mmol) was added with vigorous stirring and then heated at 100°C for 4 h. The reaction mixture 
was cool to room temperature and filtered through celite and washed with 10% MeOH/DCM. 
The filtrate was evaporated under reduce pressure then diluted with water and extracted with 
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10% MeOH/DCM (3 x 20 mL).  The combined organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated under reduce pressure to yield crude product (0.194 g,); mp: 250-
253°C; FTIR (ATR, Vmax, cm-1): 3419.04 (N-H str.) 3344.03 (N-H str.), 2960.68 (Ar-H str.), 
1530.39 (Ar C=C str.), 1245.02 (C-N str.), 1106.72 (C-F str.), 1066.85 (C-O-C str.). 1H NMR 
(400 MHz, DMSO-d6, 25°C) δ 8.20 (d, J = 8.15 Hz, 1H), 8.10 (d, J = 14.53 Hz, 1H), 7.77 (d, J 
= 2.70 Hz, 1H), 7.49 (d, J = 8.54 Hz, 1H), 7.15 – 7.13 (m, H), 7.10 – 7.05 (m, 2H), 5.37 (brs, 
2H), 3.75 (t, J = 4.32 Hz, 4H), 3.14 – 3.12 (m, 1H), 3.07 (t, J = 4.22 Hz, 4H), 0.83 – 0.82 (m, 
2H), 0.66 - 0.64 (m, 2H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 159.3, 155.7 – 153.3 (d, JC-F 
= 249.03 Hz, 1C), 154.0, 146.4, 142.2, 140.3 – 140.2 (d, JC-F = 9.76 Hz, 1C), 133.98- 133.91 (d, 
JC-F = 7.40 Hz, 1C), 128.5, 123.6, 123.0, 118.2, 114.9, 114.6 – 114.4 (d, JC-F = 23.19 Hz, 1C), 
101.7, 66.3, 50.3, 24.1, 6.2. 
4.2.2.3.1. Synthesis of ethyl 2-((4-(cyclopropylamino)-2-(3-fluoro-4-
morpholinophenyl)quinazolin-6-yl)amino)-2-oxoacetate (17a): 
 
To the solution of N4-cyclopropyl-2-(3-fluoro-4-morpholinophenyl)quinazoline-4,6-diamine 
(0.19 g, 0.50 mmol) in DCM (10 mL) were added triethyl amine (0.1 mL, 0.75 mmol), followed 
by ethyl 2-chloro-2-oxoacetate (0.07 mL, 0.75 mmol) at 0°C. The resultant mixture was stirred 
at room temperature for 2 h, quenched with sodium bicarbonate solution and extracted with 
DCM (3 X 20 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure to yield crude product which was purified by column 
chromatography on silica gel (100−200 mesh) using MeOH/DCM as an eluent to afford the 
pure yellow solid (0.1 g, 41%); mp: 125-128°C; FTIR (ATR, Vmax, cm-1): 3333.80 (N-H str.), 
2966.91 (Ar-H str.), 2861.88 (Ar-H str.), 1695.08 (C=O str.), 1543.68 (Ar C=C str.), 1247.24 
(C-N str.), 1107.00 (C-F str.), 1048.66 (C-O-C str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 
10.93 (s, 1H), 8.46 (d, J = 2.23 Hz, 1H), 8.30 – 8.26 (m, 2H), 8.18 – 8.14 (m, 1H), 7.87 (dd, J = 
9.10 Hz, J = 2.15 Hz,  1H), 7.73 (d, J = 8.88 Hz, 1H), 7.12 (t, J = 8.81 Hz, 1H), 4.33 (q, J = 6.90 
Hz, 2H), 3.76 (t, J = 5.00 Hz, 4H), 3.22 – 3.17 (m, 1H), 3.11 (t, J = 4.67 Hz, 4H), 1.33 (t, J = 
7.35 Hz, 3H), 0.89 – 0.84 (m, 2H), 0.72 – 0.68 (m, 2H).13C NMR (100 MHz, DMSO-d6, 25°C) δ 
160.6, 160.5, 157.8, 155.6, 155.6 – 153.1 (d, JC-F = 242.77 Hz, 1C), 147.3, 141.1 – 141.0 (d, JC-F 
= 8.63 Hz, 1C), 133.7, 132.9 – 132.8 (d, JC-F = 7.48 Hz, 1C), 128.1, 127.6, 124.4, 118.3 – 118.2 
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(d, JC-F = 3.31 Hz, 1C), 115.2 – 114.9 (d, JC-F = 22.90 Hz, 1C), 114.6, 113.5, 66.1, 62.4, 50.2, 
24.3, 13.8, 6.1.  
4.2.2.3.2. Synthesis of N-(4-(cyclopropylamino)-2-(3-fluoro-4-morpholinophenyl)quinazolin-6-
yl)acetamide (17b):  
 
The compound was synthesized from N4-cyclopropyl-2-(3-fluoro-4-
morpholinophenyl)quinazoline-4,6-diamine (0.15 g, 0.39 mmol) and acetyl chloride (0.04 mL, 
0.59 mmol) as described in the procedure for compound 17a. Yellow solid, yield: 31%, mp: 
160-165°C; FTIR (ATR, Vmax, cm-1): 3312.75 (N-H str.), 2966.91 (Ar-H str.), 2852.03 (Ar-H 
str.), 1666.39 (C=O str.), 1531.44 (Ar C=C str.), 1245.58 (C-N str.), 1116.11 (C-F str.), 1045.30 
(C-O-C str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 10.09 (s, 1H), 8.33 (s, 1H), 8.26 (d, J = 
8.35 Hz, 1H), 8.20 – 8.14 (m, 2H), 7.72 – 7.68 (m, 2H), 7.11 (t, J = 9.09 Hz, 1H), 3.76 (t, J = 
4.57 Hz, 4H), 3.21 – 3.16 (m, 1H), 3.10 (t, J = 4.89 Hz, 4H), 2.09 (s, 3H), 0.87 – 0.84 (m, 2H), 
0.72 – 0.69 (m, 2H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ  168.2, 160.4, 157.0, 155.1 – 
153.5 (d, JC-F = 242.90 Hz, 1C), 146.3, 140.9 – 140.8 (d, JC-F = 7.56 Hz, 1C), 135.7, 133.09 – 
133.05 (d, JC-F = 8.23 Hz, 1C), 127.9, 126.7, 124.2, 118.2, 115.0 – 114.8 (d, JC-F = 23.39 Hz, 
1C), 113.6, 112.2, 66.0, 50.2, 24.3, 23.7, 6.7.  
4.2.2.3.3. Synthesis of N-(4-(cyclopropylamino)-2-(3-fluoro-4-morpholinophenyl)quinazolin-6-
yl)-4-fluorobenzenesulfonamide (17c): 
 
To the solution of N4-cyclopropyl-2-(3-fluoro-4-morpholinophenyl)quinazoline-4,6-diamine 
(0.2 g, 0.52 mmol) in DCM (10 mL) were added pyridine (0.33 mL, 4.22 mmol), followed by 4-
fluorobenzenesulfonyl chloride (0.15 g, 0.79 mmol) at 0°C. The resultant mixture was stirred at 
room temperature for 16 h, quenched with 6N-HCl solution and extracted with DCM (3 x 20 
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mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure to yield crude residue, which was purified by column chromatography 
on silica gel (100−200 mesh) using MeOH/DCM as an eluent to afford the pure yellow solid 
product (0.072 g, 25%); mp: 210-212°C; FTIR (ATR, Vmax, cm-1): 3414.18 (N-H str.), 3264.10 
(N-H str.), 2854.40 (Ar-H str.), 1529.87 (Ar C=C str.), 1351.64 (SO2 asym.), 1246.98 (C-N str.), 
1153.53 (SO2 sym.), 1089.19 (C-O-C str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 10.30 (s, 
1H), 8.35 (s, 1H), 8.23 (d, J = 8.97 Hz, 1H), 8.12 (d, J = 14.97 Hz, 1H), 7.97 (s, 1H), 7.78 – 
7.76 (m, 2H), 7.59 (d, J = 8.98 Hz, 1H), 7.37 – 7.34 (m, 2H), 7.26 (dd, J = 8.91 Hz, J = 1.76 Hz, 
1H), 7.10 (t, J = 9.03 Hz, 1H), 3.76 (t, J = 4.70 Hz, 4H), 3.17 – 3.16 (m, 1H), 3.10 (t, J = 4.10 
Hz, 4H), 0.87 – 0.85 (m, 2H), 0.71 – 0.71 (m, 2H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ  
165.1 – 163.4 (d, JC-F = 253.16 Hz, 1C), 160.4, 157.8, 155.1 – 153.5 (d, JC-F = 242.59 Hz, 1C), 
147.5, 141.09 – 141.04 (d, JC-F = 8.73 Hz, 1C), 135.7, 133.7, 132.8 – 132.7 (d, JC-F = 7.31 Hz, 
1C), 129.7 – 129.6 (d, JC-F = 9.44 Hz, 1C), 128.6, 128.3, 124.3, 118.2, 116.4, 116.2 – 116.1 (d, 
JC-F = 22.36 Hz, 1C), 115.0 – 114.9 (d, JC-F = 25.07 Hz, 1C), 113.8, 66.0, 50.1, 24.2, 6.0.  
4.3. Biology 
M. tuberculosis H37Rv (ATCC 25618) was grown in Middlebrook 7H9 medium supplemented 
with 10% v/v oleic acid, albumin, dextrose, catalase (OADC; Becton Dickinson), 0.05% w/v 
Tween 80 (7H9-OADC-Tw), and 50 µg/mL hygromycin (7H9-OADC-Tw-hyg), where 
required. Large scale cultures were grown in 100 mL of medium in 450 cm2 roller bottles at 
37ºC and 100 rpm. M. tuberculosis strain CHEAM3 and DREAM8 expressing codon-optimized 
mCherry and DsRed from plasmids pCherry3 and pBlazeC8, respectively, were used. Assay 
plates containing 20 µL of 7H9-Tw-OADC medium with appropriate control compounds or test 
compounds were prepared in a sterile environment. 18 µL of medium was dispensed into sterile, 
black, 384-well, clear bottom plates (Greiner). 2 µL of control compounds, DMSO or test 
compounds were stamped directly into the assay plates. Controls were 100 µM rifampicin in 
column 1 (final assay concentration of 2 µM rifampicin), DMSO in column 2 (final assay 
concentration 2%) and 125 nM rifampicin in column 23 (final assay concentration of 2.5 nM). 
Test compounds were diluted to 0.35 mg/mL in DMSO and transferred directly into columns 3-
22 of assay plates (320 compounds per plate) to yield a final assay concentration of 7 µg/mL 
(final concentration of 2% DMSO). M. tuberculosis was grown to logarithmic phase (OD590 = 
0.6-0.9) and filtered through a 0.5 µm cellulose-acetate membrane filter and diluted in fresh 
medium to an OD of 0.06. A MultiDrop Combi (Thermo Fisher) was used to add 10 µL of M. 
tuberculosis culture to columns 1-23 of the assay plates; column 24 was not inoculated and used 
as a contamination control. Plates were incubated in sealed plastic bags in a humidified 
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incubator at 37 ºC for 5 days. The plate layout was arranged as 320 sample wells in columns 3-
22. The remaining four columns were reserved for plate controls. OD and fluorescence were 
read using a Synergy 4 plate reader (BioTek) with excitation/emission of 586 nm/614 nm for 
mCherry and 560 nm/590 nm for DsRed. For each well, the % inhibition was calculated with 
reference to the average maximum growth control in column 2 (DMSO only).28 
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CHAPTER 5 
Design, synthesis and spectral characterization of N/O-methylated quinazoline 
derivatives as an antitubercular agent 
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Abstract 
A novel series of N/O-methylated quinazoline derivatives (10a-o, 16a-d and 16aa-ad) were 
synthesized in good to moderate yields. All synthesized compounds were well-characterized by 
spectroscopic studies (NMR and IR) and evaluated for preliminary in-vitro screening for anti-
mycobacterium activity at 20 µM concentration against Mycobacterium tuberculosis H37Rv 
strain. The compounds did not show significant anti-mycobacterium activity. The only notable 
% zone of inhibition was observed against Mycobacterium tuberculosis strain H37Rv for 
compounds 16a which showed 34% after 24 h incubation which can be considered for further 
study like MIC, MBC etc. These new compounds may serve as starting points for the designing 
of new series of inhibitors that prevent the growth of Mycobacterium tuberculosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords 
Antimycobacterial activity; N/O-methyl quinazoline derivatives; mycobacterium tuberculosis 
H37Rv. 
  
                                                                                                                                                     Chapter 5 
Narva Deshwar Kushwaha 139                                        UKZN-2020 
 
1. Introduction 
Methylation is significantly most prevalent in design and synthesis of biologically active 
molecules.1, 2 It can be found as integral part of several commercial drugs (Figure 1). Wermuth 
precisely defines the significance of methyl group in molecular recognition as “The methyl 
group, so often considered as chemically inert, is able to alter deeply the pharmacological 
properties of a molecule”.3 Methyl group is well known for properties like London dispersion 
interactions, stereoelectronic effects on microtubules and biomacromolecules which intern 
increases the bioreceptor selectivity and potency, protects against enzyme metabolism and 
increases lipophilicity of the molecule.1, 2, 4 Thus, in context of medicinal chemistry, it is 
considered as one of the most prevalent functionalities as to date more than 67 % of small 
molecule drugs contain methyl group.5 
 
Figure 1: Drugs/Molecules containing methyl functionality. 
The heterocyclic fused ring with nitrogen has drawn attention owing to their immense 
therapeutic potential in medicinal chemistry and drug discovery.6 Natural products are also 
known to comprise of nitrogen containing heterocycles as integral part of their structure.7 
Amongst, quinazoline is well known to exist in nature.8, 9 The first synthesis of quinazoline was 
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achieved successfully in 1895 by Bischler and Lang with an extension for the extensive studies 
in 1903 by Gabriel.9 There are four isomeric forms of quinazoline (quinazoline, quinoxaline, 
cinnoline, and phthalazine) depending upon the position of nitrogen.8, 10  
Quinazoline occurs in natural product mostly as isomeric alkaloid in root and leaves of 
Saxifragaceae family, mainly in Dichroa febrifuga (also called Chinese quinine).11, 12 This 
compound was earlier known to possess anti-hypnotic and sedative action.9 Since several 
decades, this class of compound has brought diverse biological importance as such as potential 
anticancer,13, 14 antiviral,15 anticonvulsant,16 antimalarial,17 antimicrobial,18, 19 antidiabetic and 
antitubercular agents19, 20 (Figure 2). This has necessitated the effort of chemists worldwide for 
the development of better synthetic strategies by effective methods.21  
Figure 2: Quinazoline based drugs with specific activity. 
Tuberculosis (TB) is one of the main lethal bacterial infection worldwide after HIV.22 TB is 
caused by slow growing, acid fast bacillus Mycobacterium tuberculosis.23 The active TB is 
currently treated with first line drugs which are unsatisfactory due to low efficacy, high toxicity, 
long duration of treatment and involved high cost.24-26 In addition, its treatment has further 
become complicated due to emergence of drug resistance giving rise to totally drug resistant TB 
(TDR-TB), thus making the current drug treatment ineffective.27, 28 This has provoked an urge 
for the development of new and effective therapeutic agent against TB. Quinazoline based 
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derivatives bearing methyl groups have been found as drugs for treatment of several ailments. 
Several of the marketed drugs containing quinazoline core with methyl functionality have been 
summed up in Figure 3. 
 
Figure 3: Quinazoline based Drugs/Molecules containing methyl functionality. 
As part of the project, in this report we present the synthesis of quinazoline derivatives bearing 
N-methylation and O-methylation residues with complete characterization. The compounds 
were further evaluated for preliminary anti-TB studies.  
2. Results and Discussion 
2.1. Chemistry 
The synthesis of novel quinazoline derivatives (10a-o, 11, 16a-d & 16aa-ad) and their 
respective intermediates were achieved through effective and easy synthetic routes as depicted 
in Scheme 1 & 2. Intermediate 6 was synthesized as per our previous report (Chapter 4), which 
underwent methylation in presence of CH3I/ K2CO3/ DMF at rt for 24 h to yield 2-(3-fluoro-4-
morpholinophenyl)-1,3-dimethyl-6-nitro-2,3-dihydroquinazolin-4(1H)-one (7). The nitro 
reduction of 7 was performed in presence of Fe/NH4Cl to afford 6-amino-2-(3-fluoro-4-
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morpholinophenyl)-1,3-dimethyl-2,3-dihydroquinazolin-4(1H)-one (8). Afterward, a series of 
compounds (10a-o) were synthesized by reacting 8 with acid chloride/Acid/isocyanide in 
presence of their respective conditions illustrated in experimental section. 10a was further 
subjected to hydrolysis with 2N NaOH at rt for 16 h to yield 2-((2-(3-fluoro-4-
morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)amino)-2-oxoacetic 
acid (11). 
In another series, compound 12 was synthesized as per our previous report (Chapter 4) which 
was subjected to methylation in presence of CH3I/K2CO3/DMF at rt for 16 h to afford mixture 
of regioisomers 4-(2-fluoro-4-(4-methoxy-6-nitroquinazolin-2-yl) phenyl) morpholine (13) and 
2-(3-fluoro-4-morpholinophenyl)-3-methyl-6-nitroquinazolin-4(3H)-one (13a) which were 
separated by column chromatography. Both isomers 13 and 13a underwent reduction with 
Fe/NH4Cl to yield 2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-amine (14) and 6-
amino-2-(3-fluoro-4-morpholinophenyl)-3-methylquinazolin-4(3H)-one (14a), respectively. 
Each scaffold 14 & 14a were treated with acid chloride in presence of TEA/DCM at rt for 4 h to 
yield a series of final derivatives (16a-d and 16aa-ad). 
The structure of all intermediates (7, 8, 13, 13a, 14, 14a) and their respective final derivatives 
(10a-o, 16a-d and 16aa-ad) were established by spectral (IR, 1H-NMR, 13C-NMR and Mass) 
analysis. All compounds showed the acceptable analysis of predicted structures which are 
summarized in experimental section. The conversion of 6 to 7 was confirmed by the appearance 
of two methyl proton signals at around 2.95 and 2.87 ppm and disappearance of amide and 
amine protons. This was further supported by 13C NMR which showed two signals at around 
35.44 & 31.82 assign for two methyl group. The conversion of nitro to amine (8) was confirmed 
by appearance of broad singlet amine (NH2) proton at around 4.72 ppm in NMR spectra along 
with disappearance of absorption band 1315.90 cm-1 of nitro in IR spectra. Subsequently, 
derivatization of amine to the final molecules (10a-o) with acid chloride/ acid/ isocyanate were 
confirmed by the disappearance of amine (NH2) proton along with appearance of most distinct 
amide and urea protons at around 9.59-10.68 ppm and 7.78-8.43 ppm in case of (10a-m) and 
(10n-o), respectively. These finding were further supported by IR and 13C NMR analysis. The 
absorption band in the region of 1637.88-1735.49 cm-1 and 3225.89-3357.44 cm-1 in IR spectra 
along with signals in the range of 161.21-174.67 ppm in 13C-NMR spectra of compounds (10a-
m) indicate the presence of amide (C=O and N-H) group. While the IR spectra of 10n and 10o 
showed the absorption band in the region of 1637.44-1684.84 and 3341.01 – 3377.81 cm-1 
accompanied with signals at around 152.80-155.33 ppm in 13C NMR spectra are assign for urea 
(C=O and N-H) group. 
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In another series, conversion to 13 and 13a from 12 was confirmed by the appearance of 
methoxy (O-CH3) and methyl (N-CH3) protons at around 4.31 and 3.60 ppm in 1H NMR 
spectra along with carbon signals at around 54.8 and 35.0 ppm, respectively .The conversion of 
13 and 14 to respective 13a and 14a by nitro reductions were confirm by the appearance of 
amine (NH2) protons at around 5.09 ppm along with disappearance of absorption bands of nitro 
(NO2) 1342.35 and 1339.08 cm-1 in IR spectra. Now the derivatization of 14 and 14a to their 
respective derivatives (16a-d) and (16aa-ad) were confirmed by the disappearance of amine 
(NH2) proton and appearance of most distinct amide proton at around 10.26-11.14 ppm. These 
outcomes further supported by IR and 13C NMR. The presence of absorption band in the region 
of 1649.56-1701.67 and 3250.93-3344.55 in IR along with carbon signals at around 161.45-
172.07 in 13C NMR spectra indicate the presence of amide (C=O and N-H) group. 
 
 
Scheme 1: Reagents and conditions: i) 28% aqueous ammonia solution, EDC.HCl, HOBt, 
DMF, 3–5 h; ii) K2CO3, DMF, 130°C, 16 h; iii) pTSA, MeOH, 70°C, 16 h; iv) CH3I, K2CO3, 
DMF, rt, 24 h v) Fe, NH4Cl, Dioxane: EtOH: H2O (7:5:3), 100°C, 5 h; vi) Acid chloride, TEA, 
DCM, 0°C - rt, 4 h. or acid, HATU, DIPEA, DMF, rt, 16 h. or isocyanate, DIPEA, DMF, rt, 16 
h. 
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Scheme 2: Reagents and conditions: i) CH3I, K2CO3, DMF, rt, 16 h; ii) Fe, NH4Cl, Dioxane: 
EtOH: H2O (7:5:3), 100°C, 5 h; iii) TEA, DCM, 0°C - rt, 4 h. 
2.2. Biology 
The synthesized derivatives have been evaluated against M. tuberculosis (Strain H37Rv) and the 
results as % inhibition have been tabulated in Table 1.  
Table 1: Compounds tested against M. tuberculosis strain H37Rv. 
Compound (20 µM) % Inhibition Compound (20 µM) % Inhibition 
10a -8 10m 2 
10b 3 10n 8 
10c 2 10o 4 
10d -11 11 -6 
10e -9 16a 34 
10f -6 16b 30 
10g -5 16c 28 
10h -1 16d 26 
10i -6 16aa 16 
10j 17 16ab 15 
10k -6 16ac 9 
10l -1 16ad 7 
 
Compounds of these series were preliminary tested against M. tuberculosis strain H37Rv with 
20 µM concentration to find out percentage zone of inhibition, which are shown in Table 1. We 
used Rifampicin as a standard for this study. Compounds 16a and 16b showed 34 (≥ 30) 
percentage zone of inhibition, which will be further consider for the study like MIC, MBC etc. 
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3. Conclusion 
In this chapter, we report synthesis, spectral studies and preliminary anti-mycobacterial 
screening of novel N/O methylated quinazoline derivatives against Mycobacterium tuberculosis 
H37Rv strain. Novel 23 molecules had been synthesized, well-characterized by IR, NMR (1H, 
13C) and screened against Mycobacterium tuberculosis H37Rv strain. The synthesized 
compounds did not show significant % zone of inhibition. The only noteworthy percentage zone 
of inhibition was shown by compound 16a that was 34% after 24 h incubation which can be 
further consider for the study like MIC, MBC etc. The development of synthesis involving 
library of the molecule and their assessment against Mycobacterium tuberculosis strain and in-
vitro DNA gyrase enzyme inhibition assay can be of future interest.  
4. Experimental 
4.1. General consideration 
All the fine chemicals, reagents and solvents were purchased from Sigma Aldrich and Merck 
and were used without further purification unless otherwise stated. The progress of the reactions 
and the purity of the compounds were monitored by thin-layer chromatography (TLC) on pre-
coated silica gel plates procured from E. Merck and Co. (Darmstadt, Germany) visualized by 
UV lamp (254 or 365 nm). Purification was performed by using combi-flash (CombiFlash® 
NextGen 300+) column chromatography. The melting points of the synthesized compounds 
have been determined and uncorrected using a digital Stuart SMP10 melting point Apparatus. 
The Fourier transform infrared (FTIR) spectra were recorded in the spectral range of 400-4000 
cm-1 on a Bruker Alpha FT-IR spectrometer using the ATR technique. The NMR spectra (1H, 
and 13C,) were recorded using CDCl3 and DMSO-d6 on Bruker AVANCE III 400 and 600 MHz 
spectrometer. Chemical shifts were determined relative to internal standard TMS at δ 0.0 parts 
per million (ppm) and the coupling constants were reported in Hertz. The multiplicities of the 
NMR resonances were abbreviated as s (singlet), d (doublet), dd (doublet of doublet), (t 
(triplet), q (quartet), m (multiplet) and brs (broad singlet). 
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4.2. Chemistry 
4.2.1. Synthesis and spectral characterization of compounds 7 and 8; 
4.2.1.1. Synthesis of 2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-6-nitro-2,3-
dihydroquinazolin-4(1H)-one (7); 
 
To the solution of 2-(3-fluoro-4-morpholinophenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)-one 
(0.5 g, 1.34 mmol) in DMF (100 mL) were added potassium carbonate (0.92 g, 1.34 mmol) 
followed by iodomethane (0.41 mL, 6.71 mmol). The mixture was stirred for 24 h at room 
temperature and monitored by TLC, after consumption of starting material poured into ice cold 
water precipitate was formed, filtered and washed with diethyl ether to afford title compound 
(0.290 g, 54%); mp: 242-246°C; FTIR (ATR, Vmax, cm-1): 3084.53 (Ar str.), 2832.75 (Ar-H str.), 
1654.63 (C=O str.), 1606.24 (Ar C=C str.), 1315.90 (Ar-NO2 str.), 1288.46 (C-N str.), 1167.21 
(C-F str.), 1111.39 (C-O-C str); 1H NMR (400 MHz, DMSO-d6, 70°C) δ 8.52 (d, J = 2.68 Hz, 
1H), 8.18 (dd, J = 9.25 Hz, J = 2.59 Hz, 1H), 7.07 – 6.99 (m, 3H), 6.79 (d, J = 9.17 Hz, 1H), 
5.94 (s, 1H), 3.68 (t, J = 4.06 Hz, 4H), 2.95 (s, 3H), 2.96 (t, J = 4.23 Hz, 4H), 2.87 (s, 3H).  13C 
NMR (100 MHz, DMSO-d6, 70°C) δ 159.5, 155.6 – 153.1 (d, JC-F = 247.46 Hz, 1C), 150.3, 
140.48 – 140.41 (d, JC-F = 8.0 Hz, 1C), 137.4, 130.9 – 130.8 (d, JC-F = 6.61 Hz, 1C), 129.3, 
123.9, 122.33 – 122.30 (d, JC-F = 2.95 Hz, 1C), 119.5 – 119.4 (d, JC-F = 2.85 Hz, 1C), 114.0 – 
113.8 (d, JC-F = 21.11 Hz, 1C), 113.5, 112.1, 77.3, 66.0, 50.1, 35.4, 31.8.  
4.2.1.2. 6-Amino-2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-2,3-dihydroquinazolin-4(1H)-
one (8);  
 
2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-6-nitro-2,3-dihydroquinazolin-4(1H)-one (1.93 
g, 4.82 mmol) was added into the mixture of dioxane (28 mL), ethanol (20 mL) and water (12 
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mL) followed by ammonium chloride (2.57 g, 48.20 mmol). To the resultant mixture iron 
powder (1.34 g, 24.10 mmol) was added with vigorous stirring and then heated at 100°C for 4 h. 
The reaction mixture was cool to room temperature and filtered through celite and washed with 
10% MeOH/DCM. The filtrate was concentrated under reduce pressure and diluted with water 
then extracted with 10% MeOH/DCM (3 x 30 mL). Organic layer was dried over anhydrous 
Na2SO4, filtered and concentrated under reduce pressure to get solid product, which was 
triturated with diethyl ether to afford greenish solid product (1.08 g, 61%); mp: 180-184°C; 
FTIR (ATR, Vmax, cm-1): 3329.69 (N-H str.), 2860.66 (Ar-H str.), 2827.68 (Ar-H str.), 1613.08 
(C=O str.), 1503.93 (Ar C=C str.), 1242.42 (C-N str.), 1111.86 (C-F str.); 1H NMR (400 MHz, 
DMSO-d6, 25°C) δ  7.08 (s, 1H), 6.95 – 6.86 (m, 3H), 6.65 (d, J = 7.02 Hz, 1H), 6.39 (d, J = 
8.42 Hz, 1H), 5.54 (s, 1H), 4.72 (s, 2H), 3.68 (t, J = 4.71 Hz, 4H), 2.94 (t, J = 4.22 Hz, 4H), 
2.88 (s, 3H), 2.68 (s, 3H).13C NMR (150 MHz, DMSO-d6, 25°C) δ 162.0, 155.0 – 153.3 (d, JC-F 
= 246.10 Hz, 1C), 141.1, 139.56 – 139.50 (d, JC-F = 8.77 Hz, 1C), 137.4, 131.44 – 131.40 (d, JC-F 
= 5.03 Hz, 1C), 122.68 – 122.66 (d, JC-F = 2.59 Hz, 1C), 118.0, 114.5, 114.1 – 113.9 (d, JC-F = 
21.97 Hz, 1C), 112.6, 77.8, 66.0,50.1, 36.2, 32.1.  
4.2.2. General procedure for synthesis and spectral characterization of derivatives (10a-10k), 
(10l-10m) and (10n-10o); 
4.2.2.1. General procedure A for synthesis of derivatives (10a-10k);  
To the suspension of 6-amino-2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-2,3-
dihydroquinazolin-4(1H)-one (1.0 equv) in DCM were added triethyl amine (2.0 equiv), 
followed by appropriate acid chloride (9a-9k, equiv) at 0°C. The resultant mixture was stirred at 
room temperature for 2 h, quenched with sodium bicarbonate solution and extracted with DCM 
(3 X 30 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and 
evaporated under reduce pressure to give solid residue which were purified by combi-flash 
column chromatography using EA/Hexane as an eluent to afford desired title compounds (10a-
10k). 
4.2.2.2. General procedure B for synthesis of derivatives (10l & 10m);  
To the solution of 6-amino-2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-2,3-
dihydroquinazolin-4(1H)-one (1.0 equiv), HATU (1.5 equiv), and DIPEA (2.0 equiv) in DMF 
was added appropriate cinnamic acid (9l-9m, 1.5 equiv) and the solution was stirred at room 
temperature for 16 h then poured into ice cold water precipitate was formed, filtered and washed 
with diethyl ether to afford desired title compounds (10l-10m). 
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4.2.2.3 General procedure C for synthesis of derivatives (10n & 10o);  
To the solution of 6-amino-2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-2,3-
dihydroquinazolin-4(1H)-one (1.0 equiv), in dry DMF were added DIPEA (1.0 equiv), followed 
by appropriate isocyanate (9n-9o, 1.2 equiv) at 0°C and the solution was stirred at room 
temperature for 16 h then poured into ice cold water precipitate was formed, filtered to yield 
crude solid which was recrystallized with ethanol to afford desired title compounds (10n-10o). 
4.2.2.1.1. Ethyl 2-((2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)amino)-2-oxoacetate (10a);  
 
Yellow solid, yield: 59%, mp: 182-185°C; FTIR (ATR, Vmax, cm-1): 3268.67 (N-H str.), 2972.67 
(Ar-H str.), 2823.57 (Ar-H str.), 1735.49 (C=O str.), 1689.94 (C=O str.), 1539.88 (Ar C=C str.), 
1241.80 (C-N str.), 1118.13 (C-F str.), 1051.52 (C-O-C str.); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 10.68 (s, 1H), 8.19 (d, J = 1.73 Hz, 1H), 7.71 (dd, J = 8.77 Hz, J = 1.62 Hz, 1H), 6.99 – 
6.91 (m, 3H), 6.62 (d, J = 8.85 Hz, 1H), 5.72 (s, 1H), 4.29 (q, J = 6.92 Hz, 2H), 3.68 (t, J = 4.65 
Hz, 4H), 2.95 (t, J = 4.23 Hz, 4H), 2.88 (s, 3H), 2.79 (s, 3H), 1.31 (t, J = 6.74 Hz, 3H). 13C 
NMR (100 MHz, DMSO-d6, 25°C)  δ 161.2, 160.6, 155.5 – 153.0 (d, JC-F  = 244.56 Hz, 1C), 
155.0, 143.3, 140.0 – 139.9 (d, JC-F = 8.29 Hz, 1C), 131.09 – 131.04 (d, JC-F = 5.61 Hz, 1C), 
128.2, 126.5, 122.4, 119.9, 119.2, 115.5, 114.0 – 113.8 (d, JC-F = 21.67 Hz, 1C), 112.3, 77.3, 
66.0, 62.2, 50.1, 34.9, 31.9, 13.8. 
4.2.2.1.2. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)acetamide (10b);  
 
Yellow solid, yield: 36%, mp: 128-130°C; FTIR (ATR, Vmax, cm-1): 3292.10 (N-H str.), 2965.73 
(Ar-H str.), 2861.63 (Ar-H str.), 1637.88 (C=O str.), 1616.21 (C=O str.), 1505.40 (Ar C=C str.), 
1221.73 (C-N str.), 1111.61 (C-F str.), 1049.14 (C-O-C str.); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 9.80 (S, 1H), 7.97 (d, J = 2.18 Hz, 1H), 7.59 (dd, J = 9.06 Hz,  J = 2.19 Hz, 1H), 6.98 – 
                                                                                                                                                     Chapter 5 
Narva Deshwar Kushwaha 149                                        UKZN-2020 
 
6.89 (m, 3H), 6.56 (d, J = 8.82 Hz, 1H), 5.67 (s, 1H), 3.68 (t, J = 4.66 Hz, 4H), 2.94 (t, J = 4.64 
Hz, 4H), 2.88 (s, 3H), 2.76 (s, 3H), 1.99 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 167.7, 
161.4, 155.5 – 153.0 (d, JC-F = 245.78 Hz, 1C), 142.1, 139.9 – 139.8 (d, JC-F = 8.24 Hz, 1C), 
131.1 – 131.0 (d, JC-F = 5.75 Hz, 1C), 130.4, 125.2, 122.53 – 122.50 (d, JC-F = 2.66 Hz, 1C), 
119.13 – 119.10 (d, JC-F = 4.85 Hz, 1C), 118.4, 115.8, 114.0 – 113.8 (d, JC-F = 20.50 Hz, 1C), 
112.4, 77.4, 67.0, 50.1, 35.0, 31.9, 23.7. 
4.2.2.1.3. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)butyramide (10c);  
 
Yellow solid, yield: 33%, mp: 125-128°C; FTIR (ATR, Vmax, cm-1): 3317.05 (N-H str.), 2964.99 
(Ar-H str.), 2844.05 (Ar-H str.), 1638.11 (C=O str.), 1615.59 (C=O str.), 1507.37 (Ar C=C str.), 
1240.77 (C-N str.), 1113.56 (C-F str.), 1049.84 (C-O-C str.); 1H NMR (600 MHz, DMSO-d6, 
25°C) δ 9.68 (s, 1H), 7.98 (s, 1H), 7.61 (d, J = 7.92 Hz, 1H), 6.97 – 6.91 (m, 3H), 6.56 (d, J = 
8.66 Hz, 1H), 5.66 (s, 1H), 3.68 (t, J = 4.30, 4H), 2.95 (t, J = 4.26 Hz, 4H), 2.88 (s, 3H), 2.77 (s, 
3H), 2.23 (t, J = 7.33 Hz, 2H), 1.62 – 1.58 (m, 2H), 0.91 (t, J = 7.90 Hz, 3H). 13C NMR (150 
MHz, DMSO-d6, 25°C) δ 170.5, 161.4, 155.0 – 153.4 (d, JC-F = 245.45 Hz, 1C), 142.1, 139.88 – 
139.83 (d, JC-F = 8.19 Hz, 1C), 131.1 – 131.0 (d, JC-F = 5.32 Hz, 1C), 130.3, 125.2, 122.48 – 
122.47 (d, JC-F = 2.71 Hz, 1C), 119.08 – 119.06 (d, JC-F = 2.62 Hz, 1C), 118.6, 115.8, 113.9 – 
113.8 (d, JC-F = 21.22 Hz, 1C), 112.3, 77.4, 66.0, 50.1, 38.1, 35.0, 31.9, 18.5, 13.5. 
4.2.2.1.4. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)isobutyramide (10d); 
 
Yellow solid, yield: 52%, mp: 212-214°C; FTIR (ATR, Vmax, cm-1): 3290.53 (N-H str.), 2965.29 
(Ar-H str.), 2825.54 (Ar-H str.), 1678.71 (C=O str.), 1637.45 (C=O str.), 1509.35 (Ar C=C str.), 
1239.18 (C-N str.), 1117.16 (C-F str.), 1050.80 (C-O-C str.); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 9.68 (s, 1H), 7.99 (d, J = 2.50 Hz, 1H), 7.62 (dd, J = 8.79 Hz, J = 2.67 Hz, 1H), 6.98 – 
6.89 (m, 3H), 6.56 (d, J = 8.64 Hz, 1H), 5.68 (s, 1H), 3.68 (t, J = 4.71 Hz, 4H), 2.95 (t, J = 5.04 
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Hz, 4H), 2.88 (s, 3H), 2.76 (s, 3H), 2.56 – 2.53 (m, 1H), 1.08 (d, J = 6.68 Hz, 6H). 13C NMR 
(100 MHz, DMSO-d6, 25°C) δ 174.6, 161.4, 155.5 – 153.0 (d, JC-F = 248.42 Hz, 1C), 142.1, 
139.9 – 139.8 (d, JC-F = 8.57 Hz, 1C), 131.09 – 131.04 (d, JC-F = 5.93 Hz, 1C), 130.4, 125.3, 
122.4, 119.1, 118.7, 115.8, 114.0 – 113.8 (d, JC-F = 22 Hz, 1C), 112.4, 77.4, 66.0, 50.1, 35.0, 
32.0, 19.5. 
4.2.2.1.5. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)-3-methylbutanamide (10e);  
 
Yellow solid, yield: 61%, mp: 134-136°C; FTIR (ATR, Vmax, cm-1): 3325.89 (N-H str.), 2952.32 
(Ar-H str.), 2866.13 (Ar-H str.), 1638.98 (C=O str.), 1615.05 (C=O str.), 1541.64 (Ar C=C str.), 
1241.67 (C-N str.), 1115.38 (C-F str.), 1051.34 (C-O-C str.); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 9.72 (s, 1H), 7.98 (d, J = 2.48 Hz, 1H), 7.60 (dd, J = 8.96 Hz, J = 2.24 Hz, 1H), 6.99 – 
6.89 (m, 3H), 6.56 (d, J = 8.91 H, 1H), 5.68 (s, 1H), 3.68 (t, J = 4.16 Hz, 4H), 2.95 (t, J = 4.41 
Hz, 4H), 2.88 (s, 3H), 2.76 (s, 3H), 2.11 (d, J = 6.91 Hz, 2H), 2.09 – 1.98 (m, 1H), 0.92 (d, J = 
6.57 Hz, 6H). 13C NMR (100 MHz, DMSO-d6, 25°C)  δ 170.1, 161.4, 155.5 – 153.0 (d, JC-F = 
254.32 Hz, 1C), 142.2, 139.9 – 139.8 (d, JC-F = 8.05 Hz, 1C), 131.1 – 131.0 (d, JC-F = 6.02 Hz, 
1C), 130.3, 125.3, 122.5, 119.14 – 119.11 (d, JC-F = 3.06 Hz, 1C), 118.6, 115.8, 114.0 – 113.8 
(d, JC-F = 21.69 Hz, 1C), 112.4, 77.4, 66.0, 50.2, 45.5, 35.0, 32.0, 25.6, 22.3. 
4.2.2.1.6. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)cyclopropanecarboxamide (10f);  
 
Yellow solid, yield: 55%, mp: 150-153°C; FTIR (ATR, Vmax, cm-1): 3310.53 (N-H str.), 2953.18 
(Ar-H str.), 2854.68 (Ar-H str.), 1666.00 (C=O str.), 1638.88 (C=O str.), 1509.36 (Ar C=C str.), 
1241.77 (C-N str.), 1114.26 (C-F str.);  1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.05 (s, 1H), 
7.99 (s, 1H), 7.61 (d, J = 7.06 Hz, 1H), 6.94 – 6.91 (m, 3H), 6.55 (d, J = 7.99 Hz, 1H), 5.67 (s, 
1H), 3.68 (t, J = 5.03 Hz, 4H), 2.94 (t, J = 5.07 Hz, 4H), 2.88 (s, 3H), 2.76 (s, 3H), 1.67 – 1.66 
(m, 1H), 0.84 – 0.68 (m, 4H). 13C NMR (100 MHz, DMSO-d6, 25°C)  δ 171.0, 161.4, 155.5 – 
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153.0 (d, JC-F = 246.33 Hz, 1C), 142.1, 139.9 – 139.8 (d, JC-F = 8.16 Hz, 1C), 131.09 – 131.04 
(d, JC-F = 5.61 Hz, 1C), 130.5, 125.1, 122.5, 119.1, 118.4, 115.8, 114.0 – 113.8 (d, JC-F = 21.18 
Hz, 1C), 112.4, 77.4, 66.0, 50.1, 35.0, 31.9, 14.3, 6.8. 
4.2.2.1.7. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)cyclobutanecarboxamide (10g); 
  
Yellow solid, yield: 41%, mp: 110-112°C; FTIR (ATR, Vmax, cm-1): 3271.20 (N-H str.), 2941.81 
(Ar-H str.), 2854.40 (Ar-H str.), 1638.91 (C=O str.), 1616.93 (C=O str.), 1508.28 (Ar C=C str.), 
1241.46 (C-N str.), 1114.31 (C-F str.), 918.02 (C-O-C str.); 1H NMR (400 MHz, DMSO-d6, 
25°C) δ 9.59 (s,1H), 7.99 (d, J = 2.36 Hz, 1H), 7.63 (dd, J = 8.72 Hz, J = 2.69 Hz, 1H), 6.98 - 
6.89 (m, 3H), 6.55 (d, J = 8.83 Hz, 1H), 5.68 (s, 1H), 3.68 (t, J = 4.29 Hz, 4H), 3.20 – 3.12 (m, 
1H), 2.95 (t, J = 4.87 Hz, 4H), 2.88 (s, 3H), 2.76 (s, 3H), 2.25 – 2.16 (m, 2H), 2.11 – 2.04 (m, 
2H), 1.97 – 1.86 (m, 1H), 1.82 – 1.75 (m, 1H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 172.3, 
161.4, 155.5 – 153.0 (d, JC-F = 245.67 Hz, 1C), 142.1, 139.9 – 139.8 (d, JC-F = 8.03 Hz, 1C), 
131.09 – 131.03 (d, JC-F = 5.73 Hz, 1C), 130.4, 125.3, 122.53 – 122.50 (d, JC-F = 2.97 Hz, 1C), 
119.09 – 119. 06 (d, JC-F = 4.25 Hz, 1C), 118.6, 115.8, 114.0 – 113.8 (d, JC-F = 21. 35 Hz, 1C), 
112.4, 77.4, 66.0, 50.1, 39.4, 34.9, 31.9, 24.6, 17.7. 
4.2.2.1.8. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)cyclohexanecarboxamide (10h); 
 
Yellow solid, yield: 34%, mp: 135-140°C; FTIR (ATR, Vmax, cm-1): 3296.53 (N-H str.), 2924.74 
(Ar-H str.), 2852.37 (Ar-H str.), 1639.13 (C=O str.), 1616.61 (C=O str.), 1508.73 (Ar C=C str.), 
1241.15 (C-N str.), 1114.65 (C-F str.), 1047.52 (C-O-C str.);  1H NMR (600 MHz, DMSO-d6, 
25°C) δ  9.64 (s, 1H), 8.01 (d, J = 2.22 Hz, 1H), 7.61 (dd, J = 8.99 Hz, J = 2.72 Hz, 1H), 6.97 – 
6.89 (m, 3H), 6.55 (d , J = 8.97 Hz, 1H), 5.67 (s, 1H), 3.68 (t, J = 3.93 Hz, 4H), 2.95 (t, J = 4.35 
Hz, 4H), 2.88 (s, 3H), 2.76 (s, 3H), 2.28 – 2.24 (m, 1H), 1.78 – 1.73 (m, 4 H), 1.64 – 1.62 (m, 
1H), 1.43 – 1.37 (m, 2H), 129 – 1.14 (m, 3H). 3H). 13C NMR (100 MHz, DMSO-d6, 25°C)  δ 
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173.7, 161.4, 155.0 – 153.4 (d, JC-F = 244.84 Hz, 1C), 142.0, 139.8 -139.7 (d, JC-F = 8.16 Hz, 
1C), 131.09 – 131.05 (d, JC-F = 6.53 Hz, 1C), 130.5, 125.2,122.46 – 122.44 (d, JC-F = 2.46 Hz, 
1C), 119.0, 118.6, 115.8, 113.9 – 113.8 (d, JC-F = 21.41 Hz, 1C), 112.3, 77.4, 66.0, 50.1, 44.7, 
34.9, 31.9, 29.1, 25.3, 25.2. 
4.2.2.1.9. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)pentanamide (10i); 
 
Yellow solid, yield: 33%, mp: 160-165°C;  FTIR (ATR, Vmax, cm-1): 3335.00 (N-H str.), 
2958.21 (Ar-H str.), 2852.94 (Ar-H str.), 1671.25 (C=O str.), 1636.16 (C=O str.), 1509.17 (Ar 
C=C str.), 1240.23 (C-N str.), 1117.32(C-F str.), 943.28 (C-O-C str.);  1H NMR (400 MHz, 
DMSO-d6, 25°C) δ  9.73 (s, 1H), 7.98 (s, 1H), 7.61 (s, 1H), 6.94 – 6.91 (m, 3H), 6.56 (s, 1H), 
5.67 (s, 1H), 3.68 (t, J = 4.65 Hz, 4H), 2.95 (t, J = 4.41 Hz, 4H), 2.88 (s, 1H), 2.76 (s, 3H), 2.23 
(t, J = 4.57 Hz, 2H), 1.63 – 1.48 (m, 2H), 1.38 – 1.21 (m, 2H), 0.89 (t, J = 7.28 Hz, 3H). 13C 
NMR (100 MHz, DMSO-d6, 25°C) δ 170.7, 161.4, 155.4 – 153.0 (d, JC-F = 245.83 Hz, 1C), 
142.1, 139.9 – 139.8 (d, JC-F = 8.76 Hz, 1C), 131.09 – 131.04 (d, JC-F = 5.79 Hz, 1C), 130.4, 
125.2, 122.4, 119.1, 118.5, 115.8, 114.0 – 113.8 (d, JC-F = 21.53 Hz, 1C), 112.4, 77.4, 66.0, 
50.1, 35.9, 34.9, 31.9, 27.3, 21.8, 13.7. 
4.2.2.1.10. 2-Chloro-N-(2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)acetamide (10j); 
 
Yellow solid, yield: 42%, mp: 175-179°C;  FTIR (ATR, Vmax, cm-1): 3357.44 (N-H str.), 
2969.10 (Ar-H str.), 2848.67 (Ar-H str.), 1684.34 (C=O str.), 1637.28 (C=O str.), 1516.55 (Ar 
C=C str.), 1237.73 (C-N str.), 1117.70 (C-F str.);  1H NMR (400 MHz, DMSO-d6, 25°C) δ 
10.20 (s, 1H), 8.00 (s, 1H), 7.60 (d, J = 7.27 Hz, 1H), 6.98 – 6.90 (m, 3H), 6.60 (d, J = 9.17 Hz, 
1H), 5.70 (s, 1H), 4.20 (s, 2H), 3.68 (t, J = 4.29 Hz, 4H), 2.95 (t, J = 4.51 Hz, 4H), 2.88 (s, 3H), 
2.78 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 164.1, 161.2, 155.5 – 153.0 (d, JC-F = 
245.77 Hz, 1C), 142.7, 139.9 – 139.8 (d, JC-F = 7.61 Hz, 1C), 131.06 – 131.00 (d, JC-F = 6.08 
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Hz, 1C), 129.3, 125.4, 122.47 – 122.45 (d, JC-F = 3.76 Hz, 1C), 119.17 – 119.14 (d, JC-F = 2.99 
Hz, 1C), 118.8, 115.7, 114.0 – 113.8 (d, JC-F = 21.52 Hz, 1C), 112.5, 77.4, 66.0, 50.1, 43.4, 
34.9, 31.9. 
4.2.2.1.11. N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)benzamide (10k); 
 
Yellow solid, yield: 44%, mp: 230-235°C;  FTIR (ATR, Vmax, cm-1): 3271.33 (N-H str.), 
2963.52 (Ar-H str.), 2823.78 (Ar-H str.), 1663.03 (C=O str.), 1637.11 (C=O str.), 1254.29 (C-N 
str.), 1117.61 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.16 (s, 1H), 8.19 (s, 1H), 
7.96 (d, J = 7.10 Hz, 2H), 7.82 (d, J = 7.74 Hz, 1H), 7.57 – 7.51 (m, 3H), 6.97 – 6.95 (m, 3H), 
6.63 (d, J = 8.38 Hz, 1H), 5.71 (s, 1H), 3.68 (t, J = 4.66 Hz, 4H), 2.95 (t, J = 3.99 Hz, 4H), 2.90 
(s, 3H), 2.10 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 164.9, 161.4, 155.5 – 153.0 (d, 
JC-F = 246.26 Hz, 1C), 142.6, 139.9 – 139.8 (d, JC-F = 8.22 Hz, 1C), 134.8, 131.3, 131.1 – 131.0 
(d, JC-F = 5.12 Hz, 1C), 130.0, 128.3, 127.5, 126.5, 122.5, 119.9, 119.16 – 119.13 (d, JC-F = 4.03 
Hz, 1C), 115.7, 114.0 – 113.8 (d, JC-F = 21.48 Hz, 1C), 112.3, 77.4, 66.0, 50.1, 35.0, 32.0. 
4.2.2.2.1. (E)-N-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)-3-(4-methoxyphenyl)acrylamide (10l); 
 
Green solid, yield: 55%, mp: 135-140°C; FTIR (ATR, Vmax, cm-1): 3285.27 (N-H str.), 2955.21 
(Ar-H str.), 2833.57 (Ar-H str.), 1639.61 (C=O str.), 1600.19 (C=O str.), 1508.51 (Ar C=C str.), 
1241.62 (C-N str.), 1112.67 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.03 (s, 1H), 
8.09 (d, J = 2.93 Hz, 1H), 7.74 (dd, J = 8.65 Hz, J = 2.44 Hz, 1H), 7.56 (d, J = 8.93 Hz, 2H), 
7.50 (d, J = 15.78 Hz, 1H), 7.01 – 6.91 (m, 5H), 3.79 (s, 3H), 3.68 (t, J = 4.39 Hz, 4H), 2.95 (t, J 
= 4.85 Hz, 4H), 2.89 (s, 3H), 2.78 (s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C)  δ 163.4, 
161.4, 160.5, 155.5 – 153.0 (d, JC-F = 241.50 Hz, 1C), 142.3, 139.9 – 139.8 (d, JC-F = 7.75 Hz, 
1C), 139.3, 131.1 – 131.0 (d, JC-F = 5.49 Hz, 1C), 130.5, 129.3, 127.3, 125.2, 122.5, 119.7, 
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119.1, 118.5, 115.9, 114.4, 114.0 – 113.8 (d, JC-F = 22.33Hz, 1C), 112.5, 77.4, 66.0, 55.2, 50.2, 
35.0, 32.0. 
4.2.2.2.2. (E)-3-(2,3-Dimethoxyphenyl)-N-(2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-4-
oxo-1,2,3,4-tetrahydroquinazolin-6-yl)acrylamide (10m); 
 
Green solid, yield: 63%, mp: 140-145°C; FTIR (ATR, Vmax, cm-1): 3340.83 (N-H str.), 2828.03 
(Ar-H str.), 1639.51 (C=O str.), 1613.31 (C=O str.), 1504.26 (Ar C=C str.), 1264.21 (C-N str.), 
1117.46 (C-F str.), 1067.07 (C-O-C str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.14 (s, 1H), 
8.11 (s, 1H), 7.78 (s, 1H), 7.74 (d, J = 16.37 Hz, 1H), 7.19 – 7.10 (m, 3H), 6.97 – 6.93 (m, 3H), 
6.81 (d, J = 16.52 Hz, 1H), 6.62 (d, J = 8.77 Hz, 1H), 5.70 (s, 1H), 3.83 (s, 3H), 3.77 (s, 3H), 
3.68 (t, J = 4.30 Hz, 4H), 2.95 (t, J = 4.43 Hz, 4H), 2.89 (s, 3H), 2.79 (s, 3H). 13C NMR (100 
MHz, DMSO-d6, 2°C) δ 163.2, 161.4, 155.5 – 153.0 (d, JC-F = 246.05 Hz, 1C), 152.9, 147.5, 
142.4, 139.9, 134.1, 131.1 – 131.0 (d, JC-F = 5.65 Hz, 1C), 130.3, 128.3, 125.2, 124.4, 123.5, 
122.5, 119.1, 118.7, 118.5, 115.8, 114.0 – 113.8 (d, JC-F = 21.34 Hz, 1C), 114.0, 112.5, 77.4, 
66.0, 60.6, 55.7, 50.1, 34.9, 32.0. 
4.2.2.3.1. 1-(2-(3-Fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)-3-(p-tolyl)urea (10n); 
 
Light pink solid, yield: 38%, mp: 132-137°C; FTIR (ATR, Vmax, cm-1): 3377.81 (N-H str.), 
2839.33 (Ar-H str.), 1684.84 (C=O str.), 1630.31 (C=O str.), 1513.25 (Ar C=C str.), 1240.47 
(C-N str.), 1114.18 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 8.43 (s, 1H), 8.41 (s, 
1H), 7.86 (d, J = 8.43 Hz, 2H), 7.06 (d, J = 8.13 Hz, 2H), 6.97 – 6.91 (m, 3H), 6.56 (d, J = 8.81 
Hz, 1H), 5.67 (s, 1H), 3.68 (t, J = 4.57 Hz, 4H), 2.95 (t, J = 4.21 Hz, 4H), 2.89 (s, 3H), 2.77 (s, 
3H), 2.23 (s, 3H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 161.5, 155.0 – 153.4 (d, JC-F = 
247.69 Hz, 1C), 152.8, 141.5, 139.87 – 139.82 (d, J = 7.67 Hz, 1C), 137.2, 131.14 – 131.11 (d, 
JC-F = 5.61 Hz, 1C), 130.8, 130.4, 129.0, 124.8, 122.56 – 120.54 (d, JC-F = 3.32 Hz, 1C), 119.07 
– 119.05 (d, JC-F = 3.20 Hz, 1C), 118.2, 118.0, 116.2, 114.0 – 113.8 (d, JC-F = 21.21 Hz, 1C), 
112.7, 77.5, 66.1, 50.1, 35.1, 32.0, 20.2. 
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4.2.2.3.2. 1-Ethyl-3-(2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)urea (10o); 
 
Green solid, yield: 42%, mp: 155-160°C; FTIR (ATR, Vmax, cm-1): 3341.01 (N-H str.), 2965.13 
(Ar-H str.), 1637.44 (C=O str.), 1613.00 (C=O str.), 1505.40 (Ar C=C str.), 1240.37 (C-N str.), 
1113.63 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 8.23 (s, 1H), 7.78 (d, J = 2.21 Hz, 
1H), 7.40 (dd, J = 8.78 Hz, J = 2.16 Hz, 1H), 6.96 – 6.89 (m, 3H), 6.51 (d, J = 8.69 Hz, 1H), 
5.95 (t, J = 5.55 Hz, 1H), 5.64 (s, 1H), 3.68 (t, J = 4.51 Hz, 4H), 3.11 – 3.06 (m, 2H), 2.95 (t, J 
= 4.32 Hz, 4H), 2.88 (s, 3H), 2.74 (s, 3H), 1.04 (t, J = 7.38 Hz, 3H). 13C NMR (150 MHz, 
DMSO-d6, 25°C) δ 161.5, 155.3, 155.0 – 153.4 (d, JC-F = 246.42 Hz, 1C), 140.9, 139.79 – 
139.74 (d, JC-F = 8.05 Hz, 1C), 131.8, 131.1 – 131.0 (d, JC-F = 5.02 Hz, 1C), 124.3, 122.54 – 
122.52 (d, JC-F = 2.66 Hz, 1C), 119.0 – 118.9 (d, JC-F = 2.63 Hz, 1C), 117.4, 116.2, 114.0 – 
113.8 (d, JC-F = 21.17 Hz, 1C), 112.7, 77.5, 66.0, 50.1, 35.1, 33.9, 31.9, 15.4. 
4.2.2.1.1.1. Synthesis of 2-((2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)amino)-2-oxoacetic acid (11);  
 
To the suspension of ethyl 2-((2-(3-fluoro-4-morpholinophenyl)-1,3-dimethyl-4-oxo-1,2,3,4-
tetrahydroquinazolin-6-yl)amino)-2-oxoacetate (0.2 g, 0.425 mmol) in ethanol was added 2N-
NaOH (0.034 g, 0.85 mmol). The resultant mixture was stirred at room temperature for 16 h, 
diluted with water and washed with ethyl acetate. The aqueous layer was acidified with 6N-HCl, 
precipitate was formed, filtered and washed with diethyl ether to afford yellow solid product 
(0.145 g, 77%). mp 143-145°C; FTIR (ATR, Vmax, cm-1): 3296.46 (N-H str.), 2954.69 (Ar-H 
str.), 2827.00 (Ar-H str.), 1685.98 (C=O str.), 1637.87 (C=O str.), 1506.53 (Ar C=C str.), 
1240.55 (C-N str.), 1110.68 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.62 (s, 1H), 
8.24 (s, 1H), 7.71 (d, J = 8.04 Hz, 1H), 6.96 – 6.92 (m, 3H), 6.61 (d, J = 6.60 Hz, 1H), 5.71 (s, 
1H), 3.68 (t, J = 4.03 Hz, 4H), 2.95 (t, J = 4.27 Hz, 4H), 2.88 (s, 3H), 2.71 (s, 3H). 13C NMR 
(100 MHz, DMSO-d6, 25°C) 162.1, 161.2, 156.3, 155.5 – 150.0 (d, JC-F = 244 Hz, 1C), 143.2, 
140.0 – 139.9, (d, JC-F = 8.54 Hz, 1C), 131.1 – 131.0 (d, JC-F = 5.39 Hz, 1C), 128.5, 126.4, 
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122.4, 119.8, 119.2, 115.5, 114. 0 – 113.8 (d, JC-F = 22.10 Hz, 1C), 112.3, 77.4, 60.0, 50.1, 34.9, 
31.9.  
4.2.3. Synthesis and spectral characterization of compounds 12, 13, 13a, 14 and 14a; 
4.2.3.1. Synthesis of 2-(3-fluoro-4-morpholinophenyl)-6-nitroquinazolin-4-ol (12); 
 
To the solution of 2-(3-fluoro-4-morpholinophenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)-one 
(25 g, 67.3 mmol) in DMSO (100 mL) was added potassium permanganate (31.82 g, 201.41 
mmol). The mixture was heated at 120°C for 24 h and monitored by TLC after consumption of 
starting material cooled to room temperature and filtered through celite. The filtrate was poured 
into ice cold water and stirred for 30 min precipitate was formed, filtered and washed with 
diethyl ether to afford title compound (21 g, 84%); mp: 295-297°C; FTIR (ATR, Vmax, cm-1): 
3703.90 (O-H str.), 2972.62 (Ar-H str.), 2865 (Ar-H str.), 1675.24 (C=O str.), 1613.70 (Ar C=C 
str.), 1338.04 (Ar-NO2 str.), 1242.16 (C-N str.), 1116.63 (C-F str), 1055.57 (C-O-C str);  1H 
NMR (600 MHz, DMSO-d6, 70°C) δ 12.56 (brs, 1H), 8.77 (d, J = 2.05 Hz,1H), 8.46 (dd, J = 
8.88 Hz, J = 2.13 Hz, 1H), 8.04 – 7.99 (m, 2H), 7.79 (d, J = 8.92 Hz, 1H), 7.11 (t, J = 8.91 Hz, 
1H), 3.77 ( t, J = 4.32 Hz, 4H), 3.20 (t, J = 4.05 Hz, 4H). 13C NMR (150 MHz, DMSO-d6, 70°C) 
δ 161.0, 154.1 – 152.5 (d, JC-F = 244.28 Hz, 1C), 153.8, 152.5, 144.1, 142.5 – 142.4 (d, JC-F = 
7.81 Hz, 1C), 128.3, 127.9, 124.88 - 124.86 (d, JC-F = 2.27 Hz,1C), 124.16 – 124.11 (d, JC-F = 
7.74 Hz, 1C), 121.6, 120.3, 117.9 – 117.8 (d, JC-F = 3.63 Hz, 1C), 115.5 – 115.4 (d, JC-F = 24.94 
Hz 1C), 65.6, 49.5.   
4.2.3.2. Synthesis of 4-(2-fluoro-4-(4-methoxy-6-nitroquinazolin-2-yl)phenyl)morpholine (13) & 
2-(3-fluoro-4-morpholinophenyl)-3-methyl-6-nitroquinazolin-4(3H)-one (13a);  
To a mixture of 2-(3-fluoro-4-morpholinophenyl)-6-nitroquinazolin-4-ol (3.5 g, 9.45 mmol) in 
DMF (30 mL), were added K2CO3 (3.91 g, 28.35 mmol) followed by iodomethane (1.18 mL, 
18.90 mmol) at room temperature. The reaction mixture was stirred for 16 h at ambient 
temperature and poured into ice cold water, precipitate was formed, filtered and washed with 
pentane to afford a mixture of titled compounds which was separated by combi-flash column 
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chromatography using EA/Hexane as eluent. Both fractions were collected separately and 
evaporated under vacuum to afford title compounds. 
Spectral characterization of 13; 
 
Yellow solid, yield: 44%, mp: 248-250°C; FTIR (ATR, Vmax, cm-1): 2961.70 (Ar-H str.), 
2867.90 (Ar-H str.), 1588.50 (Ar C=C str.), 1342.35 (Ar-NO2 str.), 1247.20 (C-N str.), 1115.54 
(C-F str.), 1055.50 (C-O-C str); 1H NMR (400 MHz, CDCl3, 25°C) δ 9.00 (d, J = 2.68 Hz, 1H), 
8.52 (dd, J = 9.25 Hz, J = 2.56 Hz, 1H), 8.31 (dd, J = 8.52 Hz, J = 2.24 Hz, 1H), 8.23 (dd, J = 
14.37 Hz, J = 2.24 Hz, 1H), 7.98 (d, J = 9.25 Hz, 1H), 6.99 (t, J = 9.06 Hz, 1H), 4.31 (s, 3H), 
3.90 (t, J = 4.57 Hz, 4H), 3.23 (t, J = 4.64 Hz, 4H). 13C NMR (100 MHz, CDCl3, 25°C) δ 167.9, 
162.2, 156.3 – 153.9 (d, JC-F = 245 Hz, 1C), 154.7, 144.8, 143.0 – 142.9 (d, JC-F = 8.34 Hz, 1C), 
131.0 – 131.1 (d, JC-F = 8.00 Hz, 1C), 129.3, 127.3, 125.73 – 125.71 (d, JC-F = 2.64 Hz, 1C), 
121.0, 117.95 – 117.92 (d, JC-F = 4.03 Hz, 1C), 116.9 – 116.7 (d, JC-F = 23.25 Hz, 1C), 114.3, 
67.0, 54.8, 50.5.  
Spectral characterization of 13a;  
 
Yellow solid, yield: 44%, mp: 230-233°C; FTIR (ATR, Vmax, cm-1): 2971.90 (Ar-H str.), 
2866.73 (Ar-H str.), 1676.67 (C=O str.), 1612.26 (Ar C=C str.), 1339.08 (Ar-NO2 str.), 1238.89 
(C-N str.), 1112.82 (C-F str.), 1055.41 (C-O-C str);  1H NMR (600 MHz, CDCl3, 25°C) δ 9.15 
(d, J = 3.05 Hz, 1H), 8.51 (dd, J = 9.07 Hz, J = 2.19 Hz, 1H), 7.80 (d, J = 9.06 Hz, 1H), 7.36 – 
7.34 (m, 2H), 7.04 (t, J = 8.23 Hz, 1H), 3.89 (t, J = 4.51 Hz, 4H), 3.60 (s, 3H), 3.20 (t, J = 4.60 
Hz, 4H). 13C NMR (150 MHz, CDCl3, 25°C) δ 161.9, 158.1, 155.3 – 154.0 (d, JC-F = 248 Hz, 
1C), 151.3, 145.8, 142.48 – 142.43 (d, JC-F  = 7.70 Hz, 1C), 129.1, 128.5, 127.9 – 127.8 (d, JC-F 
= 8.35 Hz, 1C), 125.16 – 125.14 (d, JC-F = 4.48 Hz, 1C), 123.66 – 123.64 (d, JC-F = 6.01 Hz, 1C), 
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120.5, 118.63 – 118.60 (d, JC-F = 4.00 Hz, 1C), 116.9 – 116.8 (d, JC-F = 25 Hz, 1C), 66.9, 50.5, 
35.0.  
4.2.3.3. Synthesis of 2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-amine (14); 
 
The title compound was synthesized from 4-(2-fluoro-4-(4-methoxy-6-nitroquinazolin-2-
yl)phenyl)morpholine (2.0 g, 5.20 mmol) as described in the procedure for 8. Brown solid, 
yield: 65%; 1H NMR (400 MHz, DMSO-d6, 25°C) δ  8.17 ( dd, J = 8.14 Hz, J = 2.09 Hz, 1H), 
8.07 (dd, J = 14.97 Hz, J = 1.95 Hz, 1H), 7.64 (d, J = 8.82 Hz, 1H), 7.27 – 7.25 (m, 1H), 7.10 – 
7.09 (m, 1H), 7.06 – 7.05 (m, 1H), 5.79 (s, 2H), 4.16 (s, 3H), 3.76 (t, J = 4.71 Hz, 4H), 3.09 (t, J 
= 4.80 Hz, 4H). 
4.2.3.4. Synthesis of 6-amino-2-(3-fluoro-4-morpholinophenyl)-3-methylquinazolin-4(3H)-one 
(14a);  
 
The title compound was synthesized from 2-(3-fluoro-4-morpholinophenyl)-3-methyl-6-
nitroquinazolin-4(3H)-one (3.8 g, 9.88 mmol) as described in the procedure for 8. Brown solid, 
yield: 67%; mp: 240-243°C; 1H NMR (400 MHz, DMSO-d6, 25°C) δ  8.17 ( dd, J = 8.30 Hz, J 
= 1.79 Hz, 1H), 8.07 (dd, J = 14.96 Hz, J = 1.93 Hz, 1H), 7.64 (d, J = 8.92 Hz, 1H), 7.26 (dd, J 
= 8.97 Hz, J = 2.51 Hz, 1H), 7.12 – 7.07 (m, 2H), 5.09 (s, 2H), 4.16 (s, 3H), 3.76 (t, J = 5.03 
Hz, 4H), 3.09 (t, J = 4.74 Hz, 4H). 
4.2.4. Synthesis and spectral characterization of derivatives (16a-16d) and (16aa-16ad); 
3.2.4.1. Synthesis of ethyl 2-((2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-
yl)amino)-2-oxoacetate (16a); 
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The compound was synthesized from 2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-
amine (0.1 g, 0.28 mmol) and ethyl 2-chloro-2-oxoacetate (0.04 mL, 0.42 mmol) as described in 
general procedure A.  
Off white solid, yield: 50%, mp: 230-232°C; FTIR (ATR, Vmax, cm-1): 3332.74 (N-H str.), 
2951.85 (Ar-H str.), 2859.92 (Ar-H str.), 1701.67 (C=O str.), 1549.48 (Ar C=C str.), 1248.80 
(C-N str.), 1116.84 (C-F str.), 1047.02 (C-O-C str); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 
11.14 (s, 1H), 8.65 (d, J = 2.24 Hz, 1H), 8.23 (dd, J = 8.33 Hz, J = 1.72 Hz, 1H), 8.17 (dd, J = 
9.20 Hz, J = 2.05 Hz, 1H), 8.13 (dd, J = 14.89 Hz, J = 1.29 Hz, 1H), 7.90 (d, J = 9.28 Hz, 1H), 
7.13 (t, J = 8.83 Hz, 1H), 4.34 (q, J = 6.75 Hz, 2H), 4.23 (s, 3H), 3.77 (t, J = 4.13 Hz, 4H), 3.13 
(t, J = 4.55 Hz, 4H), 1.34 (t, J = 7.03 Hz, 3H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 166.1, 
160.2, 157.1, 155.6, 155.1 – 153.5 (d, JC-F = 244.77 Hz, 1C), 148.2, 141.58 – 141.53 (d, JC-F = 
8.41 Hz, 1C), 135.7, 131.3 – 131.2 (d, JC-F = 7.04 Hz, 1C), 128.0, 127.7, 124.5, 118.42 – 118.40 
(d, JC-F = 3.65 Hz, 1C), 115.2 – 115.0 (d, JC-F = 23.18 Hz, 1C), 114.3, 112.4, 66.0, 62.4, 54.2, 
50.0, 13.7. 
4.2.4.2. Synthesis of N-(2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-yl)acetamide 
(16b); 
 
The compound was synthesized from 2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-
amine (0.2 g, 0.56 mmol) and acetyl chloride (0.06 mL, 0.84 mmol) as described in general 
procedure A. Yellow solid, yield: 29%, mp: 250-252°C; FTIR (ATR, Vmax, cm-1): 3313.78 (N-H 
str.), 2960.89 (Ar-H str.), 1665.78 (C=O str.), 1544.43 (Ar C=C str.), 1240.93 (C-N str.), 
1115.63 (C-F str.), 983.48 (C-O-C str); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 10.31 (s, 1H), 
8.53 (d, J = 1.32 Hz, 1H), 8.21 (d, J = 8.39 Hz, 1H), 8.11 (d, J = 14.32 Hz, 1H), 7.91 (dd, J = 
8.86 Hz, J = 1.95 Hz, 1H), 7.84 (d, J = 8.89 Hz, 1H), 7.12 (t, J = 8.96 Hz, 1H), 4.21 (s, 3H), 
3.76 (t, J = 4.20 Hz, 4H), 3.11 (t, J = 4.15 Hz, 4H), 2.11 (s, 3H). 13C NMR (150 MHz, DMSO-
d6, 25°C) δ 168.7, 166.0, 156.3, 155.1 – 153.5 (d, JC-F = 245.06 Hz, 1C), 147.4, 141.4 – 141.3 (d, 
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JC-F = 7.67 Hz, 1C), 137.6, 131.58 – 131.53 (d, JC-F = 7.56 Hz, 1C), 121.0, 126.7, 124.3, 118.4, 
115.0 – 114.9 (d, JC-F = 21.44 Hz, 1C), 114.6, 110.1, 66.0, 54.0, 50.1, 24.0. 
4.2.4.3. Synthesis of N-(2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-
yl)cyclopropanecarboxamide (16c); 
   
The compound was synthesized from 2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-
amine (0.1 g, 0.28 mmol, 1 equiv) and cyclopropanecarbonyl chloride (0.038 mL, 0.42 mmol, 
1.5 equiv) as described in general procedure A. Yellow solid, yield: 27%, mp: 255-260°C; FTIR 
(ATR, Vmax, cm-1): 3269.32 (N-H str.), 2968.41 (Ar-H str.), 2857.07 (Ar-H str.), 1655.94 (C=O 
str.), 1535.45 (Ar C=C str.), 1244.51 (C-N str.), 1122.08 (C-F str.), 960.69 (C-O-C str); 1H 
NMR (600 MHz, DMSO-d6, 25°C) δ 10.56 (s, 1H), 8.53 (s, 1H), 8.19 (d, J = 8.57 Hz, 1H), 8.08 
(d, J = 14.56 Hz, 1H), 7.93 (dd, J = 8.53 Hz, J = 1.61 Hz, 1H), 7.83 (d, J = 8.90 Hz, 3H), 7.09 
(t, J = 9.13 Hz, 1H), 4.19 (s, 3H), 3.75 (t, J = 4.26 Hz, 4H), 3.10 (t, J = 4.54 Hz, 4H), 1.83 – 
1.80 (m, 1H), 0.86 – 0.83 (m, 4H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 172,0, 166.0, 156.3, 
155.1 – 153.5 (d, JC-F = 244.05 Hz, 1C), 147.3, 141.4 – 141.3 (d, JC-F = 8.74 Hz, 1C), 137.5, 
131.58 – 131.54 (d, JC-F = 7.37 Hz, 1C), 127.9, 126.7, 124.3, 118.3, 115.0 – 114.9 (d, JC-F = 
23.45 Hz, 1C), 114.6, 110.2, 66.0, 54.0, 50.1, 14.6, 7.4. 
4.2.4.4. Synthesis of 2-(cyclopropylamino)-N-(2-(3-fluoro-4-morpholinophenyl)-4-
methoxyquinazolin-6-yl)acetamide (16d); 
 
To the solution of 2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-amine (0.2 g, 0.56 
mmol) in DCM (10 mL) was added triethyl amine (0.117 mL, 0.84 mmol), followed by 2-
bromoacetyl bromide (0.074 mL, 0.84 mmol) at 0°C. The resultant mixture was stirred at room 
temperature for 4 h, precipitate was formed, filtered and washed with pentane to afford salt of 2-
bromo-N-(2-(3-fluoro-4-morpholinophenyl)-4-methoxyquinazolin-6-yl)acetamide (0.4 g), 
which was  dissolved in DMF (10 mL) and were added potassium carbonate (0.23 gm, 1.69 
mmol), followed by cyclopropanamine (0.06 mL, 0.84 mmol) at room temperature. The 
resultant mixture was stirred at room temperature for 16 h, then diluted with ethyl acetate and 
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washed with cold brine solution (3 X 10 mL).The organic layer dried over anhydrous Na2SO4, 
filtered and evaporated under reduce pressure to yield crude product which was recrystallized 
with ethanol to afford the pure yellow solid product; yield: 37%, mp: 186-188°C; FTIR (ATR, 
Vmax, cm-1): 3250.93 (N-H str.), 2959.62 (Ar-H str.), 1662.75 (C=O str.), 1578.47 (Ar C=C str.), 
1250.36 (C-N str.), 1116.64 (C-F str.), 1046.31 (C-O-C str); 1H NMR (600 MHz, CDCl3, 25°C) 
δ 9.21 (s, 1H), 8.36 (s, 1H), 8.28 (d, J = 8.44 Hz, 1H), 8.23 (d, J = 14.79 Hz, 1H), 7.93 – 7.88 
(m, 2H), 7.00 (t, J = 8.00 Hz, 1H), 4.25 (s, 3H), 3.89 (t, J = 5.38 Hz, 4H), 3.54 (s, 2H), 3.20 (t, J 
= 5.38 Hz, 4H), 2.33 – 2.32 (m, 1H), 0.56 – 0.55 (m, 2H), 0.47 – 0.46 (m, 2H). 13C NMR (150 
MHz, CDCl3, 25°C) δ 170.3, 166.8, 158.1, 156.3 – 154.7 (d, JC-F = 241.75 Hz, 1C), 149.0, 141.9 
– 141.8 (d, JC-F = 9.30 Hz, 1C), 135.7, 133.0, 128.8, 126.6, 124.8 – 124.7 (d, JC-F = 2.48 Hz, 
1C), 118.1, 116.3 – 116.2 (d, JC-F = 24.31 Hz, 1C), 115.6, 111.9, 67.1, 54.1, 53.4, 50.8, 31.7, 
6.7.    
4.2.4.5. Synthesis of ethyl 2-((2-(3-fluoro-4-morpholinophenyl)-3-methyl-4-oxo-3,4-
dihydroquinazolin-6-yl)amino)-2-oxoacetate (16aa); 
 
The compound was synthesized from 6-amino-2-(3-fluoro-4-morpholinophenyl)-3-
methylquinazolin-4(3H)-one (0.2 g, 0.56 mmol) and ethyl 2-chloro-2-oxoacetate (0.08 mL, 0.84 
mmol) as described in general procedure A. Off white solid, yield: 34%, mp: 225-227°C; FTIR 
(ATR, Vmax, cm-1): 3287.76 (N-H str.), 2951.72 (Ar-H str.), 1715.87 (C=O str.), 1673.56 (C=O 
str.), 1511.60 (Ar C=C str.), 1118.90 (C-F str.), 1055.67 (C-O-C str); 1H NMR (600 MHz, 
DMSO-d6, 25°C) δ 11.09 (s, 1H), 8.66 (d, J = 2.19 Hz, 1H), 8.12 (dd, J = 8.66 Hz, J = 2.41 Hz, 
1H), 7.65 (d, J = 8.81 Hz, 1H), 7.50 (dd, J = 13.82 Hz, J = 1.43 Hz, 1H), 7.44 (d, J = 8.48 Hz, 
1H), 7.13 (t, J = 8.98 Hz, 1H), 4.33 (q, J = 7.73 Hz, 2H), 3.76 (t, J = 4.47 Hz, 4H), 3.40 (s, 3H), 
3.11 (t, J = 4.19 Hz, 4H), 1.33 (t, J = 7.23 Hz, 3H).13C NMR (150 MHz, DMSO-d6, 25°C) δ 
161.4, 160.3, 155.6, 154.5 – 152.9 (d, JC-F = 244.63 Hz, 1C), 144.1, 143.8, 140.8 – 140.7 (d, JC-F 
= 8.07 Hz, 1C), 135.9, 128.78 – 128.73 (d, JC-F = 8.44 Hz, 1C), 127.7, 127.7, 125.39 – 125.37 
(d, JC-F = 2.82 Hz, 1C), 120.1, 118.44 – 118.42 (d, JC-F = 3.09 Hz, 1C), 116.5 – 116.4 (d, JC-F = 
12.67 Hz, 1C), 116.1, 66.0, 62.4, 50.1, 34.0, 13.8. 
4.2.4.6. Synthesis of N-(2-(3-fluoro-4-morpholinophenyl)-3-methyl-4-oxo-3,4-
dihydroquinazolin-6-yl)acetamide (16ab); 
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The compound was synthesized from 6-amino-2-(3-fluoro-4-morpholinophenyl)-3-
methylquinazolin-4(3H)-one (0.2 g, 0.56 mmol) and acetyl chloride (0.06 mL, 0.84 mmol) as 
described in general procedure A. Yellow solid, yield: 22%, mp: 270-273°C; FTIR (ATR, Vmax, 
cm-1): 3344.55 (N-H str.), 2969.43 (Ar-H str.), 1691.42 (C=O str.), 1647.42 (C=O str.), 1585.55 
(Ar C=C str.), 1234.53 (C-N str.), 1114.01 (C-F str.), 1053.57 (C-O-C str); 1H NMR (600 MHz, 
DMSO-d6, 25°C) δ 10.26 (s, 1H), 8.48 (s, 1H), 7.93 (d, J = 8.31 Hz, 1H), 7.60 (d, J = 8.76 Hz, 
1H), 7.49 (d, J = 14.10 Hz, 1H), 7.43 (d, J = 7.89 Hz, 1H), 7.13 (t, J = 8.78 Hz, 1H), 3.76 (t, J = 
4.29 Hz, 4H), 3.39 (s, 3H), 3.10 (t, J = 4.29 Hz, 4H), 2.09 (s, 3H). 13C NMR (150 MHz, DMSO-
d6, 25°C) δ 168.5, 161.5, 154.5 – 152.9 (d, JC-F = 244.59 Hz, 1C), 153.3, 142.7, 140.7 – 140.6 (d, 
JC-F = 8.14 Hz, 1C), 137.8, 128.9 – 128.8 (d, JC-F = 7.68 Hz, 1C), 127.7, 125.8, 125.3, 120.2, 
118.45 – 118.43 (d, JC-F = 3.41 Hz, 1C), 116.5 – 116.4 (d, JC-F = 22.97 Hz, 1C), 114.0, 66.0, 
50.12, 3.94, 24.0. 
4.2.4.7. Synthesis of N-(2-(3-fluoro-4-morpholinophenyl)-3-methyl-4-oxo-3,4-
dihydroquinazolin-6-yl)cyclopropanecarboxamide (16ac); 
 
The compound was synthesized from 6-amino-2-(3-fluoro-4-morpholinophenyl)-3-
methylquinazolin-4(3H)-one (0.3 g, 0.84 mmol, 1 equiv) and cyclopropanecarbonyl chloride 
(0.09 mL, 1.26 mmol, 1.5 equiv) as described in general procedure A. Yellow solid, yield: 53%, 
mp: 294-296°C; FTIR (ATR, Vmax, cm-1): 3343.88 (N-H str.), 2961.08 (Ar-H str.), 1649.56 
(C=O str.), 1619.80 (C=O str.), 1580.70 (Ar C=C str.), 1236.56 (C-N str.), 1114.58 (C-F str.), 
1052.69 (C-O-C str); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 10.52 (s, 1H), 8.48 (d, J = 2.65 
Hz, 1H), 7.96 (dd, J = 8.67 Hz, J = 2.12 Hz, 1H), 7.59 (d, J = 8.93 Hz, 1H), 7.49 (dd, J = 13.72 
Hz, J = 1.17 Hz, 1H), 7.42 (dd, J = 8.62 Hz, J = 1.03 Hz, 1H), 7.12 (t, J = 8.71 Hz, 1H), 3.76 (t, 
J = 4.78 Hz, 4H), 3.39 (s, 3H), 3.10 (t, J = 4.46 Hz, 4H), 1.83 – 1.79 (m, 1H), 0.85 – 0.82 (m, 
4H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 171.8, 161.5, 154.5 – 152. 9 (d, JC-F = 246.05 Hz, 
1C), 153.2, 142.6, 140.7 – 140.6 (d, JC-F = 8.29 Hz, 1C), 137.9, 128.9 – 128.8 (d, JC-F =  8.41 Hz, 
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1C), 127.7, 125.8, 125.34 – 125 .33 (d, JC-F = 2.37Hz, 1C), 120.2, 118.42 – 118.40 (d, JC-F = 
3.27 Hz, 1C), 116.5 – 116.3 (d, JC-F = 22.80 Hz, 1C), 114.1, 66.0, 50.1, 33.9, 14.6, 7.3. 
4.2.4.8. Synthesis of 2-(cyclopropylamino)-N-(2-(3-fluoro-4-morpholinophenyl)-3-methyl-4-
oxo-3,4-dihydroquinazolin-6-yl)acetamide (16ad); 
 
To the solution of 6-amino-2-(3-fluoro-4-morpholinophenyl)-3-methylquinazolin-4(3H)-one 
(0.2 g, 0.56 mmol) in DCM (10 mL) was added triethyl amine (0.117 mL, 0.84 mmol), followed 
by 2-bromoacetyl bromide (0.074 mL, 0.84 mmol) at 0°C. The resultant mixture was stirred at 
room temperature for 4 h, precipitate was formed, filtered and washed with pentane to afford 
crude salt of 2-bromo-N-(2-(3-fluoro-4-morpholinophenyl)-3-methyl-4-oxo-3,4-
dihydroquinazolin-6-yl)acetamide (0.5 g), which was dissolved in DMF (10 mL) and were 
added potassium carbonate (0.23 gm, 1.69 mmol), followed by cyclopropanamine (0.06 mL, 
0.84 mmol) at room temperature. The resultant mixture was stirred at room temperature for 16 
h, then diluted with ethyl acetate and washed with cold brine solution (3 x 10 mL).The organic 
layer was dried over anhydrous Na2SO4, filtered and evaporated under reduce pressure to yield 
crude product which was recrystallized with ethanol to afford the pure yellow solid product; 
yield: 35%, mp: 186-188°C; FTIR (ATR, Vmax, cm-1): 3314.18 (N-H str.), 2962.20 (Ar-H str.), 
1650.68 (C=O str.), 1620.65 (C=O str.), 1578.13 (Ar C=C str.), 1236.42 (C-N str.), 1115.21 (C-
F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 9.26 (s, 1H), 8.25 (d, J = 8.68 Hz, 1H), 8.07 (s, 
1H), 7.62 (d, J = 9.07 Hz, 1H), 7.25 – 7.22 (m, 2H), 6.96 (t, J = 8.11 Hz, 1H), 3.83 (t, J = 4.47 
Hz, 4H), 3.47 (s, 5H), 3.11 (t, J = 4.41 Hz, 4H), 2.26 – 2.24 (m, 1H), 0.48 -0.41 (m, 4H). 13C 
NMR (150 MHz, DMSO-d6, 25°C) δ 170.4, 162.5, 155.8 – 154.1 (d, JC-F  = 248.2 Hz, 1C), 
153.8, 143.8, 141.68 – 141.63 (d, JC-F = 8.32 Hz, 1C), 136.8, 129.1 – 129.0 (d, JC-F = 7.78 Hz, 
1C), 128.6, 126.5, 124.93 – 124.92 (d, JC-F = 2.84 Hz, 1C), 120.8, 118.63 – 118.61 (d, JC-F = 
2.89 Hz, 1C), 116.8 – 116.6 (d, JC-F = 23.87 Hz, 1C), 115.2, 66.9, 53.2, 50.6, 34.5, 31.6, 6.6. 
4.3. Biology 
M. tuberculosis H37Rv (ATCC 25618) was grown in Middlebrook 7H9 medium supplemented 
with 10% v/v oleic acid, albumin, dextrose, catalase (OADC; Becton Dickinson), 0.05% w/v 
Tween 80 (7H9-OADC-Tw), and 50 µg/mL hygromycin (7H9-OADC-Tw-hyg), where 
required. Large scale cultures were grown in 100 mL of medium in 450 cm2 roller bottles at 37 
ºC and 100 rpm. M. tuberculosis strain CHEAM3 and DREAM8 expressing codon-optimized 
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mCherry and DsRed from plasmids pCherry3 and pBlazeC8, respectively, were used. Assay 
plates containing 20 µL of 7H9-Tw-OADC medium with appropriate control compounds or test 
compounds were prepared in a sterile environment. 18 µL of medium was dispensed into sterile, 
black, 384-well, clear bottom plates (Greiner). 2 µL of control compounds, DMSO or test 
compounds were stamped directly into the assay plates. Controls were 100 µM rifampicin in 
column 1 (final assay concentration of 2 µM rifampicin), DMSO in column 2 (final assay 
concentration 2%) and 125 nM rifampicin in column 23 (final assay concentration of 2.5 nM). 
Test compounds were diluted to 0.35 mg/mL in DMSO and transferred directly into columns 3-
22 of assay plates (320 compounds per plate) to yield a final assay concentration of 7 µg/mL 
(final concentration of 2% DMSO). M. tuberculosis was grown to logarithmic phase (OD590 = 
0.6-0.9) and filtered through a 0.5 µm cellulose-acetate membrane filter and diluted in fresh 
medium to an OD of 0.06. A MultiDrop Combi (Thermo Fisher) was used to add 10 µL of M. 
tuberculosis culture to columns 1-23 of the assay plates; column 24 was not inoculated and used 
as a contamination control. Plates were incubated in sealed plastic bags in a humidified 
incubator at 37ºC for 5 days. The plate layout was arranged as 320 sample wells in columns 3-
22. The remaining four columns were reserved for plate controls. OD and fluorescence were 
read using a Synergy 4 plate reader (BioTek) with excitation/emission of 586 nm/614 nm for 
mCherry and 560 nm/590 nm for DsRed. For each well, the % inhibition was calculated with 
reference to the average maximum growth control in column 2 (DMSO only). 
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Abstract 
A novel series of quinazoline derivatives (9a-j and 10a-l) were designed and synthesized in 
good to moderate yields. The synthesized compounds were well-characterized by spectroscopic 
studies (NMR and IR) and evaluated against DNA gyrase and topoisomerase IV enzyme of 
Escherichia coli. Among the series, compound 10l bearing carboxylic acid group was found to 
be most active with IC50 value of 0.49 and 13.22 μM for DNA Gyrase and topoisomerase IV, 
respectively. In addition, 9f, 9i, 9j, 10c, 10j and 10k were also exhibited excellent activity 
against DNA Gyrase while comparatively less activity against topoisomerase IV. These results 
provide a basis for structure-based optimization toward dual DNA gyrase and topoisomerase IV 
inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords 
Quinazoline derivatives, DNA gyrase inhibition, Topoisomerase IV inhibition. 
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1. Introduction 
The increasing antibiotic resistance of bacteria is becoming a major health problem worldwide. 
The rising demand for antibiotics in hospitals and veterinary purpose has led to the 
accumulation of antibiotics in the aqueous environment, which exert selective pressure for 
resistant bacteria in the environment.1 The developing countries always battled against life 
threatening infectious diseases especially tuberculosis (TB) and HIV/AIDS,2-4 due to multidrug 
resistant,5 these diseases become more threatening (Figure 1). TB ranks second, standing next 
to HIV in terms of lethality.6 Rifampicin was introduced in 1970s, as a first line drug used in 
case of TB due to its sterilizing capacity and bactericidal effect,7, 8 However, it has been known 
to develop resistance towards curing TB. The global report of TB with multidrug-resistant TB 
(MDR-TB) was estimated to be 3.9% newly diagnosed and 21 % with previous history of TB.8 
MDR-TB is technically due to the resistance of Mycobacterium tuberculosis against rifampicin 
and isoniazid.9,10 In addition, Rifampicin-resistant TB (RR-TB) is detected by 
genotypic/phenotypic methods against other first-line anti-TB drugs (with/without resistance) 
and hence posing a threat to control TB.11-13.Consequently, the discovery of anti-Mycobacterium 
tuberculosis (anti-Mtb) drug is promising. Hence there is a need for novel anti-Mtb compounds 
that must have activity against resistant bacterial strains. However, the search for new 
compound remains a significant challenge for the future.14  
Bacterial DNA type II topoisomerases (DNA gyrase and topoisomerase IV) are well-established 
validated targets in antibacterial drug discovery. These enzymes are vital for control of the 
topological state of DNA during cell division and DNA replication.15 In general, DNA gyrase 
introduces negative supercoils in DNA in front of the replication fork, although topoisomerase 
IV is important for decatenation during DNA replication. DNA gyrase is consists of two A 
subunits (GyrA) and two B subunits (GyrB), whereas topoisomerase IV composed of two C 
subunits (ParC) and two E subunits (ParE), which are homologous to GyrA and GyrB, 
correspondingly.16 The resemblances in the structure of DNA gyrase and topoisomerase IV offer 
an remarkable opportunity for the dual targeting of these enzymes by novel antibacterial 
compounds, in that way reducing the possibility of bacteria to develop target based resistance 
against them.17 
The DNA gyrase inhibitors (Figure 2) i.e., quinolones/fluoroquinolones mainly target GyrA 
subunit of the DNA Gyrase complex while the Novobiocin targets the GyrB subunit. Due to the 
clinical success of the fluoroquinolone class of antibacterial, DNA Gyrase has fascinated a great 
deal of interest from both industrial and academic institutions.16-18  
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Figure 1: Mechanism of antibiotic resistance. 
Synthetic chemists always desire for the simple synthetic protocols to synthesize biologically 
active derivatives19. Several heterocyclic derivatives are well documented to possess 
pharmacological advantage for drug designing. Sir James Black (Nobel Laureate; winner of 
1988 Nobel Prize in Physiology and Medicine) once stated, “the most fruitful basis for the 
discovery of a new drug is to start with an old drug”.20  
Heterocyclic chemistry with nitrogen as integral part of fused ring are frequently found in 
natural products. They have also been part of the synthetic drugs and functional materials.21 N-
Heterocycles are frequently found in natural products, synthetic drugs, and functional materials. 
Developing novel, efficient, and practical methods for the synthesis of N-heterocycles is very 
important in organic chemistry. Among the existing N-heterocycles, many quinazolines have 
attracted great attention because they possess distinctive biological activities and physical 
activity ranging from anticancer, anti-inflammatory, antipsychotic, antidiabetic, antileishmanial, 
and antibacterial activities.22-27 A series of 2-substituted quinazolines with broad-spectrum 
antibacterial activity, inhibiting RNA synthesis and translation in a number of bacterial species 
were reported.28, 29 
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Figure 2: Commercial drugs targeting DNA Gyrase.16 
Piperazine/piperidine derivatives have also gained immense acknowledgment due to various 
types of biological properties like antifungal, antibacterial, anti-cancer, anti-HIV, antimalarial 
etc.30-32 Owing to all the significance, it is an essential starting material in the pharmaceutical 
industry.33 Substitution at one of the nitrogen atoms also enhances the biological significance 
(Figure 3). It is also well documented that bis-heterocyclic derivatives possess better 
antibacterial activity than heterocyclic compounds alone.  
                                                                                                                                       Chapter 6 
Narva Deshwar Kushwaha 173                                        UKZN-2020 
 
 
Figure 3: Significance of piperazine and piperidine in drug discovery.  
With all this in mind, we propose the fusion of piperazine/4-methyl piperidine and quinazoline 
to synthesize a series of molecules containing both moieties. 
2. Results and discussion 
2.1. Chemistry 
The synthesis of novel quinazoline derivatives (9a-j & 10a-k) and their corresponding 
intermediates were attained through effective and easy synthetic routes as depicted in Scheme-I. 
Intermediate 2 was synthesized as per our previous report (Chapter-3) while 5a-b were 
obtained by nucleophilic substitution of 3,4-difluorobenzaldehyde with 1-methylpiperazine and 
4-methylpiperidine, respectively. 6a-b were achieved by the condensation of 5a-b with 2 in 
presence of dehydrating agent (pTSA) in DMA at 130°C for 16 h, which were subjected to 
oxidation with KMnO4 in DMSO to yield (7a-b). The nitro reduction of 7a-b was performed in 
presence of Fe/NH4Cl to afford (8a-b). Subsequently, two series of final derivatives (9a-j) and 
(10a-k) were synthesized by reacting 8a-b with the acid/sulphonyl chloride in presence of TEA 
in DCM at 0°C to rt for 4 h and pyridine in DCM at 0°C to rt for 16 h correspondingly. 
The structure of all intermediates (5a-b, 6a-b, 7a-b, 8a-b,) and their respective final derivatives 
(9a-j & 10a-k) were characterized by spectral (IR, 1H-NMR, and 13C-NMR) analysis. All 
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compounds showed adequate analysis of their predicted structures, which are summarized in 
experimental section. The conversion of 3 to 5a and 5b was confirmed by the appearance of 
methyl protons at around 2.33 ppm and 0.96 ppm along with most distinct signals of aldehyde 
protons at around 9.78 ppm and 9.76 ppm correspondingly. Further, the formation of 6a-b was 
confirmed by the appearance of amide and amine protons at around 8.69 ppm and 8.59-8.51 
ppm correspondingly along with most distinct chiral protons at around 5.95 ppm. The 
conversion of 6a-b to 7a-b were confirmed by the disappearance of amide and amine along with 
chiral protons and appearance of distinct OH proton at around 12.82 ppm in NMR spectra. 
Furthermore, the formation of 8a-b was confirmed by the appearance of amine (NH2) protons at 
around 5.61-5.63 ppm in 1H-NMR while disappearance of nitro (NO2) absorption band 1334.58 
– 1340.58 cm-1 in IR spectra. Subsequently, the derivatization of 8a and 8b to 9a-i and 10a-h, 
respectively were confirmed by the vanishing of amine (NH2) proton and same time entrance of 
amide proton at around 10.04 - 11.10 ppm in 1H-NMR spectra. The absorption band of amide 
(C=O and N-H) around 1655.79 - 1671.43 cm-1 and 3081.67 - 3174.32 cm-1 in IR spectra along 
with signals of carbonyl carbon at around 161.9 – 175.4 ppm in 13C-NMR spectra confirmed the 
presence of amide group. In case of 9j and 10i-k derivatives showed the signals at around 10.60 
-10.81 ppm in 1H-NMR spectrum and broad band in the region of 3079.22 - 3088.14 cm-1, 
1316.94 - 1485.10 cm-1 and 1158.44 - 1234.94 cm-1 are assigned for N-H, asymmetric and 
symmetric mode of O=S=O group, respectively confirmed the presence of sulphonamide. 
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Scheme 1: Reagents and conditions: i) 28% aqueous ammonia solution, EDC.HCl, HOBt, 
DMF, 3–5 h; ii) K2CO3, DMF, 130°C, 16 h; iii) pTSA, DMA, 130°C, 16 h; iv) KMnO4, DMSO, 
100°C, 16 h; v) Fe, NH4Cl, Dioxane: EtOH: H2O (7:5:3), 100°C, 5 h; vi) TEA, DCM, 0°C - rt, 
4 h. or Pyridine, DCM/DMF, 0°C - rt, 16 h. vii) NaOH, EtOH, rt, 16 h. 
2.2. Biology 
All the quinazoline based synthesized derivatives (9a-i and 10a-l) were evaluated for their 
inhibitory activity against DNA gyrase (supercoiling assay) and topoisomerase IV (decatenation 
assays). The results measured as IC50 values, have been tabulated in Table 1.  
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Table 1: Inhibition of E. coli DNA Gyrase and Topoisomerase IV by quinazoline-based 
compounds. 
 
 
Compound 
 
R 
IC50 (μM) a 
DNA gyrase     
(E.coli) 
Topoisomerase IV 
(E.coli) 
Ciprofloxacin - 0.16 10.23 
9a 
 
1.46 15.58 
9b 
 
1.46 45.83 
9c 
 
1.37 101.60 
9d 
 
1.50 29.48 
9e 
 
1.81 16.39 
9f 
 
0.22 183.20 
9g 
 
1.49 24.91 
9h 
 
1.48 94.95 
9i 
 
1.98 31.31 
9j 
 
0.52 235.00 
10a 
 
1.44 87.57 
10b 
 
1.46 109.20 
10c 
 
0.60 23.79 
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10d 
 
nd 30.02 
10e 
 
nd 25.91 
10f 
 
1.79 95.43 
10g 
 
2.54 58.17 
10h 
 
nd 20.49 
10i 
 
nd 427.00 
10j 
 
0.34 239.20 
10k 
 
0.22 17.87 
10l 
 
0.49 13.22 
aConcentration of compound (mean ± SD) that inhibits the enzyme activity by 50%. nd = not 
determined. 
Most of the compounds showed good inhibitory activity against DNA gyrase and 
topoisomerases IV with IC50 values ranging 0.22-2.54 µM and 13.22-427.00 µM, respectively. 
Among the series, compound 10l bearing carboxylic acid group was found to be most active 
with IC50 value of 0.49 and 13.22 μM for DNA Gyrase and topoisomerase IV, respectively. In 
addition, 9f, 9i, 9j, 10c, 10j and 10k were also exhibited excellent activity against DNA Gyrase 
while comparatively less activity against topoisomerase IV. Comparing the IC50s for DNA 
Gyrase inhibition, all the derivatives showed moderate to high potency. However, in case of 
topoisomerase IV, the inhibition was found to be low to moderate.  
3. Conclusion 
In conclusion, we have described a series of novel quinazoline derivatives which were first time 
designed and synthesized via convenient procedure. In this chapter, we have synthesized 22 
molecules and all the structures of new compounds were characterized by spectroscopic method 
(IR and NMR) and their inhibitory activities on DNA gyrase and topoisomerase IV from E. coli 
were measured. All compounds (9a-9j and 10a-l) displayed IC50 value lower than 2 μM for 
DNA gyrase and the most active compound 10l had an IC50 of 0.49 μM. Overall, compounds 
9a, 9e, 10c, 10k and 10l are particularly motivating for further studies because they showed 
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promising balanced inhibition in the low micromolar range against both DNA gyrase and 
topoisomerase IV from E. coli.  
4. Experimental 
4.1. General consideration 
All the fine chemicals, reagents and solvents were purchased from Sigma Aldrich and Merck 
and were used without further purification unless otherwise stated. The progress of the reactions 
and the purity of the compounds were monitored by thin-layer chromatography (TLC) on pre-
coated silica gel plates procured from E. Merck and Co. (Darmstadt, Germany) visualized by 
UV lamp (254 or 365 nm). Purification was performed by using combi-flash (CombiFlash® 
NextGen 300+) column chromatography. The melting points of the synthesized compounds 
have been determined and uncorrected using a digital Stuart SMP10 melting point Apparatus. 
The Fourier transform infrared (FTIR) spectra were recorded in the spectral range of 400-4000 
cm-1 on a Bruker Alpha FT-IR spectrometer using the ATR technique. The NMR spectra (1H, 
and 13C,) were recorded using CDCl3 and DMSO-d6 on Bruker AVANCE III 400 and 600 MHz 
spectrometer. Chemical shifts were determined relative to internal standard TMS at δ 0.0 parts 
per million (ppm) and the coupling constants were reported in Hertz. The multiplicities of the 
NMR resonances were abbreviated as s (singlet), d (doublet), dd (doublet of doublet), (t 
(triplet), q (quartet), m (multiplet) and brs (broad singlet). Escherichia coli DNA gyrase, E. coli 
DNA topoisomerase IV, relaxed DNA (pHOT1) and supercoiled DNA (pBR322) were obtained 
from TopoGEN (TopoGEN. USA) and the stock solution of compound was prepared at in 
DMSO. 
4.2. Chemistry 
4.2.1. Synthesis and spectral characterization of compounds 5a, 5b, 6a, 6b, 7a, 7b and 8a, 8b; 
4.2.1.1 General procedure for synthesis of 5a and 5b;  
To the solution of 3,4-difluorobenzaldehyde (1 equiv) in DMF was added K2CO3 (2 equiv) 
followed by 4a or 4b (1.2 equiv) at room temperature. The reaction mixture was stirred at 130°C 
for 16 h, cooled to room temperature, diluted with ethyl acetate and washed with cold brine 
solution. The organic phase was dried over anhydrous Na2SO4 and evaporated under reduced 
pressure to give solid residue which was triturated with pentane and filtered to afford 
corresponding title products.  
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3-Fluoro-4-(4-methylpiperazin-1-yl)benzaldehyde (5a); 
 
Yellow solid (2.6 g, 83%); mp: 65-67°C; FTIR (ATR, Vmax, cm-1): 2932.71 (Ar-H str.), 1679.30 
(C=O str.), 1561.14 (Ar C=C str.), 1247.01 (C-N str), 1137.56 (C-F str.); 1H NMR (400 MHz, 
CDCl3, 25°C) δ  9.78 (s, 1H), 7.54 (dd, J = 8.25 Hz, J = 2.05 Hz,  1H), 7.48 (dd, J = 13.17 Hz, J 
= 1.99 Hz, 1H), 6.95 (t, J = 7.96 Hz, 1H), 3.26 (t, J = 5.11 Hz, 4H),  2.56 (t, J =  4.84 Hz, 4H), 
2.32 (s, 1H). 13C NMR (100 MHz, CDCl3, 25°C) δ 189.9, 155.9 – 153.5 (d, JC-F = 248 Hz, 1C), 
145.4 – 145.3 (d, JC-F = 8.53 Hz, 1C), 130.1 – 130.0 (d, JC-F = 6.16 Hz, 1C), 128.04 – 128.02 (d, 
JC-F = 3.26 Hz, 1C), 118.0 – 117.9 (d, JC-F = 3.86 Hz, 1C), 116.1 – 115.9 (d, JC-F = 22.10 Hz, 
1C), 54.9, 49.7, 46.1.  
3-Fluoro-4-(4-methylpiperidin-1-yl)benzaldehyde (5b); 
 
 Brown liquid (17 g, 72%); 1H NMR (400 MHz, CDCl3, 25°C) δ  9.76 (s, 1H), 7.52 – 7.44 (m, 
2H), 6.94 (t, J = 8.45 Hz, 1H), 3.64 – 3.61 (m, 2H),  2.82 – 2.76 (m, 2H), 1.73 – 1.70 (m, 2H), 
1.60 – 1.49 (m, 1H), 1.40 – 1.30 (m, 2H), 0.96 (d, J = 6.49 Hz, 3H). 13C NMR (100 MHz, 
CDCl3, 25°C) δ 189.9, 155.8 – 153.3 (d, JC-F = 252.40 Hz, 1C), 146.1, 129.4, 128.0, 118.0, 
116.0 – 115.8 (d, JC-F = 22.8 Hz, 1C), 51.1, 34.1, 30.7, 21.8. 
4.2.1.2. General procedure for synthesis of 6a and 6b;  
To the solution of 2-amino-5-nitrobenzamide (1 equiv) and 5a or 5b (1 equiv) in DMA was 
added catalytic amount of p-toluenesulfonic acid (0.2 equiv). The resultant mixture was heated 
at 130°C for 16 h, cooled to room temperature and poured into ice cold water, precipitate was 
formed filtered and washed with diethyl ether to afford corresponding title products. 
2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)-one (6a);  
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Yellow solid (16.0 g, 75%); mp: 255-257°C; FTIR (ATR, Vmax, cm-1): 3269.81 (N-H str.), 
2919.54 (Ar-H str.), 1649.88 (C=O str.), 1504.18 (Ar C=C str.), 1326.42 (Ar-NO2 str.), 1250.24 
(C-N str.), 1119.39 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 8.69 (s, 1H), 8.54 (s, 
1H), 8.42 (d, J = 2.65 Hz, 1H), 8.09 (dd, J = 9.10 Hz, J = 2.94 Hz, 1H), 7.21 – 7.17 (m, 2H), 
7.05 (t, J = 8.56 Hz, 1H), 6.83 (d, J = 9.08 Hz, 1H), 5.95 (s, 1H), 3.01 (t, J = 4.31 Hz, 4H), 2.48 
(t, J = 4.42 Hz, 4H), 2.23 (s, 3H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 161.3, 155.2 – 153.6 
(d, JC-F = 244.52 Hz, 1C), 152.0, 140.1 – 140.0 (d, JC-F = 8.44 Hz, 1C), 137.2, 135.19 – 135.15 
(d, JC-F = 6.54 Hz, 1C), 128.9, 124.1, 122.78 – 122.76 (d, JC-F = 2.74 Hz, 1C), 119.12 – 119.10 
(d, JC-F = 3.23 Hz, 1C), 114.3, 114.2 – 114.1 (d, JC-F = 20.92 Hz, 1C), 112.6, 65.2, 54.4, 49.7, 
45.5. 
2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-6-nitro-2,3-dihydroquinazolin-4(1H)-one (6b);  
 
Yellow solid (20.1 g, 94%); mp: 224-228°C; FTIR (ATR, Vmax, cm-1): 3353.37 (N-H str.), 
3264.91 (N-H str.), 2922.23 (Ar-H str.), 1650.20 (C=O str.), 1506.10 (Ar C=C str.), 1324.54 
(Ar-NO2 str.), 1235.94 (C-N str), 1109.95 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 
8.69 (s, 1H), 8.51 (s, 1H), 8.41 (d, J = 2.73 Hz, 1H), 8.10 (dd, J = 9.10 Hz, J = 2.83 Hz, 1H), 
7.20 – 7.15 (m, 2H), 7.05 (t, J = 8.21 Hz, 1H), 6.82 (d, J = 9.25 Hz, 1H), 5.94 (s, 1H), 3.31 – 
3.27 (m, 2H), 2.64 – 2.59 (m, 2H), 1.69 – 1.66 (m, 2H), 1.51 – 1.44 (m, 1H), 1.31 – 1.22 (m, 
2H), 0.93 (d, J = 6.53 Hz, 3H). 13C NMR (150 MHz, DMSO-d6, 25°C) δ 161.1, 155.2 – 153.6 
(d, J = 248.48 Hz, 1C), 151.8, 140.8 – 140.7 (d, J = 11.86 Hz, 1C), 137.1, 134.6, 128.7, 124.0, 
122.6 – 122.5 (d, J = 2.98 Hz, 1C), 119.2, 114.2, 114.0 – 113.9 (d, J = 22.5 Hz, 1C), 112.6, 
65.2, 50.4, 33.7, 29.8, 29.5. 
4.2.1.3. General procedure for synthesis of 7a and 7b;  
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To the solution of 6a or 6b (1 equiv) in DMSO was added potassium permanganate (3 equiv) at 
0°C. The mixture was heated at 100°C for 16 h then cooled to room temperature and filtered 
through celite. The filtrate was poured into ice cold water and stirred for 30 min precipitate was 
formed, filtered and washed with diethyl ether to afford title compounds. 
2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-6-nitroquinazolin-4-ol (7a); 
 
Red solid (10 g, 62%); mp: 267-270°C; FTIR (ATR, Vmax, cm-1): 3258.70 (O-H str.), 2932.84 
(Ar-H str.), 1671.87 (C=O str.), 1539.90 (Ar C=C str.), 1334.18 (Ar-NO2 str.), 1242.63 (C-N 
str), 1138.10 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ 8.77 (d, J = 2.39 Hz, 1H), 8.49 
(dd, J = 9.05 Hz, J = 2.65 HZ, 1H), 8.05 – 8.00 (m, 2H), 7.81 (d, J = 8.83 Hz, 1H), 7.12 (t, J = 
8.97 Hz, 1H), 3.20 (t, J = 5.31 Hz, 4H), 2.52 (t, J = 4.34 Hz, 4H), 2.26 (s, 3H). 13C NMR (150 
MHz, DMSO-d6, 25°C) δ 161.7, 154.3 – 152.7 (d, JC-F = 244.3 Hz, 1C), 153.0, 144.2, 142.8, 
128.7, 128.3, 125.1, 124.3, 122.0, 120.5, 118.4, 115.7 – 115.6 (d, JC-F = 24.5 Hz, 1C), 54.2, 
49.1, 45.4. 
2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-6-nitroquinazolin-4-ol (7b): 
 
Yellow solid (6.9 g, 69%); mp: 293-295°C; FTIR (ATR, Vmax, cm-1): 3177.84 (O-H str.), 
2923.58 (Ar-H str.), 1670.88 (C=O str.), 1575.63 (Ar C=C str.), 1340.58 (Ar-NO2 str.), 1240.75 
(C-N str.), 1131.27 (C-F str.),  1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.82 (s, 1H), 8.79 (d, J 
= 2.68 Hz, 1H), 8.52 (dd, J = 9.21 Hz, J = 3.01 Hz, 1H), 8.07 – 8.00 (m, 2H), 7.85 (d, J = 8.83 
Hz, 1H), 7.14 (t, J = 8.69 Hz, 1H), 3.56 (d, J = 12.22 Hz, 2H), 2.83 – 2.77 (m, 2H), 1.73 – 1.70 
(m, 2H), 1.59 – 1.52 (m, 1H), 1.33 – 1.23 (m, 2H), 0.95 (d, J = 6.25 Hz, 3H). 13C NMR (150 
MHz, DMSO-d6, 25°C) δ  154.0 -152.4 (d, JC-F = 242.59 Hz, 1C), 153.9, 114.1, 143.28, 143.23, 
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128.0, 124.9, 123.28, 123.22, 121.7, 120.3, 118.2, 115.5 – 115.3 (d, JC-F = 24.27 Hz, 1C), 49.6, 
33.4, 29.6, 21.2. 
4.2.1.4. General procedure for synthesis of 8a and 8b;  
7a or 7b (1 equiv) was added into the mixture of dioxane, ethanol and water (7:5:3) followed by 
ammonium chloride (10 equiv). To the resultant mixture iron powder (5 equiv) was added with 
vigorous stirring and then heated at 100°C for 4 h. The reaction mixture was cool to room 
temperature, filtered through celite and washed with ethyl acetate. The filtrate was concentrated 
under reduce pressure then diluted with ethyl acetate and washed with saturated sodium 
bicarbonate solution. Organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduce pressure to afford title products. 
6-Amino-2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4-ol (8a); 
 
Yellow solid (4.3 g, 46%); mp: 255-260°C; FTIR (ATR, Vmax, cm-1): 3313.65 (O-H str.), 
3175.40 (N-H str.), 2968.46 (Ar-H str.), 1620.47 (C=O str. Keto-enol), 1513.82 (Ar C=C str.), 
1255.06 (C-N str), 1136.72 (C-F str.); 1H NMR (600 MHz, DMSO-d6, 25°C) δ  11.97 (s, 1H), 
7.92 – 7.89 (m, 2H), 7.43 (d, J = 9.39 Hz, 1H), 7.21 (d, J = 2.23 Hz, 1H), 7.10 – 7.06 (m, 2H), 
5.61 (s, 2H), 3.11 (t, J = 4.91 Hz, 4H),  2.47 (t, J = 4.36 Hz, 4H), 2.22 (s, 3H). 13C NMR (150 
MHz, DMSO-d6, 25°C) δ 162.0, 154.8 – 153.2 (d, JC-F = 243.9 Hz, 1C), 147.6, 145.9, 141.4 – 
141.3 (d, JC-F = 8.9 Hz, 1C), 139.6, 128.2, 126.3 – 126.2 (d, JC-F = 7.4 Hz, 1C), 123.5, 122.4, 
121.8, 118.54 – 118.52 (d, JC-F = 3.4 Hz, 1C), 114.5 – 114.4 (d, JC-F = 24.2 Hz, 1C), 106.2, 54.4, 
49.4, 45.6.      
6-Amino-2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)quinazolin-4-ol (8b); 
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Yellow solid (4.1 g, 74%); mp: 240-243°C; FTIR (ATR, Vmax, cm-1): 3447.17 (N-H str.), 
3352.05 (O-H str.), 2918.11 (Ar-H str.), 1647.06 (C=O str. Keto-enol), 1485.40 (Ar C=C str.), 
1236.68 (C-N str), 1062.47 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ  11.99 (s, 1H), 
7.92 – 7.86 (m, 2H), 7.42 (d, J = 8.88 Hz, 1H), 7.19 (d, J = 3.00 Hz, 1H), 7.10 – 7.06 (m, 2H), 
5.63 (s, 2H), 3.46 (d, J = 12.17 Hz, 2H), 2.72 (t, J = 12.48 Hz, 2H), 1.71 (d, J = 11.89 Hz, 2H), 
1.55 – 1.48 (m, 1H), 1.34 – 1.22 (m, 2H), 0.95 (d, J = 6.61 Hz, 3H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 162.0, 155.2 – 152.8 (d, JC-F = 244.2 Hz, 1C), 147.6,145.9, 142.2 – 142.1 (d, 
JC-F = 8.80 Hz, 1C), 13.6, 128.2, 125.9 – 125.8 (d, JC-F = 8.05 Hz, 1C), 123.56 – 123.53 (d, JC-F 
= 3.75 Hz, 1C), 122.5, 121.8, 118.77 – 118.73 (d, JC-F = 3.54 Hz, 1C), 114.5 – 114.2 (d, JC-F = 
23.5 Hz, 1C), 106.2, 50.2, 33.7, 30.0, 21.7. 
4.2.1.5. General procedure for synthesis, and spectral characterization of derivatives (9a-h, 
10a-e and 10h), (9i, 10f-g) and (9j, 10i-k); 
4.2.1.5.1 General procedure A for synthesis of derivatives (9a-h, 10a-e and 10h);  
To the suspension of 6-amino-2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4-ol 
(8a)/ 6-amino-2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)quinazolin-4-ol (8b) (1.0 equiv) in 
DCM, were added triethyl amine (1.5 equiv), followed by appropriate acid chloride (1.5 equiv) 
at 0°C. The resultant mixture was stirred at room temperature for 2 h, quenched with sodium 
bicarbonate solution and extracted with DCM (3 x 20 mL). The combined organic layer was 
dried over anhydrous Na2SO4, filtered and evaporated under reduce pressure to give solid 
residue which were triturated with diethyl ether and filtered to afford desired title compounds. 
4.2.1.5.2. General procedure B for synthesis of derivatives (9i, 10f-g);  
To the solution of 6-amino-2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4-ol (8a)/ 
6-amino-2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)quinazolin-4-ol (8b) (1 equiv) in DCM 
(10 mL) was added triethyl amine (1.5 equiv), followed by 2-bromoacetyl bromide (1.2 equiv) 
at 0°C. The resultant mixture was stirred at room temperature for 2 h, precipitate was formed, 
filtered and washed with pentane to afford salt of 2-bromo-N-(2-(3-fluoro-4-(4-methylpiperazin-
1-yl)phenyl)-4-hydroxyquinazolin-6-yl)acetamide and 2-bromo-N-(2-(3-fluoro-4-(4-
methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-yl)acetamide, respectively which were  
dissolved separately  in DMF and were added potassium carbonate (1.5 equiv), followed by 
appropriate amine (1.5 equiv) at room temperature. The resultant mixture was stirred at room 
temperature for 16 h, then diluted with ethyl acetate and washed with cold brine solution (3 x 10 
mL). The organic layer dried over anhydrous Na2SO4, filtered and evaporated under reduce 
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pressure to yield crude product which was recrystallized with ethanol to afford the pure title 
products. 
4.2.1.5.3. General procedure C for synthesis of derivatives (9j, 10i-k);  
To the solution of 6-amino-2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4-ol (8a)/ 
6-amino-2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)quinazolin-4-ol (8b)  (1.0 equiv) in 
DCM were added pyridine (8.0 equiv), followed by appropriate sulfonyl chloride (1.5 equiv) at 
0°C. The resultant mixture was stirred at room temperature for 16 h, quenched with 2N-HCl 
solution and extracted with DCM (3 x 20 mL). The combined organic layer was dried over 
anhydrous Na2SO4 and evaporated under reduced pressure to yield the crude, which was 
triturated with diethyl ether and filtered to afford the desired title products. 
4.2.1.5.1.1. Ethyl 2-((2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)amino)-2-oxoacetate (9a); 
  
 Yellow solid, yield:15%, mp: 265-268°C;  FTIR (ATR, Vmax, cm-1): 3334.94 (O-H str.), 
3172.30 (N-H str.), 2930.68 (Ar-H str.), 1713.33 (C=O str.), 1660.71 (C=O str.), 1590.85 (Ar 
C=C str.), 1256.98 (C-N str.); 1167.10 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.41 
(s, 1H), 11.10 (s, 1H), 8.64 (d, J = 2.61 Hz, 1H), 8.09 (dd, J = 8.91 Hz, J = 2.51 Hz, 1H), 8.02 – 
7.96 (m, 2H), 7.70 (d, J = 8.85 Hz, 1H), 7.13 (t, J = 8.84 Hz, 1H), 4.33 (q, J = 6.87 Hz, 2H), 
3.18 (t, J = 4.78 Hz, 4H), 2.56 (t, J = 3.76 Hz, 4H), 2.29 (s, 3H), 1.33 (t, J = 7.52 Hz, 3H). 13C 
NMR (100 MHz, DMSO-d6, 25°C) δ 161.9, 160.4, 155.6, 155.0 – 152.6 (d, JC-F = 243.2 Hz, 
1C), 150.1, 145.6, 141.8, 135.6, 128.0, 127.3, 125.7 – 125.6 (d, JC-F = 7.91 Hz, 1C), 124.4, 
120.9, 118.7, 116.0, 115.2 – 115.0 (d, JC-F = 24.1 Hz, 1C), 62.5, 53.9, 48.7, 44.8, 13.8.    
4.2.1.5.1.2. N-(2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)acetamide (9b); 
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Light yellow solid, yield: 30%, mp: 250-252°C;  FTIR (ATR, Vmax, cm-1): 3270.75 (O-H str.), 
3172.40 (N-H str.), 2928.50 (Ar-H str.), 1660.77 (C=O str.), 1549.98 (Ar C=C str.), 1250.87 (C-
N str.), 1117.81(C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.32 (s, 1H), 10.27 (s, 1H), 
8.49 (d, J = 2.24 Hz, 1H), 8.00 – 7.95 (m, 2H), 7.90 – 7.87 (m, 1H), 7.65 (d, J = 8.86 Hz, 1H), 
7.13 (t, J = 9.05 Hz, 1H), 3.17 (t, J = 5.83 Hz, 4H), 2.55 (t, J = 4.73 Hz, 4H), 2.28 (s, 3H), 2.09 
(s, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 168.5, 162.0, 155.1 – 152.6 (d, JC-F = 246.2 
Hz, 1C), 149.3, 144.4, 141.9 – 141.8 (d, JC-F = 8.37 Hz, 1C), 137.5, 127.8, 126.0, 125.7 – 125.6 
(d, JC-F = 8.39 Hz, 1C), 124.1, 121.0, 118.6, 115.1 – 114.8 (d, JC-F = 22.8, 114.0, 54.2, 49.1, 
45.3, 24.0. 
4.2.1.5.1.3. N-(2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)isobutyramide (9c);     
 
Off white solid,yield: 54%, mp: 298-300°C;  FTIR (ATR, Vmax, cm-1): 3275.40 (O-H str.), 
3174.32 (N-H str.), 2958.33 (Ar-H str.), 1658.33 (C=O str.), 1550.86 (Ar C=C str.), 1252.26 (C-
N str.), 1153.22 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.14 (s, 1H), 8.50 (d, J = 
2.69 Hz, 1H), 8.00 – 7.92 (m, 3H), 7.65 (d, J = 8.99 Hz, 1H), 7.12 (t, J = 8.63 Hz, 1H), 3.15 (t, J 
= 4.93 Hz, 4H), 2.66 – 2.59 (m, 1H), 2.23 (s, 3H), 1.13 (d, J = 7.01 Hz, 6H). 13C NMR (100 
MHz, DMSO-d6, 25°C) δ 175.4, 162.0, 155.1 – 152.6 (d, JC-F = 243.5 Hz, 1C), 149.3, 144.4, 
142.1 – 142.0 (d, JC-F = 7.9 Hz, 1C), 137.6, 127.8, 126.2, 125.6 – 125.5 (d, JC-F = 7.64 Hz, 1C), 
124.2, 120.9, 118.59 – 118.55 (d, JC-F = 3.5 Hz, 1C), 115.1 – 114.8(d, JC-F = 23.9 Hz, 1C), 
114.3, 54.4, 49.4, 45.7, 35.0, 19.4. 
4.2.1.5.1.4. N-(2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-yl)-3-
methylbutanamide (9d); 
 
 Light Yellow solid, yield: 64%, mp: 296-298°C; FTIR (ATR, Vmax, cm-1): 3269.85 (O-H str.), 
3173.08 (N-H str.), 2956.05 (Ar-H str.), 1670.05 (C=O str.), 1515.71 (Ar C=C str.), 1257.36 (C-
N str), 1139.44 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.27 (brs, 1H), 10.17 (s, 
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1H), 8.51 (d, J = 2.37 Hz, 1H), 7.99 – 7.97 (m, 1H), 7.94 – 7.88 (m, 2H), 7.64 (d, J = 8.79 Hz, 
1H), 7.09 (t, J = 8.64 Hz,1H), 3.13 (t, J = 5.21 Hz, 4H), 2.46 (t, J = 4.97 Hz, 4H), 2.23 (d, J 
=7.28 Hz, 2H), 2.22 (s, 3H), 2.14 – 2.10 (m, 1H), 0.95 (d, J = 6.52 Hz, 6H). 13C NMR (100 
MHz, DMSO-d6, 25°C) δ 171.3, 162.5, 155.5 – 153.1 (d, JC-F = 244.80 Hz, 1C), 149.8, 148.2, 
142.5, 137.9, 128.3, 126.6, 126.0, 124.6, 121.4, 119.0, 115.5 – 115.3 (d, JC-F = 22.94 Hz, 1C), 
114.7, 54.9, 49.9, 46.2, 46.1, 26.0, 22.7. 
4.2.1.5.1.5. N-(2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)butyramide (9e);  
 
Light Yellow solid, yield: 40%, mp: 297-299°C; FTIR (ATR, Vmax, cm-1): 3275.50 (O-H str.), 
3172.68 (N-H str.), 2958.61 (Ar-H str.), 1656.93 (C=O str.), 1530.38 (Ar C=C str.), 1253.03 (C-
N str), 1012.45 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.31 (s, 1H), 10.19 (s, 1H), 
8.50 (d, J = 2.44 Hz, 1H), 7.99 – 7.94 (m, 2H), 7.90 (dd, J = 8.79 Hz, J = 2.53 Hz, 1H), 7.65 (d, 
J = 8.83 Hz, 1H), 7.12 (d, J = 8.76 Hz, 1H), 3.15 (t, J = 6.16 Hz, 4H), 2.49 (t, J = 5.8 Hz, 4H), 
2.33 (t, J = 6.79 Hz, 2H), 2.23 (s, 3H), 1.67 – 1.61 (m, 2H), 0.93 (t, J = 7.80 Hz, 3H). 13C NMR 
(100 MHz, DMSO-d6, 25°C) δ 171.3, 162.0, 155.1 – 152.7 (d, JC-F = 243.47 Hz, 1C), 149.3, 
142.0 – 141.9 (d, JC-F = 10.1 Hz, 1C), 137.5, 127.8, 126.1, 125.6 – 125.5 (d, JC-F = 7.8 Hz, 1C), 
124.1, 121.0, 118.5, 115.1 – 114.8 (d, JC-F = 24.2 Hz, 1C), 114.1, 54.4, 49.4, 45.6, 38.3, 18.5, 
13.6.  
4.2.1.5.1.6. N-(2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)pentanamide (9f); 
 
Light yellow solid, yield: 46%, mp: 294-296°C;  FTIR (ATR, Vmax, cm-1): 3279.92 (O-H str.), 
3173.41 (N-H str.), 2957.51 (Ar-H str.), 1656.26 (C=O str.), 1532.80 (Ar C=C str.), 1252.37 (C-
N str.), 1154.99 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.31 (s, 1H), 10.19 (s, 1H), 
8.50 (d, J = 2.14 Hz, 1H), 7.99 – 7.94 (m, 2H), 7.90 (dd, J = 8.82 Hz, J = 2.51 Hz, 1H), 7.65 (d, 
J = 8.78 Hz, 1H), 7.12 (t, J = 8.78 Hz, 1H), 3.15 (t, J = 4.81 Hz, 4H), 2.48 – 2.45 (m, 4H), 2.35 
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(t, J = 7.71 Hz, 2H), 2.23 (s, 3H), 1.64 – 1.57 (m, 2H), 1.39 – 1.30 (m, 2H), 0.91 (t, J = 7.73 Hz, 
3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 171.6, 162.1, 155.1 – 152.7 (d, JC-F = 244.92 Hz, 
1C), 149.4, 144.4, 142.1 – 142.0 (d, JC-F = 7.34 Hz, 1C), 137.5, 127.9, 126.2, 125.6 – 125.5 (d, 
JC-F = 7.75 Hz, 1C), 124.2, 121.0, 118.6, 115.1 – 114.9 (d, JC-F = 23.4 Hz, 1C), 114.2, 54.5, 
49.4, 45.7, 36.2, 27.2, 21.8, 13.7. 
4.2.1.5.1.7. N-(2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)cyclobutanecarboxamide (9g); 
 
Light yellow solid, yield: 64%, mp: 297-299°C;  FTIR (ATR, Vmax, cm-1): 3271.96 (O-H str.), 
3173.79 (N-H str.), 2955.54 (Ar-H str.), 1671.43 (C=O str.), 1518.89 (Ar C=C str.), 1256.38 (C-
N str), 1141.95 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.30 (s, 1H), 10.04 (s, 1H), 
8.50 (s, 1H), 7.99 – 7.91 (m, 3H), 7.64 (d, J = 8.68 Hz, 1H), 7.11 (t, J = 8.70 Hz, 1H), 3.26 – 
3.22 (m, 1H), 3.14 (t, J = 4.89 Hz, 4H), 2.47 (t, J = 4.78 Hz, 4H), 2.30 – 2.25 (m, 2H), 2.22 (s, 
3H), 2.16 – 2.08 (m, 2H), 2.01 – 1.89 (m, 1H), 1.86 – 1.79 (m, 1H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 173.1, 162.0, 155.1 – 152.6 (d, JC-F = 245.04 Hz, 1C), 149.3, 144.3, 142.08 
– 142.0 (d, JC-F = 7.87 Hz, 1C), 124.1, 121.0, 118.5, 115.0 – 114.8 (d, JC-F = 24.61 Hz, 1C), 
114.3, 54.4, 49.4, 45.7, 30.6, 24.6, 17.7. 
4.2.1.5.1.8. N-(2-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)cyclohexanecarboxamide(9h); 
 
Light yellow solid, yield: 65%, mp: 296-298°C;  FTIR (ATR, Vmax, cm-1): 3379.60 (O-H str.), 
3173.77 (N-H str.), 2929.33 (Ar-H str.), 1655.79 (C=O str.), 1532.07 (Ar C=C str.), 1253.27 (C-
N str.), 1153.50 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.30 (s, 1H), 10.13 (s, 1H), 
8.51 (d, J = 2.58Hz, 1H), 8.0 – 7.90 (m, 3H), 7.64 (d, J = 8.84 Hz, 1H), 7.12 (t, J = 8.32 Hz, 
1H), 3.15 (t, J = 4.95 Hz, 4H), 2.47 (t, J = 4.81 Hz, 4H), 2.40 – 2.32 (m, 1H), 1.84 – 1.75 (m, 
2H), 1.67 – 1.64 (m, 1H), 1.48 – 1.39 (m, 2H), 1.33 – 1.18 (m, 3H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 174.5, 162.0, 155.1 – 152.7 (d, JC-F = 245.7 Hz, 1C), 149.3, 144.3, 142.0 – 
141.9 (d, JC-F = 8.7 Hz, 1C), 137.6, 127.8, 126.2, 125.6 – 125.5 (d, JC-F = 8.3 Hz, 1C), 124.2, 
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120.9, 118.6 – 118.5 (d, JC-F = 3.7 Hz, 1C), 115.1 – 114.8 (d, JC-F = 23.6 Hz, 1C), 114.2, 54.4, 
49.4, 45.6, 44.9, 29.0, 25.3, 25.1. 
4.2.1.5.2.1. 2-(Cyclopropylamino)-N-(2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-
hydroxyquinazolin-6-yl)acetamide (9i);  
 
Light yellow solid, yield: 42%, mp: 250-252°C;  FTIR (ATR, Vmax, cm-1): 3280.09 (O-H str.), 
3181.76 (N-H str.), 2928.76 (Ar-H str.), 1664.34 (C=O str.), 1551.08 (Ar C=C str.), 1252.84 (C-
N str.), 1116.95 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.30 (s, 1H), 10.14 (s, 1H), 
8.52 (d, J = 2.54 Hz, 1H), 8.00 – 7.97 (m, 2H), 7.95 – 7.94 (m, 1H), 7.66 (d, J = 8.81 Hz, 1H), 
7.11 (t, J = 8.19 Hz, 1H), 3.40 (s, 2H), 3.15 (t, J = 4.33 Hz, 4H), 2.51 (t, J = 4.66 Hz, 4H), 2.25 
(s, 3H), 2.23 – 2.18 (m, 1H), 0.41 – 0.36 (m, 2H), 0.35 – 0.31 (m, 2H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 171.1, 162.5, 155.5 – 153.1 (d, JC-F = 242.7 Hz, 1C), 149.9, 145.1, 142.5 – 
142.4 (d, JC-F = 7.81 Hz, 1C), 137.4, 128.4, 126.8, 126.1 – 126.0 (d, JC-F = 7.9 Hz, 1C), 124.7, 
121.5, 119.1, 115.6 – 115.3 (d, JC-F = 24.2 Hz, 1C), 114.8, 54.8, 53.1, 49.7, 46.0, 30.5, 6.4. 
4.2.1.5.3.1. 4-Fluoro-N-(2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)benzenesulfonamide (9j); 
 
 Light yellow solid, yield: 49%, mp: 265-267°C;  FTIR (ATR, Vmax, cm-1): 3260.14 (O-H str.), 
3079.22 (N-H str.), 2956.61 (Ar-H str.), 1669.60 (C=O str. Keto-enol), 1591.19 (Ar C=C str.), 
1485.10 (SO2 asym.), 1252.64 (C-N str), 1234.94 (SO2 sym.), 1154.16 (C-F str.); 1H NMR (400 
MHz, DMSO-d6, 25°C) δ 12.37 (s, 1H), 10.64 (s, 1H), 7.97 – 7.91 (m, 2H), 7.84 – 7.79 (m, 3H), 
7.62 (d, J = 8.68 Hz, 1H), 7.58 – 7.52 (m, 1H), 7.40 (t, J = 8.75 Hz, 2H), 7.11 (t, J = 8.86 Hz, 
1H), 3.16 (t, J = 5.26 Hz, 4H), 2.53 (t, J = 4.40 Hz, 4H), 2.27 (s, 3H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 165.6 – 163.1 (d, JC-F = 251.7 Hz, 1C), 161.8, 155.0 – 152.6 (d, JC-F = 243.6 
Hz, 1C), 150.1, 145.4, 142.1 – 142.0 (d, JC-F = 8.12 Hz, 1C), 135.6, 135.6 – 135.5 (d, JC-F = 2.80 
Hz, 1C), 129.7 – 129.6 (d, JC-F = 9.94 Hz, 1C), 128.6, 127.4, 125.4 – 125.3 (d, JC-F = 7.92 Hz, 
                                                                                                                                       Chapter 6 
Narva Deshwar Kushwaha 189                                        UKZN-2020 
 
1C), 124.3, 121.2, 118.6, 116.7 – 116.5 (d, JC-F = 24.09 Hz, 1C), 115.6, 115.2 – 115.0 (d, JC-F = 
3.38 Hz, 1C), 54.3, 49.2, 45.4. 
4.2.1.5.1.9. Ethyl 2-((2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)amino)-2-oxoacetate (10a); 
 
Yellow solid, yield: 63%, mp: 297-299°C; FTIR (ATR, Vmax, cm-1): 3334.94 (O-H str.), 3172.71 
(N-H str.), 2921.56 (Ar-H str.), 1710.28 (C=O str.), 1659.26 (C=O str.), 1515.84 (Ar C=C str.), 
1250.62 (C-N str.), 1181.71 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.36 (s, 1H), 
11.09 (s, 1H), 8.63 (d, J = 2.34 Hz, 1H), 8.09 (dd, J = 8.83 Hz, J = 2.46 Hz, 1H), 7.99 – 7.94 
(m, 2H), 7.69 (d, J = 8.69 Hz, 1H), 7.11 (t, J = 8.55 Hz, 1H), 4.33 (q, J = 7.35 Hz, 2H), 3.50 (d, 
J = 12,29 Hz, 2H), 2.78 – 2.72 (m,2H), 1.71 (d, J = 10.82 Hz, 2H), 1.57 – 149 (m, 1H), 1.33 (t, 
J = 7.11 Hz, 3H), 1.30 – 1.222 (m, 2H), 0.95 (d, J = 6.46 Hz, 3H).13C NMR (100 MHz, DMSO-
d6, 25°C) δ 162.0, 160.4, 155.5, 155.1 – 152.6 (d, JC-F = 247.8 Hz, 1C), 150.2, 145.7, 142.9 – 
142.8 (d, JC-F = 8.72 Hz, 1C), 135.5, 127.9, 127.3, 124.9 – 124.8 (d, JC-F = 7.72 Hz, 1C), 124.3, 
120.9, 118.7, 116.1, 115.1 – 114.9 (d JC-F = 23.8 Hz, 1C), 62.5, 50.1, 33.7, 30.0, 21.7, 13.8.  
4.2.1.5.1.10 N-(2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)acetamide (10b); 
 
Off white solid, yield: 60%, mp: 295-298°C; FTIR (ATR, Vmax, cm-1): 3273.47 (O-H str.), 
3170.62 (N-H str.), 2912.98 (Ar-H str.), 1661.23 (C=O str.), 1538.86 (Ar C=C str.), 1242.35 (C-
N str.), 1194.11 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.08 (s, 1H), 8.30 (d, J = 
2.30 Hz, 1H), 8.05 – 7.97 (m, 2H), 7.78 (dd, J = 8.87 Hz, J = 2.45 Hz, 1H), 7.49 (d, J = 8.78 Hz, 
1H), 7.05 (t, J = 8.74 Hz, 1H), 3.46 – 3.43 (m, 2H), 2.74 – 2.68 (m, 2H), 2.70 (s, 3H), 1.73 – 
1.70 (m, 2H), 1.52 – 1.50 (m, 1H), 1.35 – 1.25 (m, 2H), 0.95 (d, J = 6.53 Hz, 3H). 13C NMR 
(100 MHz, DMSO-d6, 25°C) δ 168.7, 168.0, 155.4 – 153.0 (d, JC-F = 243.62 Hz, 1C), 147.0, 
141.44, 135.2, 126.6, 124.4, 123.9, 121.3, 118.2, 115.0 – 114.7 (d, JC-F = 23.1 Hz, 1c), 114.6, 
50.4, 33.9, 30.0, 23.9, 21.7. 
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4.2.1.5.1.11. N-(2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)isobutyramide (10c);  
 
Off white solid, yield: 46%, mp: 292-295°C; FTIR (ATR, Vmax, cm-1): 3276.53 (O-H str.), 
3172.50 (N-H str.), 2918.24 (Ar-H str.), 1659.47 (C=O str.), 1542.85 (Ar C=C str.), 1243.35 (C-
N str.), 1135.21 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ  12.28 (s, 1H), 10.14 (s, 
1H), 8.49 (d, J =2.46 Hz, 1H), 7.98 – 7.92 (m, 3H), 7.64 (d, J = 8.87 Hz, 1H), 7.11 (t, J = 8.78 
Hz, 1H), 3.51 – 3.48 (m, 2H), 2.78 – 2.72 (m, 2H), 2.66 – 2.59 (m, 1H), 1.73 – 1.70 (m, 2H), 
1.55 – 149 (m, 1H), 1.34 – 1.25 (m, 2H), 1.13 (d, J = 6.95 Hz, 6H), 0.95 (d, J = 6.56 Hz, 3H). 
13C NMR (100 MHz, DMSO-d6, 25°C) δ  175.5, 162.1, 155.1 – 152.7 (d, JC-F = 242.0 Hz, 1C), 
149.7, 144.5, 142.8 – 142.7 (d, JC-F = 8.25 Hz, 1C), 137.6, 127.8, 126.3, 125.2 – 125.1 (d, JC-F = 
8.04 Hz, 1C), 124.2, 121.0, 118.77 – 118.73 (d, JC-F = 3.43 Hz, 1C), 115.0 – 114.8 (d, JC-F = 
23.93 Hz, 1C), 114.4, 50.1, 35.0, 33.7, 30.0, 21.7, 19.4. 
4.2.1.5.1.12. N-(2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-yl)-3-
methylbutanamide (10d);  
 
Yellow solid, yield: 34%, mp: 293-295°C; FTIR (ATR, Vmax, cm-1): 3276.06 (O-H str.), 3176.62 
(N-H str.), 2948.55 (Ar-H str.), 1661.94 (C=O str.), 1524.70 (Ar C=C str.), 1244.25 (C-N str.), 
1131.48 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.29 (s, 1H), 10.17 (s, 1H), 8.50 
(d, J = 2.24 Hz, 1H), 7.98 – 7.88 (m, 3H), 7.64 (d, J = 8.82 Hz, 1H), 7.11 (t, J = 8.48 Hz, 1H), 
3.51 – 3.48 (m, 2H), 2.78 – 2.72 (m, 2H), 2.23 (d, J = 6.98 Hz, 2H), 2.14 – 2.07 (m, 1H), 1.73 – 
1.70 (m, 2H), 1.55 – 1.51 (m, 1H), 1.33 – 1.22 (m, 2H), 0.95 (d, J = 6.33Hz, 9H). 13C NMR 
(100 MHz, DMSO-d6, 25°C) δ 170.9, 162.0, 155.1 – 152.7 (d, JC-F = 243.08 Hz, 1C), 149.4, 
144.5, 142.8 – 142.7 (d, JC-F = 8.17 Hz, 1C), 137.4, 127.8, 126.2, 125.2 – 125.1 (d, JC-F = 7.71 
Hz, 1C), 124.2, 120.9, 118.74 – 118.71 (d, JC-F = 3.5 Hz, 1C), 115.0 – 114.8 (d, JC-F = 24.37 Hz, 
1C), 114.2, 50.1, 45.6, 33.7, 30.0, 25.6, 22.2, 21.7. 
4.2.1.5.1.13. N-(2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)cyclobutanecarboxamide (10e);  
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Off white solid, yield: 34%, mp: 297-299°C; FTIR (ATR, Vmax, cm-1): 3272.78 (O-H str.), 
3178.12 (N-H str.), 2917.41 (Ar-H str.), 1664.91 (C=O str.), 1518.11 (Ar C=C str.), 1249.12 (C-
N str.), 1133.35 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.28 (s, 1H), 10.04 (s, 1H), 
8.50 (s, 1H), 7.97 – 7.92 (m, 3H), 7.64 (d, J = 9.34 Hz, 1H), 7.11 (t, J = 9.0 Hz, 1H), 3.51 – 3.48 
( m, 2H), 3.26 – 3.24 (m, 1H), 2.78 – 2.72 (m, 2H), 2.28 – 2.21 (m, 2H), 2.14 – 2.08 (m, 2H), 
2.01 – 1.90 (m, 1H), 1.86 – 1.81 (m, 1H), 1.73 – 1.70 (m, 2H), 1.60 – 1.45 (m, 1H), 1.33 – 1.25 
(m, 2H), 0.95 (d, J = 6.26 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 173.1, 162.1, 155.1 
– 152.7 (d, JC-F = 242.4 Hz, 1C), 149.4, 144.4, 142.7 – 142.6 (d, JC-F = 10.65 Hz, 1C), 137.5, 
127.8, 126.2, 125.2 – 125.1 (d, JC-F = 11.02 Hz, 1C), 124.1, 121.0, 118.7, 115.0 – 114.8 (d, JC-F 
= 23.98 Hz, 1C), 114.3, 50.1, 39.6, 33.7, 30.0, 24.6, 21.7, 17.7. 
4.2.1.5.2.1. 2-(Cyclopropylamino)-N-(2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-
hydroxyquinazolin-6-yl)acetamide (10f);  
 
Off white solid, yield: 40%, mp: 283-285°C; FTIR (ATR, Vmax, cm-1): 3275.71 (O-H str.), 
3174.42 (N-H str.), 2919.54 (Ar-H str.), 1660.96 (C=O str.), 1533.07 (Ar C=C str.), 1237.71 (C-
N str.), 1131.61 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.22 (brs, 1H), 10.11 (s, 
1H), 8.52 (d, J = 2.49 Hz, 1H), 7.97 – 7.92 (m, 3H), 7.65 (d, J = 8.91 Hz, 1H), 7.10 (t, J = 8.52 
Hz, 1H), 3.50 – 3.47 (m, 2H), 2.77 – 2.71 (m, 2H), 2.22 – 2.16 (m, 1H), 1.72 – 1.69 (m, 2H), 
1.54 – 1.48 (m, 1H), 1.33 – 1.21 (m, 2H), 0.94 (d, J = 6.62 Hz, 3H), 0.40 – 0.35 (m, 2H), 0.34 – 
0.29 (m, 2H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 170.8, 162.1, 155.1 – 152.7 (d, JC-F = 
243.72 Hz, 1C), 144.6, 142.8, 142.7, 136.9, 127.9, 126.3, 125.2 – 125.1 (d, JC-F = 7.41 Hz, 1C), 
124.2, 121.0, 118.1, 115.0 – 114.8 (d, JC-F = 23.5 Hz, 1C), 114.4, 52.7, 50.1, 33.7, 30.1, 30.0, 
21.7, 6.1. 
4.2.1.5.2.2. 2-(Cyclohexylamino)-N-(2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-
hydroxyquinazolin-6-yl)acetamide (10g); 
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Yellow solid, yield: 61%, mp: 292-295°C; FTIR (ATR, Vmax, cm-1): 3267.58 (O-H str.), 3081.67 
(N-H str.), 2918.66 (Ar-H str.), 1659.56 (C=O str.), 1528.97 (Ar C=C str.), 1239.18 (C-N str.), 
1131.65 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 10.15 (s, 1H), 8.52 (d, J = 2.71 Hz, 
1H), 7.99 – 7.93 (m, 3H), 7.66 (d, J = 8.79 Hz, 1H), 7.11 (t, J = 8.48 Hz, 1H), 3.51 – 3.48 (m, 
2H), 3.35 (s, 2H), 2.78 – 2.72 (m,2H), 2.45 – 2.37 (m, 1H), 1.84 – 1.81 (m, 2H), 1.73 – 1.66 (m, 
4H), 1.56 – 1.50 (m, 2H), 1.34 – 1.25 (m, 2H), 1.22 – 1.16 (m, 2H), 1.14 – 1.04 (m, 3H), 0.95 
(d, J = 6.59 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 170.9, 162.0, 155.1 – 152.7 (d, 
JC-F = 243.55 Hz, 1C), 149.5, 144.6, 142.7 – 142.6 (d, JC-F = 8.20 Hz, 1C), 136.7, 127.9, 126.2, 
125.1 – 125.0 (d, JC-F = 8.61 HZ, 1C), 124.2, 120.9, 118.7 - 118.6 (d, JC-F = 3.87 Hz, 1C), 115.0 
– 114.7 (d, JC-F = 24.33 Hz, 1C), 114.3, 56.2, 50.15, 50.1,  33.7, 32.7, 30.0, 25.6, 24.3, 21.7. 
4.2.1.5.1.14. N-(2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-
yl)benzamide (10h);  
 
Yellow solid, yield: 27%, mp: 298-300°C; FTIR (ATR, Vmax, cm-1): 3278.50 (O-H str.), 3168.84 
(N-H str.), 2935.86 (Ar-H str.), 1662.05 (C=O str.), 1522.68 (Ar C=C str.), 1244.15 (C-N str.), 
1134.34 (C-F str.); 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.33 (s, 1H), 10.56 (s, 1H), 8.68 
(d, J = 2.49 Hz, 1H), 8.17 (dd, J = 8.95 Hz, J = 2.52 Hz, 1H), 8.01 – 7.92 (m, 4H), 7.70 (d, J = 
8.53 Hz, 1H), 7.62 – 7.54 (m, 3H), 7.14 – 7.07 (m, 1H), 3.50 (d, J = 12.10 Hz, 2H), 2.78 – 2.71 
(m, 2H), 1.71 (d, J = 12.75 Hz, 2H), 1.54 – 1.50 (m, 1H), 1.34 – 1.25 (m, 2H), 0.95 (d, J = 6.34 
Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 165.7, 162.2, 155.2 – 152.7 (d, JC-F = 246 Hz, 
1C), 154.3, 149.7, 144.9, 142.7, 137.3, 134.6, 131.8, 129.5, 128.4, 127.7, 127.2, 125.1, 124.2, 
120.9, 118.8, 115.6, 50.1, 33.7, 30.0, 21.7. 
4.2.1.5.3.2. N-(2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-yl)-4-
methylbenzenesulfonamide (10i); 
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 Off white solid, yield: 21%, mp: 298-300°C; FTIR (ATR, Vmax, cm-1): 3255.53 (O-H str.), 
3087.02 (N-H str.), 2936.03 (Ar-H str.), 1669.12 (C=O str.), 1547.04 (Ar C=C str.), 1354.95 
(SO2, asym), 1243.21 (C-N str.), 1158.44 (SO2 sym), 1131.21 (C-F str.); 1H NMR (400 MHz, 
DMSO-d6, 25°C) δ  12.33 (s, 1H), 10.60 (s, 1H), 7.94 – 7.88 (m, 2H), 7.80 (d, J = 2.51 Hz, 1H), 
7.66 (d, J = 8.20 Hz, 2H), 7.59 (d, J = 8.91 Hz, 1H), 7.54 (dd, J = 8.86 Hz, J = 2.53 Hz, 1H), 
7.34 (d, J = 8.15 Hz, 2H), 7.08 (t, J = 8.82 Hz, 1H), 3.49 – 3.46 (m, 2H), 2.76 – 2.70 (m, 2H), 
2.30 (s, 3H), 1.71 – 1.68 (m, 2H), 1.56 – 1.47 (m, 1H), 1.31 – 1.21 (m, 2H), 0.93 (d, J = 6.67 
Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 162.2, 155.5 – 153.1 (d, JC-F = 242.8 Hz, 1C), 
150.4, 143.9, 143.3, 136.8, 136.3, 130.2, 129.0, 127.4, 127.1, 125.4, 124.7, 121.6, 119.1, 115.5 
– 115.3 (d, JC-F = 20.1 Hz, 1C), 50.5, 34.2, 30.4, 22.1, 21.3. 
4.2.1.5.3.3. N-(2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-yl)-4-
(trifluoromethyl)benzenesulfonamide (10j); 
 
Off white solid, yield: 30%, mp: 295-297°C; FTIR (ATR, Vmax, cm-1): 3265.95 (O-H str.), 
3087.89 (N-H str.), 2945.30 (Ar-H str.), 1670.02 (C=O str.), 1547.90 (Ar C=C str.), 1325.51 
(SO2 asym), 1243.57 (C-N str.), 1168.68 (Sym.), 1136.01 (C-F str.), 1H NMR (400 MHz, 
DMSO-d6, 25°C) δ 12.37 (s, 1H), 10.89 (s, 1H), 7.99 – 7.97 (m, 4H), 7.94 – 7.89 (m, 2H), 7.81 
(d, J = 2.48 Hz, 1H), 7.62 (d, J = 8.73 Hz, 1H), 7.55 (dd, J = 9.8 Hz, J = 2.55 Hz, 1H), 7.08 (t, J 
= 9.03 Hz, 1H), 3.49 – 3.46 (m, 2H), 2.76 – 2.70 (m, 2H), 1.70 – 1.68 (m, 2H), 1.55- 1.47 (m, 
1H), 1.31 – 1.21 (m, 2H), 0.93 (d, J = 6.5 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 25°C) δ 
161.7, 155.0 – 152.6 (d, JC-F = 243.39 Hz, 1C), 150.3, 145.7, 143.0, 142.9 – 142.8 (d, JC-F = 8.83 
Hz, 1C), 135.1, 132.8 – 132.5 (d, JC-F = 32.1 Hz, 1C), 128.7, 127.6, 127.4, 126.73 – 126.7 (d, JC-
F = 3.61 Hz, 1C), 124.8 – 124.7 (d, JC-F = 7.86 Hz, 1C), 124.6, 124.3, 121.2, 118.7, 115.8, 115.1 
– 114.9 (d, JC-F = 24.8 Hz, 1C), 50.1, 33.7, 30.0, 21.7. 
4.2.1.5.3.4 N-(2-(3-Fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-hydroxyquinazolin-6-yl)-3-
(trifluoromethyl)benzenesulfonamide (10k); 
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 Off white solid, yield: 30%, mp: 295-297°C; FTIR (ATR, Vmax, cm-1): 3250.14 (O-H str.), 
3088.14 (N-H str.), 2921.53 (Ar-H str.), 1670.57 (C=O str.), 1550.10 (Ar C=C str.), 1316.94, 
(SO2, asym.), 1242.04 (C-N str.), 1161.90 (SO2 sym.), 1132.25 (C-F str.); 1H NMR (400 MHz, 
DMSO-d6, 25°C) δ 12.37 (s, 1H), 10.81, (s, 1H), 8.04 – 8.01 (m, 2H), 7.94 – 7.89 (m, 2H), 7.83 
– 7.79 (m, 2H), 7.62 (d, J = 8.78 Hz, 1H), 7.53 (dd, J = 8.77 Hz, J = 2.46 Hz, 1H), 7.09 (t, J = 
8.72 Hz, 1H), 3.48 (d, J = 12.01 Hz, 2H), 2.74 (t, J = 12.07 Hz, 2H), 1.71 – 1.68 (m, 2H), 1.54 – 
1.49 (m, 1H), 1.34 – 1.22 (m, 2H), 0.94 (d, J = 6.40 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 
25°C) δ 162.1, 155.5 – 153.0 (d, JC-F = 243.1 Hz, 1C), 150.8, 146.2, 143.3, 140.7, 135.5, 131.6, 
131.1, 130.5 – 130.2 (d, JC-F = 32.5 Hz, 1C), 130.3, 129.2, 128.1, 125.2 – 125.1 (d, JC-F = 7.96 
Hz, 1C), 124.8, 123.65 – 123.6 (d, JC-F = 3.84 Hz, 1C), 121.6, 119.2 – 119.1 (d, JC-F = 3.40 Hz, 
1C), 116.5, 115.6 – 115.3 (d, JC-F = 23.85 Hz, 1C), 50.4, 34.1, 30.4, 22.1. 
4.2.1.5.1.9.1 Synthesis of 2-((2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-
hydroxyquinazolin-6-yl)amino)-2-oxoacetic acid (10l):  
 
To the suspension of ethyl 2-((2-(3-fluoro-4-(4-methylpiperidin-1-yl)phenyl)-4-
hydroxyquinazolin-6-yl)amino)-2-oxoacetate (0.15 g, 0.33 mmol) in THF and EtOH was added 
aqueous lithium hydroxide (0.023 g, 0.99 mmol). The resultant mixture was stirred at room 
temperature for 4 h, then solvent was evaporated under reduce pressure, diluted with water and 
washed with ethyl acetate. The aqueous layer was acidified with 6N-HCl, and extracted with 
ethyl acetate (3 x 10 mL). The organic phase was dried over anhydrous Na2SO4, filtered, and 
concentrated under reduce pressure to afford yellow solid product (0.099 g, 70%); mp: 275-
277°C; 1H NMR (400 MHz, DMSO-d6, 25°C) δ 12.36 (s, 1H), 11.03 (s, 1H), 8.67 (d, J = 2.80 
Hz, 1H), 8.09 (dd, J = 8.84 Hz, J = 2.56 Hz, 1H), 8.00 – 7.94 (m, 2H), 7.69 (d, J = 8.85 Hz, 
1H), 7.11 (t, J = 8.94 Hz, 1H), 3.52 – 3.49 (m, 2H), 2.79 – 2.73 (m, 2H), 1.73 – 1.70 (m, 2H), 
1.55 – 1.50 (m, 1H), 1.34 – 1.22 (m, 2H), 0.95 (d, J = 6.66 Hz, 3H). 13C NMR (100 MHz, 
DMSO-d6, 25°C) δ 162.0, 161.8, 156.9, 155.0 – 152.6 (d, J = 244.8 Hz, 1C), 150.1, 145.4, 142.8 
– 142.7 (d, J = 7.99 Hz, 1C), 135.7, 127.8, 127.2, 124.9 – 124.8 (d, J = 7.7 Hz, 1C), 124.3, 
120.8, 118.7, 115.8, 115.1 – 114.9 (d, J = 23.7 Hz, 1C), 50.1, 33.7, 30.0, 21.7. 
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4.3. Biology 
4.3.1. Evaluation of inhibitory activities on E. coli DNA gyrase and topoisomerase IV 
Synthesized quinazoline derivatives were evaluated for their inhibitory activity against DNA 
gyrase and topoisomerase IV from E. coli in supercoiling and decatenation assays, respectively. 
These assays were performed based on established protocols attained from the supplier, 
TopoGEN, Inc. (Buena Vista, Colorado, USA). All of the reactions (DNA gyrase and Topo 
isomerase IV activities) loaded on a 1% agarose, TAE (40 mM Tris-acetate, 0.01 M EDTA, pH 
8.3) gel and run for 3–4 hr at 50 V. The gel was stained with 0.5 µg mL-1 ethidium bromide in 
TAE for 30 min while rocking, then destained for 10 min in deionized water. The images were 
captured on a Gel doc XR imaging system from BIO-RAD. at a wavelength of 300 nm. The 
intensity of the reaction product, for gyrase, and the decatenation product of topoisomerase were 
quantitated using Image Lab software and IC50 values were determined by non-linear regression 
analysis in Graph Pad Prism 8.  
4.3.1.1. Evaluation of inhibitory activities on E. coli DNA gyrase (supercoiling and 
relaxation) 
Supercoiling of relaxed plasmid DNA (pHOT1) was examined in a reaction volume of 20 µl 
contains of assay buffer (35 mM Tris pH 7, 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.8 mM 
spermidine, 6.5% glycerol, 0.1 mg/ml acetylated BSA, 1 mM ATP),  and 0.2 mg of relaxed 
DNA (pHOT1 a derivative of pBR322 < 3KB) substrate. Drug compounds with different 
concentrations (100, 10, 1µM) in DMSO were added and after that the reactions were initiated 
with 2 units of E. coli gyrase (TopoGEN). In order to compare the results optimum 
concentration of ciprofloxacin (10 µM) has been used as standard. The reaction proceeded for 
incubation with shaking on a mini-orbital shaker for 1 hour at 37°C. After the incubation, added 
0.1volume of 10% SDS and 10 µl of proteinase K (20mg/ml) and digest for 30 min. at 37°C. 
Then add 0.1volume of 10x loading dye (0.25% bromophenol and 50 % glycerol), followed by 
organic extraction using chloroform: isoamyl alcohol mixture (24:1 ratio), vortex briefly, 
separate blue coloured upper aqueous phase and load onto 1% agrose gel. 
The gyrase relaxation activity was assayed with corresponding supercoiled DNA using 
supercoiling buffer (without ATP and spermidine). Different concentrations of test compound 
(100, 10, 1µM) were prepared in DMSO and added to the reaction mix prior to enzyme 
addition. For the comparison, ciprofloxacin was tested in the same experiment as standard. The 
reaction proceeded for incubation for 1 hour at 37°C. After the incubation, added 0.1volume of 
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10% SDS and 10 µL of proteinase K (20mg/mL) and digest for 30 min. at 37°C. Then add 
0.1volume of 10x loading dye (0.25% bromophenol and 50 % glycerol), followed by organic 
extraction using chloroform: isoamyl alcohol mixture (24:1 ratio), vortex briefly, separate blue 
colored upper aqueous phase and load onto 1% agrose gel. The loaded DNA was stained with 
0.5 µg mL-1 ethidium bromide for 30 minutes and distain with distilled water for 10 min at room 
temperature. The photo visualized and documented with Gel doc XR imaging system from BIO-
RAD. Quantification of the intensity of the bands was performed using Image Lab software 
provided by BIO-RAD.com and IC50 was determined using Graph Pad Prism 8.  
4.3.1.2. Evaluation of inhibitory activities on E. coli topoisomerase IV (relaxation and 
decatenation) 
The inhibition activities of topoisomerase IV enzyme were assayed with corresponding assay 
buffer using relaxation and decatenation of supercoiled DNA and kinetoplast DNA substrate, 
respectively. The reaction mixture(20µl) for relaxation consist of Assay buffer (40 mM Tris pH 
7.5, 6 mM MgCl2, 10 mM DTT, 100 mM potassium glutamate, 50 mg/ml acetylated BSA, 1 
mM ATP) and 0.2mg supercoiled DNA. Different concentration of test compound in DMSO 
were added and reactions were initiated with 2 Units of E. coli TopoIV after that incubated for 
30 mins at 37°C. The stop reaction and extraction procedure were same as above for the DNA 
gyrase. 
Decatenation was assayed in a reaction volume of 20 µl of containing 40 mM Tris pH 7.5, 6 
mM MgCl2, 10 mM DTT, 100 mM potassium glutamate, 50 mg/ml acetylated BSA, 1 mM 
ATP, and 0.2 mg kDNA substrate. Test compound with different concentration (in DMSO) 
were added and the reactions were initiated with 2 units of E. coli topoIV (Topogen) that were 
incubated for 30 min at 37°C. After incubation follow the same procedure as mention in E. coli 
DNA gyrase. 
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CHAPTER 7 
1. SUMMARY AND CONCLUSION 
Tuberculosis (TB) and other microbial infections are becoming a major health problem due 
to the rapidly emerging drug resistance as well as co-infection. Tuberculosis is one of the 
leading cause of death from a single infectious agent. Keeping TB as a main target, the 
work in this thesis is divided into 6 chapters and in total 110 derivatives have been 
synthesized. Chapter 1 briefly describes, drug discovery and medicinal chemistry, history 
of antibiotic expansion, development of resistance in bacteria, history of TB drugs 
discovery, line of treatment for TB, anti-tuberculosis drugs and their specific targets and 
classification of TB drugs. In addition, we have also explored DNA gyrase and 
topoisomerase IV as a key target for anti-bacterial agents, marketed drugs and recently 
reported DNA gyrase inhibitors. This led us to explore heterocycles (Benzoxazine and 
quinazoline) as potential anti-TB targets.  
In Chapter 2, we have developed a simple, yet efficient one-pot, multicomponent, green, 
catalyst-free, and diastereospecific tandem synthesis of 1,4-benzoxazines in excellent 
yields. This one-pot, in-situ reaction proceeds by the formation of a Schiff base followed by 
base mediated O-alkylation with the phenacyl bromide and finally catalyst free 
intramolecular cyclization. Further, this versatile novel methodology provides a wide scope 
for the synthesis of differentially substituted/functionalised 1,4-benzoxazine analogues, 
which can be exploited by the researchers in academia, pharmaceutical and agrochemical 
industries in developing new building blocks for the synthesis of new active pharmaceutical 
ingredients (API’s), drugs and pesticides. 
In chapter 3, 15 compounds based on fluorinated quinazoline derivatives have been 
synthesized and well-characterized with Infrared (IR) and Nuclear Magnetic Resonance 
(NMR) spectroscopic methods (1H, 13C, COSY, HMBC, HSQC and NOESY). Additionally, 
crystal structure of 4 derivatives (13b, 13e, 13f and 13g) were solved by single X-ray 
diffractometer and the confirmation of molecules in solution- phase, using 2D NOESY 
experiments, was compared. The influence of various substituents on the core scaffold 
(Fluorinated quinazoline) on its molecular conformations, intermolecular interactions and 
on the photoluminescent properties has been described. Hirshfeld surfaces was used to 
investigate the structure-directing effects of functional groups in controlling their solid-state 
behaviour. Among the series, compounds (8, 10c-h, 13b-d and 13f-g) displayed good 
photoluminescent properties. 
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In Chapter 4, we report rational design-based synthesis, spectral studies and preliminary 
anti-mycobacterial screening of novel quinazoline derivatives against Mycobacterium 
tuberculosis H37Rv strain. A total of 21 derivatives were synthesized, well-characterized by 
IR, NMR and screened against Mycobacterium tuberculosis H37Rv strain. The notable 
percentage zone of inhibition was shown by compound 10m that was 33% after 24 h 
incubation.  
In Chapter 5, we report synthesis, spectral studies and preliminary anti-mycobacterial 
screening of novel N/O methylated quinazoline derivatives against Mycobacterium 
tuberculosis H37Rv strain. Novel 23 molecules had been synthesized, well-characterized by 
IR, NMR and screened against Mycobacterium tuberculosis H37Rv strain. The percentage 
zone of inhibition by 16a was 34% after 24 h incubation which can be further consider for 
the study like MIC, MBC etc.  
 In Chapter 6, we have replaced the central core quinolone with quinazoline ring and 
synthesized 22 derivatives. All derivatives were characterized by IR and NMR and 
evaluated against DNA gyrase and topoisomerase IV enzyme of Escherichia coli using 
Ciprofloxacin as reference drug. Among the series, compound 10l bearing carboxylic acid 
group was found to be most active with IC50 value of 0.49 and 13.22 μM for DNA Gyrase 
and topoisomerase IV, respectively. In addition, 9f, 9i, 9j, 10c, 10j and 10k were also 
exhibited excellent activity against DNA Gyrase while comparatively less activity against 
topoisomerase IV. These results provide a basis for structure-based optimization toward 
dual DNA gyrase and topoisomerase IV inhibition. 
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FUTURE WORK 
In this project, we have developed a novel green and efficient catalyst-free, the mild one-pot 
tandem synthetic method to construct 1, 4-benzoxazine which can be further exploited to 
synthesize novel potential anti-tubercular agents. Moreover, we have already synthesized 29 
benzoxazine based molecules that can be screened against Mycobacterium tuberculosis and 
evaluated against DNA gyrase and topoisomerase IV for E. coli. The most potent molecules 
can be effectively used in developing further lead compounds through three-dimensional 
quantitative structure relationship (3D-QSAR) models.  
Additionally, one of the quinazoline series showing satisfactory inhibitory activities against 
DNA gyrase and topoisomerase IV. All other quinazoline series tend to show inhibitory 
activities against DNA gyrase and topoisomerase IV. This motivate us to evaluate all other 
quinazoline based series against DNA gyrase and topoisomerase IV of Gram-negative 
bacteria.
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NOESY spectrum of compound 4 (Chapter 2) 
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Crystal structure of compound 9b (CCDC No. 1966293) (Chapter 2) 
 
Crystal structure of compound 15 (CCDC No. 1966294) (Chapter 2) 
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Crystal structure of compound 17 (CCDC No. 1997747) (Chapter 2) 
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Table S1: X-ray crystallographic data and structure refinement. 
Crystal parameters   9b   15    17 
Empirical formula C21H15Cl2NO2 C22H18ClNO2 C21H15ClN2O4 
Formula weight 384.24 363.82 394.80 
Temperature/K 100.15 100.00 149.98 
Crystal system monoclinic monoclinic monoclinic 
Space group P21/n P21/n P21/n 
a/Å 10.4411(2) 10.4686(3) 9.59130(10) 
b/Å 15.0003(3) 14.9205(4) 11.3803(2) 
c/Å 11.6037(2) 11.6719(3) 17.0706(2) 
α/° 90 90 90 
β/° 111.5660(10) 111.0760(10) 100.5990(10) 
γ/° 90 90 90 
Volume/Å3 1690.14(6) 1701.15(8) 1831.50(4) 
Z 4 4 4 
ρcalcg/cm3 1.510 1.421 1.432 
μ/mm-1 0.400 0.241 0.240 
F(000) 792.0 760.0 816.0 
Crystal size/mm3 0.29 × 0.24 × 0.16 0.36 × 0.24 × 0.16 0.36 × 0.27 × 0.23 
Radiation 
MoKα (λ = 
0.71073) 
MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.65 to 55.332 4.49 to 56.938 4.324 to 55.224 
Index ranges 
-13 ≤ h ≤ 10, -17 ≤ 
k ≤ 19, -15 ≤ l ≤ 15 
-13 ≤ h ≤ 13, -19 ≤ k 
≤ 19, -15 ≤ l ≤ 15 
-12 ≤ h ≤ 12, -14 ≤ k 
≤ 14, -21 ≤ l ≤ 22 
Reflections collected 12982 20903 25266 
Independent reflections 
3846 [Rint = 0.0359, 
Rsigma = 0.0359] 
4271 [Rint = 0.0196, 
Rsigma = 0.0154] 
4221 [Rint = 0.0171, 
Rsigma = 0.0128] 
Data/restraints/parameters 3846/0/239 4271/1/240 4221/20/272 
Goodness-of-fit on F2 1.026 1.042 1.027 
Final R indexes [I>=2σ (I)] 
R1 = 0.0308, wR2 = 
0.0753 
R1 = 0.0324, wR2 = 
0.0859 
R1 = 0.0339, wR2 = 
0.0862 
Final R indexes [all data] 
R1 = 0.0424, wR2 = 
0.0799 
R1 = 0.0368, wR2 = 
0.0897 
R1 = 0.0390, wR2 = 
0.0905 
Largest diff. peak/hole / e Å-3 0.34/-0.26 0.35/-0.25 0.37/-0.36 
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1H NMR spectrum of intermediate compound V (Chapter 2)  
 
13C{1H} NMR spectrum of intermediate compound V (Chapter 2)  
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1H NMR spectrum of intermediate compound VII (Chapter 2)  
 
13C{1H} NMR spectrum of intermediate compound VII (Chapter 2)  
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1H NMR spectrum of crude compound 4 (Chapter 2) 
 
1H NMR spectrum of compound 4 (Chapter 2) 
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13C{1H} NMR spectrum of compound 4 (Chapter 2) 
 
IR spectrum of compound 4 (Chapter 2) 
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1H NMR spectrum of crude compound 5 (Chapter 2)  
 
1H NMR spectrum of compound 5 (Chapter 2) 
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13C{1H} NMR spectrum of compound 5 (Chapter 2) 
 
IR spectrum of compound 5 (Chapter 2)  
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1H NMR spectrum of crude compound 6 (Chapter 2) 
 
1H NMR spectrum of compound 6 (Chapter 2) 
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13C{1H} NMR spectrum of compound 6 (Chapter 2) 
 
IR spectrum of compound 6 (Chapter 2)  
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1H NMR spectrum of crude compound 7 (Chapter 2) 
 
1H NMR spectrum of compound 7 (Chapter 2) 
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13C{1H} NMR spectrum of compound 7 (Chapter 2) 
 
IR spectrum of compound 7 (Chapter 2)   
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1H NMR spectrum of crude compound 8 (Chapter 2) 
 
1H NMR spectrum of compound 8 (Chapter 2) 
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13C{1H} NMR spectrum of compound 8 (Chapter 2) 
 
IR spectrum of compound 8 (Chapter 2) 
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1H NMR spectrum of crude compound 9 (Chapter 2) 
 
1H NMR spectrum of compound 9a (Chapter 2) 
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13C{1H} NMR spectrum of compound 9a (Chapter 2) 
 
IR spectrum of compound 9a (Chapter 2)  
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1H NMR spectrum of compound 9b (Chapter 2) 
 
13C{1H} NMR spectrum of compound 9b (Chapter 2) 
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IR spectrum of compound 9b (Chapter 2)  
 
1H NMR spectrum of crude compound 10 (Chapter 2) 
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1H NMR spectrum of compound 10 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 10 (Chapter 2) 
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IR spectrum of compound 10 (Chapter 2) 
 
1H NMR spectrum of crude compound 11 (Chapter 2) 
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1H NMR spectrum of compound 11a (Chapter 2) 
 
13C{1H} NMR spectrum of compound 11a (Chapter 2) 
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IR spectrum of compound 11a (Chapter 2)  
 
1H NMR spectrum of compound 11b (Chapter 2) 
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13C{1H} NMR spectrum of compound 11b (Chapter 2) 
 
IR spectrum of compound 11b (Chapter 2)  
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1H NMR spectrum of crude compound 12 (Chapter 2) 
 
1H NMR spectrum of compound 12 (Chapter 2) 
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13C{1H} NMR spectrum of compound 12 (Chapter 2) 
 
IR spectrum of compound 12 (Chapter 2)  
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1H NMR spectrum of crude compound 13 (Chapter 2) 
 
1H NMR spectrum of compound 13a (Chapter 2) 
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13C{1H} NMR spectrum of compound 13a (Chapter 2) 
 
IR spectrum of compound 13a (Chapter 2)  
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1H NMR spectrum of compound 13b (Chapter 2) 
 
13C{1H} NMR spectrum of compound 13b (Chapter 2) 
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IR spectrum of compound 13b (Chapter 2) 
 
1H NMR spectrum of crude compound 14 (Chapter 2) 
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1H NMR spectrum of compound 14 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 14 (Chapter 2) 
APPENDIX -I                                                                                                               Chapter 2 
Narva Deshwar Kushwaha                              S34                                                     UKZN-2020            
 
 
IR spectrum of compound 14 (Chapter 2) 
 
1H NMR spectrum of crude compound 15 (Chapter 2) 
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1H NMR spectrum of compound 15 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 15 (Chapter 2) 
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IR spectrum of compound 15 (Chapter 2)  
 
1H NMR spectrum of crude compound 16 (Chapter 2) 
APPENDIX -I                                                                                                               Chapter 2 
Narva Deshwar Kushwaha                              S37                                                     UKZN-2020            
 
 
1H NMR spectrum of compound 16 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 16 (Chapter 2) 
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IR spectrum of compound 16 (Chapter 2) 
 
1H NMR spectrum of crude compound 17 (Chapter 2) 
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1H NMR spectrum of compound 17 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 17 (Chapter 2) 
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IR spectrum of compound 17 (Chapter 2) 
 
1H NMR spectrum of crude compound 18 (Chapter 2) 
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1H NMR spectrum of compound 18 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 18 (Chapter 2) 
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IR spectrum of compound 18 (Chapter 2) 
 
1H NMR spectrum of crude compound 19 (Chapter 2) 
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1H NMR spectrum of compound 19 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 19 (Chapter 2) 
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IR spectrum of compound 19 (Chapter 2) 
 
1H NMR spectrum of crude compound 20 (Chapter 2) 
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1H NMR spectrum of compound 20 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 20 (Chapter 2) 
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IR spectrum of compound 20 (Chapter 2) 
 
1H NMR spectrum of crude compound 21 (Chapter 2) 
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1H NMR spectrum of compound 21 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 21 (Chapter 2) 
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IR spectrum of compound 21 (Chapter 2) 
 
1H NMR spectrum of crude compound 22 (Chapter 2) 
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1H NMR spectrum of compound 22 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 22 (Chapter 2) 
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IR spectrum of compound 22 (Chapter 2) 
 
1H NMR spectrum of crude compound 23 (Chapter 2) 
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1H NMR spectrum of compound 23 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 23 (Chapter 2) 
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1H NMR spectrum of crude compound 24 (Chapter 2) 
 
1H NMR spectrum of compound 24 (Chapter 2) 
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13C{1H} NMR spectrum of compound 24 (Chapter 2) 
 
IR spectrum of compound 24 (Chapter 2) 
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1H NMR spectrum of crude compound 25 (Chapter 2) 
 
 
1H NMR spectrum of compound 25 (Chapter 2) 
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13C{1H} NMR spectrum of compound 25 (Chapter 2) 
 
IR spectrum of compound 25 (Chapter 2) 
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1H NMR spectrum of crude compound 26 (Chapter 2) 
 
1H NMR spectrum of compound 26 (Chapter 2) 
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13C{1H} NMR spectrum of compound 26 (Chapter 2) 
 
 IR spectrum of compound 26 (Chapter 2) 
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1H NMR spectrum of crude compound 27 (Chapter 2) 
 
1H NMR spectrum of compound 27 (Chapter 2) 
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13C{1H} NMR spectrum of compound 27 (Chapter 2) 
 
IR spectrum of compound 27 (chapter 2) 
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1H NMR spectrum of crude compound 28 (Chapter 2) 
 
1H NMR spectrum of compound 28 (Chapter 2) 
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13C{1H} NMR spectrum of compound 28 (Chapter 2) 
 
IR spectrum of compound 28 (Chapter 2) 
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1H NMR spectrum of crude compound 29 (Chapter 2) 
 
1H NMR spectrum of compound 29 (Chapter 2) 
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13C{1H} NMR spectrum of compound 29 (Chapter 2) 
 
IR spectrum of compound 29 (chapter 2) 
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1H NMR spectrum of crude compound 30 (Chapter 2) 
 
1H NMR spectrum of compound 30a (Chapter 2) 
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13C{1H} NMR spectrum of compound 30a (Chapter 2) 
 
IR spectrum of compound 30a (Chapter 2) 
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1H NMR spectrum of compound 30b (Chapter 2) 
 
13C{1H} NMR spectrum of compound 30b (Chapter 2) 
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IR spectrum of compound 30b (Chapter 2) 
 
1H NMR spectrum of crude compound 31 (Chapter 2) 
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1H NMR spectrum of compound 31 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 31 (Chapter 2) 
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IR spectrum of compound 31 (Chapter 2) 
 
1H NMR spectrum of crude compound 32 (Chapter 2) 
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1H NMR spectrum of compound 32 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 32 (Chapter 2) 
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IR spectrum of compound 32 (Chapter 2) 
 
1H NMR spectrum of crude compound 33 (Chapter 2) 
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1H NMR spectrum of compound 33 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 33 (Chapter 2) 
APPENDIX -I                                                                                                               Chapter 2 
Narva Deshwar Kushwaha                              S73                                                     UKZN-2020            
 
 
IR spectrum of compound 33 (Chapter 2) 
 
1H NMR spectrum of crude compound 34 (Chapter 2) 
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1H NMR spectrum of compound 34 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 34 (Chapter 2) 
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IR spectrum of compound 34 (Chapter 2) 
 
1H NMR spectrum of crude compound 35 (Chapter 2) 
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1H NMR spectrum of compound 35 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 35 (Chapter 2) 
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IR spectrum of compound 35 (Chapter 2) 
 
1H NMR spectrum of crude compound 36 (Chapter 2) 
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1H NMR spectrum of compound 36 (Chapter 2) 
 
13C{1H} NMR spectrum of compound 36 (Chapter 2) 
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IR spectrum of compound 36 (Chapter 2) 
1H NMR spectrum of intermediate compound (with 2-amino-4-nitrophenol) (Chapter 
2) 
APPENDIX -I                                                                                                               Chapter 2 
Narva Deshwar Kushwaha                              S80                                                     UKZN-2020            
 
 
1H NMR spectrum of intermediate compound (with ethyl α-bromoacetate) (Chapter 2) 
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HRMS spectrum of compound 13a (Chapter 2) 
Generic Display Report 
 
Analysis Info 
Analysis Name 
Method 
Sample Name 
Comment 
C:\Data\Sooraj\AS1.d 
Small Molecules.m 
AS1 
Acquisition Date 
Operator 
Instrument 
3/2/2020 9:12:17 AM 
@BLADE 
micrOTOF-Q 
 
Bruker Compass DataAnalysis 4.2 printed: 3/6/2020 9:30:01 AM 
APPENDIX -I                                                                                                               Chapter 2 
Narva Deshwar Kushwaha                              S82                                                     UKZN-2020            
 
 
HRMS spectrum of compound 20 (Chapter 2) 
Generic Display Report 
Analysis Info 
Analysis Name 
Method 
Sample Name 
Comment 
C:\Data\Sooraj\AS4.d 
Small Molecules.m 
AS4 
Acquisition Date 
Operator 
Instrument 
3/2/2020 9:20:21 AM 
@BLADE 
micrOTOF-Q 
 
Bruker Compass DataAnalysis 4.2 printed: 3/6/2020 9:28:10 AM by: @BLADE Page 1 of 1 
APPENDIX -I                                                                                                               Chapter 2 
Narva Deshwar Kushwaha                              S83                                                     UKZN-2020            
 
 
HRMS spectrum of compound 30b (chapter 2)  
Generic Display Report 
Analysis Info 
Analysis Name 
Method 
Sample Name 
Comment 
C:\Data\Sooraj\AS3.d 
Small Molecules.m 
AS3 
Acquisition Date 
Operator 
Instrument 
3/2/2020 9:16:55 AM 
@BLADE 
micrOTOF-Q 
 
Bruker Compass DataAnalysis 4.2 printed: 3/3/2020 2:24:22 PM 
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HRMS spectrum of compound 32 (Chapter 2)  
Display Report 
Analysis Info 
Analysis Name C:\Data\Sooraj\S_27.d 
Method Small Molecules.m 
Sample Name S_27 
Comment 
  Acquisition Date 3/9/2020 11:22:59 AM 
Operator @BLADE 
Instrument micrOTOF-Q 228888.10139 
Acquisition Parameter 
Source Type
FocusScan BeginScan End 
ESI 
Not active 503000 m/z m/z 
Ion PolaritySet 
CapillarySet End Plate 
OffsetSet Collision Cell 
RF 
Positive 4500-
500600.0 V V 
Vpp 
Set Nebulizer
Set 
Dry HeaterSet Dry 
Gas Set Divert 
Valve 
0.32004.0 Bar 
l/min °C 
Source  
 
Bruker Compass DataAnalysis 4.2 printed: 3/9/2020 11:28:30 AM  
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Document: BATCH 8 151019 (VarioELcube) from: 2019/10/16 09:51 
INSTALLATION TEST - 25_03_2019 
varioELcube serial 
number: 19181072 
Text report 
 
No.  Name   Manuscript 
compound ID 
N  [%] C  [%] H  [%] S  [%] 
1 s 14 02 9a 3.66 64.20 3.882 0.000 
2 S22 9b 3.71 65.49 3.973 0.033 
3 S10 8 3.40 67.54 5.120 0.000 
4 S12 4 3.60 67.16 4.900 0.000 
5 S13 10 3.35 58.75 3.487 0.000 
6 S 1 D1 11a 3.72 69.63 4.947 0.000 
7 S 1D2 11b 3.77 69.35 4.940 0.000 
8 S 15 12 7.11 63.18 3.729 0.000 
9 S46 14 3.73 68.66 4.711 0.000 
10 S47 15 3.92 72.22 5.185 0.000 
11 S48 16 7.32 63.31 3.790 0.000 
12 S 49 D1 17 7.08 63.47 3.796 0.000 
13 S50 18 4.42 70.97 4.431 0.000 
14 S 56 19 4.02 63.34 3.923 8.737 
15 S 66 5 3.30 57.75 3.511 0.000 
16 S 28 23 3.57 56.13 3.656 0.000 
17 S 29 24 3.08 56.30 3.929 0.000 
18 S 30 25 2.81 49.17 2.773 0.000 
19 S 23 26 2.99 52.80 2.994 0.000 
20 S 51 27 3.13 56.72 3.709 0.000 
21 S 52 31 3.43 59.55 3.942 0.000 
22 S 55 28 3.30 52.68 3.091 0.000 
23 S 57 29 3.56 52.24 2.961 6.896 
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Document: 2020 batch 8 02032020 (VarioELcube) from: --.--.-- (modified) 
INSTALLATION TEST - 25_03_2019 
varioELcube serial 
number: 19181072 
Text report 
 
No.  Name   Manuscript 
compound ID 
N  [%] C  [%] H  [%] S  [%] 
1 S_72 21 3.66 74.11 6.017 0.048 
2 S_73 22 3.97 71.64 5.145 0.072 
3 S_78 33 3.42 66.68 4.479 0.021 
4 S_79 34 3.37 59.62 3.356 0.005 
5 S_80 35 3.46 63.36 4.062 0.006 
6 S_72(2) 21 3.67 74.30 6.010 0.000 
7 S_73(2) 22 3.96 71.74 5.146 0.034 
8 S_78(2) 33 3.42 66.86 4.503 0.009 
9 S_79(2) 34 3.36 59.58 3.324 0.000 
10 S_80(2) 35 3.46 63.38 4.033 0.000 
Name: eassuperuser, Access: varioELcube superuser Mon Mar 2 11:22:57 2020 
 varioEL cube V4.0.16 (366251fb2)2018-07-25, CHNS Mode, Ser. No.: 19181072 Elementar 
Analysensysteme GmbH 
Page 1 (of 1) 
APPENDIX -I                                                                                                               Chapter 2 
Narva Deshwar Kushwaha                              S87                                                     UKZN-2020            
 
 
Document: 2020 batch  9 04032020 (VarioELcube) from: 2020/03/04 16:05 
INSTALLATION TEST - 25_03_2019 
varioELcube serial 
number: 19181072 
Text report 
 
No.  Name   Manuscript compound ID N  [%] C  [%] H  [%] S  [%] 
1 S_7 6 3.73 66.52 4.545 0.499 
2 S_16_D2 13b 3.80 66.97 3.982 0.050 
3 S_34_D1 30a 3.01 56.63 3.186 0.015 
4 S_9_D1 7 3.16 61.96 3.547 1.354 
5 S_7b 6 3.77 68.66 4.806 11.142 
6 S_16_D2b 13b 3.73 67.20 3.863 1.778 
7 S_34_d1b 30a 3.00 56.36 3.064 1.715 
Name: eassuperuser, Access: varioELcube superuser Wed Mar 4 16:07:38 2020 
 varioEL cube V4.0.16 (366251fb2)2018-07-25, CHNS Mode, Ser. No.: 19181072 Elementar 
Analysensysteme GmbH 
Page 1 (of 1) 
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Document: oxygen batch 3 06/11/19 (VarioELcube) from: 2019/11/13 09:47 
INSTALLATION TEST - 25_03_2019 
varioELcube serial 
number: 19181072 
Text report 
 
No.  Name   Manuscript 
compound ID 
O  [%] 
1 S10 8 19.477 
2 S12 4 18.675 
3 S13 10 10.870 
4 S15 12 18.632 
5 S22 9b 12.996 
6 S23 26 10.781 
7 S28 23 14.189 
8 S29 24 15.433 
9 S30 25 9.294 
10 S46 14 15.160 
11 S47 15 11.319 
Name: eassuperuser, Access: varioELcube superuser Fri Nov 15 13:11:57 2019 
 varioEL cube V4.0.16 (366251fb2)2018-07-25, O Mode, Ser. No.: 19181072 
Elementar Analysensysteme GmbH 
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Document: oxygen batch 4 13/11/19 (VarioELcube) from: 2019/11/13 14:43 
INSTALLATION TEST - 25_03_2019 
varioELcube serial 
number: 19181072 
Text report 
 
No.  Name   Manuscript 
compound ID 
O  [%] 
1 S48 16 17.988 
2 S50 18 16.539 
3 S51 27 12.767 
4 S52 31 9.528 
5 S55 28 14.047 
6 S56 19 11.588 
7 S57 29 9.910 
8 S66 5 9.709 
9 S_1_D1 11a 14.368 
10 S_1_D2 11b 14.079 
11 S_14_D2 9a 10.580 
12 S_49_D1 17 16.767 
Name: eassuperuser, Access: varioELcube superuser Fri Nov 15 13:12:55 2019 
 varioEL cube V4.0.16 (366251fb2)2018-07-25, O Mode, Ser. No.: 19181072 Elementar 
Analysensysteme GmbH 
Page 1 (of 1) 
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Elemental analysis report 
 
 
 
 
Document: oxygen batch 2 12/03/20 (VarioELcube) from: 2020/03/12 16:48 
INSTALLATION TEST - 25_03_2019 
varioELcube 
serial number: 19181072 
Text report 
No.  Name   Manuscript 
compound ID 
O  [%] Date       Time   
1 s73a 22 10.169 2020/03/12 13:04 
2 S72A 21 16.737 2020/03/12 13:15 
3 S78A 33 9.445 2020/03/12 13:27 
4 S79A 34 8.387 2020/03/12 13:38 
5 S80A 35 12.090 2020/03/12 13:50 
6 S7A 6 11.026 2020/03/12 14:01 
7 S16A 13b 10.885 2020/03/12 14:15 
8 S34D1A 30a 8.409 2020/03/12 14:27 
9 S73B 22 9.790 2020/03/12 14:39 
10 S7B 6 10.918 2020/03/12 14:51 
11 S9D1A 7 14.119 2020/03/12 15:02 
12 S9D1B 7 14.303 2020/03/12 15:14 
13 S78B 33 8.990 2020/03/12 15:25 
14 S79B 34 8.336 2020/03/12 15:37 
15 S16B 13b 10.735 2020/03/12 15:48 
16 S34D1B 30a 8.324 2020/03/12 16:00 
17 S73C 22 9.728 2020/03/12 16:11 
18 S78C 33 8.639 2020/03/12 16:23 
19 S79C 34 8.264 2020/03/12 16:43 
Parameter report 
Temperatures   
 Pyrol. tube 1170 
 CO col.standby 40 
 Desorpt.Mid. 40 
 Cool temp. 60 
Time values   
APPENDIX – II                                                                                                            Chapter 3 
Narva Deshwar Kushwaha                              S91                                                     UKZN-2020            
 
APPENDIX – II 
SUPPLEMENTARY INFORMATION 
CHAPTER 3 
Synthesis, Crystal structure, spectroscopic and photophysical studies of novel 
fluorinated quinazoline derivatives 
Department of Pharmaceutical Chemistry, Discipline of Pharmaceutical Sciences, College of 
Health Sciences, University of KwaZulu-Natal (Westville), Durban-4000, South Africa 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX – II                                                                                                            Chapter 3 
Narva Deshwar Kushwaha                              S92                                                     UKZN-2020            
 
  
1H NMR spectrum of compound 2 (Chapter 3) 
   
13C NMR spectrum of compound 2 (Chapter 3) 
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IR spectrum of compound 2 (Chapter 3    
   
1H NMR spectrum of compound 4 (Chapter 3) 
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13C NMR spectrum of compound 4 (Chapter 3) 
  
19F NMR spectrum of compound 4 (Chapter 3) 
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IR spectrum of compound 4 (Chapter 3  
 
1H NMR spectrum of compound 5 (Chapter 3) 
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13C NMR spectrum of compound 5 (Chapter 3) 
   
19F NMR spectrum of compound 5 (Chapter 3) 
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Cosy spectrum of compound 5 (Chapter 3) 
    
 
HMBC & HSQC spectrum of compound 5 (Chapter 3) 
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